cytarabine profile

Guanosine Diphosphate Fucose: A nucleoside diphosphate sugar formed from GDPmannose, which provides fucose for lipopolysaccharides of bacterial cell walls, and for blood group substances and other glycoproteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	135412609
CHEBI ID	17009
SCHEMBL ID	21905367
MeSH ID	M0005564
PubMed CID	6253
CHEMBL ID	803
CHEBI ID	28680
SCHEMBL ID	3140
SCHEMBL ID	23152019
SCHEMBL ID	22591193
MeSH ID	M0005564

Synonym
CHEBI:17009 ,
guanosine 5'-[3-(6-deoxy-l-galactopyranosyl) dihydrogen diphosphate]
guanosine diphosphate fucose
gtpl4578
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[(3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl] hydrogen phosphate
{[(2r,3s,4r,5r)-5-(2-amino-6-oxo-6,9-dihydro-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[hydroxy({[(3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy})phosphoryl]oxy})phosphinic acid
(6-deoxy-beta-l-galactopyranosyl) ester
SCHEMBL21905367
Q27077785
guanosine 5'-diphospho- beta -l-fucose sodium salt
MLS001066340
BIDD:PXR0139
BIDD:GT0371
BRD-K33106058-003-20-6
SRI-10828-20
SRI-10828-19
LOPAC0_000316
citarabina
cytarabinum
4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1h)-one
CHEBI:28680 ,
arabinocytosine
D00168
cytarabine (jp17/usp/inn)
depocyt (tn)
cytonal
cytosine arabinoside (van)
cytosar-u
4-amino-1-beta-d-arabinofuranosyl-2(1h)-pyrimidinon [czech]
4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [czech]
nsc 287459
citarabina [inn-spanish]
cytarabinum [inn-latin]
beta-ara c
4-amino-1-b-d-arabinofuranosyl-2-(1h)-pyrimidinone
einecs 205-705-9
cytosine 1-beta-d-arabinofuranoside
1-beta-d-arabinofuranosylcytosine, cytosine arabinoside
arabinoside, cytosine
arabinofuranosyl cytidine
spongocytidine
u-19,920
arabinocytidine
aracytidine
nsc-287459
cytarabinoside
alexan
tarabine
1-.beta.-d-arabinofuranosyl-cytosine
4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
udicil
arac
2(1h)-pyrimidinone, 4-amino-1-.beta.-d-arabinofuranosyl-
arabinoside c
depocyt
depocyte
aracytine
1beta-d-arabinosylcytosine
1-beta-d-arabinofuranosyl-4-amino-2(1h)pyrimidinone
1-beta-d-arabinofuranosylcytosine
hsdb 3049
beta-d-arabinosylcytosine
ai3-52329
cytosine beta-d-arabinoside
cytarabina
arafcyt
aracytin
arabitin
cytosine beta-d-arabinofuranoside
1beta-d-arabinofuranosylcytosine
2(1h)-pyrimidinone, 4-amino-1-beta-d-arabinofuranosyl-
cytosinearabinoside
1-beta-d-arabinofaranosylcytosine
u 19920a
erpalfa
ar3 ,
cytosine, 1-beta-d-arabinosyl-
4-amino-1-beta-d-arabinofuranosyl-2(1h)-pyrimidinone
1beta-arabinofuranasylcytosine
chx 3311
ccris 913
depocyt (liposomal)
cytosine arabinofuranoside
cytosine, 1-beta-d-arabinofuranosyl-
cytosine-1-beta-d-arabinofuranoside
147-94-4
ara-c
C02961
cytosine arabinoside
CYTARABINE ,
cytosine beta-d-arabinofuranoside, crystalline, >=90% (hplc)
SR-01000075773-3
MLS000758310
smr000449317
2(1h)-pyrimidinone, 4-amino-1-y-d-arabinofuranosyl- [cas]
DB00987
NCGC00093356-03
NCGC00093356-04
HMS2090A18
HMS2051K19
C2035
NCGC00093356-05
bdbm50087289
ara-cytidine
arabinosyl cytosine
u-19920
CHEMBL803 ,
cytarabine liposome
1-(arabinofuranosyl)cytosine
A808710
BRD-K33106058-001-07-7
NCGC00093356-06
AKOS007930145
4-amino-1-((2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one
dtxsid3022877 ,
dtxcid702877
tox21_301971
NCGC00255381-01
cas-147-94-4
MLS001424023
tox21_111203
HMS2230M16
CCG-51297
cytosine-beta-arabinoside
beta-cytosine arabinoside
cytosine, beta-d-arabinoside
cytarbel
cytarabine liposome injection
beta-arabinosylcytosine
mk 8242
4-amino-1-beta-d-arabinofuranosyl-2(1h)-pyrimidinon
cytarabine [usan:usp:inn:ban:jan]
unii-04079a1rdz
4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
04079a1rdz ,
cytartbine
SL-000002
NCGC00142483-02
AM84428
S1648
AKOS015896896
gtpl4827
4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
vyxeos component cytarabine
cytarabine [who-ip]
cytarabine [ema epar]
cytarabine [usp-rs]
cytarabine [inn]
cytarabine [ep monograph]
cytarabine [usp impurity]
cytarabine [usan]
cytarabinum [who-ip latin]
cytarabine [orange book]
cytarabine [mi]
cytarabine [usp monograph]
cytarabine liposome [vandf]
cytarabine [jan]
cytarabine [hsdb]
cytarabine [vandf]
cytarabine [mart.]
cytarabine [who-dd]
HY-13605
NC00070
SCHEMBL3140
KS-5063
J-700005
J-700166
ara-cell
1-(beta-d-arabinofuranosyl)cytosine
2(1h)-pyrimidinone, 4-amino-1beta-d-arabinofuranosyl-
1-beta-d-arabinofuranosyl cytosine
1-beta-d-arabinofuranosyl-cytosine
1-beta-arabinofuranosylcytosine
SRI-10828_24
J-520199
cytarabine, european pharmacopoeia (ep) reference standard
sr-01000721860
SR-01000721860-6
cytarabine, united states pharmacopeia (usp) reference standard
cytosine beta-d-arabinofuranoside, vetec(tm) reagent grade, 90%
cytarabine, pharmaceutical secondary standard; certified reference material
cytarabine; 4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1h)-one
SR-01000075773-5
HMS3713N12
1-beta-d-arabinosyl-cytosine
cytosine, beta -d-arabinoside
beta -arabinosylcytosine
2(1h)-pyrimidinone, 4-amino-1beta -d-arabinofuranosyl-
cytosine-beta -d-arabinofuranoside
cytosine-beta -arabinoside
1-beta -d-arabinofaranosylcytosine
2(1h)-pyrimidinone, 4-amino-1- -d-arabinofuranosyl
beta -d-arabinosylcytosine
cytosine, 1-beta -d-arabinofuranosyl-
1beta -arabinofuranasylcytosine
1beta -d-arabinofuranosylcytosine
1-beta -d-arabinofuranosylcytosine
beta -cytosine arabinoside
2(1h)-pyrimidinone, 4-amino-1-beta -d-arabinofuranosyl-
1-beta -d-arabinofuranosyl-4-amino-2(1h)pyrimidinone
1beta -d-arabinosylcytosine
cytosine, 1-beta -d-arabinosyl-
SW197450-5
1-beta-d-arabinofuranosylcytosine; ara-c
Z1511499171
1-ss-d-arabinofuranosylcytosine
BCP02876
Q180983
SDCCGSBI-0050304.P002
NCGC00093356-19
SCHEMBL23152019
SCHEMBL22591193
cytosine -d-arabinofuranoside hydrochloride;cytosine arabinoside hydrochloride;ara-c hydrochloride
cytosine -d-arabinofuranoside;cytosine arabinoside;ara-c
BA164339
EN300-118320
l01bc01
arabine
citarabina (inn-spanish)
u 19,920a
cytarabine (usp impurity)
cytarabine (usp-rs)
beta-cytosine, arabinoside
1-beta-d-arabinosyl-4-amino-2(1h)pyrimidinone
1(beta-d-arabinofuranosyl)cytosine
cytarabinum (inn-latin)
u 19,920
cytarabine ocphosphate
cytarabine (usp monograph)
cytarabine (mart.)
cytarabine (usan:usp:inn:ban:jan)
wr-28453
cytarabine (ep monograph)

Excerpt	Reference	Relevance
" This drug combination was severely toxic when 3-deazauridine was administered 2 to 8 hr prior to 1-beta-D-arabinofuranosylcytosine; most mice treated in this way died within 3 days of the last treatment."	( Drug sequence-dependent toxicity and small bowel mucosal injury in mice treated with low doses of 3-deazauridine and 1-beta-D-arabinofuranosylcytosine. Jakobs, ES; Lauzon, GJ; Paterson, AR; Weinstein, WM, 1979)	0.26
" In contrast to 2'-deosyxycytidine molecular solution, which reduced all toxic manifestations and protected animals from death, the corpuscular form of the protector only the toxic effect of the antimetabolite on the intestine without affecting other toxic manifestations, the inhibition of hemopoiesis in particular."	( [Protection of the mouse digestive tract from the toxic effect of cytosine-arabinoside]. Belianchikova, NI; Bukhman, VM; Svet-Moldavskiĭ, GIa; Vyshinskaia, GIa, 1977)	0.26
" Toxic effects were evaluated with biomicroscopy, direct ophthalmoscopy, fluorophotometry, electroretinography, light, and electron microscopy."	( Toxicity of 1-(beta-D-arabinofuranosyl)cytosine after intravitreal injection in the rabbit eye. de Keizer, RJ; Diets-Ouwehand, JJ; Groen-Jansen, S; van Best, JA; Vrensen, GF, 1992)	0.28
"Cerebellar toxicity is a severe, therapy-limiting adverse reaction of cytarabine given in high doses."	( Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. Bosco, L; Bufton, MG; Faich, GA; Flynn, B; Gerstman, BB; Jolson, HM; Rinsler, SS; Simmons, WD; Stadel, BV; Williams, E, 1992)	0.28
" These drugs are often highly toxic to the host, as they have the potential to impair replication, not only in the cancer cells, but also in the normal tissues."	( Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Agur, Z; Arnon, R; Schechter, B, 1992)	0.28
" There are few reports of such toxic effects during therapy for ALL."	( Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Bowman, WP; Buchanan, GR; Jacaruso, D; Kamen, BA; Roach, ES; Rollins, N; Winick, NJ, 1992)	0.28
"This report describes these toxic effects and outlines our successful approach to the problem."	( Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Bowman, WP; Buchanan, GR; Jacaruso, D; Kamen, BA; Roach, ES; Rollins, N; Winick, NJ, 1992)	0.28
"1 to 100 microM), involved a temperature-dependent process, could not be mimicked by addition of hematopoietic growth factors, and was not related to neutralization of toxic or inhibitory substances in high-density medium."	( In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Boise, L; Grant, S; Howe, C; McCrady, C; Pettit, GR; Turner, A; Westin, E, 1991)	0.28
" Amsacrine is safe and effective therapy for patients with acute leukemia and cardiac disease."	( Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991)	0.28
" The other important adverse effect of standard-dose cytarabine is gastrointestinal toxicity, especially oral mucositis, diarrhoea, intestinal ulceration, ileus and subsequent Gram-negative septicaemia."	( The toxicity of cytarabine. Stentoft, J, )	0.13
"Acute cerebellar toxicity with ataxia and dysarthria is a well-known side effect during high-dose cytarabine therapy."	( Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Hasle, H, 1990)	0.28
" In K562 the sequence Ara-C much greater than MX was significantly more toxic (3."	( Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Büchner, T; Hiddemann, W; Krehmeier, C; Zühlsdorf, M, 1990)	0.28
" Similarly, tobramycin and amikacin were significantly less toxic than gentamicin and neomycin in this system."	( An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Botti, RE; Imperia, PS; Lass, JH; Lazarus, HM; Mack, RJ, 1989)	0.28
" It is, however, more toxic to the retina."	( Reduced toxicity of intravitreally injected liposome-encapsulated cytarabine. Khoobehi, B; Liu, KR; Niesman, MR; Peyman, GA; She, SC, 1989)	0.28
" Most of these toxic symptoms appeared 8-20 days after the first dose."	( Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia. Bagot, M; Cordonnier, C; Jais, JP; Kuentz, M; Landais, P; Oksenhendler, E; Roujeau, JC; Vernant, JP, 1989)	0.28
" The optimal toxic effect was obtained when ara-C and cis-DDP were added together."	( Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Drewinko, B; Vadi, H, 1986)	0.27
" Clinically relevant Ara-C concentrations were toxic against mitogen-stimulated blood lymphocytes."	( Effect of cytosine arabinoside on the human immunosystem: metabolism and cytotoxicity studied with mitogen-stimulated normal blood lymphocytes in vitro. Eerola, E; Veromaa, T; Vilpo, JA, 1988)	0.27
" The most severe toxic side effects on the gastrointestinal system are observed in the group that received ara-C every 6 h; no toxic death has occurred in the animals treated with 15-h or longer intervals."	( Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. Colly, LP; Peters, WG; Willemze, R, 1986)	0.27
" The toxic effects were significant and included myelosuppression, nausea, and vomiting in all patients."	( Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Burke, PJ; Donehower, RC; Karp, JE, 1986)	0.27
"The cytocidal and toxic effects of four cytotoxic drugs (CY, DDP, VCR, Ara-C) were studied using three types of ascites tumors (L 1210, JB-1, EAT) growing on three different mouse strains (B6D2F1, AKR, NMRI)."	( Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse. Maurer-Schultze, B; Schäfer, E, 1987)	0.27
" Adverse reactions were mild and reversible in all patients."	( Toxicity of high dose Ara-C in children and adolescents. Barrios, NJ; Brecher, ML; Freeman, AI; Tebbi, CK, 1987)	0.27
"The toxic and metabolic effects of cytosine arabinoside (Ara-C) were studied in vitro with normal human peripheral blood mononuclear cells."	( Effect of cytosine arabinoside on the human immunosystem: toxicity against quiescent human peripheral blood mononuclear cells in vitro. Eerola, E; Veromaa, T; Vilpo, JA, 1987)	0.27
" Except for the possible ARA-C related CNS toxicity, toxic effects were reversible."	( Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia. Gadner, H; Grümayer, ER; Panzer, S; Schmidmeier, W, 1986)	0.27
" In the absence of hepatocytes, this compound was neither toxic nor mutagenic to V79 cells, but in their presence it was highly mutagenic and extremely toxic."	( Toxicity and mutagenicity of 6 anti-cancer drugs in Chinese hamster V79 cells co-cultured with rat hepatocytes. Dickins, M; Phillips, M; Todd, N; Wright, K, )	0.13
" ADM, BLM, and cis-DDP were preferentially toxic to S, G2+M and G1 cells respectively."	( Cytotoxic effect in vivo of selected chemotherapeutic agents on synchronized murine fibrosarcoma cells. Grdina, DJ; Peters, LJ; Sigdestad, CP, 1980)	0.26
" Dose-dependent metabolism of methotrexate is unusual in that formation of the presumed toxic metabolite increases with increase in dose and is associated with a qualitative change in the pattern of drug toxicity at high compared to low doses of drug."	( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Powis, G, 1983)	0.27
" Strategies should be explored to eliminate this treatment-limiting adverse effect of potentially effective therapy."	( Ocular toxicity from high-dose cytosine arabinoside. Hansen, RM; Heuer, DK; Ritch, PS, 1983)	0.27
"Hepatotoxicity is regarded as a rare side effect of amphotericin B therapy."	( Reversible hepatotoxicity related to amphotericin B. Miller, MA, 1984)	0.27
" In addition, treatment with dipyridamole also reduced the growth inhibitory effects of cytarabine on HL-60 cells in culture and protected mice from toxic doses of this antimetabolite."	( Modulation of cytarabine uptake and toxicity by dipyridamole. Howell, SB; King, ME; Naporn, A; Young, B, 1984)	0.27
" By pairing a moderately toxic concentration of one drug with a nontoxic concentration of the other, we observed sequence-dependent differences in survival."	( Kinetic and cytotoxic effects of cytarabine and daunorubicin on cells in culture. Clarkson, BD; Doblin, J; Fried, J; Perez, AG, )	0.13
" Although the neurotoxic effects produced by different cytostatics present a different appearance and are partly of only sporadic or slight clinical importance, there is hardly a cytostatic which does not exercise a side effect on the nervous system."	( [Neurotoxic side effects of cytostatic therapy (author's transl)]. Maurach, R; Strian, F, 1981)	0.26
" Adverse prognostic factors for failure-free survival include high LDH at the time of autologous BMT, chemotherapy-refractory disease and multiple prior relapses."	( High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Andersson, B; Dimopoulos, M; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Rodriguez, M; Suki, S; Tabocoff, J; van Besien, K, 1995)	0.29
" We interpret the results as follows: ara-C kills cells in two ways: first, directly, by incorporation into DNA and chain termination; second, indirectly, by inducing the production of toxic radicals."	( Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Hu, ZB; Li, M; McCulloch, EA; Minden, MD; Miyamoto, N; Yang, GS, 1995)	0.29
" The major ocular side effect of Ara-C was corneal toxicity, with epithelial defects in 40% of eyes after 8 daily injections of 15 mg Ara-C."	( Enhancement of filtration surgery with cytosine arabinoside and reversal of toxicity with 2'-deoxycytidine. Chu, JL; Netland, PA; Shields, SR, 1994)	0.29
" All these adverse reactions were reversible."	( [Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia]. Balcar-Boroń, A; Kurylak, A; Pilecki, O; Wysocki, M, 1994)	0.29
" Neurotoxicity, a side effect associated with HDAC, has been reported in 7%-28% of patients."	( Documentation of neurotoxicity resulting from high-dose cytosine arabinoside. Holmes, W; Lundquist, DM, 1993)	0.29
" Gastrointestinal morbidity was less in the cohort treated without Ara-C; however, infectious morbidity persisted at unacceptable levels and this program was terminated as too toxic to administer."	( Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Berman, E; Gaynor, J; Gee, T; Kempin, S; Kritz, A; Little, C; Scheinberg, D; Sogoloff, H; Telford, P; Weiss, M, 1993)	0.29
" We illustrate a new statistical design strategy for monitoring both adverse and efficacy outcomes on a patient-by-patient basis in phase II and other single-arm clinical trials."	( New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. Estey, EH; Simon, RM; Thall, PF, 1996)	0.29
" In summary, the DexaBEAM/G-CSF/CBV strategy appears to be safe and effective for salvage treatment in patients with poor risk malignant lymphomas."	( Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E, 1996)	0.29
" We conclude: (1) the lower EFS and greater pulmonary and hepatic toxicity associated with increasing age indicate a need for less toxic regimens that maintain high antileukemic efficacy for older patients; (2) the high GVHD and sepsis rates seen in certain categories of patients indicate a need for careful definition of eligibility criteria for this still highly toxic treatment."	( Toxicity associated with high-dose cytosine arabinoside and total body irradiation as conditioning for allogeneic bone marrow transplantation. Graham-Pole, J; Kumar, M; Meyers, L; Miller, A; Ochoa, S; Rao, PV; Saleh, A, 1997)	0.3
" Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of > or = 2 adverse prognostic features at diagnosis or to a slow CR."	( BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B, 1997)	0.3
" In the present study, we investigated whether the tolerability of Ara-C or CBDCA, given at their least toxic circadian time, could be improved further with AcSDKP, a negative regulator of hemopoiesis, rhG-CSF or both."	( Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice. Deschamps de Paillette, E; Filipski, E; Lévi, F; Li, XM; Soulard, C, 1998)	0.3
" dose of TPA, but these adverse effects became less intense or disappeared when a lower dose of TPA was used."	( Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Cao, GS; Chang, RL; Conney, AH; Han, ZT; Liu, XJ; Newmark, HL; Sun, JZ; Tian, GF; Yang, RY; Zhu, XX, 1998)	0.3
" Doxorubicin and 4-epi-doxorubicin showed the greatest cytotoxic effect after 3 h and were also more toxic to normal bone marrow cells from donors over 40 years of age."	( Toxicity of cytostatic drugs to normal bone marrow cells in vitro. Paul, C; Sundman-Engberg, B; Tidefelt, U, 1998)	0.3
" Furthermore, CsA-treated patients had greater, and more severe, oral and intestinal mucosal toxicity, with more severe adverse events, including more cases of gram-negative bacteremia, and with a delayed hemopoietic recovery."	( Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F, 1998)	0.3
" The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting."	( Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999)	0.3
" The chemotherapy-related adverse events were monitored and correlated to SPECT and MRI."	( Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia. Bok, B; Bonnin, F; Duval, M; Elmaleh, M; Rohrlich, P; Stiévenart, JL; Véra, P; Vilmer, E, 1999)	0.3
" After high-dose ara-C (4 to 36 g/m(2)), five children had regressive neurologic signs of potential toxic origin."	( Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia. Bok, B; Bonnin, F; Duval, M; Elmaleh, M; Rohrlich, P; Stiévenart, JL; Véra, P; Vilmer, E, 1999)	0.3
" The distribution of adverse prognostic factors was comparable in the two-induction arm."	( Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001)	0.31
" The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT."	( High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E, 2001)	0.31
" The high recombinagenic activity of these two drugs suggests that--despite their therapeutic effects against cancer--a question is raised whether these drugs should be considered for adverse effects in cancer chemotherapy."	( Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster. Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML, 2002)	0.31
" Ara C was found to be toxic to cerebellar cells after potassium withdrawal at concentrations standardly used in culturing these cells (10 microM)."	( High extracellular potassium protects against the toxicity of cytosine arabinoside but is not required for the survival of cerebellar granule cells in vitro. Brown, DR; Daniels, M, 2002)	0.31
"Untreated and CCL21-pretreated mice were given doses of Ara-C that are toxic to marrow myeloid progenitors."	( The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity. Broxmeyer, HE; Cooper, S; Hromas, R, 2002)	0.31
"It was found that pretreatment with small doses of CCL21 prevented the death of normal murine marrow progenitors from the toxic effects of Ara-C."	( The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity. Broxmeyer, HE; Cooper, S; Hromas, R, 2002)	0.31
" BEAM allogeneic transplantation with early reduction in immunosuppression is safe (no treatment-related deaths) and effective in advanced Hodgkin's disease where autografts have failed."	( BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA, 2003)	0.32
"In large-scale pediatric chemo- and radiotherapy trials a proportion of patients as high as 10-15% is usually reported as having severe treatment related toxicity occasionally resulting in toxic death."	( Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Distel, L; Grabenbauer, G; Holter, W; Neubauer, S; Varon, R, 2003)	0.32
" While BEAC and BEAM appears to have equal antitumour efficacy in patients with NHL, BEAM seems to be more toxic to the gastrointestinal tract."	( BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Jantunen, E; Kuittinen, T; Nousiainen, T, 2003)	0.32
" Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab."	( Safety of rituximab therapy during the first trimester of pregnancy: a case history. Elinder, G; Kimby, E; Sverrisdottir, A, 2004)	0.32
" This regimen is a safe approach in patients < 60 years but produced severe neurotoxicity in the elderly."	( A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F, 2004)	0.32
"IDAC is a safe and effective postremission therapy for elderly patients with AML."	( A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F, 2004)	0.32
" Because araC action interferes with normal nucleoside metabolism, it is highly toxic to a number of normal cell types including bone marrow and intestinal mucosa cells."	( Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity. Cha, MC; Lin, A; Meckling, KA, 2005)	0.33
"6 fold more toxic to D/v-src than 4D/WT in cultures without added fatty acids."	( Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity. Cha, MC; Lin, A; Meckling, KA, 2005)	0.33
"Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY."	( Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Ala-Kopsala, M; Hartikainen, J; Husso-Saastamoinen, M; Jantunen, E; Kuittinen, T; Nousiainen, T; Sipola, P; Vuolteenaho, O, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"In this communication, we report an acute leukemia patient who developed conversion disorder mimicking the adverse effects of high-dose cytosine arabinoside (Ara-C) treatment after the patient received high-dose Ara-C treatment."	( Conversion disorder with convulsion and motor deficit mimicking the adverse effects of high-dose Ara-C treatment in a posttransplant acute myeloid leukemia patient: a case report and review of the literature. Ito, M; Kamijo, A; Maruta, I; Mizuno, Y; Onishi, H; Onose, M; Saito, H; Yamada, T, 2004)	0.32
" These results suggest that oridonin may be a potential antileukemia agent that targets AE oncoprotein at residue D188 with low adverse effect, and may be helpful for the treatment of patients with t(8;21) AML."	( Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Chen, J; Chen, SJ; Chen, Z; Gao, L; Gu, LJ; Kang, H; Liu, P; Shen, ZX; Wang, L; Wang, ZY; Weng, XQ; Xie, J; Yan, M; Zhang, DE; Zhang, FX; Zhou, GB, 2007)	0.34
" In the fifth patient, treatment with IT liposomal cytarabine was not continued after a single dose because of toxic cauda equina syndrome, resulting from previous intensive CNS therapy."	( Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. Benesch, M; Gadner, H; Krammer, B; Lackner, H; Mann, G; Schwinger, W; Sovinz, P; Urban, C, 2007)	0.34
"We reviewed the most recent systemic drugs used in Belgium causing toxic corneal side effects."	( [Toxic effects of medications on the cornea]. Ravet, O, 2007)	0.34
" This study indicated that induction chemotherapy which consisted of anthracycline for 3 days and cytarabine for 7 days is effective and safe for elderly patients with acute myeloid leukemia."	( [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia]. Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H, 2007)	0.34
" Current anticancer cocktails have failed to prolong survival beyond 1 year, in part owing to the natural resistance of GBM cells and to the toxic side effects of the available drugs."	( Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anderluh, G; Borges, HL; de Faria, GP; Gabilan, NH; Moura-Neto, V; Soletti, RC; Terenzi, H; Vernal, J, 2008)	0.35
" Resistance is a common reason for treatment failure with adverse side effects contributing to morbidity and mortality."	( Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Delaney, SM; Dolan, ME; Duan, S; Hartford, CM; Huang, RS; Kistner, EO; Lamba, JK; Mi, S, 2009)	0.35
" In contrast, X-ray treatment of hypoxic A549 cells containing oxo-ara-C enhanced the cytotoxic effect, indicating that toxic ara-C was preferentially released in hypoxic cells via radiolytic one-electron reduction by hydrated electrons (e(aq)(-))."	( Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Fujisawa, Y; Harada, H; Hiraoka, M; Hirata, N; Nishimoto, S; Tanabe, K, 2009)	0.35
" Liposomal cytarabine was generally well tolerated; headache was the most commonly reported adverse effect (n = 17)."	( Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Alvarez-Larran, A; Barca, EG; Deben, G; Garcia Vela, JA; Garcia, ES; Garcia-Cerecedo, T; Garcia-Marco, JA; Panizo, C; Penarrubia, MJ; Sancho, JM, 2009)	0.35
"Application of liposomal cytarabine with concomitant dexamethasone appears to be safe and well tolerated in children aged <3 years."	( Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Azizi, AA; Gruber-Olipitz, M; Gupper, A; Peyrl, A; Sauermann, R; Slavc, I; Traunmueller, F, 2009)	0.35
" Our study indicates that modified R-ESHAP is an effective and safe salvage regimen for relapsed/refractory FL, however, its efficacy for relapsed DLBCL is limited."	( Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma. Asai, T; Hangaishi, A; Imai, T; Kurokawa, M; Nannya, Y; Takahashi, T; Ueda, K; Yamamoto, G, 2010)	0.36
" In the present study, we show that GA induces actin disruption and has tumor cell-selective toxic properties, and that its selectivity is superior to those of all the clinically available antitumor agents tested."	( Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yu, T, 2010)	0.36
" In general, the most toxic compound was 5-FU."	( Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Blaha, L; Dott, W; Kovalova, L; Zounkova, R, 2010)	0.36
" The findings of the present study suggest that FLANG salvage chemotherapy is an effective regimen and that it offers a safe bridge to SCT."	( FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS, 2011)	0.37
" The most frequent side effect was grade 3/4 leukopenia."	( Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Park, K; Park, Y; Suh, C, 2012)	0.38
" Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML."	( Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Kato, J; Mori, T; Okamoto, S; Shimizu, T; Tsukada, Y; Ueda, T; Yokoyama, K, 2011)	0.37
"HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be achieved with only one or two courses."	( [The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia]. Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL, 2011)	0.37
" Though lack of difference may be attributed to the small sample size, suboptimal supportive care for intensive treatment would increase risk of toxic deaths."	( Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital. Macharia, WM, 2009)	0.35
"Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil."	( [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011)	0.37
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."	( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012)	0.38
" In conclusion, the new BeEAM regimen is safe and effective for heavily pretreated lymphoma patients."	( BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G, 2011)	0.37
"These data suggest that the CHG priming regimen is effective and safe as a novel induction therapy for elderly patients with high-risk MDS and MDS-AML."	( Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. Chang, C; He, Q; Li, X; Pu, Q; Su, J; Wu, L; Zhang, X, 2011)	0.37
" Safety was measured using the NCI classification system of common toxicity criteria for adverse events."	( [Effectiveness and safety of the FLAG-IDA regimen in acute refractory or recurrent leukaemia]. Domínguez Senín, L; Garrido Martínez, MT; Martín Chacón, E; Rodríguez Rodríguez, JN; Sánchez Argáiz, M, )	0.13
" Adverse effects were reported in 11/20 patients, but none was grade IV."	( Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement. Lassaletta, A; López-Ibor, B; Mateos, E; Molina, J; Morales, A; Moscardó, C; Navajas, A; Sábado, C; Sagaseta, M; Sastre, A, 2012)	0.38
" The major adverse effect was infection."	( [Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study]. Chen, BA; Chen, ZC; Fang, MY; He, GS; Jin, J; Liu, H; Liu, T; Ma, J; Qian, SX; Ruan, CG; Shao, ZH; Shen, ZX; Sun, AN; Wang, SY; Wu, DP; Xiao, ZJ; Xu, LP; Xu, XP, 2012)	0.38
" Thus, CAG represents a highly effective and safe salvage regimen for patients with AML who are refractory to the first induction chemotherapy."	( Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Qin, YZ; Zhang, XH; Zhu, HH, 2013)	0.39
" Stomatitis and febrile neutropenia were the most common adverse events with barasertib versus LDAC (71% vs 15% and 67% vs 19%, respectively)."	( Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Ando, K; Bay, JO; Giagounidis, A; Gröpper, S; Jabbour, EJ; Kantarjian, HM; Martinelli, G; Owen, K; Papayannidis, C; Pike, L; Quintás-Cardama, A; Schmitt, N; Stockman, PK; Wei, A, 2013)	0.39
"Barasertib produced a significant improvement in the OCRR versus LDAC and had a more toxic but manageable safety profile, consistent with previous studies."	( Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Ando, K; Bay, JO; Giagounidis, A; Gröpper, S; Jabbour, EJ; Kantarjian, HM; Martinelli, G; Owen, K; Papayannidis, C; Pike, L; Quintás-Cardama, A; Schmitt, N; Stockman, PK; Wei, A, 2013)	0.39
" The MTD was defined as the highest dose at which ≤ 1 patient within a cohort of 6 experienced a dose-limiting toxicity (DLT) (clinically significant adverse event [AE] or laboratory abnormality considered related to barasertib)."	( Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Oliver, SD; Owen, K; Ribrag, V; Rousselot, P; Sekeres, MA; Stockman, PK, 2013)	0.39
" DLTs were reported in 2 patients (both, National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 stomatitis/mucositis; 1200 mg cohort)."	( Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Oliver, SD; Owen, K; Ribrag, V; Rousselot, P; Sekeres, MA; Stockman, PK, 2013)	0.39
" In particular, patients relapsing after rituximab-containing primary treatment have an adverse prognosis, especially if this occurs within the first year after therapy or if the disease is primarily refractory."	( A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large ce Dreyling, M; Hess, G; Memmer, ML; Witzens-Harig, M, 2013)	0.39
" In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.4
"This conditioning regimen of FLAG combined with L-PAM (which did not contain BU and TBI) was associated with good outcomes and minimal late adverse effects in children with acute leukemia who have undergone allogeneic BMT from unrelated volunteer donors."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.4
" Herein, we investigate how pretreatment characteristics relate to early adverse outcomes in such patients, studying 205 consecutive individuals receiving curative-intent induction chemotherapy with cytarabine and an anthracycline ("7 + 3"; n = 175) or a "7 + 3"-like regimen (n = 30)."	( Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB, 2014)	0.4
" Elacytarabine is clinically active in relapsed/refractory AML: overall response rate (CR + CRi) was 44% (16/36 with 7 non-evaluable patients) and adverse events were manageable."	( Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Bergua, JM; Chevassut, T; Duarte, R; Gianella-Borradori, A; Hals, PA; Jacobsen, TF; Johansen, M; Knapper, S; Rasch, W; Salamero, O; Smith, M, 2014)	0.4
"In this retrospective study, a chemotherapy protocol using dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) was evaluated for efficacy and adverse event profile as a first line rescue protocol in 86 client-owned dogs previously treated with a CHOP-based protocol."	( The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. Monteith, G; Parsons-Doherty, M; Poirier, VJ, 2014)	0.4
" Recorded information regarding possible adverse events during administration while recovering from anaesthesia and during hospitalization period were evaluated."	( Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats. Cherubini, GB; Eminaga, S; Genoni, S; Palus, V, 2016)	0.43
" Decitabine was tolerated at all doses administered, and grade 3 or 4 toxic effects included non-life-threatening hepatotoxicity and hyperglycaemia."	( Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H, 2014)	0.4
" There was a statistically significantly lower rate of grades 3 and 4 gastrointestinal adverse events in the palifermin arm (21% vs."	( A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J, 2014)	0.4
" Adverse drug reactions, such as interpatient variability in sensitivity to ara-C, are considerable and may cause difficulties during chemotherapy."	( Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia. Bartyik, K; Bereczki, C; Berek, K; Endreffy, E; Erdelyi, DJ; Gabor, KM; Lautner-Csorba, O; Rarosi, F; Schermann, G; Semsei, AF; Szalai, C, 2015)	0.42
" Regimens incorporating liposomal cytarabine seem to be safe and effective treatments for lymphomas with CNS involvement."	( Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. Fornagiel, S; Giebel, S; Giza, A; Jurczak, W; Komarnicki, M; Kroll-Balcerzak, R; Kumiega, B; Machaczka, M; Ogórka, T; Rybka, J; Skotnicki, AB; Wróbel, T, 2015)	0.42
" Adverse events grade 1-4 occurred in 31 patients (60."	( Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. Behlendorf, T; Globig, C; Jahn, F; Jordan, B; Jordan, K; Müller-Tidow, C; Schmoll, HJ, 2015)	0.42
" Five patients did not complete treatments because of adverse events."	( AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Ambinder, R; Baiocchi, R; Cesarman, E; Kaplan, L; Lee, JY; Noy, A; Ratner, L; Reid, E; Wagner-Johnston, N, 2015)	0.42
"Efficacy and adverse events of patients with refractory or relapsed AML who were treated with one course of CLAG from April 1st, 2014 through December 9th, 2015 in our hospital were retrospectively reviewed."	( [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia]. Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB, 2016)	0.43
" Apart from intermittent lower extremity sensory pain in 1 liposomal cytarabine-treated patient, no permanent adverse neurological sequelae were observed."	( Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia. Abrahamsson, J; Åsberg, A; Grell, K; Harila-Saari, A; Heldrup, J; Jonsson, OG; Levinsen, M; Risteli, J; Schmiegelow, K; Taskinen, M; Vettenranta, K, 2016)	0.43
" The efficacy, adverse effects and long- term prognosis among the three groups were compared."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.43
" The adverse effects were similar in the three group, other than the lowest count of WBC (P=0."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.43
" The adverse effects were similar in the three groups."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.43
" We conclude that OP administration of BEAM conditioning is safe and may offer significant advantages, including decreased length of hospitalization, reduced costs, decreased risks for severe toxicities and infectious complications, and likely improvement in patient satisfaction and quality of life."	( Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016)	0.43
"7% of the procedures, an adverse event was reported (total number of adverse events = 61)."	( Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients. Díaz-Carrasco, MS; Espuny-Miró, A; Galera-Miñarro, A; Olmos-Jiménez, R; Pascual-Gazquez, JF, 2017)	0.46
"Nephrotoxicity is a well-known side effect of platinum-based chemotherapy."	( Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Batlle, M; Feliu, E; Ferra, C; Garcia, O; Ibarra, G; Lopez, D; Moreno, M; Pineda, A; Ribera, JM; Sancho, JM; Sorigue, M; Tapia, G; Vives, S, 2017)	0.46
"There were some adverse events in 39."	( Evaluation of standardized triple intrathecal therapy toxicity in oncohematological adult patients. Cabañas-Perianes, V; Díaz-Carrasco, MS; Espuny-Miró, A; Olmos-Jiménez, R; Valderrey-Pulido, M, 2017)	0.46
" The detection of adverse effects was significantly greater in young adults and in those administrations where the difference between cerebrospinal fluid remove volume and the administered drug was greater."	( Evaluation of standardized triple intrathecal therapy toxicity in oncohematological adult patients. Cabañas-Perianes, V; Díaz-Carrasco, MS; Espuny-Miró, A; Olmos-Jiménez, R; Valderrey-Pulido, M, 2017)	0.46
" Our preliminary results indicated that CAGLP was feasible, safe and effective as a salvage reinduction chemotherapy for primary refractory and relapsed ALL patients."	( Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia. Fang, B; Fu, Y; Liu, X; Song, Y; Wei, X; Yu, F; Zhang, Y; Zhou, H; Zhou, J; Zhou, K, 2017)	0.46
" In-hospital major adverse events occurred in one patient (0."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
"Our results provide the primary evidence that it appears to be safe and feasible to carry out the low frame rate protocol for CTO-PCI."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
" A less toxic regimen might improve the outcome of patients with lymphoma after transplantation."	( High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R, 2018)	0.48
"The occurrence of chemotherapy-related adverse cutaneous reactions in the setting of capillary leak syndrome (CLS) is quite rare."	( Chemotherapy-induced skin toxicity and capillary leak syndrome. Bridges, AG; El-Azhary, RA; Hashmi, SK; Hunjan, MK; Lehman, JS; Nowsheen, S; Ramos-Rodriguez, AJ, 2019)	0.51
"Five patients were identified, two with a diagnosis of toxic erythema of chemotherapy (TEC) and three others with a skin diagnosis of toxic epidermal necrolysis (TEN)."	( Chemotherapy-induced skin toxicity and capillary leak syndrome. Bridges, AG; El-Azhary, RA; Hashmi, SK; Hunjan, MK; Lehman, JS; Nowsheen, S; Ramos-Rodriguez, AJ, 2019)	0.51
"Although TEC is generally self-limited, both TEC and TEN can present with severe adverse skin manifestations during CLS secondary to toxicity from chemotherapy."	( Chemotherapy-induced skin toxicity and capillary leak syndrome. Bridges, AG; El-Azhary, RA; Hashmi, SK; Hunjan, MK; Lehman, JS; Nowsheen, S; Ramos-Rodriguez, AJ, 2019)	0.51
" In terms of adverse reactions, there was no statistically significant difference in the rates of myelosuppression, pulmonary infection, gastrointestinal reactions, and bleeding events between the 2 groups (P＞0."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	0.51
" As compared with control group, there was no significant difference in adverse events."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	0.51
" Gastrointestinal adverse events (GI-AEs) have not yet been reported in association with CART."	( Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Abu-Sbeih, H; Ali, FS; Curry, JL; Foo, WC; Ge, PS; Luo, W; Neelapu, SS; Okhuysen, PC; Richards, DM; Tang, T; Wang, Y; Westin, JR, 2019)	0.51
"The CHG priming regimen provided a safe and effective salvage regimen for higher risk MDS patients who were resistant to decitabine."	( The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine. Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L, 2019)	0.51
"Medical records of canine lymphoma patients with confirmed or suspected BM (group 1) or CNS (group 2) involvement, treated with a modified cyclophosphamide, epirubicin, vincristine and prednisolone protocol, including a single dose of cytarabine given as CRI, were reviewed and adverse events graded."	( Toxicity of cytarabine constant rate infusion in dogs with high-grade non-Hodgkin lymphoma with bone marrow or central nervous system involvement. Amores-Fuster, I; Blackwood, L; Finotello, R; Guillen, A; Harper, A; Killick, D; Wynne, P, 2020)	0.56
" We report a case that developed this side effect after receiving two doses of high-dose cytarabine."	( Acute cerebellar toxicity induced by high dose of cytarabine (HiDAC): A case report. Hadjibabaie, M; Radmehr, M; Rahmani, H; Solduzian, M, 2020)	0.56
" The most common serious adverse events were febrile neutropenia (19%), pneumonia (10%), and infection (8%)."	( Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. An, Q; Chiarella, M; Larson, ML; Lin, TL; Louie, AC; Roboz, GJ; Rubenstein, SE; Schiller, GJ; Solomon, SR, 2020)	0.56
" AuNPs as carriers of chemotherapeutics allow for reduced concentrations whilst maintaining the expected effect, and thus reducing the costs of therapy and adverse effects."	( Assessment of Anti-Tumor potential and safety of application of Glutathione stabilized Gold Nanoparticles conjugated with Chemotherapeutics. Barcinska, E; Inkielewicz-Stepniak, I; Sobczak, K; Steckiewicz, KP; Tomczyk, E; Wojcik, M, 2020)	0.56
" An important side effect of linezolid is linezolid-induced thrombocytopenia; so, the safety of linezolid for AML patients in myelosuppression is of concern."	( Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L, 2020)	0.56
"This retrospective clinical study suggests that it is safe to manage AML patients in complete remission during myelosuppression after standard consolidation chemotherapy with idarubicin and cytarabine, with about 7 days of linezolid therapy."	( Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L, 2020)	0.56
" The secondary outcomes included adverse events and cytogenetic risk in subgroup analyses."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.56
" When it comes to adverse drug reactions, it is not a significant difference."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.56
" The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity."	( Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. Cheng, X; Fu, C; Huang, F; Jia, X; Meng, Y; Shao, G; Wang, L; Wang, T; Wang, X; Wu, H; Yang, T, 2020)	0.56
" The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections)."	( A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L, 2021)	0.62
"BL-8040 in combination with HiDAC was safe and well tolerated at all dose levels."	( BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Abraham, M; Aharon, A; Al-Rawi, AN; Altman, JK; Andreeff, M; Bohana-Kashtan, O; Borthakur, G; Bueso-Ramos, C; Cortes, JE; DiPersio, JF; Foley-Comer, A; Foran, J; Glicko-Kabir, I; Kadosh, SE; Lustig, TM; Nagler, A; Oberkovitz, G; Ofran, Y; Peled, A; Pemmaraju, N; Pereg, Y; Rowe, JM; Samara, E; Shaw, S; Shimoni, A; Showel, MM; Sorani, E; Tallman, MS; Uy, GL; Vainstein-Haras, A, 2021)	0.62
" The secondary objectives were one-year-overall survival rate (OS) and adverse effects."	( Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients. Chai-Adisaksopha, C; Hantrakool, S; Norasetthada, L; Piriyakhuntorn, P; Rattanathammethee, T; Rattarittamrong, E; Tangchitpianvit, K; Tantiworawit, A, 2021)	0.62
"Inpatient/outpatient administration of high-dose cytarabine and intermediate-dose cytarabine is both safe and feasible."	( Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. Kubal, T; Lee, J; Li, W; McCarthy, K; Richter, K, 2022)	0.72
" Neurotoxicity is an increasingly recognized adverse effect of high-dose cytarabine therapy and occurs in 10% to 25% of patients."	( Retreatment with full-dose cytarabine in a patient with previous neurological toxicity. Casasnovas, NM; Castells, G; Manzaneque, A; Muntañola, A, 2022)	0.72
" Ten patients (25%) experienced adverse events ≥grade 3 according to RTOG toxicity criteria; in 22 patients (55%) NCI CTCAE ≥grade 3 were detected."	( Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification. Bsteh, G; Grams, A; Heugenhauser, J; Iglseder, S; Mayer, E; Muigg, A; Nevinny-Stickel, M; Nowosielski, M; Stockhammer, G, 2022)	0.72
" This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas."	( Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022)	0.72
" The most common adverse effects were febrile neutropenia (98%), mucositis (72%) and colitis (60%)."	( Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation. Boudreault, JS; Feng, X; Plante, MÉ, )	0.13
"D-CAG regimen is safe and effective in the treatment of AML patients ≥70 years old, and can partially improve the prognosis of elderly and high-risk patients."	( [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia]. Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y, 2023)	0.91
" Overall, liposomal formulations were considerably less toxic to hiPSC-CM than their free-drug counterparts."	( Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Fortin, MC; Grammatopoulos, TN; LaCroix, AS; Manca, D; Tan, L; Wang, Q, 2023)	0.91

Excerpt	Reference	Relevance
"The rationale and history of the development of physiologically based pharmacokinetic models are briefly reviewed in this paper."	( Physiologically based pharmacokinetic models for anticancer drugs. Chen, HS; Gross, JF, 1979)	0.26
" In 10 patients plasma concentration/time data were fitted to a biexponential equation and pharmacokinetic parameters were estimated from the coefficient and exponents of such equations."	( Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. Haanen, C; van der Kleijn, E; van Prooijen, R, 1977)	0.26
"The general basis of pharmacokinetics are summarized with the clinical aims of a better utilisation of drugs by the application pharmacokinetic data."	( [Pharmacokinetics of antineoplastic agents (author's transl)]. Cano, JP; Carcassonne, Y; Meyer, G, 1979)	0.26
" Pharmacokinetic calculations indicate that such drugs administered ip in large volumes are expected to maintain a significantly greater concentration in the peritoneal space than in the plasma."	( Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Bungay, PM; Dedrick, RL; DeVita, VT; Myers, CE, 1978)	0.26
" Preclinical data reveal a relationship between therapeutic response and certain pharmacokinetic parameters such as time of effective cytotoxic exposure (Teff) and the product of concentration with time (Cxt)."	( Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: a comceptual approach. Broder, LE; Carbone, PP, 1976)	0.26
"This paper presents a theoretic study of pharmacokinetic and cell kinetic models for cancer chemotherapeutic systems."	( Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations. Chuang, S, )	0.13
" The pharmacokinetic behavior of dFdC was compared with that of sera-C or BH-AC (N4-behenoyl ara-C) using experimental animals."	( [Pharmacokinetic studies of dFdC (2',2'-difluorodeoxycytidine), ara-C and BH-AC (N4-behenoyl ara-C) in experimental animals]. Fujita, H; Okamoto, M, 1992)	0.28
" The corresponding cytotoxicities were measured, and then applied to the pharmacodynamic model."	( Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs. Cuddy, DP; de Valeriola, DL; Egorin, MJ; Forrest, A; Ross, DD, 1991)	0.28
" Pharmacokinetic parameters of BHAC in uremia were not different from that in patients with normal renal function, and hemodialysis did not affect on the plasma level of BHAC."	( [Pharmacokinetics of BHAC, VP-16 and Ara-C derived from BHAC in a hemodialysed patient with AMMoL]. Kaito, K; Katayama, T; Kobayashi, M; Masuoka, H; Nishiwaki, K; Ochiai, S; Saito, A; Shimada, T; Watanabe, R; Yoshida, M, 1991)	0.28
" The prime determinants of ara-C effect then shift to multiple intracellular events including anabolism to nucleotides, catabolism via deamination by Cyd-dCyd deaminase and dCMP deaminase, half-life of ara-CTP, the extent of incorporation into DNA, and the half-life of ara-CMP residues in DNA."	( Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Capizzi, RL; Perrino, F; Powell, BL; White, JC, 1991)	0.28
" Pharmacokinetic study revealed high peaks of Ara-C concentration in plasma (6."	( [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]. Domae, N; Fukushima, T; Kagawa, D; Kamiya, K; Nakamura, T; Tsutani, H; Uchida, M; Ueda, T; Yoshida, W, 1990)	0.28
" The risk for a drug interaction under these conditions is high, and the pharmacological characteristics of the anti-cancer drugs, such as steep dose-response curves, low therapeutic indices and severe toxicities, suggest that even small changes in the pharmacokinetic profile of the affected drug could significantly alter its toxicity or efficacy."	( Pharmacokinetic drug interactions of commonly used anticancer drugs. Balis, FM, )	0.13
" This results in a decrease in ara-C catabolism and prolongs the plasma half-life of ara-C."	( Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. Capizzi, RL; Chandrasekaran, B; Dimling, J; Kute, TE; Morgan, T, 1989)	0.28
" All pharmacokinetic parameters in plasma and white cells did not correlate with response to therapy."	( Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuijt, K, 1987)	0.27
" The plasma concentration curve of BH-AC showed a biphasic curve."	( [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. Hirai, J; Ito, K; Kanno, M; Kobayashi, K; Matsuda, T; Nakamura, S; Ohtake, S; Tachimori, K; Yoshida, T, 1987)	0.27
" In contrast to ara-C triphosphate, dFdCTP is eliminated with biphasic kinetics that exhibit a terminal half-life that approaches the cell cycle time."	( Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells. Grindey, GB; Plunkett, W, 1987)	0.27
"The pharmacokinetic parameters of low dose 1-beta-D-arabinofuranosylcytosine (ara-C) infusions were studied in 11 patients, 6 males and 5 females, with a mean age of 68."	( Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Allen, S; Budman, DR; Chan, K; Chaudhri, F; Deere, M; Freeman, J; Kreis, W; Schulman, P; Vinciguerra, V; Weiselberg, L, 1985)	0.27
" Pharmacokinetic studies, however, have indicated potentially effective concentrations of Ara-C in cerebrospinal fluid (CSF) during and after high-dose infusions of the drug given intravenously."	( [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics]. Anders, C; Miller, AA; Nowrousian, MR; Ohl, S; Schmidt, CG; Seeber, S, 1985)	0.27
" Although the pharmacokinetic behaviour of these drugs has been adequately described in man, the chemical reactivity, the complexity of metabolism and disposition, the lack of simple, rapid and sensitive assays to measure plasma concentration, and the lack of defined therapeutic and toxic plasma concentrations have limited the application of routine drug monitoring in clinical oncology."	( Clinical pharmacokinetics of commonly used anticancer drugs. Balis, FM; Bleyer, WA; Holcenberg, JS, )	0.13
" By considering these pharmacokinetic behaviors, a suitable method of administration should be established."	( [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics]. Fujita, H, 1984)	0.27
"9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10."	( [Pharmacokinetics of intrathecal chemotherapy and clinical problems]. Fujimoto, T, 1984)	0.27
" Three hours after completion of the intravenous infusion the CSF concentrations were greater than the corresponding plasma concentrations owing to the long half-life of ara-C in CSF compared to that in plasma."	( Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. Aherne, GW; Harvey, VJ; Johnston, A; Lister, TA; Piall, EM; Slevin, ML, 1983)	0.27
" Pharmacokinetic data from fluorescence plasma assays suggest no difference among patients with normal or mildly abnormal liver function studies receiving full doxorubicin doses."	( Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Bachur, NR; Brenner, DE; Wesley, M; Wiernik, PH, 1984)	0.27
" It may be possible to use such information in pharmacokinetic models that incorporate existing knowledge and judgment to predict pharmacokinetics in intact animals including man."	( Species similarities in pharmacokinetics. Bischoff, KB; Dedrick, RL, 1980)	0.26
" Cytarabine distribution was bi- or tri-compartmental; plasma final half-life was greater than 4 hrs in six patients."	( High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics. Marie, JP; Pochat, L; Pommier, Y; Zittoun, RA, 1983)	0.27
" The results are discussed in relation to the pharmacokinetic availability of drugs in the plasma compartment of patients treated by different therapuetic regimens."	( Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity. Balconi, G; D'Incalci, M; Erba, E; Garattini, S; Morasca, L; Ottolenghi, L; Salmona, A, 1980)	0.26
" There was a large interpatient variability of the area under the time versus concentration curve (AUC) for all three drugs."	( Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1995)	0.29
" During a phase I study in patients with advanced low-grade non-Hodgkin lymphomas or acute myeloid leukemia, the pharmacokinetic parameters of Ara-CMP-Stearate (kindly provided by ASTA Medica, Frankfurt, Germany) were determined by HPLC analysis."	( Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative. Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S, 1995)	0.29
" Ventricular and lumbar pharmacokinetic studies were done following intralumbar administration of DTC-101, an extended-release formulation of cytarabine."	( Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Chamberlain, MC; Howell, SB; Kim, S; Kormanik, P, 1995)	0.29
" Eight patients who were treated with 14 courses underwent pharmacokinetic CSF sampling from the lumbar sac and lateral ventricle."	( Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Chamberlain, MC; Howell, SB; Kim, S; Kormanik, P, 1995)	0.29
" Pharmacokinetic analysis revealed that their uptake rates were sufficiently large for selective drug targeting."	( Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Fujita, T; Hashida, M; Kamijo, A; Nishikawa, M; Sezaki, H; Takakura, Y, 1993)	0.29
" Validity for our method was supported by the successful assay of over 400 pediatric plasma and 50 CSF samples for pharmacokinetic analysis."	( Alkylsulphonic acid ion pairing with radial compression columns for determining plasma or cerebrospinal fluid 1-beta-D-arabinofuranosylcytosine in pediatric pharmacokinetic analysis. Ravindranath, Y; Stout, ML, 1995)	0.29
" The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59."	( Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F, 1995)	0.29
" Pharmacokinetic monitoring showed an increase of the Ara-C plasma levels up to twice the steady-state level within 10 minutes after discontinuation of the Ara-C infusion."	( Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report. Bömelburg, T; Boos, J; Gerding, H; Jürgens, H, 1993)	0.29
" No significant changes in mean mitoxantrone plasma elimination rates (ie, terminal plasma half-life and total-body clearance rate) occurred as the mitoxantrone dose doubled, indicating linear pharmacokinetics."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.29
" Pharmacokinetic and pharmacodynamic interactions between CdA and ara-C during therapy were investigated."	( Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Chucrallah, A; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W, 1996)	0.29
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
" The drug was administered intravenously and orally to ICR mice to assess its pharmacokinetic parameters in plasma and whole blood."	( Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. Hänseler, E; Rentsch, KM; Schott, H; Schwendener, RA, 1997)	0.3
"Cytarabine is intracellularly activated and correlations have been established between the pharmacokinetic behaviour of active metabolites and their antileukemic effect."	( Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal. Arning, M; Burk, M; Fartash, K; Heyll, A; Schneider, W; Volmer, M, 1997)	0.3
" Pharmacokinetic and pharmacodynamic studies were performed on specimens from 20 patients."	( Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S, 1998)	0.3
" Furthermore, a method for pharmacodynamic modeling is introduced that permits a quantitative approach for the assessment of the sensitivity of tumor cells to anticancer drugs and combined treatments."	( Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Guchelaar, HJ; Haanen, C; Koopmans, RP; Reutelingsperger, CP; Vermes, I, 1998)	0.3
" From all of pharmacokinetic data, the oral administration of SPAC at 150 to 300 mg/m2/day was pharmacokinetically concluded to be comparable to the continuous infusion of ara-C at 20 mg/m2/day."	( [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies]. Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y, 1998)	0.3
" The half-life of ACNU was very short (0."	( Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. Abe, T; Fujiki, M; Hori, S; Kaku, T; Kawashima, H; Konisi, Y; Mori, T; Morikawa, N; Takeyama, M, 1998)	0.3
" Pharmacokinetic evaluations were performed during 34 treatment cycles in 28 patients."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3
"An in vitro pharmacokinetic simulation system that can simulate plasma pharmacokinetics was established to evaluate the cytotoxicity of two representative antileukemic agents, 1-beta-D-arabinofuranosylcytosine (ara-C) and daunorubicin."	( Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Goto, N; Kishi, S; Nakamura, T; Ueda, T, 1999)	0.3
" The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future."	( In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999)	0.3
" Nine patients were evaluable clinically, and seven patients underwent testing to determine the pharmacokinetic profile of Ara-C in the cerebrospinal fluid (CSF)."	( Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Esteva, FJ; Forman, AD; Holmes, FA; Hortobagyi, GN; Meyers, CA; Plunkett, W; Soh, LT, 2000)	0.31
" Using a pharmacodynamic (PD) approach, the authors examined the validity of this model for patients with acute myeloid leukemia (AML) undergoing dose-intensive postinduction chemotherapy (HDT)."	( Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. Bernstein, SH; Jusko, WJ; Krzyzanski, W; Nichol, J; Wetzler, M, 2002)	0.31
" This rapid deamination is the reason for the ongoing search for effective formulations and derivatives of cytarabine that cannot be deaminated and exhibit better pharmacokinetic parameters."	( Clinical pharmacokinetics of cytarabine formulations. Hamada, A; Kawaguchi, T; Nakano, M, 2002)	0.31
" Pharmacokinetic studies in the phase I trial revealed marked heterogeneity in peak levels of clofarabine among patients at the end of infusion, however; there was a linear, dose dependent increase in clofarabine concentration in the plasma."	( Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W, 2004)	0.32
"Ara-C water solution was taken as reference, the concentration of Ara-C was determined by HPLC, and the pharmacokinetic parameters were calculated."	( [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits]. He, L; Jiang, XH; Li, CR; Yang, JY; Zhou, J, 2006)	0.33
"To evaluate the pharmacokinetic characteristics of L-valyl-ara-C, a peptidomimetic prodrug of ara-C."	( Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C. Cheon, EP; Han, HK, 2007)	0.34
" Plasma pharmacokinetic profiles of ara-C and L-valyl-ara-C were also evaluated in rats."	( Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C. Cheon, EP; Han, HK, 2007)	0.34
" An open phase II pharmacokinetic and clinical study was performed to evaluate antileukemic efficacy, IDA pharmacokinetics and to investigate the presence of IDA and its reduced metabolite idarubicinol (IDAol) in cerebrospinal fluid (CSF) of patients treated with HD-IDA."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.34
" The mean terminal half-life measured for IDA in this group of patients (14."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.34
" Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.34
" A pharmacokinetic model was developed to assess the disposition of the coencapsulated drugs in mice, including the free and encapsulated fractions after measurement of the total plasma concentrations."	( Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. Bayne, WF; Mayer, LD; Swenson, CE, 2009)	0.35
" Although there is an urgent need for new treatment options for infants with leptomeningeal dissemination of a malignant brain tumour, there are no clinical and pharmacokinetic data available on this drug for children aged <3 years."	( Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Azizi, AA; Gruber-Olipitz, M; Gupper, A; Peyrl, A; Sauermann, R; Slavc, I; Traunmueller, F, 2009)	0.35
" Noncompartmental pharmacokinetic analysis of CSF and plasma was performed."	( Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Azizi, AA; Gruber-Olipitz, M; Gupper, A; Peyrl, A; Sauermann, R; Slavc, I; Traunmueller, F, 2009)	0.35
" After intralumbar administration, the elimination half-life of free cytarabine, measured in the ventricular CSF during two courses in one patient, was significantly shorter (32."	( Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Azizi, AA; Gruber-Olipitz, M; Gupper, A; Peyrl, A; Sauermann, R; Slavc, I; Traunmueller, F, 2009)	0.35
"We included 55 patients with PCNSL and available pharmacokinetic (PK) data from the International Extranodal Lymphoma Study Group (IELSG) no."	( Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Cavalli, F; Cerny, T; Ferreri, AJ; Huitema, AD; Joerger, M; Krähenbühl, S; Reni, M; Schellens, JH; Zucca, E, 2010)	0.36
" Ara-C and its metabolite Ara-U in plasma and dialyzate were measured chromatographically, and the data subjected to pharmacokinetic analysis."	( Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. Cain, M; Cull, GM; Hackett, LP; Ilett, KF; Radeski, D, 2011)	0.37
" We show the feasibility of real-time, direct pharmacodynamic monitoring by flow cytometry during clinical trials combining intensive chemotherapy and signal transduction inhibitors."	( Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D, 2012)	0.38
" Pharmacokinetic parameters were dose-independent and exhibited low inter-patient variability."	( Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Chiarella, MT; Feldman, EJ; Kolitz, JE; Lancet, JE; Liboiron, BD; Louie, AC; Mayer, LD; Swenson, CE; Trang, JM, 2012)	0.38
" Pharmacokinetic parameters were estimated using the best-fit compartmental analysis for both CRI and SC routes."	( The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. Crook, KI; Early, PJ; Gallagher, R; Messenger, KM; Muñana, KR; Papich, MG, 2013)	0.39
" The present study was designed to prospectively collect pharmacokinetic and safety data on age-adapted intrathecal liposomal cytarabine in children aged >3 years."	( Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. Azizi, AA; Chocholous, M; Höferl, M; Jäger, W; Peyrl, A; Sauermann, R; Slavc, I, 2014)	0.4
"The average elimination half-life values in children aged 3-10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40."	( Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. Azizi, AA; Chocholous, M; Höferl, M; Jäger, W; Peyrl, A; Sauermann, R; Slavc, I, 2014)	0.4
"Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses."	( Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B, 2015)	0.42
" Much attention has focussed on pharmacokinetic interactions attributable to effects on hepatic microsomal enzymes, but not on competition for the renal organic anion transport system."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
" MTX elimination half-life was correlated with age, renal function and antiretroviral regimen."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
" The median MTX elimination half-life was 21."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
"Although there is potential competition for active renal tubular transporters between MTX and tenofovir, no prolongation of MTX half-life was observed."	( The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. Bendle, M; Boffito, M; Bower, M; Dalla Pria, A; Ramaswami, R, 2016)	0.43
" Finally, volasertib and cytarabine did not influence the pharmacokinetic characteristics of each other."	( Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF, 2018)	0.48
" None of the evaluated covariates had a clinically significant impact on plasma exposure to total cytarabine or daunorubicin, while bilirubin and formulation showed statistically significant effects on pharmacokinetic parameters of cytarabine and daunorubicin, respectively."	( Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies. Banerjee, K; Gibbons, JA; Marier, JF; Vasilinin, G; Wang, Q, 2019)	0.51
" The quantitative determination of Ara-C in plasma is challenging due the required sensitivity because of the short half-life of this drug (i."	( Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. Berda-Haddad, Y; Ciccolini, J; Costello, R; Donnette, M; Fanciullino, R; Farnault, L; Giocanti, M; Hau, LTT; Lacarelle, B; Ouafik, L; Solas, C; Venton, G, 2019)	0.51
"Provide pharmacokinetic data for orally administered CO and determine accumulation and functional consequences of Ara-CTP within peripheral blood leukocytes."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13

Excerpt	Reference	Relevance
"Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia."	( Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine. Bodey, GP; Freireich, EM; McCredie, KB; Whitecar, JP, 1976)	0.26
"Three hundred twenty-six patients with acute myelocytic leukemia were randomly and prospectively assigned to four therapeutic regimens: cytosine arabinoside either alone or in combination with daunorubicin, 6-mercaptopurine, or 6-thioguanine."	( Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL, 1975)	0.25
"Streptococcal preparation (OK-432), a new type of anti-cancer agent, was given to the patients with advanced cancer in combination with Mitomycin-C, 5-FU and Cytosine arabinoside."	( Clinical studies on streptococcal preparation (OK-432) combined with mitomycin-C, 5-FU and cytosine arabinoside in advanced cancer patients. Hattori, T; Nimoto, M; Tohge, T; Yamagata, S, 1975)	0.25
" Together, our studies show that GM-CSF can safely be administered to AML patients in combination with induction chemotherapy to recruit leukemic cells into the cell cycle."	( Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Andreeff, M; Bettelheim, P; Geissler, K; Lechner, K; Schulz, G; Sillaber, C; Tafuri, A; Valent, P; Vieder, L, 1992)	0.28
" Hematopoietic growth factors synergize with inhibitors of DNA synthesis given at low doses to induce a more mature phenotype or to enhance leukemia cell kill when combined with high doses of DNA inhibitors."	( Hematopoietins in combination with 1-beta-D-arabinofuranosylcytosine: a possible strategy for improved treatment of myeloid disorders. Brach, MA; Herrmann, F; Mertelsmann, RH, 1992)	0.28
"A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients."	( A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS, 1992)	0.28
"Forty-three patients with advanced malignant lymphoma resistant to previous chemotherapy were randomized in two groups: one received a high dose versus a low-dose cytosine arabinoside, in combination with dexamethasone and cisplatinum."	( [Comparative study of high doses vs conventional doses of cytosine arabinoside combined with cisplatin and dexamethasone in patients with refractory lymphoma]. Avilés, A; Díaz-Maqueo, JC; García, EL; Guzmán, R; Poot, JJ; Talavera, A, )	0.13
" rhGM-CSF (250 micrograms/m2/d, continuous intravenous infusion) was administered in 18 pts suffering from de novo AML in combination with standard induction chemotherapy (3 + 7 = daunorubicin 45 mg/m2 days 1 through 3, cytosine-arabinoside [Ara-C] 200 mg/m2 continuous infusion days 1 through 7)."	( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Andreeff, M; Bettelheim, P; Gorischek, C; Haas, O; Haimi, J; Muhm, M; Sillaber, C; Tafuri, A; Valent, P; Vieder, L, 1991)	0.28
"63 evaluable patients with myelodysplastic syndromes (MDS) and 15 with acute myelogenous leukemia (AML) were randomized between low-dose ara-C (arm A) and low dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3) (arm B)."	( Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Billström, R; Carneskog, J; Grimfors, G; Hellström, E; Kimby, E; Lindemalm, C; Oberg, G; Robèrt, KH; Samuelsson, J; Winqvist, I, 1990)	0.28
"This study observed the effect of chemotherapy combined with Chinese herbs and western drugs on white blood cell count in 31 patients with gastric cancer."	( [Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients]. Chen, JZ, 1990)	0.28
" From 1980 to 1982, 96 patients with SCLC were treated, 37 of whom by chemotherapy combined with surgery."	( [Chemotherapy combined with selective resection in small cell lung cancer--analysis of 239 patients]. Cao, YF; Chen, YR; Fang, MS; Huang, OL; Liao, ML; Wu, SC; Wu, SF; Wu, SZ; Xu, CW; Yang, XF, 1986)	0.27
"We conducted a Phase I-II trial of 4-demethoxydaunorubicin (idarubicin, IDR) in combination with 1-beta-D-arabinofuranosylcytosine (ara-C) in 51 patients with relapsed or refractory acute nonlymphocytic leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia in blast crisis."	( 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Arlin, ZA; Berman, E; Clarkson, BD; Daghestani, A; Gee, TS; Hancock, C; Kempin, S; Raymond, V; Stevens, YW; Williams, L, 1989)	0.28
" Further investigation of this drug combination in untreated patients with ANLL is warranted."	( Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989)	0.28
"A study was made of the effect of two-hour treatment of Chinese hamster cells with cytosine arabinoside (AraC) combined with hydroxyurea (HU) at the G1 phase of the cell cycle on lethal and mutagenic effects of X-radiation (50 to 400 cGy)."	( [Mutations of resistance to 6-thioguanine following roentgen irradiation and subsequent treatment with cytosine arabinoside combined with hydroxyurea in Chinese hamster cells in the G1 phase]. Elisova, TV; Feoktistova, TP; Stavrakova, NM, )	0.13
"Between 1984 and 1987 14 patients with acute non-lymphocytic leukemia were treated with sequential high-dose cytosine arabinoside in combination with asparaginase."	( [Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia]. Daus, H; Pees, HW; Radtke, H; Schwamborn, J; Thumser, B, 1988)	0.27
" Since it was suggested that Harr could induce leukemic cells to differentiate and Ara-C might be a weak inducer of leukemic cell differentiation, we investigated the effect of Harr in combination with Ara-C on inducing differentiation of leukemic cells."	( A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine. Deng, ML; Guo, RJ; Huang, CL; Liang, YM; Liu, FZ; Qiao, QD; Wu, MT, 1988)	0.27
"The effects of vincristine (VCR) in combination with methotrexate (MTX) and other antitumor agents were evaluated by cell growth inhibition assay using a human acute lymphoblastic leukemia cell line (MOLT-3)."	( Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Holland, JF; Kano, Y; Ohnuma, T; Okano, T, 1988)	0.27
"The effect of retinoic acid (RA) alone and in combination with cytosine arabinoside (Ara-C) on differentiation of fresh human myeloid leukaemic cells from patients with AML was studied."	( Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells. Hassan, HT; Rees, JK, )	0.13
" We treated nine patients (6 with MDS, 3 with AML) with 13-cis-retinoic acid (up to 100 mg/m2/day) in combination with either 6-thioguanine (20-40 mg/day in 14-57 day courses) or with vincristine (1-2 mg as a single injection during a four-day course of RET)."	( Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations. Berney, JJ; Francis, GE; Guimaraes, JE; Hamblin, TJ; Knowles, SM; Mufti, GJ; Secker-Walker, LM, 1987)	0.27
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)."	( Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987)	0.27
"Etoposide combined with cytarabine, doxorubicin, and 6-thioguanine was used to treat 34 patients with acute nonlymphoblastic leukemia (ANLL) in an age-adjusted protocol, with patients greater than 50 years old receiving fewer days of therapy."	( Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age. Anderson, NR; Arkin, CF; Bern, MM; Corkery, JC; Huberman, MS; Lokich, JJ; Paul, SD; Phillips, DF; Sonneborn, HA; Wallach, SR, 1987)	0.27
" These observations suggest that high-dose Ara-C combined with L-asparaginase should be added to the treatment of leukemia which is refractory to conventional chemotherapy."	( [Complete remission obtained in refractory acute lymphocytic leukemia using high-dose cytosine arabinoside combined with low-dose L-asparaginase]. Haruyama, H; Ijichi, H; Inagaki, C; Isemura, T; Ito, K; Nakagawa, M; Nishio, A; Omori, I; Shimazaki, C, 1985)	0.27
"The cytotoxicity of vincristine (VCR), beta-cytosine arabinoside (Ara-C), or adriamycin (ADRIA) in combination with 5-azacytidine (Aza-CR) to L1210 leukemia in vivo was measured to determine if schedule-dependent synergistic or antagonistic drug interaction occurred."	( Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. Coulter, DM; Presant, CA; Valeriote, F; Vietti, TJ, 1981)	0.26
"The anti-tumor effect of twice a week instillation of 30 mg mitomycin C combined with 200 mg cytosine arabinoside dissolved in 30 ml saline was studied in 37 bladder tumor patients."	( [Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside]. Fujioka, H; Matsuda, M; Matsumiya, K; Nakano, E; Osafune, M; Sonoda, T; Tada, Y; Takaha, M, 1984)	0.27
"The use of the aqueous extracts of Eleutherococcus senticosus in combination with either cytarabine or N6-(delta 2-isopentenyl)-adenosine gave additive antiproliferative effects against L1210 murine leukemia."	( Cytotoxic effects of Eleutherococcus senticosus aqueous extracts in combination with N6-(delta 2-isopentenyl)-adenosine and 1-beta-D-arabinofuranosylcytosine against L1210 leukemia cells. Hacker, B; Medon, PJ, 1984)	0.27
"In a prospective randomized study, 53 patients with advanced gastric cancer previously untreated by chemotherapy were randomly assigned to treatment with 5-FU alone or combined with mitomycin and cytarabine (MFC)."	( Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cocconi, G; DeLisi, V; Di Blasio, B, 1982)	0.26
"In a twelve-month period, 56 consecutive patients with acute leukemia, aged 15-50, were treated by administration of a 10-day continuous infusion of Ara-C in combination with adriamycin, oncovin and prednisone (10 day ADOAP)."	( Adriamycin combined with 10-day Ara-C, vincristine, and prednisone (10-day ADOAP) in the treatment of adult acute leukemia patients under fifty years of age. A Southwest Oncology Group Study. Amare, M; Morrison, FS; Oishi, N; Pendleton, O; Saiki, JH; Schreiter, SL; Stuckey, WJ; Vial, R, 1982)	0.26
"In an 18-month period, 340 consecutive adult patients with acute leukemia were treated using a 7-day continuous infusion of Ara-C in combination with rubidazone, vincristine and prednisone (ROAP)."	( Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study. Amare, M; Balcerzak, S; Benjamin, R; Costanzi, JJ; Hussein, K; Morrison, FS; Pendleton, OJ; Ryan, DH, 1982)	0.26
" In this study, maturation and proliferation of fresh APL cells were examined when induced in vitro by granulocyte or granulocyte/macrophage colony-stimulating factors (G-CSF or GM-CSF) in combination with ATRA."	( Potentiated maturation with a high proliferating activity of acute promyelocytic leukemia induced in vitro by granulocyte or granulocyte/macrophage colony-stimulating factors in combination with all-trans retinoic acid. Endo, K; Ichinohasama, R; Imaizumi, M; Inoue, S; Koizumi, Y; Sato, A; Sawai, T; Suwabe, N; Suzuki, H; Yoshinari, M, 1994)	0.29
" A second relapse occurred in May, 1994, and intermittent-dose ara-C/mitoxantrone, combined with granulocyte colony-stimulating factor (G-CSF), led to a third remission."	( [Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia]. Anzai, S; Fujimaki, K; Fujisawa, S; Fukawa, H; Hattori, M; Motomura, S; Okubo, T, 1995)	0.29
" Since most clinical regimens for tumor therapy consist of several drugs, we investigated the antineoplastic action of Ado in combination with 5-aza-2'-deoxycytidine (5-Aza-CdR), a potent inhibitor of DNA methylation or cytosine arabinoside (Ara-C), a potent inhibitor of DNA synthesis."	( Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Côté, S; Momparler, RL, 1993)	0.29
"Because recombinant human granulocyte colony-stimulating factor (G-CSF) has been reported to increase the sensitivity of acute myelogenous leukemia (AML) blast cells to cytosine arabinoside (Ara-C) in vitro, we treated a patient with refractory AML with an Ara-C-based regimen in combination with G-CSF (G-CSF/Ara-C therapy)."	( Recombinant human granulocyte colony-stimulating factor in combination with continuous infusion of cytosine arabinoside for the treatment of refractory acute myelogenous leukemia. Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Ohkawa, K; Oku, N; Shimazaki, C, 1993)	0.29
" MDS-AML patients in this pilot study did respond better, and with minimal toxicity, when standard induction chemotherapy was given in combination with rhGM-CSF."	( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Bernell, P; Hast, R; Kimby, E, 1994)	0.29
" We treated a patient with acute myelogenous leukemia (AML) in a state of second resistant relapse, with high-dose chemoradiotherapy combined with rhGM-CSF (total body irradiation: TBI 3Gy x 4, on days -8 & -7; cytosine arabinoside: Ara-C 3g/m2, iv, q12h, on days -5-2; rhGM-CSF 250 micrograms/m2/day, cont."	( [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)]. Aoki, Y; Inoue, T; Irie, S; Kikuno, K; Okamoto, S; Shimane, M; Takada, M; Takahashi, S; Tanosaki, R; Tojo, A, 1993)	0.29
"Sixteen patients with intracerebral tumors received intraarterial cisplatin, teniposide, and BCNU combined with intravenous cisplatin, teniposide, and cytosine arabinoside."	( Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. Belanger, G; Benoit, B; DaSilva, V; Grahovac, Z; Hugenholtz, H; Richard, MT; Russell, N; Stewart, DJ, 1993)	0.29
" At our institution, we are currently testing the efficacy and toxicity of regimens in which cytarabine or diaziquone are administered in combination with Bu and Cy."	( New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide. Devine, SM; Geller, RB; Holland, HK; Saral, R; Wingard, JR, 1993)	0.29
"To determine the maximally tolerated dose of mitoxantrone in combination with cytarabine in patients with acute leukemia and advanced phases of chronic myelogenous leukemia (CML), and to assess the pharmacokinetics of high-dose mitoxantrone in this patient population."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.29
" Mitoxantrone pharmacokinetics were evaluated by high-performance liquid chromatography (HPLC) in 15 patients given a single dose of mitoxantrone ranging from 40 to 80 mg/m2 in combination with cytarabine."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.29
"The recommended phase II dose of mitoxantrone is 80 mg/m2 administered over 15 minutes as a single intravenous infusion in combination with cytarabine 3 g/m2/d for 5 days."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.29
"193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate dose cytosine arabinoside (AraC) both combined with mitoxantrone (mitox) according to the previously established sequential HD-AraC/mitox regimen (S-HAM)."	( High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R, 1993)	0.29
" When combined with Cytarabine, Idarubicin increased the incidence and severity of gastrointestinal symptoms."	( [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group]. Kimura, K; Masaoka, T; Ogawa, M; Yamada, K, 1993)	0.29
"The antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) on leukemia were studied."	( [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice]. Kiyota, T; Kuriyama, H; Watanabe, A, 1996)	0.29
" We conclude that idarubicin in combination with cytarabine and etoposide is a highly effective regimen for induction in children with AML."	( Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Chantada, G; Cygler, AM; Felice, MS; Gallego, M; Rossi, J; Sackmann-Muriel, F; Zubizarreta, P, )	0.13
" If it is possible to induce apoptosis in tumor cells effectively by anticancer drugs in combination with IgM-anti-Fas MoAb, then we may be able to develop a new strategy for cancer chemotherapy."	( Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Matsuda, T; Nakamura, S; Nakamura, Y; Ohtake, S; Takeshima, M, )	0.13
" As a single agent, it resulted in effectively controlling leukocytosis and in producing sporadic karyotypic conversions; its clinical use in combination with interferon (IFN-alpha) for the treatment of CML could thus be considered."	( Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G, 1997)	0.3
"The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in children with relapsed or refractory leukemia."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	0.3
"A dose of idarubicin 12 mg/m2/d for 3 days given in combination with fludarabine and cytarabine was tolerated."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	0.3
" The drug induced functional and morphologic differentiation of myeloid leukemia cells in combination with 2'-deoxyadenosine (dAd), but not dCF alone."	( Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine. Honma, Y; Niitsu, N; Umeda, M, 1997)	0.3
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."	( A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E, )	0.13
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."	( A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E, )	0.13
" Eighteen adult patients with relapsed/refractory ALL were treated on a phase I study of high-dose cytarabine combined with a single escalating dose of idarubicin."	( A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Drullinsky, P; Golde, DW; Maslak, P; Scheinberg, D; Weiss, MA, 1998)	0.3
"Combinations of nucleoside analog drugs, such as F-araA and ara-C, combined with Topoisomerase II inhibitors, such as anthracyclines, are synergistic against human leukemic T-cells and induce apoptotic cell death."	( Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Avramis, VI; Cohen, LJ; Danenberg, P; Kwock, R; Mukherjee, SK; Nandy, P; Solorzano, MM, )	0.13
" However, when SK&F 107647 was administered in combination with low doses of amphotericin B, there was a significant reduction in organism burden in the lungs, liver, spleen, and kidneys compared with the burdens in the organs of untreated control animals and in the lungs and kidneys compared with the burdens in the lungs and kidneys of animals treated with amphotericin B alone."	( Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits. Gonzalez, C; Lee, J; Lyman, CA; Schneider, M; Walsh, TJ, 1999)	0.3
"To determine the safety and efficacy of the combination of idarubicin, cytarabine and etoposide ("ICE") for induction and consolidation treatment of acute myeloid leukemia (AML), and of dose-intensification of cytarabine in this setting, 54 previously untreated patients in three cohorts were studied by sequential dose escalation of cytarabine, in combination with standard doses of idarubicin and etoposide."	( A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA, 1999)	0.3
"It is necessary to decrease the doses of daunorubicin and etoposide when they are administered with PSC-833, presumably because of the effect of the modulator on the pharmacokinetics of these agents."	( Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP, 1999)	0.3
"Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)."	( Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999)	0.3
" Among these agents, cytarabine may be the best agent for the combination with fludarabine phosphate."	( In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S, 2000)	0.31
"A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy."	( Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Aul, C; Beelen, D; Büchner, T; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Hehlmann, R; Heinecke, A; Heyll, A; Hiddemann, W; Hochhaus, A; Lengfelder, E; Löffler, H; Ludwig, WD; Reichert, A; Sauerland, MC; Saussele, S; Schoch, C; Seifarth, W; Staib, P; Wörmann, B, 2000)	0.31
"A dose-escalation study was realized in order to assess the maximally tolerated dose (MTD) of high-dose mitoxantrone in a single injection combined with cytarabine and etoposide (EMA regimen) in refractory or relapsed acute myelogenous leukemia (AML)."	( Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A, 2000)	0.31
" The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph(+) leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y."	( In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001)	0.31
" ATRA combined with low-dose Ara-C could be an alternative treatment for this kind of patient."	( [All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report]. Asahara, S; Chinzei, T; Hasuike, N; Maeda, N; Maeda, Y; Okada, Y; Okutani, T; Saigo, K; Satake, S; Takata, M; Tamura, M; Tasaka, K; Tomofuji, Y, 2001)	0.31
" Therefore, we examined the effect of an HMG-CoA reductase inhibitor (simvastatin) alone and in combination with cytosine arabinoside (ARA-C) on the proliferation of two AML cell lines."	( Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. Bar-Sef, A; Elis, A; Fabian, I; Lishner, M, 2001)	0.31
" The present work focuses on the therapeutic efficacy and the toxicity of interferon (IFN) alpha 2b in combination with cytosine arabinosine (Ara-C) in patients younger than age 18 years enrolled in the randomized trial CML 91, which compared the efficacy of IFN and cytosine arabinoside (Ara-C) with IFN alone in 810 patients with CML in the chronic phase."	( Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia. Boccara, JF; Brice, P; Demeoq, F; Guilhot, F; Guilhot, J; Guyotat, D; Millot, F; Philippe, N; Thyss, A; Vilque, JP; Wetterwald, M, 2002)	0.31
"We conclude that ATRA in combination with Ida and Ara-C can be administered safely to high-risk AML patients."	( All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. Anglaret, B; Archimbaud, E; Belhabri, A; Chelghoum, Y; Dhedin, N; Dombret, H; Fière, D; Michallet, M; Reman, O; Thomas, X; Vekhoff, A; Wattel, E, 2002)	0.31
"To observe the effect of cytosine arabinoside (Ara-C) combined with recombinant human granulocyte colony-stimulating factor (rhG-CSF) on mobilization of autologous peripheral blood stem cells (APBSCs) among malignant lymphoma patients and investigate appropriate dose of Ara-C."	( [Mobilization of autologous peripheral blood stem cells by cytosine arabinoside combined with recombinant human granulocyte colony-stimulating factor]. Han, X; He, X; Liu, P; Shi, Y; Yang, J, 2002)	0.31
"Ara-C combined with rhG-CSF is safe and highly effective for APBSC mobilization."	( [Mobilization of autologous peripheral blood stem cells by cytosine arabinoside combined with recombinant human granulocyte colony-stimulating factor]. Han, X; He, X; Liu, P; Shi, Y; Yang, J, 2002)	0.31
"The AML-BFM REZ 97 study included two reinduction blocks with L-DNR (2 x 60 mg/m (2) n = 38, since 2/1999 3 x 60 mg/m (2) n = 31) combined with cytarabine (500 mg/m (2) 4 d)."	( [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Boos, J; Creutzig, U; Fleischhack, G; Hempel, G; Reinhardt, D; Schulz, A, )	0.13
"To identify the optimal schedule for infusion of cytarabine (ara-C) given with cladribine (2-CdA) to pediatric patients with acute myeloid leukemia (AML), and to compare the effects of the two schedules on the pharmacokinetics of ara-C triphosphate (ara-CTP) in leukemic cells."	( Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X, 2002)	0.31
"Intracellular accumulation of ara-CTP is increased when 2-CdA is given with ara-C, but no schedule-dependent differences in this effect were seen."	( Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X, 2002)	0.31
" A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML."	( Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Alvarez, R; Beran, M; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, AM, 2002)	0.31
" We report the case of a 49 year-old female with advanced mantle cell lymphoma (MCL), who successfully underwent auto-peripheral blood stem cell transplant (auto-PBSCT) in combination with in vivo purging of tumor cells using rituximab."	( [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab]. Hino, N; Ishibashi, K; Kanaji, N; Uno, H, 2002)	0.31
" It is concluded that Valspodar 10 mg/kg per 24 h in combination with daunorubicin 45 mg/m(2) for 3 days and cytarabine 1 g/m(2) twice daily for 4 days is tolerable in this heavily pre-treated group of patients."	( A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Björkholm, M; Brinch, L; Evensen, S; Gruber, A; Gustavsson, B; Hedenus, M; Juliusson, G; Liliemark, J; Löfvenberg, E; Nesthus, I; Paul, C; Simonsson, B; Sjo, M; Stenke, L; Tangen, JM; Tidefelt, U; Udén, AM, 2003)	0.32
" This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan."	( Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003)	0.32
" Therefore, we studied whether Ara-C in combination with the purine analogues exerts synergistic or antagonistic effects on cell proliferation, phosphatidylserine exposure and disruption of mitochondrial membrane potential (MMP) in the AML cell lines HL60 and HEL."	( In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Boehrer, S; Chow, KU; Hoelzer, D; Knau, A; Mitrou, PS; Napieralski, S; Nowak, D; Weidmann, E, 2003)	0.32
" Thus several groups decided to investigate this new combination with the hypothesis that cell resistance would be less frequent."	( Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. Berthaud, P; Berthou, C; Buzyn, A; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Najman, A; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M, 2003)	0.32
" Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally."	( Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T, 2004)	0.32
" Cytarabine metabolism was significantly decreased when combined with caspofungin or itraconazole."	( In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA, 2004)	0.32
"From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen)."	( [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)]. Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M, 2004)	0.32
" From March 1987 to March 1994, 40 newly diagnosed patients with AML were randomized to receive either bolus or CI-MTZ, administered for 3 days at 10 mg/m2/day in combination with CI-cytarabine for 7 days at 100 mg/m2/day."	( A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Canpinar, H; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekuzman, G, 2004)	0.32
" In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)."	( Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N, 2005)	0.33
"Patients with relapsed or primary resistant AML (duration of first response, zero to 12 months) were randomly assigned to receive either mitoxantrone 8 mg/m(2), etoposide 80 mg/m(2), and cytarabine 1 g/m(2) daily for 6 days (MEC) in combination with lintuzumab 12 mg/m(2), or MEC alone."	( Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N, 2005)	0.33
"One hundred twelve patients with geriatric acute myeloid leukemia (AML), refractory or relapsed AML, or myelodysplastic syndrome and refractory anemia with excess of blasts in transformation (MDS-RAEBt) were entered into this study to receive CAG (aclarubicin and low-dose cytosine arabinoside [Ara-C]in combination with granulocyte colony-stimulating factor [G-CSF]) with the objective of evaluating the efficacy and tolerance of this regimen."	( Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP, 2005)	0.33
" A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease."	( Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Albitar, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Gerson, S; Giles, F; Jabbour, E; Kantarjian, H; Karsten, V; Kornblau, S; O'Brien, S; Ravandi, F; Sznol, M; Thomas, D; Verstovsek, S; Yee, K, 2005)	0.33
" Dose-limiting toxicities (gastrointestinal and myelosuppression) were seen with 500 and 600 mg/m(2) of cloretazine combined with the 4-day ara-C schedule but not seen with the 3-day schedule."	( Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Albitar, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Gerson, S; Giles, F; Jabbour, E; Kantarjian, H; Karsten, V; Kornblau, S; O'Brien, S; Ravandi, F; Sznol, M; Thomas, D; Verstovsek, S; Yee, K, 2005)	0.33
" Therefore, we evaluated a pilot clinical trial of ara-C in combination with UCN-01 in patients with relapsed AML."	( Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z, 2006)	0.33
" We performed intrathecal MTX and Ara-C in combination with systemic docetaxel treatments in the patient, a 44-year-old woman with carcinomatous meningitis from invasive lobular carcinoma previously treated with anthracycline and paclitaxel."	( [Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel]. Jida, M; Kubo, M; Maeda, H; Miyatani, K; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Yamane, M, 2005)	0.33
" The ability of 17-AAG to abrogate the function of heat-shock protein Hsp90 and modulate cellular sensitivity to anticancer agents has prompted recent research to use this compound in drug combination therapy."	( Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W, 2006)	0.33
" Because of its wide spectrum of actions, it is reasonable to consider the combination with other anticancer drugs in clinical application."	( Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S, 2007)	0.34
" This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan."	( Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I, 2006)	0.33
"The effect of gemtuzumab ozogamicin (GO) alone, or combined with low-dose cytarabine or etoposide, on the proliferation of acute myeloid leukaemia blast cells in vitro was investigated."	( Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells. Adams, JA; Liu, JA; Morris, KL, 2006)	0.33
" During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL)."	( Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F, 2007)	0.34
" We performed a phase I dose-escalation study of cytarabine combined with fixed doses of vinorelbine, paclitaxel, etoposide and cisplatin (VTEPA) for patients with relapsed/refractory lymphoma."	( Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E, 2006)	0.33
" Twenty-three patient pairs treated with either DHAP in combination with rituximab or DHAP alone could be analysed after matching for important prognostic factors."	( DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Flieger, D; Glasmacher, AG; Gorschlueter, M; Hensel, M; Mey, UJ; Olivieri, A; Orlopp, KS; Rabe, C; Schmidt-Wolf, IG; Strehl, JW, 2006)	0.33
"High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.34
" administration of 40 mg/m2 of IDA, combined with HD Ara-C, with a degree of myelosuppression equivalent to that reported with this agent administered in standard doses."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.34
"The aim of this study was to evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol in elderly patients with acute myeloid leukemia (AML)."	( Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Jiang, YQ; Li, JY; Lu, H; Qian, SX; Shen, YF; Tian, T; Wu, HX; Xu, W; Zhang, SJ, 2007)	0.34
" The primary objective of the study was to establish the maximum tolerated dose of 3-AP when given in combination with a fixed dose of cytarabine."	( Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Delaney, SM; Dolan, ME; Gajria, D; Karrison, TG; Larson, RA; Odenike, OM; Ratain, MJ; Stock, W, 2008)	0.35
"While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in combination with chemotherapy has not been determined."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.35
"The Children's Oncology Group AAML00P2 trial sought to define the MTD of GMTZ in combination with cytarabine and mitoxantrone and cytarabine and l-asparaginase chemotherapy regimens."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.35
"The MTD for GMTZ in combination with cytarabine and mitoxantrone was 3 mg/m(2) while the MTD in combination with cytarabine and l-asparaginase was 2 mg/m(2)."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.35
" In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism."	( CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL, 2008)	0.35
" We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer antisense oligonucleotide shown in preclinical studies to decrease levels of the R2 subunit of ribonucleotide reductase, to determine the maximum tolerated dose in adults with relapsed/refractory acute myeloid leukemia."	( Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Blum, W; Byrd, JC; Chan, K; Devine, S; Grever, MR; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Marcucci, G; Pang, J; Vukosavljevic, T; Wei, X; Xie, Z; Zwiebel, JA, 2008)	0.35
"Twenty-three adults (ages 18-59 years) were enrolled in this dose escalation phase I trial, receiving high-dose AraC twice daily combined with infusional GTI-2040."	( Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Blum, W; Byrd, JC; Chan, K; Devine, S; Grever, MR; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Marcucci, G; Pang, J; Vukosavljevic, T; Wei, X; Xie, Z; Zwiebel, JA, 2008)	0.35
" This study examined the efficacy and tolerability of GO combined with cytarabine (GOCYT) in children with refractory/relapsed CD33(+) AML."	( Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Baruchel, A; Bertrand, Y; Boutard, P; Brethon, B; Bruno, B; Chevret, S; Dalle, JH; de Lumley, L; Jérome, C; Leblanc, T; Nelken, B; Oudot, C; Yakouben, K, 2008)	0.35
"This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML)."	( Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC, 2009)	0.35
" Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given after vorinostat."	( Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009)	0.35
"These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias."	( Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009)	0.35
"The objective of this study was to investigate the efficacy and toxicity of standard-dose idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukemia (AML)."	( [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia]. Chen, LJ; Li, JY; Lu, H; Lu, RN; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W, 2009)	0.35
"To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.35
"Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.35
"We have investigated the effect of cloretazine (VNP40101M or Laromustine), a novel sulfonylhydrazine alkylating agent with significant antileukaemic activity, alone, or combined with cytarabine or daunorubicin, on the proliferation, viability and apoptosis of cell lines and acute myeloid leukaemia blast cells in vitro."	( Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Adams, JA; Liu Yin, JA; Morris, KL, 2009)	0.35
"To evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol for patients with relapsed acute myeloid leukemia (AML)."	( [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia]. Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, SJ; Zhu, BG, 2009)	0.35
"The aim of study was to evaluate the clinical efficacy and toxicity of fludarabine combined with cytarabine (FA) regimen in the treatment of patients with refractory and/or relapsed acute myeloid leukemia (AML)."	( [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia]. Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF, 2009)	0.35
"To observe the clinical efficacy of Chinese drugs combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and to investigate the prognostic relevance of the main parameters in AML treated with integrative medicine."	( Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM, 2009)	0.35
" We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.35
"Twenty-four patients with rapidly relapsed or refractory AML were treated with escalating doses of AEG35156 (12 to 250 mg/m(2)) as an intravenous solution over 2 hours and 32 patients were treated with the highest planned dose of 350 mg/m(2) in combination with idarubicin and high-dose cytarabine reinduction chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.35
" Among the patients receiving 350 mg/m(2) of AEG35156 in combination with chemotherapy, 10 (91%) of 11 who were refractory to a single induction chemotherapy regimen achieved CR/CRp after reinduction with AEG35156 and chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.35
"At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.35
"We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin."	( Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A, 2010)	0.36
"We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia."	( Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Asou, N; Eto, K; Horikawa, K; Kugimiya, MH; Mitsuya, H; Nishimura, S; Shimomura, T; Suzushima, H; Tsuda, H; Wada, N; Yamasaki, H, 2010)	0.36
" 43 patients with relapsed/refractory or secondary AML or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine."	( Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS, 2010)	0.36
"Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7) in 162 patients with chronic myeloid leukemia."	( Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Beverloo, HB; Cornelissen, JJ; Daenen, SM; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, PJ; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Wijermans, PW; Willemze, R; Wittebol, S, 2010)	0.36
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
"The cytotoxic effects of GO in combination with antileukemic agents were studied against human CD33 antigen-positive leukemia HL-60, U937, TCC-S and NALM20 cells."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
" After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7."	( Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. Buhk, JH; Hoffmann, AL; Strik, H, 2009)	0.35
" Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients."	( Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Ohno, R, 2006)	0.33
" We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML."	( A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B, 2010)	0.36
"To evaluate the curative effect and adverse effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome."	( [Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome]. Chen, S; He, Y; Zhu, Y, 2010)	0.36
"The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP."	( Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Park, K; Park, Y; Suh, C, 2012)	0.38
" Bortezomib has shown single agent activity of 33% in relapsed MCL and has an additive/synergistic effect in vitro when combined with drugs currently used to treat MCL."	( Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P, 2010)	0.36
"The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome."	( A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ, 2011)	0.37
"To explore the effect of low dose of homoharringtonine (HHT) and cytarabine (Ara-c) combined with granulocyte colony-stimulating factor (G-CSF) priming (HAG regimen) on relapsed or refractory acute myeloid leukemia (AML)."	( Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. Cao, XM; Chen, YX; Gu, LF; He, AL; Liu, J; Ma, XR; Wang, FX; Zhang, WG, 2011)	0.37
"Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma."	( Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Andresen, S; Bolwell, BJ; Copelan, E; Dean, R; Hill, BT; Kalaycio, M; Pohlman, B; Rybicki, L; Smith, S; Sobecks, R; Sweetenham, J; Tench, S, 2011)	0.37
"Sorafenib in combination with cytarabine resulted in strong anti-AML activity in vitro and in vivo."	( Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S, 2011)	0.37
"This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas."	( (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H, 2011)	0.37
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."	( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012)	0.38
"To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia."	( Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)	0.37
"Sorafenib in combination with clofarabine and cytarabine is tolerable and shows activity in relapsed/refractory pediatric AML."	( Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)	0.37
" Its favorable toxicity profile in-vivo favors its combination with other cytotoxic drugs."	( The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C, 2012)	0.38
" The authors examined the in vitro and clinical activity of the histone deacetylase inhibitor valproic acid (VA) combined with cytosine arabinoside (AraC) in elderly patients with AML unsuited to intensive therapy."	( Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Fan, HM; Gill, D; Keane, C; Lane, S; McMillan, NA; Mollee, P; Murphy, R; Saunders, N; Spurr, T, 2012)	0.38
"ALL cell lines (SEM, RS4;11, Jurkat and MOLT4) were treated with NVP-BEZ235 alone, or in combination with cytarabine (AraC), doxorubicin (Doxo) or dexamethasone (Dexa)."	( The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Dahlhaus, M; Fischer, K; Freund, M; Glass, A; Junghanss, C; Lange, S; Schult, C, 2012)	0.38
" NVP-BEZ235 combined with AraC, Doxo or Dexa synergistically enhanced the cytotoxicity compared to single-drug treatment, even in glucocorticoid-resistant cells."	( The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Dahlhaus, M; Fischer, K; Freund, M; Glass, A; Junghanss, C; Lange, S; Schult, C, 2012)	0.38
"This study was purposed to analyze the clinical features and evaluate the efficacy of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)."	( [Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)]. Gan, SL; Liu, YF; Meng, XL; Sun, H; Sun, L; Wan, DM; Zhou, JW, 2012)	0.38
"Although induction chemotherapy comprising high-dose cytarabine (HiDAC) in combination with idarubicin and etoposide or 'ICE' for adult acute myeloid leukaemia (AML) produces a complete remission rate of nearly 80%, gastrointestinal toxicity is significant."	( High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Avery, S; Coutsouvelis, J; Lee, D; Low, M; Opat, S; Patil, S; Salem, H; Schwarer, A; Spencer, A; Walker, P; Wei, A, 2013)	0.39
" We retrospectively evaluated the efficacy and toxicity of fractionated doses of gemtuzumab ozogamicin (GO) combined with a standard 3 + 7 induction regimen in young patients with AML in first relapse."	( Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C, 2012)	0.38
" This study showed that 3 mg/m² of GO in combination with enocitabine and daunorubicin may be a recommendable dose for a phase 2 study in Japanese elderly patients with CD33-positive AML."	( Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. Gotoh, M; Ito, Y; Mihara, M; Miyawaki, S; Naoe, T; Ohnishi, K; Ohtake, S; Ohyashiki, K; Takada, S; Wakita, A, 2012)	0.38
"This study was aimed to further explore the apoptosis-inducing effect of bortezomib combined with cytarabine (Ara-C) on U937 cell line."	( [Mechanism of apoptosis synergistically induced by bortezomib combined with cytarabine in U937 cell line]. DU, SH; DU, X; He, C; Jia, PM; Tong, JH; Zhou, L, 2012)	0.38
" LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg."	( Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D, 2013)	0.39
"To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts."	( Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M, 2013)	0.39
" Whereas, in high-risk patients, cytarabine (AraC) is often considered useful in combination with anthracycline to prevent relapse, its usefulness in standard-risk APL is uncertain."	( Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Adès, L; Cassinat, B; Chevret, S; Chomienne, C; de Botton, S; Deconinck, E; Degos, L; Dombret, H; Fenaux, P; Ferrant, A; Guerci-Bresler, A; Huguet, F; Lambert, JF; Lamy, T; Lioure, B; Pigneux, A; Quesnel, B; Raffoux, E; Thomas, X; Vekhoff, A; Vey, N, 2013)	0.39
" One hundred nine patients aged 18-65 years were randomly assigned to either imatinib 800 mg (n = 55) or to imatinib 800 mg in combination with two successive cycles of cytarabine 200 mg/m(2) for 7 days (n = 54)."	( High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE, 2013)	0.39
" We performed a multi-center phase II trial investigating the safety and efficacy of ofatumumab, a monoclonal antibody against CD20, combined with ICE or DHAP second-line therapy in patients with relapsed or refractory DLBCL, grade 3b follicular lymphoma, or transformed follicular lymphoma."	( Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Czuczman, MS; Edvardsen, K; Fayad, L; Fecteau, D; Fennessy, M; Henkel, K; Jewell, RC; Joyce, R; Kharfan-Dabaja, MA; Liao, Q; Lisby, S; Lossos, IS; Matasar, MJ; Moskowitz, CH; Rodriguez, MA; Shea, TC; Singh, RP; Spitzer, G, 2013)	0.39
"The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5'-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts."	( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013)	0.39
"The antitumor activity of elacytarabine, was tested at the maximal tolerable dose (MTD; 50 mg/kg) and half MTD (25 mg/kg), alone and in combination with the antibodies bevacizumab (5 mg/kg), cetuximab (20 mg/kg) and trastuzumab (4 mg/kg) in two human non-small cell lung cancer xenografts."	( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013)	0.39
" In the elacytarabine-, bevacizumab- and trastuzumab-insensitive MAKSAX xenograft, the combination of either bevacizumab or trastuzumab with elacytarabine at the MTD or half MTD resulted in intermediate activity, suggesting a beneficial effect of the combinations, whereas for cetuximab, the effect was enhanced when combined with elacytarabine given at the MTD, but not half-MTD."	( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013)	0.39
"To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells."	( Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014)	0.4
" The CAG regimen [low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF)] has been used to treat relapsed and refractory AML patients, and showed good therapeutic efficacy."	( Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Jin, Z; Lin, G; Liu, L; Ma, A; Si, Y; Sun, Y; Wang, L; Wu, D; Zhang, X; Zhang, Y; Zhao, G, 2014)	0.4
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."	( Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)	0.4
" A total of 56 elderly patients with de novo AML were treated with homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor (HCG)."	( Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia. Chen, C; Xu, W; Yang, J, 2015)	0.42
" To overcome this problem, we investigated the use of reduced-intensity preconditioning umbilical cord blood transplantation (RICBT) combined with recombinant G-CSF (rG-CSF) with high-dose Ara-C, fludarabine, melphalan, and 4 Gy of TBI in a phase I/II study in patients with non-remitting myeloid hematologic malignancies."	( A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. Akahane, D; Asano, M; Gotoh, M; Ito, Y; Katagiri, S; Kitahara, T; Ohyashiki, K; Okabe, S; Suguro, T; Tauchi, T; Yoshizawa, S, 2014)	0.4
" In this phase 1/2 study, the tolerability and overall response rate of clofarabine in combination with cytarabine was investigated in children with recurrent/refractory AML."	( AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, RB; Horton, TM; Loken, MR; Meshinchi, S; Perentesis, JP; Razzouk, BI; Taub, JW; Whitlock, JA, 2014)	0.4
" The recommended pediatric phase 2 dose of clofarabine in combination with cytarabine was 52 mg/m(2)/day for 5 days."	( AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, RB; Horton, TM; Loken, MR; Meshinchi, S; Perentesis, JP; Razzouk, BI; Taub, JW; Whitlock, JA, 2014)	0.4
"This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML)."	( A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO, 2014)	0.4
"Patients with <400 mg/m(2) prior anthracycline received bortezomib combined with idarubicin (12 mg/m(2) days 1-3) and low-dose cytarabine (100 mg/m(2) days 1-7) (Arm A)."	( A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO, 2014)	0.4
" A Phase 1 study demonstrated the safety of high dose pravastatin given with idarubicin and cytarabine in patients with AML and also demonstrated an encouraging response rate."	( SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C, 2014)	0.4
"This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used."	( [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2014)	0.4
"This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes."	( [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes]. Cui, GX; Wu, WZ; Zhang, YP, 2014)	0.4
" Escalating vosaroxin doses (10-minute infusion; 10-90 mg/m(2); days 1, 4) were given in combination with cytarabine on one of two schedules: schedule A (24-hour continuous intravenous infusion, 400 mg/m(2)/day, days 1-5) or schedule B (2-hour intravenous infusion, 1 g/m(2)/day, days 1-5)."	( A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK, 2015)	0.42
"Treating MDS/AML with decitabine alone, in combination with half or one course CAG regimen produced high efficacy."	( [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen]. Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D, 2014)	0.4
"This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission."	( Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia. Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S, 2014)	0.4
"We determined the safety, pharmacokinetics, pharmacodynamics, and recommended phase II dose of MK-8776 (SCH 900776), a potent, selective checkpoint kinase 1 (Chk1) inhibitor, as monotherapy and in combination with gemcitabine in a first-in-human phase I clinical trial in patients with advanced solid tumor malignancies."	( Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP, 2015)	0.42
"Forty-three patients were treated by intravenous infusion with MK-8776 at seven dose levels ranging from 10 to 150 mg/m(2) as monotherapy and then in combination with gemcitabine 800 mg/m(2) (part A, n = 26) or gemcitabine 1,000 mg/m(2) (part B, n = 17)."	( Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP, 2015)	0.42
"MK-8776 was well tolerated as monotherapy and in combination with gemcitabine."	( Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP, 2015)	0.42
"This study was to investigate the therapeutic effectiveness and side effect of decitabine combined with modified CAG regimen for relapse or refractory patients with acute myeloid leukemia."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"After treatment by using decitabine combined with modified CAG regimen, 7 patients achived complete remission, 1 patient achived partial remission, 2 patient did not achieve remission, the overall remission rate was 80% (8/10), the median time of white blood cell count recovery was 18."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"The treatment of decitabine combined with modified CAG regimen for relapsed and refractory AML shows high response rate, low side effects, so it worthy to further clinical study."	( [Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia]. Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY, 2015)	0.42
"All patients in this study were treated with decitabine of 15 mg/m2 for 5 days and G-CSF for priming, in combination with cytarabine of 10-mg/m2 q12h for 7 days and aclarubicin of 10 mg/day for 4 days (D-CAG)."	( Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y, 2015)	0.42
"The present multicenter, open-label, dose-escalation study aimed to evaluate the tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of Debio1143 (formerly AT-406), a new IAP antagonist, when given along with a standard "7 plus 3 regimen" of daunorubicin and cytarabine to poor-risk patients with AML during the induction cycle."	( Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C, 2015)	0.42
"Debio1143 ≤ 400 mg/d showed good tolerability in combination with daunorubicin and cytarabine."	( Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C, 2015)	0.42
"We compared the efficacy of high-dose cytarabine alone to that of intermediate-dose cytarabine combined with anthracyclines as consolidation therapy."	( Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Choi, CW; Kang, KW; Kim, BS; Kim, DS; Kim, SJ; Lee, SR; Park, Y; Sung, HJ, 2015)	0.42
"To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
" All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
"Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases."	( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia]. Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015)	0.42
"The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia (sAML)."	( Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R, 2015)	0.42
"The efficacy and safety of a modified CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen with an increased aclarubicin dosage [high-dose (HD)-CAG] were observed in 145 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and compared to the results of 172 patients treated with a conventional CAG regimen."	( Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y, 2015)	0.42
"We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"Decitabine alone or combination with AAG can improve outcome of AML/MDS with a complex karyotype, there being no significant difference decitabine in inducing remission rates in patients with different karyotype."	( Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y, 2015)	0.42
"25 μM) and to determine the targeted killing ability of T cell subtypes induced by the diabody or ds-diabody combination with Ara-C both in vitro and in vivo."	( Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. Fan, D; Li, W; Wang, J; Xiong, D; Yan, Y; Yang, M; Yang, Y; Zhang, Q; Zhang, X, 2015)	0.42
"T cell therapy induced by diabody or ds-diabody combined with low dose of Ara-C was effective against cancer cell-lines and in clinical trials."	( Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. Fan, D; Li, W; Wang, J; Xiong, D; Yan, Y; Yang, M; Yang, Y; Zhang, Q; Zhang, X, 2015)	0.42
"To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years."	( [Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion]. Hu, HL; Huang, YJ; Li, J; Liu, J; Sun, WJ; Xi, XQ; Zhao, HX, 2015)	0.42
"In this study we retrospectively analyzed 53 refractory or relapsed CN- AML patients receiving the therapy including decitabine combined with CAG and CAG- like regimen in our center from April 2011 to October 2014."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	0.42
"Decitabine combined with CAG or CAG-like regimen was an effective and safe treatment for refractory or relapsed CN- AML patients."	( [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen]. Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z, 2015)	0.42
" We conducted a phase 1b trial to determine the maximum tolerated dose (MTD) of lenalidomide in combination with R-ESHAP (rituximab, etoposide, cisplatin, cytarabine, methylprednisolone) (LR-ESHAP) in patients with relapsed or refractory DLBCL."	( Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016)	0.43
"The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
"252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
" We developed a phase I study to evaluate the safety and tolerability of Len in combination with intermediate dose AraC (1."	( A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Brady, WE; Dickey, NM; Ford, LA; Griffiths, EA; L Bashaw, H; Sperrazza, J; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M, 2016)	0.43
"To observe the efficacy and safety of modified Shengma Biejia Decoction (MSBD) combined with CAG program in treating elderly acute myeloid leukemia (AML) patients with yin deficiency toxin stasis syndrome (YDTSS)."	( [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome]. Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX, 2016)	0.43
"MSBD combined with CAG program in treating elderly AML patients with YDTSS, with efficacy enhancing toxicity reducing effect, had distinct advantages in improving physical condition and clinical symptoms, and reducing transfusion dependency."	( [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome]. Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX, 2016)	0.43
"Western blots and real-time RT-PCR were used to determine levels of Mcl-1 after ABT-199 treatment alone or in combination with cytarabine or daunorubicin."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.43
"Our results demonstrate that sequestration of Bim by Mcl-1 is a mechanism of intrinsic ABT-199 resistance and supports the clinical development of ABT-199 in combination with cytarabine or daunorubicin for the treatment of AML."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.43
"To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML)."	( [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016)	0.43
"Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency."	( [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016)	0.43
"To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.43
"Low dose TD combined with modified VCMP regimen for treatment of newly diagnosed aged patients with MM is safe and effective, which may be used as the first line treatment regimen for population in aged MM patients."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.43
" Subsequently, each agent was used in combination with CNDAC at fixed concentration ratios."	( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)	0.43
"As sensitization of leukemia cells with granulocyte colony-stimulating factor (G-CSF) can enhance the cytotoxicity of chemotherapy in myeloid malignancies, a pilot study was conducted in order to evaluate the effect of G-CSF priming combined with low-dose chemotherapy in patients with higher risk myelodysplastic syndrome (MDS)."	( Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients. Cao, XM; Chen, YX; Gu, LF; He, AL; Wang, FX; Wang, JL; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH, 2016)	0.43
"Homoharringtonine combined with aclarubicin and cytarabine (HAA) is a highly effective treatment for acute myeloid leukemia (AML), especially for t(8;21) AML."	( Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein. Cao, J; Chen, C; Chen, W; Ding, NN; Feng, H; Niu, MS; Qiu, TT; Wu, QY; Xu, KL; Zhu, HH, 2016)	0.43
"Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine."	( A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. Angenendt, L; Berdel, WE; Butterfass-Bahloul, T; Edemir, S; Gerss, J; Kewitz, T; Knoblauch, N; Krug, U; Mikesch, JH; Müller-Tidow, C; Sauer, T; Schliemann, C; Urban, M; Vehring, K; Wiebe, S, 2016)	0.43
"Our data suggest that salvage therapy with fractionated GO combined with intermediate-dose cytarabine and daunorubicin in very high-risk patients may serve as a potential bridge therapy to RIC transplant."	( Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? Barraco, F; Ducastelle-Leprêtre, S; Labussière-Wallet, H; Nicolini, FE; Paubelle, E; Plesa, A; Salles, G; Thomas, X; Wattel, E, 2017)	0.46
" We conducted a prospective study of 23 elderly patients (median age, 68 years; range, 60 to 87 years) with newly diagnosed AML to evaluate the efficacy and toxicity of decitabine plus granulocyte colony-stimulating factor priming, low-dose aclarubicin, and cytarabine (DCAG) chemotherapy combined with HLA-mismatched stem cell microtransplantation (SC-MST) without graft-versus-host disease (GVHD) prophylaxis."	( Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y, 2017)	0.46
" A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose."	( A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T, 2017)	0.46
"Plerixafor, in combination with high-dose cytarabine and etoposide, was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS."	( A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T, 2017)	0.46
"Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve survival with a clinically manageable safety profile, administered alone and in combination with cytarabine in patients with acute myeloid leukaemia."	( Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF, 2018)	0.48
"The pharmacokinetics of volasertib in patients with acute myeloid leukaemia alone or in combination with cytarabine is predictable and associated with low-to-mild patient variability with the exception of the high variability associated with the volume of distribution of the central compartment, having no effect on the area under the plasma concentration-time curve."	( Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. Fleury, A; Freiwald, M; Fritsch, H; Haug, K; P Solans, B; Trocóniz, IF, 2018)	0.48
" After demonstrating the safety and feasibility in a phase I study, we conducted a phase II clinical study of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor) regimen combined with IM for patients with RR-AML."	( A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K, 2017)	0.46
"To investigate the clinical efficacy of low-dose decitabine combined with CAG regimen in patients with myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB) through retrospective analysis."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
"Thirty-six patients with MDS-RAEB who ever received low-dose decitabine combined with CAG regimen were enrolled into decitabine + CAG group and 40 patients with MDS-RAEB treated by decitabine alone in our center were enolled into the control group."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
"Low-dose decitabine combined with CAG regimen has better clinical efficacy for patients with MDS-RAEB than that of decitabine alone."	( [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M, 2017)	0.46
" Drug combination effects were quantified by median effect analysis."	( Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Chen, Y; Cheng, N; Jiang, Y; Liu, X; Nowak, B; Plunkett, W; Qiang, B, 2018)	0.48
"To evaluate the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Clinical trials evaluating the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation were reviewed for the treatment of newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
" A phase III trial illustrated that midostaurin in combination with standard chemotherapy improved event-free survival, disease-free survival, and overall survival in patients with newly diagnosed FLT3-mutation-positive AML compared with standard chemotherapy alone."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Midostaurin in combination with standard induction and consolidation is safe and efficacious in newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"To investigate the curative effect and safety of decitabine combined with IAG regimen for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	0.46
"Decitabine combined with IAG regimen is an effective for treating senile MDS-transformed AML patients."	( [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia]. Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY, 2017)	0.46
"To investigate the therapeutic effectiveness and side effects of decitabine combined with or without cytarabine-based low dose regimen for acute myeloid leukemia in geratic patients."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	0.48
"Decitabine combined with or without cytarabine-based low dose regimen is promising for the treatment of geriatric acute myeloid leukemia, thus improving the overall response rate, and prolonging overall survival time."	( [Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia]. DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH, 2018)	0.48
" A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]."	( Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M, 2018)	0.48
"We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy."	( Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y, 2018)	0.48
" This supports the therapeutic potential of pan-PIM kinase inhibitors, especially in combination with other anticancer agents chosen based on their role in overlapping signaling networks."	( Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. Boer, J; Bowman, K; Burke, K; Covington, M; Diamond, S; Dostalik Roman, V; Feng, H; Hall, L; Hollis, G; Huber, R; Koblish, H; Lambert, QT; Li, YL; Marando, C; Margulis, A; Reuther, GW; Scherle, P; Shin, N; Vaddi, K; Wang, K; Wang, Q; Wynn, R; Xue, CB; Yao, W; Yeleswaram, S; Zhang, K, 2018)	0.48
"Thalidomide in combination with chemotherapy is an alternative treatment option for elderly patients with AML."	( Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia. Chen, C; Xu, W; Yang, J, 2018)	0.48
"In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics."	( Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics. Hu, LN; Li, GQ; Lin, HQ; Shen, Q; Sun, XF; Zhang, XY; Zhou, JH, 2018)	0.48
"We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine."	( A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Almakadi, M; Aslostovar, L; Bhatia, M; Boyd, AL; Collins, TJ; Foley, R; Julian, JA; Kim, RB; Leber, B; Leong, DP; Levine, MN; Tirona, RG; Xenocostas, A, 2018)	0.48
" In this study, we investigated the anti-leukemia effects of emodin alone or in combination with cytarabine (Ara-C) on multidrug-resistant AML HL-60/ADR cells and in a mouse xenograft model of human highly tumorigenic AML HL-60/H3 cells."	( Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. Chen, Y; Gan, D; Hu, J; Huang, Q; Lin, D; Luo, X, 2018)	0.48
"Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation."	( Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. Chen, Y; Gan, D; Hu, J; Huang, Q; Lin, D; Luo, X, 2018)	0.48
" High remission rate and low early mortality combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for older adults not suitable for intensive chemotherapy."	( Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Agarwal, S; Chyla, B; Enjeti, A; Fakouhi, KM; Fiedler, W; Hayslip, J; Hong, WJ; Hou, JZ; Humerickhouse, R; Lee, S; Lin, TL; Popovic, R; Roboz, GJ; Salem, AH; Savona, M; Strickland, SA; Tiong, IS; Walter, RB; Wei, AH; Xu, T, 2019)	0.51
" A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML."	( A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019)	0.51
"PubMed, EMbase, The Cochrane Library, WanFang Data and CNKI databases were searched to collect randomized controlled trials (RCTs) of decitabine combined with CAG regimen for intermediate or high risk MDS and AML from inception to March, 2018."	( [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis]. Cao, YP; Li, JG; Zhang, JL, 2019)	0.51
"Ibrutinib alone or in combination with cytarabine or azacitidine demonstrated an acceptable safety profile."	( Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS, 2019)	0.51
"The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacitidine or decitabine] or low-dose cytarabine [LDAC])."	( Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH, 2019)	0.51
" However, the effect of EDO-S101 in combination with traditional chemotherapy drugs has not been studied in AML."	( A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells. Guo, W; Huang, X; Jin, J; Li, F; Li, X; Mao, S; Yu, M, 2019)	0.51
" By inhibiting the primary export protein, XPO1, selinexor localizes and activates tumor suppressor proteins in the nucleus and inhibits DNA damage repair, rationalizing combination with DNA-damaging agents."	( Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J, 2020)	0.56
"This was a single-arm phase I clinical trial of selinexor combined with cytarabine and daunorubicin (7+3)."	( Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J, 2020)	0.56
" For this particular group we evaluated the efficacy and safety of fludarabine, cytarabine, granulocyte colony-stimulating factor (FLAG) in combination with etoposide (FLAG-Eto) in 36 patients."	( Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J, 2020)	0.56
"To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute Myeloid leukemia by a meta-analysis."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.56
" We evaluated and cross-checked the randomized clinical trials (RCTs) comparing daunorubicin combined with cytarabine (DA) and idarubicin combined with cytarabine (IA) by two reviewers independently according to Cochrane Handbook for Systematic Reviewers of Interventions."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.56
"To study the efficacy of small dose HAG combined with decitabine regimen in the treatment of elderly patients with acute myeloid leukemia (AML)."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	0.56
" The AML patients in CAG group was treated with CAG regimen, while the AML patients in combined treatment group was treated with small dose HAG regimen combined with decitabine."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	0.56
"Small dose HAG regimen combined with decitabine for elderly patients with acute myeloid leukemia has a certain curative efficacy."	( [Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia]. Luo, ZQ; Pan, PJ, 2020)	0.56
" Cytarabine (ara-C) is currently the main drug used to treat AML patients and is usually combined with different chemotherapeutic agents."	( The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells. Qi, W; Song, B; Sun, L; Xu, X; Yan, X; Zhao, D, 2020)	0.56
"We recommend the "venetoclax + HMAs combined with dose-adjusted CAH/HAG" regimen as an effective treatment for adult R/RAML."	( Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports. Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B, 2020)	0.56
"BL-8040 in combination with HiDAC was safe and well tolerated at all dose levels."	( BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Abraham, M; Aharon, A; Al-Rawi, AN; Altman, JK; Andreeff, M; Bohana-Kashtan, O; Borthakur, G; Bueso-Ramos, C; Cortes, JE; DiPersio, JF; Foley-Comer, A; Foran, J; Glicko-Kabir, I; Kadosh, SE; Lustig, TM; Nagler, A; Oberkovitz, G; Ofran, Y; Peled, A; Pemmaraju, N; Pereg, Y; Rowe, JM; Samara, E; Shaw, S; Shimoni, A; Showel, MM; Sorani, E; Tallman, MS; Uy, GL; Vainstein-Haras, A, 2021)	0.62
"To evaluate the efficacy of decitabine combined with low-dose CEG regimen (DCEG) and decitabine combined with low-dose CAG regimen (DCAG) in the treatment of elderly patients with MDS and MDS-transformed acute myeloid leukemia (AML)."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
" The treament results of decitabine combined with CEG and decitabine combined with CAG were compared."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
"Decitabine combined with CEG regimen could improve the survival of patients with high-risk MDS and MDS-transformed AML."	( [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen]. He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ, 2020)	0.56
"The clinical efficacy and safety of DAURISMO (glasdegib) combined with low-dose cytarabine (LDAC) were demonstrated in the BRIGHT AML 1003 study among newly diagnosed acute myeloid leukemia patients who are not eligible to receive intensive chemotherapy."	( The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. Bell, T; Charaan, M; Heeg, B; Hu, Y; van Oostrum, I, )	0.13
"IONPs combined with Ara-C showed the effectiveness on reducing AML burden in the mice engrafted with LSCs and extending mouse survival by increasing LSC's ROS level to induce LSC apoptosis."	( Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species. Bao, X; Dou, J; Guo, M; Li, L; Mei, F; Xu, H; Xue, R; Zhang, Y; Zhao, F; Zheng, D, 2021)	0.62
" Herein, we reported the first case with DEK/CAN-positive AML who achieved complete remission of molecular biology via decitabine combined with a medium-dose cytarabine regimen."	( Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report. Zhang, X, 2021)	0.62
" We evaluated two new lower-intensity regimens with clofarabine (n = 119) or cladribine (n = 129) combined with low-dose cytarabine (LDAC) alternating with decitabine."	( Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X, 2021)	0.62
" We analyzed the effects of roflumilast combined with ESHAP (etoposide, cisplatin, methylprednisolone, and cytarabine) chemotherapy in experimental and clinical settings."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
"We found that roflumilast is efficient when combined with other chemotherapy drugs, especially cytarabine."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
"We found that roflumilast, when combined with ESHAP chemotherapy, for relapsed/refractory DLBCL was clinically active and well tolerated."	( Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Chung, JS; Kim, DY; Kim, SW; Nam, J; Shin, HJ, 2022)	0.72
" This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in ND-AML and R/R-AML."	( Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M, 2021)	0.62
" In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL)."	( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report. Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)	0.62
"The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy."	( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report. Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)	0.62
" Recent studies have shown that venetoclax combined with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) may have a good effect on these patients."	( Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. Kuang, P; Liu, T; Qin, Y, 2023)	0.91
"We analyzed the treatment effects of chidamide and decitabine in combination with a HAG (homoharringtonine, cytarabine, G-CSF) priming regimen (CDHAG) in acute myeloid leukemia (AML) patients with TP53 mutation."	( Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation. Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B, 2022)	0.72
" Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naïve patients unfit for intensive induction."	( Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Babushok, DV; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Graveno, ME; Hexner, EO; Loren, AW; Luger, SM; Mangan, BL; Martin, ME; McCurdy, SR; Nietupski, R; Perl, AE; Porter, DL; Pratz, KW, 2022)	0.72
"Although there is no proven standard therapy for leptomeningeal metastases (LM), treatment often includes intrathecal chemotherapy combined with whole brain radiation therapy (WBRT)."	( Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification. Bsteh, G; Grams, A; Heugenhauser, J; Iglseder, S; Mayer, E; Muigg, A; Nevinny-Stickel, M; Nowosielski, M; Stockhammer, G, 2022)	0.72
" A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA + VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML."	( Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M, 2022)	0.72
"Venetoclax in combination with intensive therapies is explored in both the upfront and relapse/refractory (R/R) setting, and available data suggest that such regimens are effective albeit with added hematological and infectious toxicity."	( Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Amit, O; Apel, A; Bar-On, Y; Frisch, A; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shargian, L; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M, 2022)	0.72
"Venetoclax in combination with nucleoside analogs such as hypomethylating agents (HMA) and low-dose cytarabine (LDAC) has led to unprecedented response and survival outcomes in patients with acute myeloid leukemia (AML)."	( Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Ball, BJ; Koller, PB; Pullarkat, V, 2022)	0.72
" We treated 174 consecutive patients with newly diagnosed CBF-AML in a prospective clinical trial of FLAG-based induction/consolidation in combination with gemtuzumab ozogamicin (FLAG-GO; N = 65) or in combination with idarubicin (FLAG-IDA; N = 109)."	( Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X, 2022)	0.72
"Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients with high-risk acute myeloid leukemia (AML)."	( Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Cahill, K; Chen, C; Fulton, N; Han, D; He, C; Liang, G; Odenike, O; Stock, W; Wang, L; You, Q; Zhang, W, 2023)	0.91
"In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children."	( Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023)	0.91
"To evaluate the clinical efficacy and safety of decitabine combined with modified CAG regimen (D-CAG regimen) in patients aged ≥70 years with newly diagnosed acute myeloid leukemia (AML)."	( [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia]. Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y, 2023)	0.91
"Venetoclax (VEN) in combination with intensive chemotherapy (IC) is increasingly used to treat patients with high-risk acute myeloid leukemia (AML)."	( Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M, 2023)	0.91

Excerpt	Reference	Relevance
" Neither cyclo-C nor ara-C is well absorbed after oral administration, and the drug concentration in the plasma is too low to be measurable."	( Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs. Abbott, RL; Carter, CJ; Ho, DH; Loo, TL; McBride, CM, )	0.13
" The therapeutic advantage of combination chemotherapy may reside in the whole organism, reflecting increased bioavailability of drug, reduced dose-limiting toxicity or reduced impairment of host defenses; it may reside in the tumor cells, reflecting the multiple molecular mechanisms of interaction mentioned above."	( Multiple basis of combination chemotherapy. Grindey, GB; Mihich, E, 1977)	0.26
"Several reports document an inverse correlation between bioavailability of maintenance chemotherapeutic agents and the likelihood of relapse in childhood."	( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Blatt, J; Gula, MJ; Lucas, K, )	0.13
" Unlike the other currently available anthracyclines, idarubicin has significant oral bioavailability (average 28%), and an oral dosage form is currently under investigation."	( Idarubicin: an anthracycline antineoplastic agent. Cersosimo, RJ, 1992)	0.28
"Rectal bioavailability of Ara-C (serum AUC 4 h: 65 micrograms h-1 ml-1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 micrograms h-1 ml-1)."	( Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C. Engle, KK; Higuchi, T; Liversidge, GG; Nishihata, T, 1986)	0.27
"Acylcarnitines were tested as potential absorption-enhancing agents for drugs that are poorly absorbed from the gastrointestinal tract."	( Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract. Alexander, J; Engle, K; Fix, JA; Gardner, CR; Leppert, PS; Porter, PA; Selk, SJ, 1986)	0.27
" Since the absorption rate is not clinically relevant in patients on long-term glycoside therapy, our results indicate that digitoxin is preferable to digoxin in such patients."	( Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion. Kuhlmann, J; Rietbrock, N; Wilke, J, 1982)	0.26
"Based on the hypothesis that the selectivity of the antitumor action of a drug is dependent on a multiplicity of systemic and target cell factors, the role of pharmacokinetics and biotransformation in determining drug bioavailability and the target cell determinants of the action of arabinosylcytosine and of methotrexate are briefly discussed."	( Biochemical pharmacological determinants of drug action in cancer therapeutics. Mihich, E, 1980)	0.26
" The reasons are the better and more consistent bioavailability of intravenous versus oral MP, higher blood and CSF levels, compliance, and preliminary evidence suggesting superior remission experience for intravenous Mtx and 6MP than for Mtx alone."	( Intravenous mercaptopurine: life begins at 40. Pinkel, D, 1993)	0.29
" Lipophilic drug such as behenoyl ara-C is well absorbed and stored in red blood cell membrane, which is re-utilized effectively for the maintenance of plasma drug levels."	( [Pharmacodynamics and action mechanism of antitumor agents]. Nakamura, T; Ueda, T, 1993)	0.29
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under the curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
"8% was absorbed and metabolized to AraC and AraU, defining the metabolic bioavailability of this prodrug."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3
" The bioavailability of ara-C was about 4% via prodrug administration."	( Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C. Cheon, EP; Han, HK, 2007)	0.34
"Cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C, 1) suffers from low oral bioavailability due to low intestinal membrane permeability and poor metabolic stability, and intravenous infusion is usually adopted as the clinical standard dosing administration."	( Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Chen, Y; He, Z; Jing, Y; Li, G; Shi, S; Sun, J; Sun, Y; Xu, Y; Yin, S, )	0.13
" However, the bioavailability of Ara-C is relatively low due to its low lipophilicity."	( Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine. Cui, C; Cui, G; Duan, W; Liu, B; Liu, H; Peng, S; Wang, L; Zhao, M, 2009)	0.35
" We found no correlation with demographic, clinical, or biochemical parameters, and differences in bioavailability might be the most important explanation to interpatient variability."	( Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Britt-Marie, F; Curt, P; Frost, BM; Gudmar, L; Hasle, H; Hellebostad, M; Henrik, H; Josefine, P; Jukka, K; Kanerva, J; Kjeld, S; Lönnerholm, G; Marit, H; Palle, J; Petersson, C; Schmiegelow, K, 2009)	0.35
"Intrathecal chemotherapy is integral to curing childhood leukemia; however, bioavailability is limited by the blood-brain barrier."	( Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. Reilly, AF; Rheingold, SR; Seif, AE, 2010)	0.36
"Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)."	( Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ, 2012)	0.38
"Sodium metaarsenite (NaAs2O3: code name KML001) is an orally bioavailable arsenic compound with potential anti-cancer activity."	( Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside. Choi, JH; Kim, ES; Kim, S; Lee, YY; Park, BB; Won, YW; Yoon, JS, 2015)	0.42
" Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies."	( Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L, 2015)	0.42
" Bile acid transporters are highly expressed both in enterocytes and hepatocytes and to increase the oral bioavailability and investigate the potential application of cytarabine for liver cancers, a transporter- recognizing prodrug strategy was applied to design and synthesize four conjugates of cytarabine with cholic acid (CA), chenodeoxycholic acid (CDCA), hyodeoxycholic acid (HDCA) and ursodeoxycholic acid (UDCA)."	( Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. He, Z; Li, D; Shang, L; Sun, J; Zhang, D, 2016)	0.43
"CNDAC (2'-C-cyano-2'-deoxy-1-β-d-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematologic malignancies and solid tumors."	( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)	0.43
" However, the poor water solubility and low bioavailability observed with oral BBR administration has limited its clinical use."	( Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine. Gao, L; Gong, L; Li, J; Qiu, H; Shen, R; Shi, Z; Sun, H; Tian, Z; Yang, L; Zhang, G, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"1 μg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration."	( The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery. Early, PJ; Mancini, SL; Mariani, CL; Munana, KR; Olby, NJ; Pastina, BO, )	0.13

Excerpt	Relevance	Reference
" The analysis of the maintaining therapy in 22 patients affected with an acute myelocytic leukemia and living for more than 6 months revealed that the interval therapy with a high dosage of cytostatic combinations in the sense of the COAP scheme is preferable compared with the daily administration of 6-mercaptopurin, in addition methotrexate twice a week."	( [Problems in maintenance therapy in acute myeloid leukemias in adults]. Gürtler, R; Raderecht, C, 1975)	0.25
" This drug combination does not appear to offer any therapeutic advantage within the dosage range tested in disseminated malignant melanoma."	( Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma. Baker, LH; Izbicki, RM; Ratanatharathorn, V; Samson, MK, 1976)	0.26
" The ultimate goal will be to utilize this basic information to design an optimal dosage regimen and treatment schedule for the safe and effective cancer chemotherapy of each individual patient."	( Physiologically based pharmacokinetic models for anticancer drugs. Chen, HS; Gross, JF, 1979)	0.26
" The maximum concentrations of the two cytotoxic drugs were chosen to be twice the known peak plasma levels of commonly employed dosage schedules."	( Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Moody, MR; Morris, MJ; Moyé, LA; Schimpff, SC; Wiernik, PH; Young, VM, 1978)	0.26
" In fact, when the optimum dosage of 75 (mumol/kg)/day x 5 was used, the administration of ara-C alone was followed by an increased life span (ILS) of 45%."	( Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone. Hong, CI; Nechaev, A; West, CR, 1979)	0.26
" The validity of therapy with either of these drugs in generalized herpetic infections is questioned because activity was minimal against the infecting agent even when the dosage of the drug was sufficient to produce serious defects in certain developing tissues."	( Experimental infection with herpes simplex virus type 2 in newborn rats: Effects of treatment with iododeoxyuridine and cytosine arabinoside. Hatch, LA; Percy, DH, 1975)	0.25
" It is assumed that the treatment with cytarabine should be started as early as possible with a dosage of 3 mg/kg body weight given intravenously once a day in a single injection for 5 days."	( Cytarabine treatment of herpes simplex encephalitis in infants and small children. A report on three cases with a short review of the literature. Ekelund, H; Lagerkvist, B, 1975)	0.25
" The uniformly fatal course of the encephalitis was not altered by any dosage of cytosine arabinoside."	( Experimental herpes simplex virus encephalitis: Comparative effects of treatment with cytosine arabinoside and adenine arabinoside. Butler, SR; Casagrande, S; Fitzwilliam, JF; Griffith, JF, 1975)	0.25
" The mortality rate from viral infection was significantly reduced (greater than or equal to 30%) by the following treatment regimens: cytosine arabinoside, adenine arabinoside, iododeoxyuridine, and ribavirin, administered daily for seven consecutive days starting immediately after inoculation of virus, at dosage levels of 4-20 mg/kg, 20-100mg/kg, 100mg/kg, and 20-100 mg/kg, respectively; and chlorite-oxidized oxyamylose, polyriboinosinic-polyribocytidylic acid, and mouse interferon, administered 24 hr before viral challenge, as single doses of 100-500 mg/kg, 20mg/kg, and 10(7)-10(8) international reference units/kg respectively."	( Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs. De Clercq, E; Luczak, M, 1976)	0.26
" 46% complete and 12% partial remissions were obtained in 37 patients treated with cytosine arabinoside and 6-thioguanine doubling the dosage of the above mentioned regimen followed by 3 cycles of TRAP (and COAP)."	( [Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)]. Fülle, HH, 1977)	0.26
" Cerebrospinal fluid examination prior to the last dosage of cytosine arabinoside revealed a mononuclear pleocytosis and increased protein."	( Paraplegia following intrathecal cytosine arabinoside. Gale, RP; Wolff, L; Zighelboim, J, 1979)	0.26
" CA and CYT were each given in the dosage of 120 mg/m2 intravenously, daily in 3 divided doses, for 4 days."	( Improved survival in young children with acute granulocytic leukemia treated with combination therapy using cyclophosphamide, oncovin, cytosine arabinoside, and prednisone. Madanat, FF; Sullivan, MP, 1979)	0.26
" Cytosine-arabinoside at low dosage exhibited no toxicity, but did not delay the appearance of overt leukemia."	( Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias. Najean, Y; Pecking, A, 1979)	0.26
" Increase in lifespan of L1210 leukemia-bearing mice was demonstrated after intraperitoneal injection of Ara-C-AB with both the dosage schedules of three days before and one day after inoculation of L1210 cells at the dose of 30 mg equivalent Ara-C/kg."	( Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate. Hashida, M; Kojima, T; Muranishi, S; Sezaki, H, 1978)	0.26
" Cytosine arabinoside and hydroxyurea were unsuccessful and excessively toxic chemotherapeutic agents in this setting, although optimal dosing schedules were difficult to achieve because they caused moderately severe bone marrow suppression."	( Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Alberts, DS; Durie, BG; Salmon, SE, )	0.13
" At the dosages and dosage scheduling used, the double combination of 2'-dCF and 9-beta-D-arabinofuranosyladenine 5'-phosphate gave minimal but significant increases in life-span."	( Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210. Caron, N; Kimball, AP; Lee, SH, 1977)	0.26
" The induction therapy was repeated monthly up to the dosage limits imposed by daunorubicin cardiotoxicity in an attempt to lengthen subsequent remission duration."	( Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cassileth, PA; Katz, ME, 1977)	0.26
" It appeared necessary to further study the dosage and dosage schedule of the anticancer agents, along with the necessity for taking ample care of patients presenting such disorders."	( Effects of anticancer agents of the intestinal epithelium. A morphologic study. Itaya, H; Kitade, F; Teranishi, S, 1976)	0.26
" The most sensitive parameters in dose-response and cell-survival simulations are deoxycytidine kinase activity, ara-CTP half-life, renal clearance of ara-C, and cell-kinetic parameters for proliferation and cell killing."	( Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside. Aroesty, J; Carter, G; Lincoln, T; Morrison, P, 1976)	0.26
"More precise definition of the cytokinetic parameters of human tumor growth will clearly help both in predicting the outcome of disease in individual patients and in planning the dosage schedules of single chemotherapeutic agents and combinations of agents to achieve optimal results."	( Growth kinetics of solid tumors. Implications for chemotherapy. Curby, WA; Rosenoer, VM, 1975)	0.25
" Radiochromatography and bioassay data from BDF mice dosed intraperitoneally with cyclocytidine demonstrated that 65%-95% of the 14C-radioactivity in a number of tissues was the parent compound itself."	( Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice. Liss, RH; Neil, GL, )	0.13
" Also discussed are the sensitivity of drug effects to variation in dosage schedule and the different nodes of drug actions exerted on each cell cycle phase."	( Analysis of the effects of antitumor drugs on cell cycle kinetics. Brenkus, LB; Wiig, KM; Woo, KB, )	0.13
" The dose-response curve of [125I] Iododeoxyuridine ([125I]dUrd) incorporation toward bFGF was parallel to that of CST specific activity, and maximal stimulation was reached at 5 ng/ml bFGF for both."	( Differential regulation of cerebroside sulfotransferase and 2',3'-cyclic nucleotide 3'-phosphodiesterase by basic fibroblast growth factor in relation to proliferation in rat oligodendrocyte cultures. Dalençon, D; Fressinaud, C; Labourdette, G; Sarliève, LL, 1992)	0.28
" Both methods can be used to assess the sensitivity of blasts to chemotherapeutic drugs, but different dose-response curves are obtained with each."	( A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia. McCulloch, EA; Yang, GS, 1992)	0.28
" Individual differences in plasma level courses with identical dosage are irrelevant regarding treatment response."	( [Is the pharmacokinetic profile of cytarabine clinically relevant?]. Boos, J, )	0.13
" Larger numbers of patients will be needed to ascertain whether specific guidelines for dosage modifications can be made on the basis of serial WBC."	( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Blatt, J; Gula, MJ; Lucas, K, )	0.13
" Unlike the other currently available anthracyclines, idarubicin has significant oral bioavailability (average 28%), and an oral dosage form is currently under investigation."	( Idarubicin: an anthracycline antineoplastic agent. Cersosimo, RJ, 1992)	0.28
" The dosage of cytarabine in the intensive consolidation arm is 3 gm/M2/day IV on days 1-6."	( Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Andersen, JW; Bennett, JM; Cassileth, PA; Harrington, DP; Hines, JD; Lazarus, HM; Mazza, JJ; McGlave, PP; O'Connell, MJ; Paietta, E, 1992)	0.28
" Our analysis shows that the elimination of somatic cells or viruses depends not only on the drug's pharmacokinetic and pharmacodynamic properties, but also the duration of the dosing interval per se and on the life-cycle parameters, that is, the duration of the drug-susceptible life phase, the duration of the whole life cycle, and the proliferation rate."	( A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Agur, Z; Cojocaru, L, 1992)	0.28
" Although 2008/C13 cells were slightly cross-resistant to 4-hydroperoxycyclophosphamide, the drug displayed a steep dose-response (colony growth inhibition) effect toward these cells."	( Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Bhalla, K; Bullock, G; Holladay, C; Ibrado, AM; Jasiok, M; Lutzky, J; Singh, S, 1992)	0.28
" These models predict that toxicity to the host of cell-cycle-phase-specific drugs can be minimised if the dosing interval is an integer multiple of the average intermitotic interval of the susceptible host cells."	( Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Agur, Z; Arnon, R; Schechter, B, 1992)	0.28
" Of all the tested drug dosage levels (25, 50, and 75 mg/kg, respectively) compound 23 had no toxic deaths and compound 22 yielded only one toxic death at the highest dosage level."	( Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride. Birnbaum, GI; Cheng, YC; Clarke-Katzenburg, RH; Gabe, EJ; Giziewicz, J; Lin, TS; Liu, MC; Luo, MZ; Mancini, WR; Prusoff, WH, 1991)	0.28
" BH-AC inhibited the replication of HCMV and depicted almost as the same dose-response curve as Ganciclovir (DHPG)."	( Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. Eizuru, Y; Kumura, K; Minamishima, Y; Nakamura, K, 1990)	0.28
" Dose-response curves for each agent indicate the following absolute potency: FUDR greater than FUR greater than ARA-C greater than 5-FU = bleomycin greater than DFUR."	( Evaluation of antiproliferative agents using a cell-culture model. Senderoff, RI; Smith, DR; Sokoloski, TD; Weber, PA, 1990)	0.28
" The dosage and schedules, clinical pharmacology and toxicities of the commonly used intrathecal agents, methotrexate and cytarabine (cytosine arabinoside; Ara-C) are discussed in detail."	( Current pharmacological treatment approaches to central nervous system leukaemia. Balis, FM; Blaney, SM; Poplack, DG, 1991)	0.28
" OCI/AML-4 cells are sensitive to cytosine arabinoside (ara-C), but the ara-C dose-response curve can be changed by altering the regulatory milieu in suspension culture."	( OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside. Koistinen, P; Lyman, SD; McCulloch, EA; Minden, MD; Wang, C; Wang, YF; Williams, DE; Yang, GS, 1991)	0.28
"This report describes an unexpected adverse effect in three children receiving teniposide at 3-5 times the conventional dosage (i."	( Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Baker, DK; McLeod, HL; Pui, CH; Rodman, JH, 1991)	0.28
" Late intensification consisted of a 5-day course of ARA-C and one dose of ADR which was repeated until the cumulative dosage of ADR reached 465 mg/m2."	( Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group. Bessho, F; Kigasawa, H; Nakazawa, S; Ohkawa, Y; Sugita, K; Tsuchida, M; Tsukimoto, I; Tsunematsu, Y; Yamada, K; Yamamoto, M, 1991)	0.28
" Control blasts exposed to increasing ara-C concentrations gave very similar dose-response curves; in striking contrast, blast cells cultured in hydrocortisone, then pulsed with ara-C did not lose colony-forming ability even though the same population was sensitive to 3HTdR."	( Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside. McCulloch, EA; Minden, MD; Minkin, S; Wang, C; Yang, GS, 1991)	0.28
" As mitoxantrone exhibits a steep dose-response curve against ovarian cancer cells and acute myeloid leukemia cells in vitro, we evaluated the safety and efficacy of high dose mitoxantrone with HiDAc in the treatment of ALL."	( Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Ahmed, T; Arlin, ZA; Arnold, P; Baskind, P; Cook, P; Feldman, EJ; Finger, LR; Mittelman, A; Puccio, C; Razis, ED, 1991)	0.28
" The patients were randomised at diagnosis to receive either three further courses of Ara-C (five days) and DNR (two days) in the same dosage or three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation."	( Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology. , 1991)	0.28
" Maintenance with the same drugs in a modified dosage schedule continued for approximately 2 years."	( Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. Belasco, JB; Luery, N; Scher, C, 1990)	0.28
" It was shown, that under certain conditions the use of definite components allows for preparing a dosage form of lyophylized sterile liposomal cytarabine capable of being stored for a year."	( [Various aspects of production of a therapeutic form of liposomal cytarabine]. Afonin, NI; Oksinoĭd, OE; Pleteneva, OP, 1990)	0.28
"In order to reduce the incidence of severe complications noted with regimens containing high-dose cytarabine (HD ARA-C), wer used a combination of mitoxantrone (MTZ) in optimal dosage (12 mg/m2/day for 5 days) and cytarabine in intermediate dosage (1 g/m2 twice daily for 3 or 5 days)."	( Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N, 1990)	0.28
"Cytosine arabinoside (ara-C) is being employed at low dosage as differentiative rather than a cytotoxic agent in the therapy of leukemias."	( Synthesis of a 60 kD nuclear DNA binding protein induced by cytosine arabinoside in the HL 60 leukemic cell line. Bianchi-Scarră, G; Capra, V; Fiorentini, P; Garrĕ, C; Ravazzolo, R, 1990)	0.28
" Modifications in timing and dosage and the addition of hematopoietic growth factors will be evaluated in subsequent trials."	( Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group. Hiddemann, W; Kirchner, H; Koch, P; Maschmeyer, G; Ollech-Chwoyka, J; Pflüger, KH; Pfreundschuh, M; Schmitz, N; Tirier, C; Wagner, T, 1990)	0.28
" Four different graphic representations of the raw data and fitted curves provide visual indications of goodness of fit of the estimated dose-response surface to the data and visual indications of the intensity of drug interaction."	( Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Greco, WR; Park, HS; Rustum, YM, 1990)	0.28
" For each drug in each cell line, a highly reproducible dose-response relationship was observed."	( Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Averette, HE; Boike, G; Nguyen, H; Perras, J; Petru, E; Ramos, R; Sevin, BU, 1990)	0.28
" The risk for a drug interaction under these conditions is high, and the pharmacological characteristics of the anti-cancer drugs, such as steep dose-response curves, low therapeutic indices and severe toxicities, suggest that even small changes in the pharmacokinetic profile of the affected drug could significantly alter its toxicity or efficacy."	( Pharmacokinetic drug interactions of commonly used anticancer drugs. Balis, FM, )	0.13
" The schedule and dosage of each chemotherapy were as follows."	( [Non-cross-resistant sequential combination chemotherapy consisting of cis-diammine-dichloroplatinum (II) mainly, based on synchronization theory, in human bladder cancer xenografts in athymic nude mice]. Okada, K; Yamauchi, T; Yoshida, O, 1986)	0.27
" For aza-dC a dose-response relationship was demonstrated for doses up to 50 mg kg-1 (3 times q 12 h); a higher dose resulted in only a slight increase in median survival time (MST)."	( Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Colly, LP; Lurvink, E; Richel, DJ; Willemze, R, 1988)	0.27
" Reproducible dose-response data were obtained with cells treated with radiation or drugs and assayed after 4 days in culture."	( A novel dye exclusion assay for measurement of cell response following in vitro exposure to radiation or drugs. Bean, EA; Hanson, JA; Moore, JL; Nute, SR, 1989)	0.28
" 3H-thymidine incorporation was measured after the addition of drug or vehicle to these confluent cells, and dose-response curves were generated."	( An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Botti, RE; Imperia, PS; Lass, JH; Lazarus, HM; Mack, RJ, 1989)	0.28
" Fourteen of 15 episodes of streptococcal sepsis occurred after therapy with either continuous or large dosage intermittent cytosine arabinoside."	( Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Cullen, J; Freeman, AI; Hicks, RA; Jackson, MA; Sotiropoulos, SV; Woods, GM, 1989)	0.28
" At every dosage examined, pretreatment with etoposide given 6 hr before ara-C was the most effective antitumor schedule in L1210 leukemia."	( [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia]. Kawasaki, H; Ohkubo, T; Ooi, K; Sakurai, M, 1989)	0.28
" Low dosage Ara-C has been used with great success in several clinical trials."	( Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells. Hassan, HT; Rees, JK, 1989)	0.28
" In order to reduce the incidence of severe complications noted with HDARA-C-containing regimens, we used a combination of intravenous (IV) idarubicin (IDARUB) at optimal dosage and cytarabine (ARA-C) at intermediate dosage."	( Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F, 1989)	0.28
" Several dose-response schedules and various sequences were tested to determine the optimal delivery schedule."	( Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. Berek, JS; Knox, RM; Schink, JC, 1989)	0.28
" FETAX advantages include rapid data collection, the ability to measure stage-dependent effects, and the ability to use a large number of embryos to obtain excellent dose-response curves with narrow confidence limits."	( Analysis of the activity of DNA, RNA, and protein synthesis inhibitors on Xenopus embryo development. Bantle, JA; Courchesne, CL, 1985)	0.27
" The data also demonstrated effectiveness with aqueous and solid dosage forms (Witepsol H-15 suppositories)."	( Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract. Alexander, J; Engle, K; Fix, JA; Gardner, CR; Leppert, PS; Porter, PA; Selk, SJ, 1986)	0.27
" Dosage decisions were based on whether or not the antibody-dependent cellular-cytotoxicity (ADCC) or natural killer (NK) cytotoxicity levels had been reduced to a level more than 2 standard deviations below the control range."	( Cytosine arabinoside induced changes in natural killer and antibody dependent cellular cytotoxicity functions in multiple sclerosis patients. Durkos-Smith, D; Ellison, GW; Fahey, JL; Moody, DJ; Myers, LW, 1986)	0.27
" The cytostatic effect of cytosine arabinoside (ara-C) prodrug liposomes against L1210 leukemia showed to be superior to free ara-C treatment in respect to drug dosage and treatment schedule."	( [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy]. Hartmann, HR; Hengartner, H; Rubas, W; Schott, H; Schwendener, RA; Supersaxo, A, 1987)	0.27
" The preliminary results of a cooperative protocol using very low dosage of cytosine arabinoside (3mg/m2/twice daily) with or without androgens are given."	( Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature. Baumelou, E; Calvo, F; Casassus, P; Chomienne, C; Ciccone, F; Degos, L; Fenaux, P; Gris, JC; Najean, Y; Thomas, G, 1987)	0.27
" Both patients exhibited significant increases in Ph-positive cells, to 46 and 72% of marrow metaphases, during subsequent chemotherapy with hydroxyurea, in dosage sufficient to maintain granulocytopenia and a normal serum B12 level."	( Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Bigner, SH; Gockerman, JP; Sokal, JE, 1988)	0.27
" The dose-response curves resulting from either the survival factors or the clonogenic assay were always nearly identical."	( Drug testing in established cell lines by flow cytometric vitality measurements versus clonogenic assay. Dörmer, P; Ellwart, JW; Kremer, JP, 1988)	0.27
" Regression analysis of the dose-response curves was used to assess the drug concentration that inhibited 90% +/- 5% (LD90) of colony growth."	( Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosyl-cytosine, and etoposide. Barreau, P; Calvo, F; Cavazzana, M; Dal Cortivo, L; Dresch, C; Facchin, P; Geny, B, 1988)	0.27
" We have identified both an effective and a toxic dosing schedule."	( Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Canellos, GP; Ernst, TJ; Griffin, JD; Rosenthal, DS, 1988)	0.27
"0 microM, was included with each agent in dose-response studies, a synergistic enhancement of the antiproliferative effects was observed."	( Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Cohen, A; Estrov, Z; Freedman, MH; Gelfand, EW, 1988)	0.27
" The optimal dosing for MV26PD remains to be determined."	( Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. Anderson, J; Bloomfield, CD; Cooper, MR; Ginsberg, SJ; Gottlieb, AJ; Hurd, DD; Lachant, NA, 1988)	0.27
" Dose-response curves for cisplatin or fluorouracil on MTS cells closely followed those from monolayer cells, indicating good drug penetration into the MTS core."	( Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids. Biller, HF; Holland, JF; Kohno, N; Ohnuma, T, 1988)	0.27
" No clear daily dose-response was noted."	( [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)]. Kimura, K; Ohno, R, 1988)	0.27
" It is suggested that DNA repair processes determining a linear component of the dose-response curve are modified within the dose-range under study."	( [Cytogenetic effect of irradiation and subsequent cytosine arabinoside and hydroxyurea treatment on Chinese hamster cells in the G1 phase of the cell cycle]. Elisova, TV; Feoktistova, TP; Stavrakova, NM, )	0.13
" Marked patient-to-patient variation was found using either method; however, the slopes of the dose-response curves were usually greater when cells were exposed to drug in suspension rather than in methylcellulose."	( The sensitivity to cytosine arabinoside of the blast progenitors of acute myeloblastic leukemia. Curtis, JE; McCulloch, EA; Nara, N; Senn, JS; Tritchler, DL, 1986)	0.27
" The dosage was 150 mg/m2/dose for each drug."	( Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood. Arakawa, S; Esumi, N; Imashuku, S; Todo, S, 1986)	0.27
"Sixty-four patients with refractory acute leukemia were treated with high-dose cytosine arabinoside given at a dosage of 3 g/m2 intravenously over two hours every 12 hours for four to 12 doses, repeated at two- to three-week intervals."	( Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Estey, EH; Freireich, EJ; Iacoboni, S; Kantarjian, HM; Keating, MJ; McCredie, KB; Plunkett, W; Walters, RS, 1986)	0.27
" The cytotoxic effect of cytosine arabinoside even at low dosage remains important."	( [Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine]. Audhuy, B; Barats, JC; Blaise, AM; Boilletot, A; Flesch, M; Herbrecht, R; Pignon, B; Rozenbaum, A, 1986)	0.27
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)."	( Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987)	0.27
"In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals."	( [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas]. Benavides, M; Delgado, M; Gastiaburu, J; Goldschmidt, E; Machover, D; Mathe, G; Misset, JL; Vandenbulcke, JM, 1987)	0.27
"The dose-response relationship between extracellular concentration of cytosine arabinoside (ara-C) and intracellular formation of the putative active metabolites of ara-C [ara-C incorporation into DNA and intracellular pools of ara-C in triphosphate form (ara-CTP)] was investigated in blast cells obtained from patients with acute nonlymphocytic leukemia (ANLL) by exposing these cells in vitro to 10, 100, or 1,000 nmol/L of ara-C."	( Metabolism of ara-C by blast cells from patients with ANLL. Akman, SA; Joneckis, CC; Ross, DD; Schiffer, CA; Thompson, BW, 1986)	0.27
" Higher daily doses (5 mg/kg or more) produced higher CR rates, and all of the CR were observed among the patients receiving a total BHAC dosage of 50 mg/kg or more in a period of 10 days or more."	( Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Amaki, I; Hattori, K; Hirota, Y; Hoshino, A; Ichimaru, M; Ito, M; Kimura, I; Kimura, K; Maekawa, T; Ohno, R, 1985)	0.27
" The drug was infused to 4 patients with pre-leukemia (refractory anemia with excess blasts), 5 patients with acute myelogenous leukemia, and 2 patients with secondary leukemia due to chemotherapy, at a dosage of 20 mg/m2/day over 21 days."	( Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Allen, S; Budman, DR; Chan, K; Chaudhri, F; Deere, M; Freeman, J; Kreis, W; Schulman, P; Vinciguerra, V; Weiselberg, L, 1985)	0.27
" It partly depends on dosage and partly on duration of treatment."	( [Non-hematologic toxicity in high-dose cytarabine therapy]. Küchler, R; Kuse, R, 1985)	0.27
" approximately a factor of two in the linear (low dose) portion of the dose-response curve."	( The role of short-lived DNA lesions in the production of chromosome-exchange aberrations. Gumauskas, E; Holmberg, M, 1986)	0.27
" The drug combination was administered by intravenous infusion twice a week for two consecutive weeks at a dosage of 150 mg/m2 for each drug."	( [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia]. Arakawa, S; Esumi, N; Imashuku, S; Todo, S, 1986)	0.27
" We therefore, attempted to improve the complete remission rate in patients with low ara-CTP levels by decreasing the intermittent ara-C dosing interval, thereby raising the minimum ara-CTP level in leukemic cells between doses."	( Pharmacologically directed ara-C therapy for refractory leukemia. Danhauser, L; Estey, E; Iacoboni, S; Keating, MJ; Liliemark, JO; Plunkett, W, 1985)	0.27
" A dose-response relationship existed when therapy was initiated at 4 h after virus inoculation."	( Antiviral activity of cytarabine in herpesvirus-infected rats. Renis, HE, 1973)	0.25
" 14C levels in most tissues were higher at 4 hr than at 12 hr after dosing and were generally undetectable at 24 hr."	( Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats. Parker, RJ; Priester, ER; Sieber, SM, )	0.13
" With the exception of high dose methotrexate, drug doses and administration schedules remain empirical with a standard starting dose and subsequent dosage modifications determined by ensuing drug toxicities."	( Clinical pharmacokinetics of commonly used anticancer drugs. Balis, FM; Bleyer, WA; Holcenberg, JS, )	0.13
"Four types of 1-beta-D-arabinofuranosylcytosine (ara-C) conjugates with poly-L-glutamic acid (PLGA) or poly-N5-(2-hydroxyethyl)-L-glutamine (PHEG) were prepared in an attempt to enhance the efficacy of the drug in simple dosage schedules."	( Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Fukushima, H; Hara, T; Kato, Y; Saito, M; Takeda, Y, 1984)	0.27
" It was concluded that although the 3 assays did not produce identical dose-response curves, the assays were equally valid when used for predictive testing because selection of cut-off points which were based on retrospective correlations between in vitro sensitivity data and response data, as established by other authors, compensated for differences in sensitivity between the assays."	( A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. Ford, CH; Howell, A; Newman, CE; Wilson, AP, 1984)	0.27
"The cytokinetic response of Ehrlich ascites tumor (EAT) cells in vivo upon chronic treatment at low dosage levels with cytarabine (1-beta-D-arabinofuranosylcytosine, ara-c) bleomycin (BLM) and peplomycin (PEP) was estimated."	( Cytostatic and cytotoxic response of Ehrlich ascites tumor cells in vivo on chronic treatment with cytarabine, bleomycin, and peplomycin. Engel, P; Friedel, G; Futterman, G; Goerttler, K; Stoehr, M, 1984)	0.27
" The dose-response curve for NCS-induced damage suggested a two-hit-type event in the formation of chromosome breaks."	( Induction and repair of DNA and chromosome damage by neocarzinostatin in quiescent normal human fibroblasts. Hittelman, WN; Pollard, M, 1982)	0.26
" In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg."	( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. Hsiung, GD; Mayo, DR, 1984)	0.27
"Ara-C at very low dosage has been reported to decrease the host toxicity of ara-AMP or ara-A in combination with 2'-deoxycoformycin, a potent adenosine deaminase inhibitor, while increasing the toxicity to intracerebral L1210 leukemia."	( Biochemical and biophysical approaches to improving the anticancer effectiveness of Ara-adenine. Eyring, H; Miles, DL; Miles, DW, 1982)	0.26
" The dosage levels explored were 60, 120, 240, 400, and 600 mg/sq m/day."	( Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection. Armstrong, D; Fox, JJ; Leyland-Jones, B; Lopez, C; Philips, FS; Schneider, R; Tan, CT; Watanabe, KA; Young, CW, 1983)	0.27
" Only a large dosage increment of AraC can overcome refractoriness of leukaemic blast cells."	( Experience with intermediate and high dose cytosine arabinoside in refractory acute leukaemia. Fibbe, WE; Willemze, R; Zwaan, FE, 1983)	0.27
" Therapeutic response to both drugs has been linked to plasma concentration of parent compound, and a nonlinear dose-response relationships might exist at high doses."	( Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Powis, G, 1983)	0.27
"Between July 1, 1981 and November 1, 1982, 45 patients with acute nonlymphocytic leukemia (age, greater than or equal to 70 years) were randomly assigned to receive induction chemotherapy using either daunorubicin, cytosine arabinoside, and 6-thioguanine in full dosage (F DAT) or an attenuated schedule of the same drugs (At DAT) as part of an Eastern Cooperative Oncology Group controlled trial."	( Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. Begg, CB; Bennett, JM; Bonner, H; Glick, JH; Kahn, SB; Mazza, JJ, 1984)	0.27
" 5-Fluorouracil at high dosage may cause cerebellar ataxia, but may also do so at low dosage when combined with thymidine infusions."	( Neurological complications of antineoplastic therapy. Shapiro, WR; Young, DF, 1984)	0.27
" It is suggested that ocular toxicity results from inhibition of corneal epithelial DNA synthesis and is related to both drug dosage and duration of drug exposure."	( Ocular toxicity from high-dose cytosine arabinoside. Hansen, RM; Heuer, DK; Ritch, PS, 1983)	0.27
" PL-AC was given orally at a dosage of 50-1200 mg daily."	( [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies]. Ishigami, S; Kubota, Y; Masaoka, T; Nakamura, H; Shibata, H; Takubo, T; Tanaka, T; Ueda, T; Yoshitake, J, 1983)	0.27
" Morphological studies and indirect evidence suggest that this schedule, dosage and route of administration for cytosine-arabinoside may promote differentiation within the malignant clone rather than acting as a cytotoxic agent."	( [Reduced dosage of cytosine arabinoside in the treatment of acute myelocytic leukemia. Apropos of 3 cases]. Andrey, C; Beris, P; Chapuis, B; de Loes, S; Maurice, P; Plancherel, C, 1983)	0.27
" A group of 16 patients in relapse received idarubicin at a dosage of 5-6 mg/m2/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine."	( Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia. Lambertenghi-Deliliers, G; Maiolo, AT; Pacciarini, MA; Pogliani, E; Polli, EE, 1983)	0.27
" The initial and terminal half-lives were not influenced by the dose or schedule of administration and no accumulation of ara-C occurred with repeated dosage in the same patients."	( Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. Aherne, GW; Harvey, VJ; Johnston, A; Lister, TA; Piall, EM; Slevin, ML, 1983)	0.27
" Rechallenge with a lower dosage prompted a rapid rise in the levels, with subsequent return to normal when the medication was withdrawn."	( Reversible hepatotoxicity related to amphotericin B. Miller, MA, 1984)	0.27
" By comparing a continuous Ara-C infusion during 24 h with two Ara-C injections at the same total dosage given 12 h apart, it was found that the tumor load was significantly more reduced in the latter group."	( Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia. Colly, LP; Hagenbeek, A; van Bekkum, DW, 1984)	0.27
" We conclude that cytosine arabinoside at this dosage causes a cerebellar degeneration with characteristic clinical and pathological features."	( Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Hines, JD; Winkelman, MD, 1983)	0.27
" Preliminary pharmacokinetic data were obtained in mice and humans to determine appropriate dipyridamole dosage ranges for in vitro testing."	( Modulation of cytarabine uptake and toxicity by dipyridamole. Howell, SB; King, ME; Naporn, A; Young, B, 1984)	0.27
" Although the dosage of the anticancer chemotherapy was quite small, this treatment may have promoted the regression of the tumor in conjunction with activated antitumor immunity of the host."	( [A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy]. Furuta, K; Hara, K; Kiyomitsu, Y; Nakazaki, S; Shinoda, M; Watanabe, K; Yajima, K; Yasuda, S; Yokoyama, T, 1984)	0.27
" We now report on the preferential induction of cytostasis by anguidine in normal WI-38 fibroblasts, occurring at one-tenth of the dosage required to inhibit the cycle progression of WI-38 VA13 cells, the SV40 transformant."	( Selective protection by anguidine of normal versus transformed cells against 1-beta-D-arabinofuranosylcytosine and Adriamycin. Barlogie, B; Drewinko, B; Hromas, R; Swartzendruber, D, 1983)	0.27
" Twenty years later the optimum dosage and schedule are still being sought."	( Introduction to the symposium on high-dose cytosine arabinoside. Henderson, ES, 1982)	0.26
" Two other non-T-/non-B-cells showed unique ara-C dose-response curves."	( Differences in chemotherapeutic susceptibility of human T-, B-, and non-T-/non-B-lymphocytes in culture. Arkin, H; Holland, JF; Ohnuma, T, 1980)	0.26
" Strong suppression of mitogen-induced polyclonal activation by MDP was obtained by using a large range of cell concentrations in cultures and over various dosage levels of the stimulating mitogens (LPS and NWSM)."	( Inhibition of mitogen-induced polyclonal activation by by a synthetic adjuvant, muramyl dipeptide (MDP). Bourgeois, E; Chedid, L; Leclerc, C; Löwy, I, 1980)	0.26
" Kinetics of ara-C were not altered by repeated dosing over a 6-day period."	( Effects of high-dose cytarabine. Greco, FA; Hande, KR; McDonough, DA; Stein, RS; Wolff, SN, 1982)	0.26
" at a total daily dosage of 15 to 100 mg/kg, was found to inhibit the incorporation of [3H]TdR into cortical DNA and also inhibited the proliferation of glial cells after cortical trauma."	( Effects of DNA synthesis inhibitors on post-traumatic glial cell proliferation. Billingsley, ML; Mandel, HG, 1982)	0.26
" Chemotherapy was given by vein twice a week for four weeks at dosage of 300 mg/m2 for ara-C and 50, 75, 110, 165, or 200 mg/m2 for VM-26."	( Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Aur, RJ; Avery, TL; Dahl, GV; Pratt, CB; Rivera, G; Wood, A, 1980)	0.26
" When the optimum dosage of ara-C [38 (mumol/kg)/day X 5] was given to mice bearing L1210, the ILS value found was 89%."	( Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids. Buchheit, DJ; Hong, CI; Kirisits, AJ; Nechaev, A; West, CR, 1980)	0.26
"Double dosing and single sampling seems to be the simplest and most reliable method for detecting clastogens in the mouse peripheral blood micronucleus test."	( An optimal, generalized sampling time of 30 +/- 6 h after double dosing in the mouse peripheral blood micronucleus test. Higashikuni, N; Sutou, S, 1995)	0.29
"0448) than did those who received octreotide at the 150 micrograms dosage level."	( Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Davidson, TG; Dix, SP; Geller, RB; Gilmore, CE; Holland, HK; Lin, LS; Topping, DL; Wingard, JR, 1995)	0.29
" To summarize the dose-response curves obtained in this assay, we considered a model that assumes the existence of a resistant subpopulation of progenitor cells."	( Assessing sensitivity in suspension to cytosine arabinoside: statistical analysis, associations with clinical outcome and experimental design. Chow, A; Minkin, S, )	0.13
" Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin."	( Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Capizzi, RL; Fleming, RA; Oliver, LK; Omura, GA; Peterson, BA; Rosner, GL; Schiffer, CA; Silver, RT; Smith, SJ; Weiss, RB, 1995)	0.29
" Anthracycline dose-response curves are characterized by an initial shoulder, followed by exponential decrease in survival with increasing dose."	( Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. McCulloch, EA; Minden, MD; Yang, GS, 1994)	0.29
"The therapeutic efficacy of cell cycle phase-specific drugs can be improved by repeated administrations, the dosing interval being related to the cell cycle time of the susceptible normal host tissue."	( Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Agur, Z; Schechter, B; Tagliabue, G; Ubezio, P, 1994)	0.29
"These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger."	( Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. Berg, DT; Davis, RB; Frei, E; Mayer, RJ; McIntyre, OR; Moore, JO; Omura, GA; Powell, BL; Schiffer, CA; Schulman, P, 1994)	0.29
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction."	( Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994)	0.29
" Nevertheless, we found a dose-response effect in these patients with relapsed and resistant Hodgkin's disease."	( Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D, 1993)	0.29
"Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells."	( High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Bhalla, K; Bullock, G; Grant, S; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Tang, C; Tourkina, E, 1993)	0.29
" For consolidation with NOVE, rhGM-CSF was given according to the same dosage schedule."	( Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B, 1993)	0.29
"Twenty-seven patients with B-cell chronic lymphocytic leukemia (CLL) or a related lymphoid malignancy were treated with high-dose cytosine arabinoside (ara-C) at a dosage of 3 gm/m2 administered over 2 hours every 12 hours at one to four doses per course, which were repeated at 4-week intervals."	( High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Estey, E; Hagemeister, FB; Hall, R; Kantarjian, HM; Keating, MJ; McLaughlin, P; Plunkett, W; Robertson, LE, 1993)	0.29
" In the trial, the dosage of granisetron tablet was 2 mg once a day, and the drug was given before each chemotherapy for 6 consecutive days."	( [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993)	0.29
" Considering effectiveness and safety, the clinical optimal dosage of Idarubicin when used concomitantly with Cytarabine was judged to be 12 mg/m2 once daily for 3 consecutive days."	( [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group]. Kimura, K; Masaoka, T; Ogawa, M; Yamada, K, 1993)	0.29
" These in vitro studies support our hypothesis that enhanced metabolism of ara-C in DS cells may be a contributing factor to the superior survival rate of DS children with AML and is possibly based on a gene dosage effect of genes localized to chromosome 21 including cystathionine-beta-synthase."	( Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Buck, SA; Gurney, JG; Matherly, LH; Ravindranath, Y; Stout, ML; Taub, JW, 1996)	0.29
" These patients received a total of 16 doses of busulfan dosed as 1 mg/kg/dose q 6 h beginning at 09."	( Association of busulfan area under the curve with veno-occlusive disease following BMT. Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC, 1996)	0.29
" After initial chemotherapy, he received intravenous methotrexate (total dosage 1,035 mg), intrathecal methotrexate (total dosage 221 mg), and whole brain irradiation (2,400 cGy)."	( Lenńox-Gastaut syndrome associated with leukoencephalopathy. Ikuta, H; Mitsufuji, N; Sawada, T; Yoshioka, H, 1996)	0.29
" Cytosine arabinoside was administered on day 1 of the treatment cycle at 0h and 12h at the dosage of 500 mg/m2 (1 hour infusion), and cisplatin at 6h and 18h of the same day with a dose of 20 mg/m2."	( Modulation of cisplatin antitumor activity by short infusional high-dose cytosine arabinoside in advanced pretreated head and neck carcinoma: a phase II study. Jelic, S; Kovcin, V; Mitrovic, L; Nikolic-Tomasevic, Z; Popov, I; Radulovic, S; Tomasevic, Z, 1996)	0.29
" Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone."	( Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996)	0.29
") over 30 minutes daily on days 1 to 3, in combination with BH-AC 300 mg/m2 over 4 hours daily on days 1 to 7 (in patients aged 41 to 65 years, BH-AC dosage was decreased to 200 mg/m2/d)."	( Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS, 1996)	0.29
" For cytosine arabinoside, the dose-response curve is a simple negative exponential that can be described by a D10 value, a measure of slope."	( Regulation of the synthesis of bcl-2 protein by growth factors. Hu, ZB; McCulloch, EA; Minden, MD, 1996)	0.29
" FLANG (27 patients) had a shorter duration (3 days), reduced Ara-C dosage (1 g/sqm) and administration of mitoxantrone (10 mg/sqm) at the end of Ara-C infusion."	( High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Balleari, E; Canepa, L; Carrara, P; Celesti, L; Cerri, R; Clavio, M; Damasio, E; Gatti, AM; Ghio, R; Gobbi, M; Miglino, M; Patrone, F; Pierri, I; Sessarego, M; Vallebella, E, )	0.13
" No difference in toxicity was observed between the two dosage regimens."	( A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Ahmed, T; Beer, M; Case, DC; Damon, L; Feldman, EJ; Linker, C; Ries, C; Rugo, H; Seiter, K, 1997)	0.3
" Recombinant GM-CSF was initially administered at standard dosage (5 micrograms/kg/day) until a white blood cell count > or = 2 x 10(9)/L was achieved on two consecutive examinations, and thereafter at a low dose (1 microgram/kg/day) for 5 to 9 months."	( Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Andrizzi, C; Carlo-Stella, C; Garau, D; Mandelli, F; Meloni, G; Montefusco, E; Regazzi, E; Rizzoli, V; Savoldo, B; Vignetti, M, )	0.13
" We describe the case history of a woman with advanced breast cancer, presenting with superior vena cava obstruction occurring after radiotherapy and chemotherapy, who had a durable remission following inadvertent dosing with cytarabine."	( A durable response to cytarabine in advanced breast cancer. Czaykowski, PM; Oza, A; Samuels, T, 1997)	0.3
"Treated with low dosage (5 ng."	( [Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells]. Fang, M; Wang, RH; Xue, SB; Zhang, HQ, 1996)	0.29
" The dose-response relationships are biphasic ("bell shaped"), maximal responses being obtained with 10(-6) M concentrations of MPF."	( Trophic effects of melanotropin-potentiating factor (MPF) on cultures of cells of the central nervous system. Allen, YS; Ensor, DM; Miles, JB; Morley, JS; Owen, DB, 1997)	0.3
" At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing."	( Topotecan in combination chemotherapy. Kaufmann, SH; Rowinsky, EK, 1997)	0.3
" These studies provide clinical evidence that a dose-response effect is present for cytarabine in AML."	( Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Bishop, JF; Bradstock, K; Lowenthal, RM; Matthews, JP; Young, GA, 1998)	0.3
" These results suggest that increasing DNM dosage in induction is one of the possible approaches to improve the outcome of adult ALL by decreasing the relapse occurrence."	( Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. April, F; Meneghini, V; Perona, G; Pizzolo, G; Ricetti, MM; Solero, P; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R, 1998)	0.3
" The IC consisted of methotrexate, hydrocortisone and cytarabine, dosed according to patient age."	( Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Chavez, CM; Holdsworth, MT; Raisch, DW; Winter, SS, 1998)	0.3
"The hematologic toxicity of arabinosylcytosine (Ara-C) and carboplatin (CBDCA) as well as the stimulating effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on murine bone marrow vary according to their dosing time along the 24-h time scale."	( Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice. Deschamps de Paillette, E; Filipski, E; Lévi, F; Li, XM; Soulard, C, 1998)	0.3
" Additional studies with TPA after the determination of optimum dosing regimens are needed to determine whether long-lasting or permanent remissions of myelocytic leukemia can be achieved."	( Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Cao, GS; Chang, RL; Conney, AH; Han, ZT; Liu, XJ; Newmark, HL; Sun, JZ; Tian, GF; Yang, RY; Zhu, XX, 1998)	0.3
" The data suggest a dose-response relationship for increasing doses of idarubicin with 0/3 complete responses (CR) at 20 mg/m2, 1/3 CR at 30 mg/m2, and 7/12 (58%) CR at idarubicin doses > or = 40 mg/m2."	( A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Drullinsky, P; Golde, DW; Maslak, P; Scheinberg, D; Weiss, MA, 1998)	0.3
"Although cytosine arabinoside (AraC) represents the most effective single agent in the treatment of adults with acute myeloid leukemia (AML) when given at doses exceeding 200 to 500 mg per application, its optimal dosage is still a matter of controversial discussion."	( Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Aul, C; Bartholomäus, A; Bettelheim, P; Büchner, T; Hiddemann, W; Kern, W; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R; Wörmann, B, 1998)	0.3
" After administration of YNK01 at a dosage of 100-150 mg/m2 plasma levels of AraC were comparable to those achieved after low-dose AraC treatment (20 mg/m2) while at doses of YNK01 of 450-600 mg/m2 concentrations of standard-dose AraC (100 mg/m2) were obtained."	( Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M, 1998)	0.3
" All three cell lines, however, share identical dose-response curves in terms of their growth inhibition, suggesting that CD437-mediated inhibition of growth and induction of apoptosis represent two distinct and separable processes."	( Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Bhalla, K; Dawson, MI; Fontana, JA; Han, Z; Ordónez, JV; Poirer, G; Reichert, U; Rishi, AK; Sheikh, MS; Shroot, B; Sun, RJ; Tschang, SH; Wyche, J; Zhang, Y, 1998)	0.3
" infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy (HDC) for peripheral blood progenitor cell (PBPC) mobilization (MOB) or prior to autologous PBPC rescue."	( Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999)	0.3
" Cytarabine was given to Cohort 1 at the conventional dosage of 100 mg/m2 per day by continuous infusion for 7 days in induction and 5 days in consolidation; to Cohort 2 at high-dose (HiDAC) (3 g/m2 intravenously twice daily on days 1, 3, 5 and 7) during induction with conventional dosage during consolidation; to Cohort 3 HiDAC was given for both induction and consolidation."	( A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA, 1999)	0.3
" At this dosage it would appear that cytarabine had no effect on survival and did not improve remission rates."	( Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. Aulitzky, W; Döhner, H; Domkin, D; Fischer, T; Huber, C; Huhn, D; Koch, B; Kolb, HJ; Kreiter, H; Lindauer, M; Neubauer, A, 1999)	0.3
"Our aim was to compare and evaluate apoptosis formation as detected by propidium-iodide (PI)/annexin-V or PI/fluorescein-diacetate (FDA) as dose-response parameters in a human promyelocytic leukemia cell line, HL60."	( Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Bartkowiak, D; Baust, H; Högner, S; Nothdurft, W; Röttinger, EM, 1999)	0.3
" The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity."	( Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999)	0.3
"The combination CEF using this schedule and dosage in metastatic breast cancer is more effective with less toxicity than CNF, except for alopecia, and was associated with longer survival."	( Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Alvarez, E; Buesa, JM; Corral, N; Estaban, E; Estrada, E; Fernández, JL; Lacave, AJ; Muñiz, I; Palacio, I; Vieitez, JM, 1999)	0.3
" Epidoxorubicin (70 mg/m2) was added in patients who previously received a suboptimal dosage of antracycline."	( Stop-flow in mediastinum and thorax for resistant lymphoma. Abate, G; Aigner, KR; Amicucci, G; Benita, C; Capannolo, B; D'Alessandro, V; Filippo, R; Gianfranco, A; Giuseppe, A; Guadagni, S; Luca, M; Marsili, L; Pozone, T; Roland, AK; Russo, F; Stefano, G; Tullio, P; Valfredo, D, )	0.13
" Adjustment of cytarabine and etoposide dosage was feasible for achieving targeted plasma drug concentrations; however, the potential clinical efficacy of this approach was offset by substantial acute and long-term toxicity."	( Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Arnaout, MK; Behm, FG; Belt, JR; Crom, WR; Mirro, J; Radomski, KM; Raimondi, SC; Ribeiro, RC; Santana, VM; Srivastava, DK; Tong, X, 2000)	0.31
" Severe combined immunodeficient mice implanted with CBS-transfected CEM cells demonstrated greater responsiveness to therapy, reflected in significantly prolonged survivals after ara-C administration compared with mice implanted with wild-type cells and treated with the same dosage schedule."	( Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Dutcher, JA; Ge, Y; Huang, X; Matherly, LH; Mohammad, RM; Ravindranath, Y; Stout, ML; Taub, JW, 2000)	0.31
" CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C."	( Intrathecal chemotherapy with antineoplastic agents in children. Biagi, E; Conter, V; Lazzareschi, I; Milani, M; Riccardi, R; Ruggiero, A; Sparano, P, 2001)	0.31
" We recommend an adequate dosage of 60 mg/m(2)daunorubicin for 3 days in combination with standard dose Ara-C and 6-thioguanine given for induction and consolidation, followed by a prolonged monthly maintenance chemotherapy for a duration of at least 1 year."	( Acute myeloid leukaemia (AML): treatment of the older patient. Büchner, T; Haferlach, T; Heinecke, A; Hiddemann, W; Sauerland, MC; Schoch, C, 2001)	0.31
" Two different mechanisms were proposed for this phenotype: (i) classical mutation of drug metabolizing genes or (ii) chromosome reassortments, catalyzed by cancer- and cell line-specific aneuploidy, which generate, via new gene dosage combinations, a plethora of cancer phenotypes, including drug resistance."	( Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Duesberg, P; Hehlmann, R; Stindl, R, 2001)	0.31
" A corresponding dose effect in the induction treatment of patients aged 60 years and older has been found with daunorubicin 60 vs 30 mg/m2 as part of the thioguanine/ AraC/daunorubicin (TAD) regimen with the higher dosage significantly increasing the response rate and survival in these older patients who represent a poor-risk group as a whole."	( Remission induction therapy: the more intensive the better? Andreesen, R; Aul, C; Balleisen, L; Berdel, W; Büchner, T; Eimermacher, H; Gassmann, W; Grüneisen, A; Haase, D; Haferlach, T; Hartlapp, J; Heinecke, A; Hiddemann, W; Hirschmann, WD; Löffler, H; Ludwig, WD; Maschmeyer, G; Pielken, HJ; Rasche, H; Reis, HE; Sauerland, MC; Schoch, C; Staib, P; Uhlig, J; Weh, HJ; Wörmann, B, 2001)	0.31
" Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities."	( A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001)	0.31
"Published randomized trials on different cytarabine doses for the treatment of acute myeloid leukemia (AML) provide evidence of a dose-response effect."	( Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Dölken, G; Fiedler, F; Hasenclever, D; Helbig, W; Herold, M; Kämpfe, D; Krahl, R; Kubel, M; Mantovani, L; Niederwieser, D; Pasold, R; Pönisch, W; Schmoll, HJ; Súbert, R, 2002)	0.31
" At every dosage examined, pretreatment with etoposide given 6 h before ara-C was the most effective antitumor schedule in L1210 leukemia."	( [The mechanism of synergistic interaction between etoposide and cytarabine]. Ooi, K, 2002)	0.31
" However, some trials showed that increasing the dosage of anthracyclines within induction therapy improved treatment outcome substantially."	( Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H, 2002)	0.31
" The combined dosing of NDP with GEM resulted in synergistically enhanced inhibition of tumor growth against Ma44/GEM."	( Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer. Hojo, K; Maekawa, R; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T, 2002)	0.31
" It is suggested that leukemia mice could be effectively treated by the novel aminosteroid and the efficacy maybe paralleled with the dosage of the novel aminosteroid."	( [Effect of a novel aminosteroid on animal model of murine myelomonocytic leukemia]. He, Q; Jiang, DZ; Na, XD, 2000)	0.31
" More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment."	( Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. Crews, KR; Howard, SC; Hudson, JQ; Razzouk, BI; Ribeiro, RC; Wimmer, PS, 2002)	0.31
" The dosage of the immune suppressive reagents that were administered to prevent the rejection of the transplanted kidney were reduced during chemotherapy to minimize the adverse effect of immune suppression, and G-CSF was administrated to shorten the neutropenic period."	( [Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient]. Fuchigami, K; Fukushima, T; Hata, T; Honda, M; Jinnai, I; Kuriyama, K; Miyazaki, Y; Togami, K; Tomonaga, M; Yamasaki, J, 2003)	0.32
" The dosage of corticosteroid was decreased in all of them."	( [Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria]. Bai, J; Cao, YR; Cui, ZZ; Fu, R; He, GS; Jia, HR; Liu, H; Qin, TJ; Shao, ZH; Shi, J; Sun, J; Tu, HF; Wu, YH; Yang, TY; Zhao, MF, 2004)	0.32
"Forty-three previously untreated patients with CML in chronic phase were randomly assigned to receive either IFN alpha 2 b (5MU sqm/daily) or IFN alpha 2 b in the same dosage plus monthly courses of low-dose AraC."	( [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine]. Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Rraffac, S; Stecová, N; Svorcová, E; Tóthová, E, 2000)	0.31
" This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship."	( Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E, 2005)	0.33
" The results of growth curve analyses replicated these findings and suggested a significant adverse effect of cumulative dosage of intrathecal methotrexate on estimated Wechsler Performance IQ."	( Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. Barrowman, NJ; Dunlap, H; Halton, JM; Hsu, E; Keene, DL; Kuehn, SM; Matzinger, MA; Montour-Proulx, I, 2005)	0.33
" Low-dose Ara-C was given subcutaneously at a dosage of 10 mg/m2 every 12 hours on days 1 to 14."	( Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP, 2005)	0.33
" Serum concentration reached peak value starting about 48 hours after drug administration and was maintained at close to peak value throughout the dosing interval."	( Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Cortes, J; Fettner, S; Hooftman, L; Kantarjian, H; O'Brien, S; Rakhit, A; Rittweger, K; Talpaz, M, 2005)	0.33
"Pegasys provided a significant advantage over standard IFN-alpha by enabling once-weekly dosing while maintaining acceptable safety, tolerability, and activity profiles."	( Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Cortes, J; Fettner, S; Hooftman, L; Kantarjian, H; O'Brien, S; Rakhit, A; Rittweger, K; Talpaz, M, 2005)	0.33
" In analogy to the benefit of patients under the age of 60 years from high-dose AraC there are dosage related therapeutic effects in the patients over 60 years in particular for daunorubicin in the induction treatment, and for maintenance versus no maintenance in the post-remission treatment."	( Treatment of older patients with AML. Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Grüneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Mesters, RM; Rasche, H; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Schumacher, A; Serve, HL; Staib, P; Wörmann, B, 2005)	0.33
"Micronucleus induction was studied for the DNA target clastogens mitomycin C (MMC) and 1-beta-D-arabinofuranosylcytosine (Ara-C), and also the non-DNA target aneugen colchicine (COL) in order to evaluate the dose-response relationship at very low dose levels."	( Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine. Asano, N; Dertinger, SD; Hayashi, M; Morita, T; Tometsko, CR; Torous, DK, 2006)	0.33
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."	( Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006)	0.33
" (6) In practice, the longer dosing interval with liposomal cytarabine is not associated with a gain in efficacy or quality of life, mainly because adverse effects are more common than with standard cytarabine."	( Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine. , 2006)	0.33
" Fixing synergistic drug ratios in pharmaceutical carriers provides an avenue by which anticancer drug combinations can be optimized prospectively for maximum therapeutic activity during preclinical development and differs from current practice in which dosing regimens are developed empirically in late-stage clinical trials based on tolerability."	( Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG, 2006)	0.33
" Non-linear modulating influence was registered even at low dosage of cytostatics which actually could not affect leukemic cell viability."	( [Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes]. Antonenko, EV; Cherepovich, VS; Grinëv, VV; Lotkova, ES; Shakhlevich, EV, 2006)	0.33
" Early efficacy data suggest that DepoCyt is fairly well tolerated, and its use allows reduced dosing frequency from twice a week to once every other week and may improve the outcome compared with frequent intrathecal injections of unencapsulated cytarabine."	( Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Angst, MS; Drover, DR, 2006)	0.33
" It is worthwhile to compare literature data to assess an optimal dosage of ara-C in pediatric patients."	( Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. Cinatl, J; Hollatz, G; Koehl, U; Kornhuber, B; Kreuter, J; Mutschler, E; Rohrbach, E; Schwabe, D; Visschedyk, K, 2007)	0.34
" Optimal dosage of genistein as single agent and in combination with ara-C was first determined in vitro."	( Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Cheang, PT; Chen, CS; Fred Wong, WS; Han, JH; Khan, M; Shen, J; Stephen Wong, CH; Tai, YC; Xie, Z; Zhou, J, 2007)	0.34
" Statistically significant therapeutic outcome was observed when the dosage of both araC conjugates was increased 10-times compared to araC."	( Antileukemic activity of sulfonamide conjugates of arabinosylcytosine. Miadokova, E; Novotny, L; Phillips, OA; Rauko, P, 2006)	0.33
" GO at a dosage of 3 mg/m2 was administered as a 2-h intravenous infusion on days 1 and 14, cytarabine at 100 mg/m2 on days 1-7, and mitoxantrone at 12 mg/m2 on days 1-3."	( Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Carluccio, P; Giannoccaro, M; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G; Spinosa, G, 2007)	0.34
" Nine patients were enrolled at increasing dosage levels of ara-C (8, 12, and 16 g/m2 per dose level)."	( Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N, 2007)	0.34
" However, a 4- to 5-day spaced dosing schedule (injections on day 0, 4, 8, and 13) was proved to be safer in terms of weight loss and hematological and other toxicity."	( Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. Couvreur, P; Desmaële, D; Dubernet, C; Marque, PE; Mouelhi, SL; Reddy, LH, 2008)	0.35
" These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim."	( A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T, 2008)	0.35
" Only liver toxicities and nausea/vomiting exhibited any dosage effect."	( Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. Camitta, B; Dubowy, R; Graham, M; Hakami, N; Kletzel, M; Mahoney, D; Newman, E; Ravindranath, Y, 2008)	0.35
" Following complete staging after course 2, radiotherapy was applied at a dosage of 3600-4140 cGy in conventional schedule (180 or 200 cGy per day) to whole brain (with 3600 cGy to eyes in one case because of eye involvement) and then 2 additional courses of R-IDARAM (totally four courses) chemotherapy regimen were applied."	( Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases. Alptekin, M; Erkutlu, I; Kilciksiz, S; Okan, V; Pehlivan, M; Sari, I; Yilmaz, M, 2008)	0.35
" Weight-based dosing has been suggested to better predict toxicity of the conditioning regimen."	( Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008)	0.35
"Sustained release thermosensitive solution containing cytarabine-loaded liposome delivery system offers the possibility of reduced dosing frequency and sustained drug action."	( Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. Kulkarni, V; Mulik, R; Murthy, RS, 2009)	0.35
" Knowledge of the pharmacokinetics, dosing schedules and potential toxicities of IT chemotherapeutic drugs is important in the design of CNS prophylaxis and treatment in hematologic malignancies."	( Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Chan, JC; Kwong, YL; Yeung, DY, 2009)	0.35
"Cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C, 1) suffers from low oral bioavailability due to low intestinal membrane permeability and poor metabolic stability, and intravenous infusion is usually adopted as the clinical standard dosing administration."	( Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Chen, Y; He, Z; Jing, Y; Li, G; Shi, S; Sun, J; Sun, Y; Xu, Y; Yin, S, )	0.13
" Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT."	( The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Brown, AW; McGregor, BA; Osswald, MB; Savona, MR, 2009)	0.35
"Individualised dosing of HD-MTX might have the potential to improve clinical outcome in patients with PCNSL, even when administered concurrently with HD-AraC."	( Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Cavalli, F; Cerny, T; Ferreri, AJ; Huitema, AD; Joerger, M; Krähenbühl, S; Reni, M; Schellens, JH; Zucca, E, 2010)	0.36
" 37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine)."	( [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism]. Chen, YX; He, AL; Ji, YY; Liu, J; Wang, FX; Wang, JL; Zhang, PY; Zhang, WG; Zhang, WJ; Zhao, XM, 2010)	0.36
" The enhanced efficacy obtained for intermediate dosing frequency in the consolidation setting suggests that the anti-leukemic activity of synergistic drug ratios is dependent on both duration of exposure and maintenance above a therapeutic threshold."	( Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Ciofani, T; Fan, M; Harasym, TO; Huang, R; Lim, WS; Mayer, LD; Tardi, PG; Xie, X, 2010)	0.36
" The overall response rate and OS did not differ significantly according to the dosage of alemtuzumab (70 mg vs."	( Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Park, K; Park, Y; Suh, C, 2012)	0.38
"The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP."	( Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Park, K; Park, Y; Suh, C, 2012)	0.38
" Hence, the study on the systems reported herein could provide a good basis for designing aza nucleoside prodrug systems that are less hydrophilic than their parental drugs and can be used, in different dosage forms, to release the parent drug in a controlled manner."	( Prodrugs of aza nucleosides based on proton transfer reaction. Karaman, R, 2010)	0.36
" Pharmacokinetics demonstrated a dose-response for total and unbound plasma flavopiridol unrelated to total protein, albumin, peripheral blast count, or toxicity."	( Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011)	0.37
"Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level."	( Cytarabine dose for acute myeloid leukemia. Biemond, BJ; de Greef, GE; Ferrant, A; Gratwohl, A; Graux, C; Gregor, M; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Pabst, T; Schaafsma, MR; Schanz, U; Schouten, HC; Sonneveld, P; Theobald, M; van Putten, W; Vellenga, E; Verdonck, LF, 2011)	0.37
" This decrease suggests that daunorubicin, cytosine arabinoside, etoposide and mitoxantrone may impair the metabolism of other active substances metabolized by this isoenzyme, which should be taken into consideration in planning the dosage scheme in individual patients and considering interactions between drugs."	( Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics."	( Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM, 2012)	0.38
" Enrichment was most robust early after Ara-C application and was correlated with dosage and duration of chemotherapy."	( In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application. Brennig, S; Lachmann, N; Moritz, T; Rattmann, I; Schambach, A; Williams, DA, 2012)	0.38
" The data also demonstrate marked differences in hematotoxicity between alternative Ara-C dosing schemes and suggest thorough in vivo toxicity studies to optimize further Ara-C dosing en route to safe and stable enrichment of gene-corrected hematopoiesis."	( In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application. Brennig, S; Lachmann, N; Moritz, T; Rattmann, I; Schambach, A; Williams, DA, 2012)	0.38
" These results show that, with addition of appropriate stabilizers, VPGs can be autoclaved with high stability, and it is a promising dosage form for treatment of GBM after injection into resectable or nonresectable neoplasms with sustained release properties."	( Sterilization stability of vesicular phospholipid gels loaded with cytarabine for brain implant. Cai, C; Gu, P; He, H; Lin, X; Qi, N; Tang, X; Xu, H; Zhang, Y, 2012)	0.38
"Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL."	( Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Bloomfield, CD; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Marcucci, G; McDonnell, D; Mrózek, K; Powell, BL; Stock, W; Stone, RM; Vardiman, JW; Westervelt, P; Wetzler, M, 2013)	0.39
" Non-hematologic effects had onset by 24 units/m(2) with shallow dose-response until maximum frequency and severity were observed at the 101-134 units/m(2) dose levels."	( Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Chiarella, MT; Feldman, EJ; Kolitz, JE; Lancet, JE; Liboiron, BD; Louie, AC; Mayer, LD; Swenson, CE; Trang, JM, 2012)	0.38
" This was inspected carefully to ensure that the drug, strength, dosage form, and any other ingredients listed were indeed what were expected."	( Successful importation of cytarabine into the United States during a critical national drug shortage. Hunnisett-Dritz, D, 2012)	0.38
"Dose-limiting toxicities consisting of corrected QT interval prolongation and grade 3 palmar-plantar erythrodysesthesia occurred at 140 mg flat dosing (dose level 5, equivalent to 80 mg/m(2))."	( Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Carraway, HE; Flatten, KS; Freshwater, T; Gladstone, DE; Gore, SD; Greer, JM; Horowitz, JA; Isaacs, R; Karp, JE; Kaufmann, SH; Levis, MJ; Loechner, S; Mackey, K; McDevitt, MA; Parry, DA; Peterson, K; Pratz, KW; Schneider, P; Showel, MM; Smith, BD; Sorge, C; Thomas, BM, 2012)	0.38
" LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg."	( Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D, 2013)	0.39
" We aimed to compare two dosing regimens of tosedostat."	( Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Advani, AS; Charman, A; Cortes, J; Feldman, E; Kantarjian, H; Rizzieri, D; Spruyt, R; Toal, M; Yee, K, 2013)	0.39
" Methotrexate levels can help guide intrathecal dosing of methotrexate, but no such test is commercially available for cytarabine."	( Successful large-volume cerebrospinal fluid aspiration for an accidental overdose of intrathecal cytarabine. Al-Zubaidi, M; Amar, S; Feiz-Erfan, I; Makar, G; Mehta, D, 2013)	0.39
" No guidelines exist for chemotherapy dosing of acute myeloid leukemia (AML) patients at extremes of weight."	( Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Advani, AS; Earl, M; Gallagher, EM; Kalaycio, ME; Kusick, KN; Maciejewski, JP; Mukherjee, S; Sekeres, MA; Tiu, RV; Wenzell, CM; Yeh, JY, 2013)	0.39
" This article reviews the current published literature on the dosing of pharmacologic agents used for HCT preparative regimens with specific focus on the obese patient population."	( Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J, 2014)	0.4
" Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA."	( Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P, 2014)	0.4
" After six cycles of R-IDARAM at 3-weekly intervals, radiotherapy was applied at a dosage of 2000-4000 cGy in conventional schedule (180 or 200 cGy/day) to whole brain or spinal cord in all patients."	( Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. Cen, J; Li, C; Liu, X; Ma, Y; Mei, K; Qian, L; Shen, J; Wang, Y; Zhao, D, 2014)	0.4
" High-dose cytarabine is clearly effective and there definitely is a dose-response relationship for cytarabine and remission duration."	( Optimal therapy for adult patients with acute myeloid leukemia in first complete remission. Wiernik, PH, 2014)	0.4
" A stratified dosing strategy based on the relative CDA activity would increase efficiency."	( Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Ciccolini, J; Etienne-Grimaldi, MC; Giovannetti, E; Honeywell, RJ; Losekoot, N; Maulandi, M; Milano, G; Peters, GJ; Serdjebi, C, 2014)	0.4
" However, an effective combination with other drugs and a feasible dosage has not been identified."	( Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH, 2015)	0.42
" MRD may serve as a biomarker for optimal biologic dosing of ARA-C, and SDAC regimen appears to yield more frequent MRD negativity."	( Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A, 2015)	0.42
" This review examines studies that have established the various dosing options and considers whether there is a true standard for post remission therapy for patients with AML."	( Optimal dose and schedule of consolidation in AML: is there a standard? Schiffer, CA, )	0.13
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."	( High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)	0.42
" The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy."	( Myelopathy following intrathecal chemotherapy in adults: a single institution experience. Cachia, D; Chi, L; Cortes, JE; Daver, N; Kamiya-Matsuoka, C; Kantarjian, HM; Pinnix, CC; Woodman, K, 2015)	0.42
" TwHF extract was administered at a dosage of 10 mg three times daily for 12 months."	( Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety. Han, Y; Jiang, H; Li, T; Li, Y; Lv, W; Qiu, Z; Routy, JP; Song, X; Sun, M; Wang, F; Xie, J; Zhang, X, )	0.13
" Therefore, in study AML-BFM 2004 we aimed to improve outcome of HR-patients by adding moderately dosed 2-Chloro-2-Deoxyadenosine (2-CDA) to the respective consolidation treatment backbone without increasing toxicity."	( Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M, 2015)	0.42
"Data from solid tumor malignancies suggest that actual body weight (ABW) dosing improves overall outcomes."	( Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. Abhyankar, S; Aljitawi, O; Bivona, C; Bray, WM; Ganguly, S; Grauer, D; Henry, D; Lin, TL; McGuirk, J; Rockey, M; Singh, A, 2015)	0.42
" Study design evaluated the relationship between percentage of ABW dosing and complete response (CR) rates in patients newly diagnosed with AML."	( Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. Abhyankar, S; Aljitawi, O; Bivona, C; Bray, WM; Ganguly, S; Grauer, D; Henry, D; Lin, TL; McGuirk, J; Rockey, M; Singh, A, 2015)	0.42
"Intensive chemotherapy with cytarabine and an anthracycline for untreated acute myeloid leukemia (AML) has remained largely unchanged over the past 40 years, despite many large trials examining the choice and dosing of these agents."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
"We will review the major published clinical trials for untreated AML that have established the dosing choice and schedule for intensive therapy, as well as trials for patients not eligible for more intensive therapy."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
"While one or two cycles of anthracycline and cytarabine-based combination regimens remain the standard of care for younger and older patients with AML deemed fit to receive induction chemotherapy, controversy remains regarding the optimal selection and dosing schedule for anthracyclines."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
"The efficacy and safety of a modified CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen with an increased aclarubicin dosage [high-dose (HD)-CAG] were observed in 145 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and compared to the results of 172 patients treated with a conventional CAG regimen."	( Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y, 2015)	0.42
"Hematologic toxicity represents a major side effect of cytotoxic chemotherapy frequently preventing adequately dosed chemotherapy application and impeding therapeutic success."	( Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1). Brennig, S; Buchegger, T; Hetzel, M; Lachmann, N; Moritz, T; Schambach, A, 2015)	0.42
"Our results provide an alternative approach for predicting what combinations, dosing and scheduling of drug delivery should be used to better individualize therapy of AML."	( Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside. Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH, 2016)	0.43
" JLSG-02 has been revised from JLSG-96 in the following respects: prednisolone dosage during Induction A increased; duration of maintenance therapy extended from 24 to 48 weeks; cyclosporine introduced to Induction B for progressive disease."	( Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Bessho, F; Fujimoto, J; Horibe, K; Imamura, T; Imashuku, S; Ishii, E; Kawaguchi, H; Kobayashi, R; Koga, Y; Kudo, K; Morimoto, A; Sakashita, K; Shioda, Y; Tsunematsu, Y; Yasui, M, 2016)	0.43
" We retrospectively analyzed the outcome of 79 adult patients who underwent auto-HSCT for lymphoma using this regimen in two centers, with 1- and 2-day dosing of MEL, respectively."	( Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kako, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R, 2016)	0.43
" Dosing was resumed at 400 mg, and four additional DLTs were observed: G4 neutropenia and G4 thrombocytopenia at 400 mg and G4 thrombocytopenia (two patients) at 500 mg."	( Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. Banerji, U; Fancourt, C; Hirsch, H; Hong, DS; Johnson-Levonas, AO; Knox, CD; Lam, R; Mahipal, A; Meister, AK; Rose, S; Russo, G; Somaiah, N; Wagner, AJ, 2017)	0.46
" ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing may improve outcomes while reducing toxicity."	( Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC, 2017)	0.46
" However, a clinically available therapeutic regimen for this compound needs to be established and its functional mechanisms in relation to the dosing schedule need to be clarified."	( Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo. Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C, 2018)	0.48
" Using a mouse lymphoma model, we show clear dosage effect of UTX copy number during tumorigenesis, which strongly supports the EXITS theory."	( UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma. Chen, CD; Jiang, H; Li, X; Liu, M; Zhang, Y; Zheng, L, 2018)	0.48
" In in vitro studies, film-released arabinofuranosyl cytidine (AraC), a mitotic inhibitor, selectively killed glial cells in film-supported mixed neural cell cultures; with widened dosage windows for drug efficacy and tolerance compared to drugs in solution."	( Film interface for drug testing for delivery to cells in culture and in the brain. Kaplan, DL; Tang-Schomer, MD; Whalen, MJ, 2019)	0.51
" Although standard dosing intervals range from 2 to 4 weeks, it is unclear whether sustained cytotoxic cerebrospinal fluid (CSF) concentrations can be achieved beyond 14 days from drug injection."	( Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine. Bohn, JP; Oberacher, H; Pall, G; Reinstadler, V; Steurer, M; Stockhammer, G; Wolf, D, 2019)	0.51
" There are marked differences in drug dosing and scheduling depending on the protocols when treating AML patients with AraC."	( Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. Berda-Haddad, Y; Ciccolini, J; Costello, R; Donnette, M; Fanciullino, R; Farnault, L; Giocanti, M; Hau, LTT; Lacarelle, B; Ouafik, L; Solas, C; Venton, G, 2019)	0.51
" Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells."	( Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine. Cho, WC; Kobarfard, F; Kumar, P; Martins, N; Martorell, M; Pezzani, R; Rajabi, S; Redaelli, M; S Mileski, K; Salehi, B; Selamoglu, Z; Sharifi-Rad, J; Subhra Santra, T, 2019)	0.51
" A lack of clarity regarding the proper dosing of post-remission cytarabine has made consensus building on dosing and schedule a challenge."	( Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Derman, BA; Larson, RA, 2019)	0.51
" CPX-351 is a liposomal encapsulated formulation of cytarabine and daunorubicin in a 5:1 molar ratio that has been demonstrated to deliver synergistic ratiometric dosing of these drugs in pre-clinical studies."	( Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Asghari, H; Lancet, J, 2020)	0.56
" Clinical CYT and quizartinib pharmacokinetic dosage regimens were modeled."	( Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Den Haese, J; Elmeliegy, M; Jusko, WJ; Talati, C; Wetzler, M, 2020)	0.56
" We enumerate the practical issues faced in the use of midostaurin like antifungal prophylaxis, dosage of concomitant chemotherapy agents as well as available data on sequencing of the FLT3 inhibitors."	( Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC, 2020)	0.56
" Attempts to improve the dosing regimen of gemcitabine were aimed at maximising the intracellular gemcitabine triphosphate concentrations."	( Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action. Beijnen, JH; Derissen, EJB, 2020)	0.56
" The increasing prevalence of obesity and the toxicity risk with this therapy renders important the quantification of potential risks with weight-based dosing in this patient population."	( Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. Benitez, LL; Bixby, DL; Burke, PW; Marini, BL; Ochs, MA; Perissinotti, AJ; Pettit, KM, 2021)	0.62
" Ondansetron is an effective antiemetic drug widely used to prevent CINV; however, the effective administrative dosing strategies among pediatrics remain unclear."	( Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021)	0.62
"In all, 194 children undergoing chemotherapy were randomized to receive either single daily dosing (0."	( Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021)	0.62
"No significant differences were found between the two dosing strategies concerning number of emesis episodes and parent's satisfaction."	( Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021)	0.62
"Ondansetron administered as divided dosing should be considered among children aged under 7 years to prevent chemotherapy-induced nausea and among patients receiving low emetogenic chemotherapy to maintain their appetite."	( Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C, 2021)	0.62
" Fourteen patients were included, and selinexor dosage was 60 mg (3 patients), 80 mg (3 patients), and 100 mg (7 patients) weekly."	( A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S, 2021)	0.62
" Jude Total 15 (T15, n=365) and pegaspargase in Total 16 (T16, n=524), we tallied the dose intensities for all drugs on the low-risk or standard-risk arms, analyzing 504,039 dosing records."	( Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Cheng, C; Crews, KR; Evans, WE; Finch, ER; Gruber, TA; Inaba, H; Jeha, S; Karol, SE; Kornegay, NM; Liu, Y; Metzger, ML; Panetta, JC; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Smith, CA; Yang, JJ; Yang, W, 2022)	0.72
" The dosage of adrenal glucocorticoids was reduced by more than half compared with that before chemotherapy."	( Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis. Chen, Y; Fu, R; Li, L; Liu, C; Liu, H; Liu, Z; Shao, Z; Wang, H; Zhao, X, 2022)	0.72
" Dosing was modified for elderly patients."	( Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022)	0.72
" However, the dosage of venetoclax is fixed, irrespective of body surface area (BSA) or weight."	( Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T, 2022)	0.72
" Dosage adjustments for drug interactions and safety varied between centers."	( Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A, 2023)	0.91
" However, the current study demonstrates that obesity is not a factor in survival, and strict adherence to body surface area-based dosing is not necessary because dose adjustments do not affect outcomes."	( Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. Bennett, JM; Cripe, LD; Fernandez, HF; Foran, JM; Ketterling, RP; Lai, C; Lazarus, HM; Levine, RL; Litzow, MR; Luger, SM; Paietta, E; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS; Zhang, Y, 2023)	0.91
" The contribution offers a fire-new dosage form of ARA for long-lasting delivery, thus filling the vacancy in nanococrystal studies about marine drugs."	( The first nano-cocrystal formulation of marine drug cytarabine with uracil based on cocrystal nanonization strategy for long-acting injection exhibiting enhanced antitumor activity. Bu, FZ; Li, YT; Meng, SS; Wu, ZY; Yan, CW; Yu, YM, 2023)	0.91
" Optimal dosing protocols for immunomodulation in dogs have not been defined."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13
" Application of functional and active metabolite assessment is feasible and may provide more relevant data to determine optimal dosing regimens for Ara-C-based treatments."	( Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. Dickinson, PJ; Knych, HK; Kol, A; Pypendop, BH; Questa, M; Rodrigues, CA; Vernau, KM; Vernau, W; Zwueste, DM, )	0.13
"AML cell lines resistant to AraC were first constructed by repeated dosing for 5 months."	( Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling. Chen, Y; Huang, P; Li, H; Luo, X; Su, Q; Zhang, P, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
antimetabolite	A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antiviral agent	A substance that destroys or inhibits replication of viruses.
immunosuppressive agent	An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
GDP-fucose	A GDP-hexose in which the hexose component is a fucosyl residue.
beta-D-arabinoside
pyrimidine nucleoside
monosaccharide derivative	A carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Transport of small molecules	392	95
SLC-mediated transmembrane transport	135	67
Transport of vitamins, nucleosides, and related molecules	27	18
Transport of nucleotide sugars	7	12
Signaling Pathways	1269	117
Signaling by NOTCH	113	14
Pre-NOTCH Expression and Processing	24	13
Pre-NOTCH Processing in the Endoplasmic Reticulum	2	4
Metabolism of proteins	1058	144
Post-translational protein modification	666	112
Asparagine N-linked glycosylation	164	78
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein	50	68
Synthesis of substrates in N-glycan biosythesis	37	56
GDP-fucose biosynthesis	6	16
Disease	1278	231
Disorders of transmembrane transporters	102	43
SLC transporter disorders	45	37
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C)	0	1
colanic acid building blocks biosynthesis	9	49
GDP-L-fucose biosynthesis I (from GDP-D-mannose)	2	13
superpathway of GDP-mannose-derived O-antigen building blocks biosynthesis	12	39
GDP-L-galactose biosynthesis	2	12
L-ascorbate biosynthesis I (L-galactose pathway)	9	23
VTC2 cycle	2	13
extended VTC2 cycle	2	13
GDP-L-fucose biosynthesis I (from GDP-D-mannose)	1	6
Xyloglucan biosynthesis	1	8

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	3.1623	0.0032	45.4673	12,589.2998	AID2517
endonuclease IV	Escherichia coli	Potency	7.9433	0.7079	12.4324	31.6228	AID2565
glp-1 receptor, partial	Homo sapiens (human)	Potency	1.2589	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	0.8913	0.1000	20.8793	79.4328	AID588453
phosphopantetheinyl transferase	Bacillus subtilis	Potency	100.0000	0.1413	37.9142	100.0000	AID1490
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	7.6959	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
USP1 protein, partial	Homo sapiens (human)	Potency	0.2818	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	0.0728	0.0008	11.3822	44.6684	AID686978; AID686979
AR protein	Homo sapiens (human)	Potency	11.9272	0.0002	21.2231	8,912.5098	AID743035; AID743063
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	0.0933	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	11.1044	0.0123	7.9835	43.2770	AID1346984; AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.4686	0.0013	10.1577	42.8575	AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.9770	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	14.5602	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	9.5793	0.0002	29.3054	16,493.5996	AID1259244; AID743069; AID743080
G	Vesicular stomatitis virus	Potency	23.9185	0.0123	8.9648	39.8107	AID1645842
67.9K protein	Vaccinia virus	Potency	0.4467	0.0001	8.4406	100.0000	AID720579
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	11.2202	0.0355	20.9770	89.1251	AID504332
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	45.5130	0.0391	47.5451	146.8240	AID1224845; AID1224896
chromobox protein homolog 1	Homo sapiens (human)	Potency	28.1838	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	2,238.7200	0.0100	39.5371	1,122.0200	AID1479
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.1158	0.0041	9.9848	25.9290	AID504444
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	0.2578	0.0003	23.4451	159.6830	AID743065; AID743067
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	0.7699	0.0037	8.6189	23.2809	AID2660; AID2667; AID2668
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	30.1313	0.4256	12.0591	28.1838	AID504536
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	9.8148	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	11.4051	0.0056	12.3677	36.1254	AID624032; AID624044
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0398	0.8913	12.0676	28.1838	AID1487
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	21.6899	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	23.9185	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	23.9185	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.4219	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	21.6899	0.0015	51.7393	15,848.9004	AID1259244
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	0.9268	0.0037	8.1081	23.2809	AID2667
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	23.9185	0.0123	8.9648	39.8107	AID1645842
Ataxin-2	Homo sapiens (human)	Potency	14.1254	0.0119	12.2221	68.7989	AID588378
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	23.9185	0.0123	8.9648	39.8107	AID1645842
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.0076	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]	Homo sapiens (human)	IC50 (µMol)	25.5870	1.1530	6.2803	9.9630	AID602235
transactivating tegument protein VP16 [Human herpesvirus 1]	Human alphaherpesvirus 1 (Herpes simplex virus type 1)	IC50 (µMol)	16.2470	0.9460	4.7016	9.4870	AID602236
nuclear receptor coactivator 3 isoform a	Homo sapiens (human)	IC50 (µMol)	7.5330	0.1476	4.3309	9.9200	AID602234
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Thymidine kinase, cytosolic	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.0160	1.2105	3.0000	AID210895; AID306718
Thymidine kinase	Human alphaherpesvirus 1 strain SC16	IC50 (µMol)	1,000.0000	0.1000	1.8491	7.9433	AID210531
Cytochrome P450 3A4	Homo sapiens (human)	Ki	190.0000	0.0001	1.4162	9.9000	AID55393
Thymidine kinase	Human herpesvirus 3 strain Dumas	IC50 (µMol)	1,000.0000	3.2000	3.2000	3.2000	AID210892; AID306722
Cytidine deaminase	Homo sapiens (human)	Ki	190.0000	0.0000	1.4333	2.3000	AID55393
E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0006	0.3582	10.0000	AID1422083
Enoyl-[acyl-carrier-protein] reductase [NADH]	Francisella tularensis subsp. tularensis SCHU S4	IC50 (µMol)	59.0000	0.0500	1.9125	6.0000	AID756998
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Thymidine kinase	Human alphaherpesvirus 1 (Herpes simplex virus type 1)	IC50 (µMol)	1,000.0000	0.1500	4.8167	9.0000	AID306720
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
LMP1 [Human herpesvirus 4]	human gammaherpesvirus 4 (Epstein-Barr virus)	AbsAC35_uM	7.2400	7.2400	7.2400	7.2400	AID652043
LMP1 [Human herpesvirus 4]	human gammaherpesvirus 4 (Epstein-Barr virus)	AC50	0.9180	0.0680	39.9389	277.4300	AID504882; AID588398
Thymidylate synthase	Mus musculus (house mouse)	ED50	0.0300	0.0300	0.0300	0.0300	AID212472
Deoxycytidine kinase	Homo sapiens (human)	Km	3.0400	0.4000	3.5790	8.5000	AID1222351
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
nucleobase-containing compound metabolic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
nucleotide biosynthetic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
pyrimidine nucleoside salvage	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
deoxycytidine metabolic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
thymidine metabolic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
DNA biosynthetic process	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleobase-containing compound metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
protein homotetramerization	Thymidine kinase, cytosolic	Homo sapiens (human)
DNA synthesis involved in mitotic DNA replication	Thymidine kinase, cytosolic	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
pyrimidine nucleotide metabolic process	Deoxycytidine kinase	Homo sapiens (human)
CMP biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
dAMP salvage	Deoxycytidine kinase	Homo sapiens (human)
nucleoside phosphate biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
cell surface receptor signaling pathway	Cytidine deaminase	Homo sapiens (human)
pyrimidine-containing compound salvage	Cytidine deaminase	Homo sapiens (human)
cytidine deamination	Cytidine deaminase	Homo sapiens (human)
cytosine metabolic process	Cytidine deaminase	Homo sapiens (human)
negative regulation of cell growth	Cytidine deaminase	Homo sapiens (human)
UMP salvage	Cytidine deaminase	Homo sapiens (human)
negative regulation of nucleotide metabolic process	Cytidine deaminase	Homo sapiens (human)
response to cycloheximide	Cytidine deaminase	Homo sapiens (human)
cellular response to external biotic stimulus	Cytidine deaminase	Homo sapiens (human)
regulation of cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein polyubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
blood vessel remodeling	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of heart rate	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrioventricular valve morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocardial cushion morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ventricular septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
atrial septum development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
traversing start control point of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of cell population proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to xenobiotic stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to toxic substance	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to iron ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of protein processing	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of neuron projection development	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein ubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein sumoylation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein destabilization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to magnesium ion	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein localization to nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to cocaine	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
establishment of protein localization	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to ether	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of DNA-templated transcription	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of mitotic cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to antibiotic	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of protein export from nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to steroid hormone	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of muscle cell differentiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
proteolysis involved in protein catabolic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein autoubiquitination	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cardiac septum morphogenesis	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex assembly	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hydrogen peroxide	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to vitamin B1	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to alkaloid	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to growth factor stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to peptide hormone stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to estrogen stimulus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to hypoxia	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to gamma radiation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to UV-C	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
fibroblast activation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cellular response to actinomycin D	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of signal transduction by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to formaldehyde	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
amyloid fibril formation	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
response to water-immersion restraint stress	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
negative regulation of apoptotic process	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cell cycle	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
regulation of gene expression	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
deoxycytidine kinase activity	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
thymidine kinase activity	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
ATP binding	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
nucleoside kinase activity	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
deoxynucleoside kinase activity	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
thymidine kinase activity	Thymidine kinase, cytosolic	Homo sapiens (human)
protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
ATP binding	Thymidine kinase, cytosolic	Homo sapiens (human)
zinc ion binding	Thymidine kinase, cytosolic	Homo sapiens (human)
identical protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
deoxyadenosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxycytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxyguanosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
ATP binding	Deoxycytidine kinase	Homo sapiens (human)
protein homodimerization activity	Deoxycytidine kinase	Homo sapiens (human)
cytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
nucleoside binding	Cytidine deaminase	Homo sapiens (human)
cytidine deaminase activity	Cytidine deaminase	Homo sapiens (human)
protein binding	Cytidine deaminase	Homo sapiens (human)
zinc ion binding	Cytidine deaminase	Homo sapiens (human)
identical protein binding	Cytidine deaminase	Homo sapiens (human)
protein homodimerization activity	Cytidine deaminase	Homo sapiens (human)
p53 binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin-protein transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
5S rRNA binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
zinc ion binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
SUMO transferase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
enzyme binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
receptor serine/threonine kinase binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
identical protein binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
peroxisome proliferator activated receptor binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ribonucleoprotein complex binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
ubiquitin protein ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
NEDD8 ligase activity	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
disordered domain specific binding	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
cytoplasm	Thymidine kinase 2, mitochondrial	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Thymidine kinase, cytosolic	Homo sapiens (human)
cytosol	Thymidine kinase, cytosolic	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleoplasm	Deoxycytidine kinase	Homo sapiens (human)
cytosol	Deoxycytidine kinase	Homo sapiens (human)
mitochondrion	Deoxycytidine kinase	Homo sapiens (human)
cytoplasm	Deoxycytidine kinase	Homo sapiens (human)
extracellular region	Cytidine deaminase	Homo sapiens (human)
cytosol	Cytidine deaminase	Homo sapiens (human)
secretory granule lumen	Cytidine deaminase	Homo sapiens (human)
tertiary granule lumen	Cytidine deaminase	Homo sapiens (human)
ficolin-1-rich granule lumen	Cytidine deaminase	Homo sapiens (human)
cytosol	Cytidine deaminase	Homo sapiens (human)
nuclear body	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
nucleolus	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytoplasm	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
cytosol	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
plasma membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
transcription repressor complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
endocytic vesicle membrane	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
protein-containing complex	E3 ubiquitin-protein ligase Mdm2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID100352	Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID124798	Antitumor activity against L1210 tumor in mice, at a dose of 500 mg/kg peroral administration in the presence of 100 mg/kg of zebularine.	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID130778	Antitumor activity against L1210/ara-C leukemia in mice (Percent increase in life span.) at the dose of 200 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID81283	Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Synthesis and biological activity of 5-phenylselenenyl-substituted pyrimidine nucleosides.
AID338733	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
AID200650	In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Synthesis and evaluation of several new (2-chloroethyl)nitrosocarbamates as potential anticancer agents.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID338735	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
AID717966	Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered 5 times a week for one cycle relative to control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
AID355584	Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID130780	Antitumor activity against L1210/ara-C leukemia in mice (Percent increase in life span.) at the dose of 250 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1589124	Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human KB cells	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID451311	Resistance ratio of IC50 for deoxynucleoside analogue-resistant mouse L1210 10K cells to IC50 for deoxynucleoside analogue-sensitive mouse L1210 cells	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID451294	Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID138050	Survival time treated / survival time (T/C) for antitumor activity against Ip implanted L1210 / 0 lymphoid leukemia in mice at a dose of 200 mg/kg per day after treatment 1-5;16/7	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
AID475911	Antitumor activity against human H460 cells after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis, X-ray crystal structure study and antitumoral evaluations of 5,6-disubstituted pyrimidine derivatives.
AID130644	Antitumor activity against L1210/ara-C leukemia in mice (Percent increase in life span.) at the dose of 1000 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID127729	Average survival time includes only those mice that died prior to day 60 at 75 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID135726	Toxicity in mice after 12-13 days at a dose of 100 mg/kg/day; 12/8	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1134736	Toxicity in CDF1 mouse assessed as change in body weight at 20 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID389365	Growth inhibition of human KB cells by MTT method	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins.
AID1135472	Antiviral activity against Herpes simplex virus 1 Sheely assessed as inhibition of virus-induced cytopathic effect at 37 degC after 72 hrs by two-fold dilution method	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID138549	Antitumor activity against L1210 leukemia in mice (Average 7-day weight change (%)) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1739160	Antitumor activity against human MV4-11 cells xenografted in Balb/c nude mouse assessed as reduction in tumor volume at 40 mg/kg, iv administered once daily for 21 days (Rvb = 1.00 g)	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
AID1292259	Cytotoxicity against human MCF7cells after 72 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID99173	Cross resistance profile versus L1210/R71 cells.	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1135050	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 50 mg/kg, ip qd administered for 5 days relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID1542690	Induction of apoptosis in human U937 cells assessed as necrotic cells at 0.3 uM measured after 1 day by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 2.5 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID1222350	Activity of human recombinant N-terminal His-tagged DCK Ala119Gly mutant expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID105668	In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID43716	In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID138730	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change) at the dose of 1000 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID97223	Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 5-350	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1135049	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 25 mg/kg, ip qd administered for 5 days relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID98955	Antitumor activity against the ic implanted L1210 lymphoid leukemia in mice expressed as optimal dose (1-9qd treatment schedule) required to produce greatest increase in life span was determined	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1135722	Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 0.01 to 0.1 uM after 6 days by [3H]thymidine incorporation method relative to control	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation.
AID475909	Antitumor activity against human SW620 cells after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis, X-ray crystal structure study and antitumoral evaluations of 5,6-disubstituted pyrimidine derivatives.
AID44362	Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID116596	Percent increase in life span calculated as (T/C-1)X100 at a dose of 20 mg/kg/day X5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID132045	Increase of life span was determined against Ip implanted L1210 / 0 lymphoid leukemia in mice at a dose of 400 mg/kg per day after treatment 5	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
AID44009	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates.
AID229265	Ratio of IC50 for Parental L1210 to that of multidrug resistant L1210.	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID152827	Antitumor activity was determined against the ip implanted P388 leukemia in mice by range in survival days at 500 mg/kg (treatment of 1qd schedule) dosage; Range is 14-15	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID154166	Percent inhibition of [123I]UdR incorporation in the DNA synthesis assay in P388 cell lines at a concentration of 10 E-3 M	1983	Journal of medicinal chemistry, Nov, Volume: 26, Issue:11	Synthesis and biological evaluation of sparsomycin analogues.
AID133648	Dose producing greatest increase in life span expressed as optimum dose (L1210/ara-C II) (qd 1-5)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1197746	Stimulation of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID1360495	Growth inhibition of human SMMC7721 cells at 0.01 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID261688	Activity against NCI60 cell line xenograft in nude mouse by HF assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID1222351	Activity of human recombinant N-terminal His-tagged wild type DCK expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID353086	Cytotoxicity against human SF268 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9	Synthesis of potent antitumor and antiviral benzofuran derivatives.
AID1123322	Antiviral activity against Herpes simplex virus-1 KOS infected in human skin fibroblast cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID427703	Cytotoxicity against human SNU638 cells by sulforhodamine B method	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Discovery of a new template for anticancer agents: 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosyl-cytosine (2'-F-4'-seleno-ara-C).
AID338736	Cytotoxicity against human MB9812 cells after 3 days by trypan blue exclusion technique
AID654376	Growth inhibition of HDF cells after 72 hrs by WST-1 assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation.
AID118369	Compound was tested for the ability to suppress humoral immune response in mice treated for days 0,+1,and +2 at dose of 25 mg/kg (control = 7.0)	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID137885	Ratio of survival time of treated to control mice at 50 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID1124452	Antiviral activity against Herpes simplex virus type 1 infected in Swiss albino mouse assessed as increase in mouse survival at 0.14 mg/kg, ic single dose after 6 hrs of infection relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Synthesis and antitumor and antiviral activities of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-iminopyrimidine and its derivatives.
AID1134740	Toxicity in CDF1 mouse assessed as change in body weight at 5 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID152681	Antitumor activity against the ip implanted P388 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1407817	Antiproliferative activity against human Jurkat E6-1 cells	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
AID746834	Therapeutic index, ratio of IC50 for human CD34-positive blood stem/progenitor cells to IC50 for human MA9.3 cells	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.
AID23702	Partition coefficient (logP)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID42743	In vitro cytotoxicity was evaluated against renal CAKI-1 cells	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Synthesis and evaluation of several new (2-chloroethyl)nitrosocarbamates as potential anticancer agents.
AID96698	Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 100 mg/kg (treatment of 1-9qd schedule) dosage; Range is 11-18	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID124599	Median T/C calculated based on survivors at 71 mg/kg (292 umol) per day against Ip-implanted L1210 lymphoid leukemia mice	1993	Journal of medicinal chemistry, Jun-11, Volume: 36, Issue:12	Nucleoside conjugates. 13. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of thioether lipids with improved water solubility.
AID140522	Tested for in vivo antitumor activity against Lewis Lung Carcinoma cell line in mice and tumor weight change at 100 mg/Kg per day	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID137176	Antitumor activity against L1210/ara-C leukemia in mice (median survival) at the dose of 250 mg/kg; Value represented as Test/Control = 9/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID138575	Antitumor activity against L1210 leukemia in mice (Average 7-day weight change) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID116793	Percent increase in life span of drug-treated mice relative to tumored, vehicle treated controls at a dose of 500 mg/kg orally in the presence of 500 mg/kg of zebularine.	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID630371	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	2011	Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21	Synthesis and anticancer activity of 5'-chloromethylphosphonates of 3'-azido-3'-deoxythymidine (AZT).
AID116601	Percent increase in life span in mice bearing lymphoid leukemia, treatment schedule is 1-9 qd.	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols.
AID208532	In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Design, synthesis, and antineoplastic activity of 2'-deoxy-2'-methylidenecytidine.
AID1360496	Growth inhibition of human SMMC7721 cells at 0.1 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1124448	Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Synthesis and antitumor and antiviral activities of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-iminopyrimidine and its derivatives.
AID1145829	Antiviral activity against Herpes Simplex virus HF infected in African green monkey BGM cells assessed as plaque reduction measured on day 5 by disk diffusion assay	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID138897	Mean body weight change on 5th day at a dose of 100 mg/kg/day	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID208863	In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID355586	Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID416482	Induction of erythroid differentiation in human K562 cells assessed as benzidine-positive cells at 500 mM after 6 days	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis of glycose carbamides and evaluation of the induction of erythroid differentiation of human erythroleukemic K562 cells.
AID1123146	Cytotoxicity against mouse P815 cells assessed as growth inhibition after 96 hrs	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID40606	Tested in vitro inhibitory activity against murine B16 melanoma cells line	1993	Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25	Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides.
AID116792	Percent increase in life span of drug-treated mice relative to tumored, vehicle treated controls at a dose of 500 mg/kg oral treatment	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID289357	Antitumor activity against human CCRF-HSB2 cells by modified MTT assay	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	Antitumor studies. part 3: design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID85383	Growth inhibition against HSV-1 virus in BSCL cells at the dose of 1.4 ug/mL and 22h time of treatment.	1983	Journal of medicinal chemistry, Jan, Volume: 26, Issue:1	Antiviral compounds. 1. Structure-activity relationship of some antiviral enediones derived from aldehydo sugars.
AID97102	Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 100 mg/kg (treatment of 1-9qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID284055	Growth inhibition of human KB cells by MTT assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID1159292	Cytotoxicity against human HCT116 cells by SRB assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Structure-activity relationships of 2'-modified-4'-selenoarabinofuranosyl-pyrimidines as anticancer agents.
AID410582	Inhibition of erythroid differentiation in human K562 cell assessed benzidine positive cells at 200 uM after 6 days by benzidine staining assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	New uracil dimers showing erythroid differentiation inducing activities.
AID97615	Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent median survival rate (treated/control) at 100 mg/kg (treatment of 1-9qd schedule) dosage; 14/7.0	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID436680	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor growth at 89 umol/kg, ip administered 24 hrs after tumor implantation once daily for 7 consecutive days measured after 24 hrs last post dose	2009	European journal of medicinal chemistry, Oct, Volume: 44, Issue:10	Novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids: synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation.
AID1360489	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID468160	Cytotoxicity against human CEM cells after 2 days	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	Synthesis and in vitro cytostatic activity of new beta-D-arabino furan[1',2':4,5]oxazolo- and arabino-pyrimidinone derivatives.
AID89631	In vitro inhibitory effect measured against human stomach adenocarcinoma ST-KM tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID122629	Change in weight of mouse on day 8 was measured in L1210 lymphoid leukemia inoculated mice after ip administration at dose of 20 mg/kg/day X5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID128055	Antitumor activity against L1210 leukemia in mice (Average weight per mouse on day 1.) at the dose of 250 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID274776	Distribution of araCTP in Swiss Webster mouse liver at 100 mg/kg, ip measured as AUC (0-4h)	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
AID82976	In vitro concentration required to induce apoptosis in HL60 cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID139211	Weight change on day 8 in L1210/ara-C (I) Lymphoid Leukemia in mice( ip implanted) at a dose of 60 mg/kg/day (qd=1-15)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID133642	Dose producing greatest increase in life span expressed as optimum dose (L1210/ara-C I) (qd 1)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1123323	Antiviral activity against Herpes simplex virus-2 LYONS infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID44349	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID201681	Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
AID1150988	Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in life span at 200 umol/kg/day, po using 0.9% (W/V) aqueous NaCl vehicle for 5 days 24 hrs after tumor inoculation	1976	Journal of medicinal chemistry, Aug, Volume: 19, Issue:8	Nucleic acids. 16. Orally active derivatives of ara-cytidine.
AID284051	Growth inhibition of human NCI-H460 cells by MTT assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID97116	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 400 mg/kg (treatment of 1qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID116640	Percent increase in life span of drug-treated mice relative to tumored, vehicle treated controls at a dose of 100 mg/kg oral treatment	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID98816	Antileukemic activity against L1210 leukemia cells in female B6D2F1/J mice at 34 mg/kg dose (post inoculation life span, days)	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID128064	Antitumor activity against L1210 leukemia in mice (Average weight per mouse on day 1.) at the dose of 50 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID72420	Tested in vitro against human ovarian cancer cells (G-401) for anticancer activity at dose 1 uM (Cell number 1*10 e-4)	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Synthesis of N-acetylglucosamine-modified ara-C and its effect on ovarian cancer cells.
AID97292	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by 45-day survivors in mice at 400 mg/kg (treatment of 1qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID93849	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against KB human cell lines after 144 hr	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Improved synthesis and antitumor activity of 1-deazaadenosine.
AID101082	Inhibitory concentration on multidrug-resistant L1210 leukemia cells.	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID210459	Anticancer activity carried out in vitro against human T-lymphocyte CEM/0	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Synthesis and biological evaluation of purine-containing butenolides.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID137174	Antitumor activity against L1210/ara-C leukemia in mice (median survival) at the dose of 200 mg/kg; Value represented as Test/Control = 7/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID132913	Percentage increase in life span after 12-13days	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID389364	Growth inhibition of human CCRF-HSB-2 cells by MTT method	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins.
AID355579	Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID96848	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 400 mg/kg (treatment of 1qd schedule) dosage; Range is 9-11	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID98767	Antileukemic activity against L1210 leukemia cells in female B6D2F1/J mice at 34 mg/kg dose(Mean increased life span, calculated as (T/C-1)X100)	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID154855	Antitumor activity was determined against the ip implanted P388 leukemia in mice by change in tumor weight at 200 mg/kg (treatment of 1-5qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID122631	Change in weight of mouse on day 8 was measured in L1210 lymphoid leukemia inoculated mice after ip administration at dose of 40 mg/kg/day X5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID261687	Antiproliferative activity against NCI60 cell line	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID1360490	Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID427702	Cytotoxicity against human A549 cells by sulforhodamine B method	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Discovery of a new template for anticancer agents: 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosyl-cytosine (2'-F-4'-seleno-ara-C).
AID320428	Antitumor activity against human CCRF-HSB2 cells by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Antitumor studies. Part 4: Design, synthesis, antitumor activity, and molecular docking study of novel 2-substituted 2-deoxoflavin-5-oxides, 2-deoxoalloxazine-5-oxides, and their 5-deaza analogs.
AID1360499	Growth inhibition of human SMMC7721 cells at 5 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID89281	In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID96540	Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 100 mg/kg (treatment of 1-9qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID116595	Percent increase in life span calculated as (T/C-1)X100 at a dose of 10 mg/kg/day *5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID338732	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
AID167741	Dose required to reduce primary rabbit kidney cell growth	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID411722	Cytotoxicity against human 2209-23 cells by WST1 cell ciability assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
AID306718	Inhibition of human TK1 assessed as [methyl-3H]dThd phosphorylation	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID502465	Antitumor activity against mouse S180 cells transplanted in ICR mouse assessed as inhibition of tumor weight at 8.9 umol/kg, ip	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis.
AID135728	Toxicity in mice after 15-18 days at a dose of 60 mg/kg/day; 15.5/8.5	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID124261	In vivo activity against transplanted Mel-B16 tumors of mice	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID108522	Number of animals survived after 30-days in mice bearing lymphoid leukemia, treatment schedule is 1-9 qd.	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols.
AID1292263	Selectivity index, ratio of IC50 for HDF cells to IC50 for human KB cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID132923	Percentage increase in life span after 7-8 days	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID341998	Antimicrobial activity against Streptococcus sp. 07686-2 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1123325	Antimetabolic activity against primary rabbit kidney cells assessed as inhibition of [methyl-3H]dThd incorporation into DNA after 16 hrs	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID75536	Compound was tested for the inhibition of glioblastoma	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID137057	Antitumor activity against L1210/ara-C leukemia in mice (median survival) at the dose of 1000 mg/kg; Value represented as Test/Control = 8/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID210892	Inhibitory concentration against Varicella- zoster virus thymidine kinase(VZV TK)	2001	Bioorganic & medicinal chemistry letters, May-21, Volume: 11, Issue:10	Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors.
AID1222329	Activity of human recombinant N-terminal His-SUMO fused wild type CDA expressed in Escherichia coli BL21(DE3) cells assessed as arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID411721	Antiviral activity against Hepatitis C virus infected human 2209-23 cells by genotype 1b replicon assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
AID416475	Induction of erythroid differentiation in human K562 cells assessed as benzidine-positive cells after 6 days	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Synthesis of glycose carbamides and evaluation of the induction of erythroid differentiation of human erythroleukemic K562 cells.
AID96839	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 200 mg/kg (treatment of 1-5qd schedule) dosage; Range is 15-17	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID155571	Antiviral activity against Para influenza virus type 3 strain C243 was evaluated in african green monkey kidney	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID88959	In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID361405	Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID433254	Cytotoxicity against human H441 cells after 72 hrs by trypan blue cell exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis of radiolabeled cytarabine conjugates.
AID152349	Effective dose to inhibit the replication of P388 cell line in vitro.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogues and crystal structure of 1-(3-deoxy-beta-D-threo-pentofuranosyl)cytosine.
AID1134746	Half life of the compound	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID687160	Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID57470	Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID654377	Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation.
AID1135044	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as median survival time at 50 mg/kg, ip qd administered for 5 days (Rvb = 9 days)	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID431398	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID89111	In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID431520	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as tumor weight at 89.28 umol/kg/day, ip administered for 7 consecutive days after 24 hrs of tumor implantation measured after 24 hrs post dose	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis, DNA intercalation and 3D QSAR analysis of cis-2,4,5-trisubstituted-1,3-dithiolanes as a novel class of antitumor agents.
AID338738	Cytotoxicity against human EH118MG cells after 3 days by trypan blue exclusion technique
AID100203	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose of 25 mg/kg/day x 5 was determined as mean survival of treated group compared to untreated; 9.5/8	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID210538	Phosphorylating activity of viral HSV -2 (333) induced thymidine kinase relative to dThdK was determined	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID132925	Percentage increase in life span after 7 days	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1145834	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 100 mg/kg, ip administered as single dose measured on day 30 relative to vehicle-treated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID98818	Antileukemic activity against L1210 leukemia cells in female B6D2F1/J mice at 93 mg/kg dose (post inoculation life span, days)	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID1135817	Retention time of the compound by liquid chromatography	1978	Journal of medicinal chemistry, Nov, Volume: 21, Issue:11	Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1549407	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Synthesis and biological activities of artemisinin-piperazine-dithiocarbamate derivatives.
AID1134725	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 6.25 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1542692	Induction of apoptosis in human U937 cells assessed as early apoptotic cells at 0.3 uM measured after 2 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 0.7 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID427705	Cytotoxicity against human PC3 cells by sulforhodamine B method	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Discovery of a new template for anticancer agents: 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosyl-cytosine (2'-F-4'-seleno-ara-C).
AID138713	Antitumor activity against L1210 leukemia in mice (Average 7-day weight change) at the dose of 500 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1740798	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges.
AID1740806	Selectivity index, ratio of IC50 for cytotoxicity against human HDF cells to IC50 for cytotoxicity against human A549 cells	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges.
AID81809	Differentiating activity of compound in HL60 cells at conc 0.4 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID1632122	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID167039	Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID654371	Growth inhibition of human A549 cells after 24 hrs by WST-1 assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation.
AID135620	Long time survivors are the number mice that survived for >60 days relative to the number of treated mice 25 mg/kg; 0 / 5	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID94990	Effect of compound on erythroid differentiation of K562 cells was determined after a period of 9 days at concentration 500 nM	1999	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21	Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID99057	Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID341999	Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID127728	Average survival time includes only those mice that died prior to day 60 at 50 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID208539	Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
AID128050	Antitumor activity against L1210 leukemia in mice (Average weight per mouse on day 1.) at the dose of 200 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID502466	Antitumor activity against mouse S180 cells transplanted in ICR mouse assessed as inhibition of tumor weight at 89 umol/kg, ip	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis.
AID451300	Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID130645	Antitumor activity against L1210/ara-C leukemia in mice (Percent increase in life span.) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1292264	Selectivity index, ratio of IC50 for HDF cells to IC50 for human MCF7 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID94986	Effect of compound on erythroid differentiation of K562 cells was determined after a period of 7 days at concentration 500 nM	1999	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21	Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID419502	Volume of distribution at steady state in human administered 1 to 12 g doses with 2 to 3.5 hrs iv infusion	2009	Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14	In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID133374	Range of survival days for antitumor activity against Ip implanted L1210 / 0 lymphoid leukemia in mice at a dose of 400 mg/kg per day after treatment 5	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
AID124260	In vivo activity against transplanted Mam-17/Adr tumors of mice	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID434133	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.
AID100061	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 5 mg/kg/day x 5 was determined and number of animals survived on 30 th day were reported; 0/7	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID630372	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	2011	Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21	Synthesis and anticancer activity of 5'-chloromethylphosphonates of 3'-azido-3'-deoxythymidine (AZT).
AID105312	In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID1506323	Growth inhibition of human bone marrow cells	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
AID1542697	Induction of apoptosis in human U937 cells assessed as late apoptotic cells at 0.3 uM measured after 3 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 1.75 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID130784	Antitumor activity against L1210/ara-C leukemia in mice (Percent increase in life span.) at the dose of 50 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID95873	Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID1542691	Induction of apoptosis in human U937 cells assessed as live cells at 0.3 uM measured after 2 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 95.05 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID139205	Weight change on day 8 in L1210/ara-C (I) Lymphoid Leukemia in mice( ip implanted) at a dose of 100 mg/kg/day (qd=1,5,9)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1134738	Toxicity in CDF1 mouse assessed as change in body weight at 10 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1422083	Inhibition of MDM2 (unknown origin)	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID153311	Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent median survival rate (treated/control) at 500 mg/kg (treatment of 1qd schedule) dosage; 15.0/11.0	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1542693	Induction of apoptosis in human U937 cells assessed as late apoptotic cells at 0.3 uM measured after 2 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 1.75 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID1740802	Selectivity index, ratio of IC50 for cytotoxicity against human HDF cells to IC50 for cytotoxicity against human SK-BR-3 cells	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges.
AID284052	Growth inhibition of human HCT116 cells by MTT assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents.
AID687162	Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID361403	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID124800	Antitumor activity against L1210 tumor in mice, at a dose of 500 mg/kg peroral administration in the presence of 500 mg/kg of zebularine.	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID594972	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as tumor growth inhibition at 100 umol/kg/day, ip qd for 7 days measured 24 hrs after last dose relative to control	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	A class of novel N-isoquinoline-3-carbonyl-L-amino acid benzylesters: synthesis, anti-tumor evaluation and 3D QSAR analysis.
AID83139	In vitro concentration required to induce apoptosis in HL60R cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID1855688	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
AID89280	In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID138718	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change (%)) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID137884	Ratio of survival time of treated to control mice at 25 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID687161	Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID100054	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 18.2 mg/kg/day x 5 was determined and number of animals survived on 30 th day were reported; 0/8	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID99793	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 18.2 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID137018	Antitumor activity against L1210 leukemia in mice (median survival) at the dose of 100 mg/kg; Value represented as Test/Control = 16/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID88952	In vitro inhibitory effect measured against human osteosarcoma HOS tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID135746	Toxicity in mice after 13-15 days at a dose of 60 mg/kg/day; 14/8.5	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1292257	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID88953	In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID153288	Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent increase in life span at 500 mg/kg (treatment of 1qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1150997	Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in life span at 200 umol/kg/day, po using 0.9% (W/V) aqueous NaCl vehicle for 5 days 24 hrs after tumor inoculation in presence of THU 10 mg/kg/day on days 1 to 5	1976	Journal of medicinal chemistry, Aug, Volume: 19, Issue:8	Nucleic acids. 16. Orally active derivatives of ara-cytidine.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1879227	Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay	2022	Bioorganic & medicinal chemistry letters, 04-01, Volume: 61	Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.
AID1222327	Activity of human recombinant N-terminal His-SUMO fused CDA Ala70Thr mutant expressed in Escherichia coli BL21(DE3) cells assessed as arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID355642	Cytotoxicity against mouse Panc03 cells at 1.5 ug/disk by corbett disk diffusion assay
AID139208	Weight change on day 8 in L1210/ara-C (I) Lymphoid Leukemia in mice( ip implanted) at a dose of 200 mg/kg/day (qd=1)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1222328	Activity of human recombinant N-terminal His-SUMO fused CDA Lys27Gln mutant expressed in Escherichia coli BL21(DE3) cells assessed as arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID124263	In vivo activity against transplanted Panc-03 tumors of mice	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID1134726	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 5 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1134734	Toxicity in CDF1 mouse assessed as change in body weight at 40 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1222346	Drug metabolism assessed as intrinsic clearance for human recombinant N-terminal His-tagged DCK Ala119Gly mutant-mediated cytosine-beta-D-arabinofuranoside-5'-MP formation expressed in Escherichia coli BL21(DE3) incubated for 3 mins by liquid chromatograp	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID85387	Inhibition of viral DNA synthesis in HSV-1 virus at the dose of 1.4 ug/mL.	1983	Journal of medicinal chemistry, Jan, Volume: 26, Issue:1	Antiviral compounds. 1. Structure-activity relationship of some antiviral enediones derived from aldehydo sugars.
AID120066	Median survival time expressed as (T/C) was measured at dose of 20 mg/kg/day X5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID214064	In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID105305	Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID72422	Tested in vitro against human ovarian cancer cells (G-401) for anticancer activity at dose 10 uM (Cell number 1*10 e-4)	1994	Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21	Synthesis of N-acetylglucosamine-modified ara-C and its effect on ovarian cancer cells.
AID1159296	Cytotoxicity against human PC3 cells by SRB assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Structure-activity relationships of 2'-modified-4'-selenoarabinofuranosyl-pyrimidines as anticancer agents.
AID502463	Cytotoxicity against human K562 cells after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis.
AID98041	Effective dose to inhibit the replication of L1210 cell line in vitro.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogues and crystal structure of 1-(3-deoxy-beta-D-threo-pentofuranosyl)cytosine.
AID1292267	Cytotoxicity against human 143B cells after 72 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1159297	Cytotoxicity against human K562 cells by SRB assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Structure-activity relationships of 2'-modified-4'-selenoarabinofuranosyl-pyrimidines as anticancer agents.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID155995	In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID135621	Long time survivors are the number mice that survived for >60 days relative to the number of treated mice at 50 mg/kg; 0 / 5	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID1145837	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 1000 mg/kg, ip administered as single dose measured on day 30 relative to vehicle-treated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID1222324	Activity of human recombinant N-terminal His-SUMO fused CDA Ala70Thr mutant expressed in Escherichia coli BL21(DE3) cells assessed as intrinsic clearance for arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID135301	No of survivors after 45 days at a dose of 200 mg/kg/day	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID116437	Percent increase in life span at 100 mg/kg (411 umol) per day	1993	Journal of medicinal chemistry, Jun-11, Volume: 36, Issue:12	Nucleoside conjugates. 13. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of thioether lipids with improved water solubility.
AID341996	Antimicrobial activity against Streptococcus sp. 07941-1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID142338	Anticancer activity carried out in vitro against murine leukemia P388	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Synthesis and biological evaluation of purine-containing butenolides.
AID341997	Antimicrobial activity against Streptococcus sp. 07706-1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID127727	Average survival time includes only those mice that died prior to day 60 at 25 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID81806	Differentiating activity of compound in HL60 cells at conc 0.08 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID154291	The compound was tested for anticancer activity against P815(arc-C resistant) cell lines of mouse leukemia	1980	Journal of medicinal chemistry, Oct, Volume: 23, Issue:10	Nucleosides. 116. 1-(beta-D-Xylofuranosyl)-5-fluorocytosines with a leaving group on the 3' position. Potential double-barreled masked precursors of anticancer nucleosides.
AID99782	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 5 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID135744	Toxicity in mice after 9-12 days at a dose of 200 mg/kg/day; 10.5/9.5	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID138726	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change (%)) at the dose of 500 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1134718	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 80 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID746835	Cytotoxicity against human MA9.3 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.
AID198969	Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID342000	Antimicrobial activity against Staphylococcus aureus CCM 885 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1150996	Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in life span at 100 umol/kg/day, po using 0.9% (W/V) aqueous NaCl vehicle for 5 days 24 hrs after tumor inoculation in presence of THU 10 mg/kg/day on days 1 to 5	1976	Journal of medicinal chemistry, Aug, Volume: 19, Issue:8	Nucleic acids. 16. Orally active derivatives of ara-cytidine.
AID1123153	Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 0.1 ug/ml after 24 hrs relative to control	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID132914	Percentage increase in life span after 13-15 days	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID99511	The compound was tested for anticancer activity against L5178Y (sensitive) cell lines of mouse leukemia	1980	Journal of medicinal chemistry, Oct, Volume: 23, Issue:10	Nucleosides. 116. 1-(beta-D-Xylofuranosyl)-5-fluorocytosines with a leaving group on the 3' position. Potential double-barreled masked precursors of anticancer nucleosides.
AID117643	In vivo activity against transplanted Mam-16/C/Adr tumors of mice; Not active	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID82836	Compound was tested for the inhibition of human HL60 Leukemia	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1589117	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID55975	Relative velocity was determined against deaminase purified from human acute myeloblastic leukemia cells	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID1229558	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationships of Neplanocin A Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Their Antiviral and Antitumor Activities.
AID135735	Toxicity in mice after 7-8 days at a dose of 100 mg/kg/day; 7/9	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID97634	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent median survival rate (treated/control) at 400 mg/kg (treatment of 1qd schedule) dosage; 9.5/8.0	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1375116	Antitumor activity against human HL60 cells xenografted in zebrafish embryo assessed as inhibition of cell migration at 200 ug/ml measured after 3 days of incubation by CM-Dil staining-based microscopic method relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.
AID84938	Antiviral activity against Herpes simplex virus -2 strain MS was evaluated in african green monkey kidney	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID1542694	Induction of apoptosis in human U937 cells assessed as necrotic cells at 0.3 uM measured after 2 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 2.5 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID490287	Antiproliferative activity against mouse r/m HM-SFME-1 cells after 24 hrs by MTT assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity.
AID490286	Antiproliferative activity against mouse SFME cells after 24 hrs by MTT assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity.
AID746836	Cytotoxicity against human CD34-positive blood stem/progenitor cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID654372	Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation.
AID89279	In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID1134733	Toxicity in CDF1 mouse assessed as change in body weight at 50 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID138731	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1135093	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 18.3 mg/kg, ip qd administered for 5 days co-administered with 27 mg/kg prednisone relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID122796	Dose producing greatest increase in life span >/=25% in mice bearing lymphoid leukemia, treatment schedule is 1-5 qd; 5-80 [mg(umol)/kg] /day	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols.
AID138727	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change (%)) at the dose of 50 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID83137	In vitro concentration required to induce apoptosis in HL60R cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID433255	Cytotoxicity in human H441 cells at 2 uM after 72 hrs by trypan blue cell exclusion assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis of radiolabeled cytarabine conjugates.
AID150342	Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID99488	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
AID98957	Antitumor activity against the ip implanted L1210 leukemia in mice expressed as optimal dose (1-5qd treatment schedule) required to produce greatest increase in life span was determined	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID1549406	Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Synthesis and biological activities of artemisinin-piperazine-dithiocarbamate derivatives.
AID98035	Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID138895	Mean body weight change on 17th day at a dose of 100 mg/kg/day	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID608163	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
AID89105	In vitro inhibitory effect measured against human malignant fibrous histiocytoma MFH-ST tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID135305	No of survivors after 45 days at a dose of 60 mg/kg/day	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID98814	Antileukemic activity against L1210 leukemia cells in female B6D2F1/J mice at 156 mg/kg dose (post inoculation life span, days)	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID1542695	Induction of apoptosis in human U937 cells assessed as live cells at 0.3 uM measured after 3 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 95.05 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID138898	Mean body weight change on 5th day at a dose of 200 mg/kg/day	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID89130	In vitro inhibitory effect measured against human osteosarcoma OST tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID155991	Tested in vitro against PC-13 human lung large cell carcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID306719	Inhibition of human TK2 assessed as [methyl-3H]dThd phosphorylation	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID142336	Inhibitory activity against murine leukemia L1210 cells	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID105661	Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
AID451297	Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID43616	Anticancer activity carried out in vitro against breast carcinoma MCF-7	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Synthesis and biological evaluation of purine-containing butenolides.
AID96553	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 400 mg/kg (treatment of 1-5qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID210863	Rate of phosphorylation relative to human CytodCydK was determined	1987	Journal of medicinal chemistry, Nov, Volume: 30, Issue:11	Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID1123319	Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID87474	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 144 hr	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Improved synthesis and antitumor activity of 1-deazaadenosine.
AID100491	Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and functional evaluation of a peptide derivative of 1-beta-D-arabinofuranosylcytosine.
AID89494	In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID1145836	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as survival at 500 mg/kg, ip administered as single dose measured on day 30 relative to vehicle-treated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID1124451	Antiviral activity against Pseudorabies virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Synthesis and antitumor and antiviral activities of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-iminopyrimidine and its derivatives.
AID152363	Antitumor activity against ip implanted P388 leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 20-200	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID341995	Antimicrobial activity against Escherichia coli ATCC 25922 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1134723	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 12.5 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID155865	In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID99918	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 5 mg/kg/day x 5 was determined as Survival time in days; Range is 9-22 days	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID53936	In vitro cytotoxicity was evaluated against colon DLD-1 cells	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	Synthesis and evaluation of several new (2-chloroethyl)nitrosocarbamates as potential anticancer agents.
AID687164	Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1135092	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 18.2 mg/kg, ip qd administered for 5 days co-administered with 27 mg/kg prednisolone relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1589119	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID434132	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1879226	Antiviral activity against HCV by replicon assay	2022	Bioorganic & medicinal chemistry letters, 04-01, Volume: 61	Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.
AID431395	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1632125	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID137030	Antitumor activity against L1210 leukemia in mice (median survival) at the dose of 200 mg/kg; Value represented as Test/Control = 17/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID608261	Toxicity in ICR mouse xenografted with mouse S180 cells assessed as effect on kidney weight at 2 umol/kg	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
AID1292268	Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID1360503	Growth inhibition of human LO2 cells at 2.5 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID306722	Inhibition of VZV TK assessed as [methyl-3H]dThd phosphorylation	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID137886	Ratio of survival time of treated to control mice at 75 mg/kg	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID451313	Resistance ratio of IC50 for deoxynucleoside analogue-resistant human MCF7 1K cells to IC50 for deoxynucleoside analogue-sensitive human MCF7 cells	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID124913	Change in weight in mice bearing ip-implanted L1210 lymphoid leukemia on day 8 at 200 mg/kg or 822 umol/kg per day	1993	Journal of medicinal chemistry, Jun-11, Volume: 36, Issue:12	Nucleoside conjugates. 13. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of thioether lipids with improved water solubility.
AID687165	Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID89647	In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID116799	Percent increase in life span of leukemic mice administered, with compound at 100 mg/kgx5, intraperitoneally	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	2'-Fluorinated isonucleosides. 1. Synthesis and biological activity of some methyl 2'-deoxy-2'-fluoro-2'-pyrimidinyl-D-arabinopyranosides.
AID155844	In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Nucleosides and nucleotides. 97. Synthesis of new broad spectrum antineoplastic nucleosides, 2'-deoxy-2'-methylidenecytidine (DMDC) and its derivatives.
AID678994	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	2000	Biochemical pharmacology, Jul-15, Volume: 60, Issue:2	Role of organic cation transporters in the renal secretion of nucleosides.
AID124262	In vivo activity against transplanted Panc-02 tumors of mice	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID130631	Antitumor activity against L1210 leukemia in mice (Percent increase in life span.) at the dose of 250 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID44350	Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1134724	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 10 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID44363	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID1135720	Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 1 uM after 6 days by [3H]thymidine incorporation method relative to control	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation.
AID97287	Antitumor activity was determined against the ip implanted L1210 leukemia in mice by 45-day survivors in mice at 200 mg/kg (treatment of 1-5qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID451296	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID338734	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
AID1134727	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 3.12 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID94681	Tested in vitro against KKLS human stomach adenocarcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID1632126	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID1360500	Growth inhibition of human LO2 cells at 0.01 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1146019	Antiviral activity against Herpes simplex virus 2 Curtis assessed as inhibition of virus-induced cytopathic effect at 37 degC after 72 hrs by two-fold dilution method	1977	Journal of medicinal chemistry, Jun, Volume: 20, Issue:6	Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses.
AID154858	Antitumor activity was determined against the ip implanted P388 leukemia in mice by change in tumor weight at 500 mg/kg (treatment of 1qd schedule) dosage	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID364005	Inhibition of rat brain protein kinase C	2008	European journal of medicinal chemistry, Jul, Volume: 43, Issue:7	Antitumor studies -- part 2: structure-activity relationship study for flavin analogs including investigations on their in vitro antitumor assay and docking simulation into protein tyrosine kinase.
AID769615	Cytotoxicity against human KB cells after 72 hrs by SRB assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis of 3'-azido-2',3'-dideoxy-5-fluorouridine phosphoramidates and evaluation of their anticancer activity.
AID124632	In vivo antitumor activity against intraperitoneally inoculated L1210 lymphoid leukemic mice (Weight change observed on day 8.Treatment schedule is 1-9 qd)	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols.
AID306720	Inhibition of HSV1 TK assessed as [methyl-3H]dThd phosphorylation	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID1855689	Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
AID98769	Antileukemic activity against L1210 leukemia cells in female B6D2F1/J mice at 93 mg/kg dose(Mean increased life span, calculated as (T/C-1)X100)	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID1123149	Antiviral activity against HSV1 2931 infected in African green monkey Vero cells assessed as inhibition of virus replication at 10 ug/ml after 24 hrs relative to control	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID1542698	Induction of apoptosis in human U937 cells assessed as necrotic cells at 0.3 uM measured after 3 days by muse Annexin V/dead cell reagent staining-based flow cytometry (Rvb = 2.5 %)	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives.
AID1360501	Growth inhibition of human LO2 cells at 0.1 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID139213	Weight change on day 8 in L1210/ara-C (I) Lymphoid Leukemia in mice( ip implanted) at a dose of 60 mg/kg/day (qd=1-9)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1135091	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as median survival time at 18.3 mg/kg, ip qd administered for 5 days co-administered with 27 mg/kg prednisone (Rvb = 9 days)	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID124583	Median T/C calculated based on survivors at 100 mg/kg (411 umol) per day against Ip-implanted L1210 lymphoid leukemia mice	1993	Journal of medicinal chemistry, Jun-11, Volume: 36, Issue:12	Nucleoside conjugates. 13. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of thioether lipids with improved water solubility.
AID137036	Antitumor activity against L1210 leukemia in mice (median survival) at the dose of 250 mg/kg; Value represented as Test/Control = 13/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID133644	Dose producing greatest increase in life span expressed as optimum dose (L1210/ara-C I) (qd 1-15)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1589126	Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human U87 cells	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID1123321	Antiviral activity against Herpes simplex virus-1 KOS infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID608166	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
AID1135056	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 18.2 mg/kg, ip qd administered for 5 days relative to control	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID137047	Antitumor activity against L1210 leukemia in mice (median survival) at the dose of 50 mg/kg; Value represented as Test/Control = 14/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID100058	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined and number of animals survived on 30 th day were reported; 0/8	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID135618	Long time survivors are the number mice that survived for >60 days relative to the number of treated mice at 75 mg/kg; 0 / 5	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID95323	Tested in vitro against KATO-III human stomach adenocarcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID120070	Median survival time expressed as (T/C) was measured at dose of 40 mg/kg/day X5	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID1292266	Selectivity index, ratio of IC50 for HDF cells to IC50 for human 143B cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID135299	No of survivors after 45 days at a dose of 100 mg/kg/day	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
AID1145826	Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID608259	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as tumor growth inhibition at 0.89 umol/kg, ip administered 1 day after tumor inoculation qd for 7 days	2011	European journal of medicinal chemistry, Aug, Volume: 46, Issue:8	A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis.
AID1916657	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1222349	Activity of human recombinant N-terminal His-tagged DCK Ile24Val mutant expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID99780	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID687157	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1595846	Antitumor activity against human Z138 cells xenografted in nu/nu mouse assessed as tumor weight at 40 mg/kg, iv administered 5 times a week for 3 weeks and measured after 21 days (Rvb = 1.74 g)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.
AID594979	Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as decrease of tumor weight at 100 umol/kg, ip qd for 7 days measured 24 hrs after last dose	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	A class of novel N-isoquinoline-3-carbonyl-L-amino acid benzylesters: synthesis, anti-tumor evaluation and 3D QSAR analysis.
AID1222326	Activity of human recombinant N-terminal His-SUMO fused wild type CDA expressed in Escherichia coli BL21(DE3) cells assessed as intrinsic clearance for arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID128068	Antitumor activity against L1210/ara-C leukemia in mice (Average weight per mouse on day 1.) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID81672	Differentiating activity of compound in HL60 cells at conc 0.016 ug/mL	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID124259	In vivo activity against transplanted Mam-17 tumors of mice	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
AID427706	Cytotoxicity against human K562 cells by sulforhodamine B method	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Discovery of a new template for anticancer agents: 2'-deoxy-2'-fluoro-4'-selenoarabinofuranosyl-cytosine (2'-F-4'-seleno-ara-C).
AID1145831	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 500 mg/kg, ip administered as single dose relative to vehicle-treated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID475910	Antitumor activity against human MCF7 cells after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis, X-ray crystal structure study and antitumoral evaluations of 5,6-disubstituted pyrimidine derivatives.
AID1589127	Selectivity index, ratio of IC50 for cytotoxicity in human NHDF cells to IC50 for cytotoxicity in human HepG2 cells	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
AID1135905	Antiviral activity against Vesicular stomatitis virus infected in rabbit primary kidney cells assessed as inhibition of viral cytopathogenicity after 2 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Antiviral activity of aliphatic nucleoside analogues: structure-function relationship.
AID1292265	Selectivity index, ratio of IC50 for HDF cells to IC50 for human HepG2 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
AID138721	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change (%)) at the dose of 200 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID105667	In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.
AID475907	Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis, X-ray crystal structure study and antitumoral evaluations of 5,6-disubstituted pyrimidine derivatives.
AID1123151	Cytotoxicity against mouse L5178Y cells assessed as growth inhibition after 96 hrs	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.
AID1229560	Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationships of Neplanocin A Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Their Antiviral and Antitumor Activities.
AID96383	Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID1222338	Ratio of Vmax for human recombinant N-terminal His-tagged wild type DCK expressed in Escherichia coli BL21(DE3) cells to Vmax for human recombinant N-terminal His-tagged DCK Pro122Ser mutant expressed in Escherichia coli BL21(DE3) cells	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID654373	Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation.
AID274780	Ratio of AUC for araCTP level in liver to plasma of Swiss Webster mouse	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
AID138588	Antitumor activity against L1210 leukemia in mice (Average 7-day weight change) at the dose of 250 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID136892	Antitumor activity against L1210 leukemia in mice (median survival) at the dose of 1000 mg/kg; Value represented as Test/Control = 15/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID106856	Tested in vitro against MKN-45 human stomach adenocarcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID100073	Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 9.2 mg/kg/day x 5 was determined and number of animals survived on 30 th day were reported; 1/7	1980	Journal of medicinal chemistry, Dec, Volume: 23, Issue:12	Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
AID138734	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change) at the dose of 200 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID218494	In vitro cytotoxicity against Vero cells.	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID101083	Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1123326	Antimetabolic activity against primary rabbit kidney cells assessed as inhibition of [2-14C]dUrd incorporation into DNA after 16 hrs	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID138723	Antitumor activity against L1210/ara-C leukemia in mice (Average 7-day weight change (%)) at the dose of 250 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID433260	Cytotoxicity against human H441 cells by glucosaminidase assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis of radiolabeled cytarabine conjugates.
AID1375115	Antitumor activity against human HL60 cells xenografted in zebrafish embryo assessed as inhibition of cell proliferation at 200 ug/ml measured after 3 days of incubation by CM-Dil staining-based microscopic method relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.
AID137058	Antitumor activity against L1210/ara-C leukemia in mice (median survival) at the dose of 100 mg/kg; Value represented as Test/Control = 7/8	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID1134737	Toxicity in CDF1 mouse assessed as change in body weight at 12.5 mg/kg, ip measured on day 5 relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID1134721	Antitumor activity in mouse L1210 cells allografted in CDF1 mouse assessed as increase in life span at 25 mg/kg, ip administered as qd for 9 days relative to control	1979	Journal of medicinal chemistry, Oct, Volume: 22, Issue:10	Synthesis and antitumor activity of 5-azacytosine arabinoside.
AID502467	Antitumor activity against mouse S180 cells transplanted in ICR mouse assessed as inhibition of tumor weight at 0.89 umol/kg, ip	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis.
AID89278	In vitro inhibitory effect measured against human lung adenocarcinoma PC-3 tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID1360497	Growth inhibition of human SMMC7721 cells at 0.5 ug/ml after 72 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID409744	Antitumor activity against human CCRF-HSB2 cells by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds.
AID342001	Antimicrobial activity against Streptococcus pyogenes AP1 after 20 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
AID1222325	Activity of human recombinant N-terminal His-SUMO fused CDA Lys27Gln mutant expressed in Escherichia coli BL21(DE3) cells assessed as intrinsic clearance for arabinofuranosyl uridine formation by liquid chromatography-tandem mass spectrometry	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
AID208867	In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Design, synthesis, and antineoplastic activity of 2'-deoxy-2'-methylidenecytidine.
AID85090	In vitro antiviral activity against Herpes simplex virus -2 strain MS was evaluated in african green monkey kidney	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID152592	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the P388 murine cell lines after 72 hours	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Improved synthesis and antitumor activity of 1-deazaadenosine.
AID306721	Inhibition of Drosophila melanogaster dNK assessed as [methyl-3H]dThd phosphorylation	2007	Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID1266628	Antitumor activity against human KG1 cells xenografted in mouse assessed as tumor regression at 100 mg/kg, po qd measured after 11 days post tumor implantation	2015	Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21	Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Tria
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID289358	Antitumor activity against human KB cells by modified MTT assay	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	Antitumor studies. part 3: design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins.
AID89110	In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID1506322	Growth inhibition of human umbilical cord cells	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
AID1632129	Selectivity index, ratio of IC50 for HDF to IC50 for human KB cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID133410	In vivo percent inhibition of Lewis Lung Carcinoma cell line in mice at 100 mg/Kg per day (p<0.001) compared with NCDAC	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
AID1632131	Selectivity index, ratio of IC50 for HDF to IC50 for human HepG2 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Synthesis, Antibacterial, and Anticancer Evaluation of Novel Spiramycin-Like Conjugates Containing C(5) Triazole Arm.
AID89467	In vitro inhibitory effect measured against human lung suamous-cell carcinoma QG-56 tumor cells at 100 ug/mL	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro.
AID156483	Tested in vitro against PC-8 human lung adenocarcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID1135804	Antiviral activity against HSV1 CL101 infected in African green monkey Vero cells assessed as inhibition of plaque formation at 200 uM after 40 hrs relative to control	1978	Journal of medicinal chemistry, Nov, Volume: 21, Issue:11	Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID1135090	Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as median survival time at 18.2 mg/kg, ip qd administered for 5 days co-administered with 27 mg/kg prednisolone (Rvb = 9 days)	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone.
AID138064	Survival time treated / survival time (T/C) for antitumor activity against Ip implanted L1210 / 0 lymphoid leukemia in mice at a dose of 400 mg/kg per day after treatment 1;8/7	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
AID1123320	Antiviral activity against Vaccinia virus infected in human skin fibroblast cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil.
AID1135721	Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 100 uM after 6 days by [3H]thymidine incorporation method relative to control	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation.
AID44010	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Amino acid phosphoramidate nucleosides: potential ADEPT/GDEPT substrates.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145832	Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 1000 mg/kg, ip administered as single dose relative to vehicle-treated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Reactions of 2-acyloxyisobutyryl halides with nucleosides. Synthesis and biological evaluation of some 3"-acyl and 3',5'-diacyl derivatives of 1-beta-D-arabinofuranosylcytosine.
AID84060	In vitro antiviral activity against Herpes simplex virus -1 strain KOS was evaluated in african green monkey kidney	1985	Journal of medicinal chemistry, Apr, Volume: 28, Issue:4	Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID140005	Death due to toxicity occurring at a maximum body weight decrease of 10 to 22% from the average post injection body weight at 25 mg/kg; 2 / 5	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
AID128074	Antitumor activity against L1210/ara-C leukemia in mice (Average weight per mouse on day 1.) at the dose of 500 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID451298	Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay	2009	Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17	Special feature of mixed phosphotriester derivatives of cytarabine.
AID82982	In vitro inhibitory concentration against proliferation of HL60 cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID130617	Antitumor activity against L1210 leukemia in mice (Percent increase in life span.) at the dose of 100 mg/kg	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
AID45400	Effect on cross resistance of CHO cells resistant to colchicine (CHRC5)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID123366	In vivo antitumor activity against intraperitoneally inoculated L1210 Lymphoid leukemic mice (Dose producing greatest increase in life span, treatment schedule is 1- 9 qd)	1985	Journal of medicinal chemistry, Feb, Volume: 28, Issue:2	Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols.
AID201690	Tested in vitro against SW-48 human colon adenocarcinoma	1993	Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26	Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5726 (38.10)	18.7374
1990's	3071 (20.43)	18.2507
2000's	2676 (17.80)	29.6817
2010's	2683 (17.85)	24.3611
2020's	874 (5.82)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	2,424 (15.65%)	5.53%
Reviews	7 (3.13%)	6.00%
Reviews	1,051 (6.79%)	6.00%
Case Studies	2 (0.89%)	4.05%
Case Studies	2,172 (14.02%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	26 (0.17%)	0.25%
Other	215 (95.98%)	84.16%
Other	9,814 (63.37%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1164)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With Haploidentical Natural Killer Cells in High-risk Acute Myeloid Leukemia [NCT02229266]	Phase 2	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to low recruitment rate)
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]	Phase 3	1,033 participants (Actual)	Interventional	2010-12-31	Active, not recruiting
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia [NCT00840177]	Phase 2	115 participants (Actual)	Interventional	2009-12-10	Completed
Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00041132]	Phase 2	56 participants (Actual)	Interventional	2002-09-30	Completed
A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC# 731636, IND#) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma [NCT00354107]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2007-01-31	Terminated
T-Cell or Natural Killer (NK) Cell Adback in Patients With Lymphoid Malignancies Receiving Allogeneic Stem Cell Transplantation With Campath-IH Containing Conditioning Regimens [NCT00536978]	Phase 2	22 participants (Actual)	Interventional	2007-09-30	Completed
ALinC 17, Classification ©), B-precursor Induction Treatment (I) [NCT01225874]		3,762 participants (Actual)	Interventional	1999-12-31	Completed
Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia [NCT01132586]	Phase 1	61 participants (Actual)	Interventional	2010-05-31	Completed
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation [NCT01237808]	Phase 3	144 participants (Actual)	Interventional	2011-03-31	Completed
Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen [NCT01063439]	Phase 2	42 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine [NCT01180322]	Phase 2	277 participants (Actual)	Interventional	2010-11-30	Completed
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease [NCT00302003]	Phase 3	287 participants (Actual)	Interventional	2006-02-28	Completed
A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies [NCT01321346]	Phase 1	30 participants (Actual)	Interventional	2011-03-31	Completed
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) [NCT03013998]	Phase 1/Phase 2	2,000 participants (Anticipated)	Interventional	2016-11-30	Recruiting
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]	Phase 3	170 participants (Actual)	Interventional	1996-03-31	Completed
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations [NCT05521087]	Phase 1	80 participants (Anticipated)	Interventional	2024-05-29	Not yet recruiting
A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations [NCT05453903]	Phase 1	150 participants (Anticipated)	Interventional	2022-10-04	Recruiting
A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Entospletinib (ENTO) as Monotherapy in Japanese Subjects With Relapsed or Refractory Hematologic Malignancies and in Combination With Chemotherapy in Japanese Subjects With [NCT03135028]	Phase 1	9 participants (Actual)	Interventional	2017-05-19	Terminated(stopped due to No signal of efficacy with Entospletinib)
Leukemia Stem Cell Detection in Acute Myeloid Leukemia [NCT02927938]	Phase 3	18 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to Study terminated 7/23/2019 due to limited participation and testing challenges.)
An Open Label, Single Arm, Single-Center Exploratory Study to Evaluate the Efficacy and Safety of Selinexor and HAAG +/- HMA in Relapsed/Refractory Acute Leukemia (AML) Patients [NCT05805072]		20 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Single-arm, Open, Multicenter, Phase II Study to Investigator the Efficacy and Safety of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT05241093]	Phase 2	18 participants (Anticipated)	Interventional	2022-03-29	Recruiting
A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection Combined With Chemotherapy in Previously Untreated de Novo Acute Myeloid Leukemia [NCT05941585]		90 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study [NCT04375631]	Phase 1	120 participants (Anticipated)	Interventional	2020-12-03	Recruiting
Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With T Cell or NK Cell Lymphoma [NCT01178658]	Phase 2	42 participants (Anticipated)	Interventional	2010-07-31	Recruiting
Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patien [NCT01193400]	Phase 2	75 participants (Anticipated)	Interventional	2010-09-30	Terminated
A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies [NCT00429416]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2004-03-31	Completed
Prexasertib in Combination With Mitoxantrone, Etoposide and Cytarabine (MEC) in Relapsed/Refractory Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) - a Phase I Trial [NCT03735446]	Phase 1	2 participants (Actual)	Interventional	2019-01-18	Terminated(stopped due to Sponsor Decision)
A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS) [NCT00071799]	Phase 3	358 participants (Actual)	Interventional	2003-11-01	Completed
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients [NCT04112589]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2019-12-26	Active, not recruiting
Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors [NCT00054327]	Phase 2	34 participants (Actual)	Interventional	2000-11-30	Completed
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03518112]	Phase 2	6 participants (Actual)	Interventional	2018-04-18	Terminated(stopped due to Due to Competing Studies)
A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma [NCT00945724]	Phase 2	54 participants (Actual)	Interventional	2009-04-30	Active, not recruiting
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML) [NCT02642965]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2016-05-02	Completed
Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies [NCT01139151]	Phase 1	31 participants (Actual)	Interventional	2010-08-31	Completed
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML) [NCT01265199]	Phase 1	29 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Study was terminated before a MTD was determined for administrative reasons)
A Monocenter Prospective Single Arm Study of Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for Induced Therapy in Adults de Novo Acute Myeloid Leukemia (Non-M3) [NCT05906914]	Phase 2	30 participants (Anticipated)	Interventional	2023-06-29	Recruiting
Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin' [NCT00078949]	Phase 3	849 participants (Actual)	Interventional	2003-08-27	Completed
A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT03194932]	Phase 1	62 participants (Actual)	Interventional	2017-07-11	Completed
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study [NCT05959720]		180 participants (Anticipated)	Observational [Patient Registry]	2023-09-05	Recruiting
A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission [NCT04968015]	Phase 2	134 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin Chemotherapy [NCT04049539]	Phase 1/Phase 2	28 participants (Anticipated)	Interventional	2021-01-29	Recruiting
Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes. [NCT03259516]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-25	Terminated(stopped due to Slow recruitment rate)
A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT03207334]	Phase 2	0 participants (Actual)	Interventional	2018-11-30	Withdrawn(stopped due to Insufficient funding)
A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old [NCT02432872]		300 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia [NCT01358253]	Phase 4	100 participants (Actual)	Interventional	2010-12-31	Completed
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous Leukemia [NCT03709758]	Phase 1	64 participants (Anticipated)	Interventional	2018-10-17	Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML [NCT05183035]	Phase 3	98 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy [NCT02427620]	Phase 2	131 participants (Anticipated)	Interventional	2015-06-03	Active, not recruiting
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML [NCT01411267]	Phase 1	24 participants (Actual)	Interventional	2011-09-01	Completed
A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [NCT03629873]	Phase 2	69 participants (Anticipated)	Interventional	2018-02-01	Active, not recruiting
High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803) [NCT01141712]	Phase 2	43 participants (Actual)	Interventional	2010-04-30	Completed
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms [NCT06034470]	Phase 1	30 participants (Anticipated)	Interventional	2024-01-13	Recruiting
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT03813147]	Phase 1	12 participants (Actual)	Interventional	2019-05-17	Active, not recruiting
A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCL [NCT03072771]	Phase 1	14 participants (Actual)	Interventional	2017-08-01	Completed
A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma [NCT00166439]	Phase 2	50 participants (Actual)	Interventional	2005-03-31	Completed
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00137111]	Phase 3	501 participants (Actual)	Interventional	2000-07-08	Completed
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in Refractory/Relapsed Acute Lymphoblastic Leukemia [NCT05578378]	Phase 2/Phase 3	32 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma [NCT00133991]	Phase 2	23 participants (Actual)	Interventional	2005-07-31	Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia [NCT03564704]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2016-02-14	Recruiting
Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02834390]	Phase 1	7 participants (Actual)	Interventional	2016-08-12	Completed
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) [NCT02070458]	Phase 1	30 participants (Actual)	Interventional	2014-10-08	Completed
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS [NCT01567059]	Phase 2	34 participants (Actual)	Interventional	2012-05-31	Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma [NCT03553238]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2016-02-14	Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399]	Phase 2	550 participants (Anticipated)	Interventional	2020-12-04	Suspended(stopped due to Other - FDA Partial Clinical Hold)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02545283]	Phase 3	447 participants (Actual)	Interventional	2015-12-30	Terminated(stopped due to The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.)
Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years [NCT01358201]	Phase 4	100 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML) [NCT02255162]	Phase 1	8 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to Slow Accrual)
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study [NCT05598593]	Phase 2	70 participants (Anticipated)	Interventional	2022-10-23	Recruiting
CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML) [NCT04326439]	Phase 2	8 participants (Actual)	Interventional	2020-01-24	Terminated(stopped due to Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.)
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC) [NCT02527174]	Phase 1	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Volasertib no longer available)
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML [NCT01161550]	Phase 1	11 participants (Actual)	Interventional	2010-11-30	Completed
Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance [NCT01587430]	Phase 4	245 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation [NCT00647049]	Phase 2	78 participants (Anticipated)	Interventional	2007-01-31	Recruiting
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT01174888]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT02421939]	Phase 3	371 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia [NCT05665114]	Phase 1	18 participants (Anticipated)	Interventional	2022-12-24	Recruiting
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra [NCT01011920]	Phase 2	126 participants (Actual)	Interventional	2009-11-30	Completed
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587]	Phase 2	31 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Original investigator for the trial has left)
Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00098774]	Phase 2	47 participants (Actual)	Interventional	2004-10-31	Completed
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults [NCT00372593]	Phase 3	1,070 participants (Actual)	Interventional	2006-08-31	Completed
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135]		168 participants (Actual)	Interventional	2004-11-30	Completed
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial [NCT05586074]	Phase 3	324 participants (Anticipated)	Interventional	2023-03-03	Recruiting
A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Risk Cytogenetics [NCT04659616]	Phase 1	32 participants (Anticipated)	Interventional	2021-01-14	Recruiting
A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL [NCT05931263]	Phase 3	104 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study [NCT02728050]	Phase 1/Phase 2	84 participants (Actual)	Interventional	2016-12-01	Completed
A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen [NCT00074165]	Phase 2	17 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to Lack of accrual)
A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnose [NCT00046930]	Phase 3	449 participants (Actual)	Interventional	2002-09-17	Completed
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis [NCT02205762]	Phase 2/Phase 3	1,400 participants (Anticipated)	Interventional	2016-11-02	Recruiting
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma [NCT03719560]	Phase 2	0 participants (Actual)	Interventional	2019-07-01	Withdrawn(stopped due to lack of funding)
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II [NCT00838240]	Phase 1/Phase 2	114 participants (Anticipated)	Interventional	2008-11-30	Recruiting
A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients [NCT02502968]	Phase 2	194 participants (Anticipated)	Interventional	2015-09-30	Recruiting
Phase Ib/II Study of Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Uproleselan Plus Cladribine Plus LDAC in Patients With Treated Secondary AML (TS-AML) [NCT04848974]	Phase 1/Phase 2	37 participants (Anticipated)	Interventional	2021-06-11	Recruiting
A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients [NCT02472626]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Drug Supply Issues)
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second [NCT04229979]	Phase 3	140 participants (Anticipated)	Interventional	2021-02-08	Recruiting
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP [NCT02741388]	Phase 1	39 participants (Actual)	Interventional	2016-10-31	Completed
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562]	Phase 3	1,400 participants (Anticipated)	Interventional	2020-07-21	Recruiting
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid [NCT02339740]	Phase 3	158 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement [NCT01593488]	Phase 2	31 participants (Anticipated)	Interventional	2012-03-31	Active, not recruiting
A Phase I/II, Open-label Single Institution Study Evaluating Rapamycin in Combination With High-dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies [NCT00776373]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2007-01-31	Terminated
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML [NCT03384212]	Phase 3	120 participants (Anticipated)	Interventional	2016-08-01	Recruiting
A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia [NCT02403310]	Phase 1	21 participants (Actual)	Interventional	2015-06-18	Completed
A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML [NCT00528333]	Phase 2	211 participants (Actual)	Interventional	2007-09-30	Completed
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations [NCT02283177]	Phase 2	44 participants (Actual)	Interventional	2015-01-31	Completed
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years [NCT00369317]	Phase 3	205 participants (Actual)	Interventional	2007-03-31	Completed
The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial [NCT03873311]	Phase 4	114 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycop [NCT02416388]	Phase 2/Phase 3	3,100 participants (Anticipated)	Interventional	2015-01-31	Recruiting
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00703820]	Phase 3	324 participants (Actual)	Interventional	2008-08-04	Completed
Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. [NCT03500133]	Phase 4	500 participants (Anticipated)	Interventional	2017-10-06	Recruiting
A PHASE III, MULTICENTRE, RANDOMIZED, OPEN LABEL CLINICAL TRIAL OF AZACYTIDINE (VIDAZA®) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. [NCT02319135]	Phase 3	289 participants (Actual)	Interventional	2014-10-31	Completed
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study [NCT05258799]		130 participants (Anticipated)	Interventional	2022-01-21	Recruiting
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML [NCT04354025]	Phase 2	0 participants (Actual)	Interventional	2023-06-30	Withdrawn(stopped due to Principal investigator decided not to move forward with the study.)
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]	Phase 2	66 participants (Actual)	Interventional	2010-12-14	Completed
Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis [NCT03113162]	Phase 1	15 participants (Anticipated)	Interventional	2015-05-29	Recruiting
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen [NCT02481310]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2015-10-28	Active, not recruiting
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome [NCT02328950]		50 participants (Anticipated)	Observational	2014-12-31	Recruiting
A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS [NCT00503880]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2007-05-07	Terminated(stopped due to Genzyme discontinued Funding)
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058) [NCT05849662]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02484391]	Phase 2	50 participants (Anticipated)	Interventional	2015-09-30	Completed
Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma [NCT00336583]	Phase 2	27 participants (Actual)	Interventional	2006-06-30	Completed
A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML [NCT04107727]	Phase 2	273 participants (Actual)	Interventional	2019-09-05	Active, not recruiting
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutate [NCT03591510]	Phase 2	23 participants (Anticipated)	Interventional	2019-03-13	Recruiting
An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML [NCT03661515]	Phase 1	16 participants (Actual)	Interventional	2018-07-17	Completed
A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia [NCT01145846]	Phase 3	316 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial [NCT05404516]	Phase 2	88 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer [NCT00831636]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2008-04-30	Completed
"Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine Versus Conventional 7+3 Induction Chemotherapy of Acute Myeloid Leukemia in Young Adults" [NCT05177731]	Phase 3	188 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Prospective Randomized Comparison of High-dose Cytarabine an High-dose Daunorubicin in the Induction Chemothrapy for Acute Myeloid Leukemia [NCT03507842]	Phase 3	380 participants (Actual)	Interventional	2018-03-01	Enrolling by invitation
A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Ol [NCT00927498]	Phase 3	280 participants (Actual)	Interventional	2007-12-31	Completed
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS [NCT04493164]	Phase 2	30 participants (Anticipated)	Interventional	2020-12-30	Recruiting
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults [NCT02003222]	Phase 3	488 participants (Actual)	Interventional	2014-05-19	Active, not recruiting
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma [NCT01661881]	Phase 2	23 participants (Actual)	Interventional	2012-08-16	Active, not recruiting
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma [NCT03579927]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-10-03	Withdrawn(stopped due to Lack of Funding)
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia [NCT02723994]	Phase 2	171 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT00390793]	Phase 2	107 participants (Actual)	Interventional	2006-09-28	Active, not recruiting
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults [NCT02228772]	Phase 1	19 participants (Actual)	Interventional	2014-12-31	Completed
Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment [NCT04945096]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies [NCT02587598]	Phase 1/Phase 2	97 participants (Actual)	Interventional	2015-12-29	Terminated
A Phase I Study of MEK Inhibitor MEK162 Combined With Idarubicin and Cytarabine Induction in Patients With Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia [NCT02049801]	Phase 1	1 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to logistics)
CPX-351 Plus Enasidenib for Relapsed Acute Myelogenous Leukemia Characterized by the IDH2 Mutation [NCT03825796]	Phase 2	2 participants (Actual)	Interventional	2019-04-12	Active, not recruiting
Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma [NCT00571493]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2006-04-14	Completed
"Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed ELN 2022 Intermediate or Adverse-risk AML or High Risk MDS Patients Intended to Undergo Allogeneic Stem Cell Transplantation, a Phase 2, Single-arm, Open-Label Study" [NCT05829434]	Phase 2	108 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]	Phase 3	5,000 participants (Anticipated)	Interventional	2018-07-15	Recruiting
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL) [NCT03571321]	Phase 1	15 participants (Anticipated)	Interventional	2019-05-28	Recruiting
An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients [NCT02835222]	Phase 2	100 participants (Anticipated)	Interventional	2018-02-02	Recruiting
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) [NCT02013648]	Phase 3	203 participants (Anticipated)	Interventional	2014-07-31	Active, not recruiting
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) [NCT01979536]	Phase 2	137 participants (Actual)	Interventional	2013-11-13	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT01424982]	Phase 2	88 participants (Actual)	Interventional	2011-10-05	Active, not recruiting
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells [NCT02072811]	Phase 3	400 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML [NCT02109627]	Phase 1	17 participants (Actual)	Interventional	2015-05-01	Terminated(stopped due to Low Accrual)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations [NCT00079482]	Phase 2	224 participants (Actual)	Interventional	2003-10-31	Completed
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement [NCT03724084]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2019-01-25	Terminated(stopped due to Other - Study agent no longer available)
Randomized Phase 3 Trial of Decitabine Versus Patient's Choice With Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00260832]	Phase 3	485 participants (Actual)	Interventional	2005-11-30	Completed
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia [NCT01130506]	Phase 1	17 participants (Actual)	Interventional	2010-05-17	Completed
Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT00422591]	Phase 2	175 participants (Actual)	Interventional	2006-12-31	Completed
Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and [NCT02198482]	Phase 2	6 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems)
A Phase 3, Prospective, Randomized Multi-center Intervention Trial of Early Intensification in AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance: A MYNERVA-GIMEMA Study [NCT04174612]	Phase 3	172 participants (Anticipated)	Interventional	2020-04-24	Recruiting
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG [NCT00039377]	Phase 2	58 participants (Actual)	Interventional	2002-04-30	Completed
High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease [NCT00003631]	Phase 2	118 participants (Actual)	Interventional	1998-08-31	Completed
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) [NCT03836209]	Phase 2	181 participants (Actual)	Interventional	2019-12-06	Active, not recruiting
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT02303821]	Phase 1	130 participants (Anticipated)	Interventional	2015-02-16	Recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]	Phase 3	847 participants (Actual)	Interventional	2014-10-04	Active, not recruiting
"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" [NCT01920737]	Phase 2	39 participants (Actual)	Interventional	2013-08-31	Active, not recruiting
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) [NCT04663347]	Phase 1/Phase 2	662 participants (Anticipated)	Interventional	2020-11-03	Recruiting
Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutation [NCT02298166]	Phase 3	9 participants (Actual)	Interventional	2016-11-17	Terminated(stopped due to The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an Investigator Initiated Trial this became valid on 2020/03/09)
Safety, Tolerability and Efficacy of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma，a Phase 1/2a Study [NCT06141109]	Phase 1/Phase 2	39 participants (Anticipated)	Interventional	2022-01-18	Recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) [NCT02981628]	Phase 2	80 participants (Anticipated)	Interventional	2017-06-19	Active, not recruiting
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma [NCT02203526]	Phase 1	93 participants (Anticipated)	Interventional	2014-08-14	Recruiting
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]	Phase 3	669 participants (Actual)	Interventional	2014-12-17	Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma [NCT00408005]	Phase 3	1,895 participants (Actual)	Interventional	2007-01-22	Active, not recruiting
an Single Center，Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia. [NCT04722952]	Phase 3	30 participants (Anticipated)	Interventional	2021-05-01	Recruiting
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) [NCT00075725]	Phase 3	3,154 participants (Actual)	Interventional	2003-12-29	Completed
Venetoclax, Cladribine Plus Low-dose Cytarabine for Relapsed/Refractory Philadelphia Chromosome-negative (Ph-) B-cell Acute Lymphoblastic Leukemia (B-ALL): a Single-arm, Multicenter Study [NCT05657652]		36 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease [NCT00025259]	Phase 3	1,734 participants (Actual)	Interventional	2002-09-30	Completed
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma [NCT00732498]	Phase 2	28 participants (Actual)	Interventional	2006-05-15	Completed
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT03147612]	Phase 2	21 participants (Actual)	Interventional	2018-02-08	Active, not recruiting
Clinical Study on the Safety and Efficacy of QN-023a Targeting CD33 in Acute Myeloid Leukemia [NCT05665075]	Phase 1	19 participants (Anticipated)	Interventional	2022-12-24	Recruiting
A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) [NCT01127009]	Phase 1	3 participants (Actual)	Interventional	2010-07-31	Completed
Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study [NCT01230983]	Phase 3	573 participants (Actual)	Interventional	1996-06-30	Completed
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes [NCT03446638]		0 participants (Actual)	Interventional	2019-05-31	Withdrawn(stopped due to administratively withdrawn)
Clinical Study of Mitoxantrone Hydrochloride Liposome, Carmostine, Etoposide and Cytarabine as Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma [NCT05681403]		53 participants (Anticipated)	Interventional	2023-01-15	Not yet recruiting
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission [NCT01146977]	Phase 2	43 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant [NCT01481272]	Phase 2	77 participants (Actual)	Interventional	2011-11-30	Completed
Immune Reconstitution and Biomarker Identification in Patients With Newly Diagnosed Low and Intermediate Risk Hodgkins Lymphoma Receiving Chemotherapy With or Without Radiation Therapy: TXCH-HD-12A [NCT01858922]	Phase 2	40 participants (Actual)	Interventional	2012-12-19	Active, not recruiting
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome [NCT03071276]	Phase 2	37 participants (Actual)	Interventional	2016-01-14	Terminated(stopped due to Due to slow enrollment)
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]		76 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia. [NCT03381118]	Phase 2	16 participants (Actual)	Interventional	2017-06-30	Terminated(stopped due to Unexpected toxicity)
Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma [NCT01178645]	Phase 2	42 participants (Anticipated)	Interventional	2010-07-31	Recruiting
Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of Refractory/Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess: a Multicenter, Single-arm, Prospective Clinical Study [NCT03356080]	Phase 2	50 participants (Anticipated)	Interventional	2017-07-07	Recruiting
A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA [NCT02954653]	Phase 1	8 participants (Actual)	Interventional	2016-11-28	Terminated(stopped due to The study was terminated due to a change in sponsor prioritization.)
Efficacy and Safety of Venetoclax Combined With BEAM (Carmustine, Etoposide Cytarabine and Melphalan) Pretreatment in Autologous Stem Cell Transplantation for Diffuse Large B-cell Lymphoma: a Single-center, Randomized Clinical Study [NCT05863845]		52 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement [NCT02329080]	Phase 2	76 participants (Actual)	Interventional	2014-12-31	Active, not recruiting
A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation [NCT03315520]	Phase 2	100 participants (Anticipated)	Interventional	2016-01-22	Recruiting
A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03760445]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-11-15	Withdrawn(stopped due to It was determined that the study design may not be optimal given the changing AML treatment landscape.)
Effectiveness of Microcurrents Therapy in Pressure Ulcers in Elderly People: Controlled and Randomized Triple Blind Clinical Trial [NCT03753581]		30 participants (Actual)	Interventional	2018-10-31	Completed
An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary Disease [NCT05456269]	Phase 1	0 participants (Actual)	Interventional	2022-07-29	Withdrawn(stopped due to commercial reason)
An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia [NCT00804856]	Phase 2	180 participants (Actual)	Interventional	2008-11-27	Completed
A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia [NCT02791919]	Phase 1	0 participants (Actual)	Interventional	2017-05-25	Withdrawn(stopped due to Other - Protocol moved to Disapproved)
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia [NCT01822015]	Early Phase 1	55 participants (Actual)	Interventional	2013-03-15	Completed
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia [NCT02875093]	Phase 1	23 participants (Actual)	Interventional	2017-01-20	Terminated(stopped due to Study Termination)
Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry [NCT01294449]		394 participants (Actual)	Observational	2011-03-31	Completed
A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT01019317]	Phase 2	151 participants (Actual)	Interventional	2009-11-30	Completed
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) [NCT01191801]	Phase 3	711 participants (Actual)	Interventional	2010-12-17	Completed
A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00734773]	Early Phase 1	0 participants (Actual)	Interventional	2008-11-30	Withdrawn(stopped due to Lack of funding)
[NCT02662647]	Phase 2	30 participants (Actual)	Interventional	2015-04-30	Completed
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) [NCT04113616]	Phase 1/Phase 2	86 participants (Anticipated)	Interventional	2019-09-25	Active, not recruiting
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00878254]	Phase 2	25 participants (Actual)	Interventional	2009-03-25	Active, not recruiting
EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial [NCT02858804]	Phase 4	55 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation [NCT00691015]	Phase 2	48 participants (Actual)	Interventional	2008-05-31	Completed
A Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT00583102]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2001-06-30	Terminated(stopped due to Slow accrual, PI left institution)
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma [NCT00669877]	Phase 2	56 participants (Actual)	Interventional	2002-08-31	Completed
Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX [NCT00299182]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2006-03-31	Completed
Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transpl [NCT00689169]	Phase 2	75 participants (Actual)	Interventional	2007-08-31	Completed
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML [NCT00656617]	Phase 2	106 participants (Actual)	Interventional	2008-04-30	Completed
Single Arm,Open Label,Phase I Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia [NCT05659992]	Phase 1	30 participants (Anticipated)	Interventional	2022-01-10	Recruiting
A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT01904643]	Phase 1	17 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Accrual factor)
Reduced Intensity Conditioning Regimen for Low- and Intermediate-risk Myelodysplastic Syndrome Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412266]	Phase 2	50 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related Changes [NCT04802161]	Phase 2	78 participants (Anticipated)	Interventional	2022-08-24	Recruiting
Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML [NCT00880243]	Phase 3	473 participants (Actual)	Interventional	1999-03-31	Completed
A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS [NCT00516828]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2007-11-27	Completed
A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old o [NCT00290498]	Phase 2	67 participants (Actual)	Interventional	2005-08-01	Completed
A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient [NCT04402723]	Phase 1	8 participants (Actual)	Interventional	2018-11-06	Terminated(stopped due to Corporate policy adjustments)
A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse/Refractory AML and Relapsed/Progressed High/Very High Risk MDS [NCT04275518]	Phase 1	102 participants (Anticipated)	Interventional	2020-07-06	Recruiting
A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia [NCT02277847]	Phase 4	400 participants (Anticipated)	Interventional	2010-03-31	Enrolling by invitation
Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma [NCT00004231]	Phase 2	0 participants	Interventional	1999-10-31	Completed
A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT03515200]	Phase 1	12 participants (Actual)	Interventional	2018-04-20	Terminated(stopped due to Due to departure of PI from St. Jude)
Combination of Rituximab and Methotrexate Followed by Rituximab and Cytarabine in Elderly Patients With Primary CNS Lymphoma [NCT03569995]	Phase 2	35 participants (Anticipated)	Interventional	2018-11-30	Recruiting
A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia [NCT03324243]	Phase 2	0 participants (Actual)	Interventional	2018-01-31	Withdrawn(stopped due to Withdrawn: Study halted prior to enrollment of first participant)
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells [NCT02797470]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2016-06-23	Active, not recruiting
Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study [NCT02926586]	Phase 4	200 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT03263936]	Phase 1	37 participants (Actual)	Interventional	2017-07-11	Completed
"A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058" [NCT01187810]	Phase 1	3 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to drug supply)
AGORA-1 /ALFA 2100 Study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML [NCT05199051]	Phase 2	50 participants (Anticipated)	Interventional	2023-06-03	Recruiting
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia [NCT03913559]	Phase 2	32 participants (Anticipated)	Interventional	2019-05-14	Recruiting
"A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial" [NCT03092674]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2018-02-02	Active, not recruiting
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) [NCT02570542]	Phase 2	59 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms [NCT02084563]	Phase 2	455 participants (Actual)	Interventional	2012-10-31	Completed
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML [NCT03384225]	Phase 3	120 participants (Anticipated)	Interventional	2016-08-01	Recruiting
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old [NCT03257241]	Phase 3	582 participants (Anticipated)	Interventional	2017-07-03	Recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]	Phase 2	79 participants (Actual)	Interventional	2005-04-30	Completed
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy [NCT02067143]	Phase 2	204 participants (Actual)	Interventional	2014-05-20	Completed
A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence Pretrial of Daunorubicin Cytarabine Liposome for Injection in Older, Naive AML Patients [NCT04920500]		16 participants (Anticipated)	Interventional	2020-09-04	Recruiting
Safety and Efficacy of an Outpatient Schedule of Rituximab, Cytarabine, Carboplatin, and Dexamethasone in Relapsed/Refractory Non-Hodgkin Lymphoma. Phase I/II Trial. [NCT03892421]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2018-04-05	Completed
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in [NCT06099366]	Phase 2	116 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance [NCT02756962]	Phase 2	110 participants (Anticipated)	Interventional	2016-07-06	Recruiting
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML [NCT02115295]	Phase 2	458 participants (Anticipated)	Interventional	2014-05-19	Recruiting
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD [NCT01371981]	Phase 3	1,645 participants (Actual)	Interventional	2011-06-20	Active, not recruiting
Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Aclarubicin in Patients With Refractory/Relapsed Acute Myeloid Leukemia: a Phase 2 Clinical Trial [NCT03181815]	Phase 2	48 participants (Anticipated)	Interventional	2016-01-01	Recruiting
A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease. [NCT05886049]	Phase 1	28 participants (Anticipated)	Interventional	2023-12-19	Not yet recruiting
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05554419]	Phase 2	184 participants (Anticipated)	Interventional	2024-08-16	Not yet recruiting
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients Wit [NCT04778397]	Phase 3	346 participants (Anticipated)	Interventional	2021-07-01	Active, not recruiting
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas [NCT02130869]	Phase 1	8 participants (Actual)	Interventional	2014-10-10	Completed
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) [NCT00103285]	Phase 3	5,377 participants (Actual)	Interventional	2005-04-11	Completed
Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma [NCT00126191]	Phase 2	10 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to closed due to slow accrual)
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia [NCT05157971]	Phase 1	6 participants (Anticipated)	Interventional	2022-03-17	Recruiting
Phase I Study of Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): ALL-6 Protocol [NCT00940524]	Phase 1	7 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia [NCT02873338]	Phase 2	75 participants (Actual)	Interventional	2016-08-31	Completed
Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML) [NCT02573363]	Phase 1	25 participants (Actual)	Interventional	2015-10-07	Completed
Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study [NCT00715637]	Phase 3	420 participants (Anticipated)	Interventional	2007-06-30	Active, not recruiting
A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma [NCT00908180]	Phase 2	47 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT06007911]	Phase 1	36 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Inducti [NCT05766514]	Phase 2	98 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [NCT05476770]	Phase 1	54 participants (Anticipated)	Interventional	2022-11-11	Recruiting
Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) [NCT05319587]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	2022-09-29	Recruiting
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics [NCT03897127]	Phase 3	882 participants (Anticipated)	Interventional	2019-09-04	Recruiting
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT03263572]	Phase 2	90 participants (Anticipated)	Interventional	2017-11-29	Recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT02877303]	Phase 2	80 participants (Anticipated)	Interventional	2016-11-01	Recruiting
A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation [NCT02719574]	Phase 1/Phase 2	336 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients With AML [NCT01031368]	Phase 1	29 participants (Actual)	Interventional	2009-12-31	Completed
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00549848]	Phase 3	600 participants (Actual)	Interventional	2007-10-29	Completed
An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia [NCT01034410]	Phase 2	90 participants (Anticipated)	Interventional	2010-01-31	Terminated
Aezea (Cenersen) in Combination With Chemotherapy for Treatment of Acute Myelogenous Leukemia Subjects ≥55 Years of Age With No Response to Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study [NCT00967512]	Phase 2	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to Study Was Terminated due to lack of Funding.)
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia [NCT04231851]	Phase 2	30 participants (Anticipated)	Interventional	2020-02-19	Recruiting
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) [NCT00098839]	Phase 1/Phase 2	134 participants (Actual)	Interventional	2005-02-28	Completed
Phase 1b/2, Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and PK and PD Profiles of Voreloxin Injection in Combination With Cytarabine in Patients With Relapsed or Refractory AML [NCT00541866]	Phase 1/Phase 2	110 participants (Actual)	Interventional	2007-10-06	Completed
A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) [NCT00974792]	Phase 2	150 participants (Anticipated)	Interventional	2006-01-31	Recruiting
Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma [NCT01563614]	Phase 1	1 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to No patients can be recruited for this trial anymore due to other therapeutical approaches that became available.)
A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS [NCT00840684]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2009-01-31	Completed
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811]	Phase 2	97 participants (Actual)	Interventional	2004-06-30	Completed
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]	Phase 1/Phase 2	302 participants (Actual)	Interventional	2003-06-30	Completed
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00450801]	Phase 2	22 participants (Actual)	Interventional	2004-04-30	Completed
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia [NCT01027923]	Phase 1	6 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Withdrawal of support from sponsor)
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma [NCT00004228]	Phase 3	393 participants (Actual)	Interventional	2000-06-30	Completed
S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia [NCT00945815]	Phase 2	35 participants (Actual)	Interventional	2010-09-30	Completed
A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies [NCT00908167]	Phase 1	44 participants (Actual)	Interventional	2009-09-30	Completed
Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia [NCT00931645]	Phase 3	241 participants (Actual)	Interventional	2001-04-30	Completed
A Phase I, Open-label, Multi-centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML) [NCT00926731]	Phase 1	4 participants (Actual)	Interventional	2009-06-30	Completed
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) [NCT03634228]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2018-12-17	Terminated(stopped due to This study was terminated early due to lack of adequate response, and did not move to the Phase II portion of the study)
Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patien [NCT00006045]	Phase 3	0 participants	Interventional	2000-03-31	Active, not recruiting
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation [NCT00049517]	Phase 3	657 participants (Actual)	Interventional	2002-12-19	Completed
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) [NCT03962465]	Phase 1	36 participants (Anticipated)	Interventional	2022-07-22	Active, not recruiting
A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247) [NCT00907517]	Phase 1	24 participants (Actual)	Interventional	2009-07-29	Terminated
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT03575325]	Phase 2	11 participants (Actual)	Interventional	2018-10-11	Completed
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy [NCT02638428]	Phase 2	90 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse [NCT00544999]	Phase 1	21 participants (Anticipated)	Interventional	2007-09-30	Recruiting
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia [NCT02635074]	Phase 1	2 participants (Actual)	Interventional	2016-11-30	Terminated(stopped due to safety)
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT00873093]	Phase 2	148 participants (Actual)	Interventional	2009-03-31	Completed
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]	Phase 1	7 participants (Actual)	Interventional	2016-01-13	Completed
A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults [NCT02660762]	Phase 2	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease [NCT00070187]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2003-11-30	Completed
Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma [NCT02758925]	Phase 2	78 participants (Anticipated)	Interventional	2016-06-30	Not yet recruiting
An Open-Label Phase 2 Trial of LY2181308 Sodium Administered in Combination With Idarubicin and Cytarabine to Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT00620321]	Phase 2	24 participants (Actual)	Interventional	2008-03-31	Completed
A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All [NCT00005977]	Phase 3	83 participants (Actual)	Interventional	2000-09-30	Completed
DFCI ALL Adult Consortium Protocol: Adult ALL Trial [NCT01005758]	Phase 2	180 participants (Anticipated)	Interventional	2009-01-31	Not yet recruiting
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05628623]	Phase 2	184 participants (Anticipated)	Interventional	2023-10-23	Not yet recruiting
Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115) [NCT02670707]	Phase 3	124 participants (Anticipated)	Interventional	2016-03-07	Recruiting
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors [NCT02813135]	Phase 1/Phase 2	460 participants (Anticipated)	Interventional	2016-08-03	Recruiting
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression [NCT01806571]	Phase 2	34 participants (Actual)	Interventional	2015-03-12	Completed
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treat [NCT00520130]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2007-10-30	Completed
A Multi-center Prospective Single Arm Clinical Study of Reduced Intensive 3 + 5 Idarubicin and Cytarabine Chemotherapy Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome [NCT06050941]	Phase 2	60 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
A Dose Escalation And Phase II Study Of Gemtuzumab Ozogamicin (CMA-676; Mylotarg) With High-Dose Cytarabine For Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML) [NCT00006265]	Phase 2	60 participants (Actual)	Interventional	2001-03-31	Completed
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia [NCT04817241]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2022-02-10	Active, not recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]	Phase 3	6,720 participants (Anticipated)	Interventional	2019-07-03	Recruiting
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma [NCT04626791]	Phase 2	45 participants (Anticipated)	Interventional	2021-08-03	Recruiting
A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML [NCT00512252]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2007-07-31	Completed
A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) [NCT00337168]	Phase 2	36 participants (Actual)	Interventional	2006-10-31	Completed
Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI≥ 2) Diffuse Large B-Cell Lymphoma [NCT01325194]	Phase 2	143 participants (Actual)	Interventional	2011-03-31	Completed
CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning [NCT00368355]	Phase 2	46 participants (Actual)	Interventional	2000-04-30	Completed
Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years [NCT00416598]	Phase 2	546 participants (Actual)	Interventional	2006-11-15	Completed
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype [NCT02443077]	Phase 3	302 participants (Anticipated)	Interventional	2016-10-12	Active, not recruiting
A Phase I Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (AML) [NCT04915612]	Phase 1	18 participants (Anticipated)	Interventional	2021-05-21	Recruiting
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]	Phase 2	40 participants (Anticipated)	Interventional	2020-05-29	Recruiting
Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents [NCT03896269]	Phase 1	38 participants (Anticipated)	Interventional	2019-05-14	Recruiting
A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic S [NCT03672539]	Phase 2	50 participants (Anticipated)	Interventional	2018-11-07	Recruiting
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML) [NCT03629171]	Phase 2	52 participants (Anticipated)	Interventional	2018-10-29	Recruiting
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]	Phase 3	106 participants (Actual)	Interventional	2009-03-09	Completed
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT02676323]	Phase 1	19 participants (Actual)	Interventional	2016-05-03	Terminated(stopped due to Slow accrual)
Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome [NCT05342584]	Phase 1	99 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas [NCT00591630]	Phase 2	30 participants (Actual)	Interventional	2007-11-14	Completed
A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [NCT00594815]		52 participants (Actual)	Interventional	2002-08-28	Completed
A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell Transplantation [NCT04526288]	Phase 2	1 participants (Actual)	Interventional	2021-08-09	Terminated(stopped due to Terminated due to low accrual)
A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT04100330]	Phase 2	0 participants (Actual)	Interventional	2020-01-31	Withdrawn(stopped due to Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted feasibility of completing study within shelf-life of current IP supply)
Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS [NCT02576301]	Phase 1/Phase 2	105 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma [NCT00720447]	Phase 2	25 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma [NCT00577629]	Phase 2	39 participants (Actual)	Interventional	2005-06-18	Completed
A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML [NCT00915252]	Phase 2	214 participants (Actual)	Interventional	2009-07-31	Completed
Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes [NCT00451997]	Phase 2	10 participants (Actual)	Interventional	2004-03-31	Completed
High Dose Cytarabine And Mitoxantrone Therapy For Relapsed And Refractory Acute Myeloid And Lymphocytic Leukemia: Effects Of GM-CSF Versus G-CSF On Dendritic Cells And Leukemia Associated Antigen-Specific T-Lymphocytes [NCT00053131]	Phase 2	0 participants	Interventional	1999-01-31	Completed
Randomized Comparison of Consolidation Treatment in Elderly Patients With Acute Myeloid Leukemia: Idarubicin (IDA) Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone [NCT04216771]	Phase 2/Phase 3	320 participants (Anticipated)	Interventional	2020-01-31	Recruiting
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]	Phase 3	4,000 participants (Anticipated)	Interventional	2002-11-30	Recruiting
Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase [NCT00025402]	Phase 3	1,000 participants (Anticipated)	Interventional	1997-07-31	Active, not recruiting
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) [NCT02680951]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Withdrawn due to lack of participants.)
A Phase II Study of CPX-351 as a Novel Therapeutic Approach for Patients With Myelodysplastic Syndromes (MDS) After Hypomethylating Agent Failure [NCT03957876]	Phase 2	25 participants (Anticipated)	Interventional	2019-07-25	Recruiting
The Efficiency and Safety of N-acetylcysteine for Prevention of Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation [NCT05907486]	Phase 3	260 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission [NCT00002514]	Phase 3	1,929 participants (Actual)	Interventional	1993-05-07	Completed
Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia [NCT00017342]	Phase 2	0 participants	Interventional	2001-07-31	Completed
Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [NCT00968253]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2009-11-30	Completed
A Single Arm Pilot Study of Intrathecally Administered DepoCyt® With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors [NCT00964743]		2 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Low Accrual)
A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT02652871]	Phase 1	36 participants (Anticipated)	Interventional	2016-05-09	Completed
Dose-intense Idarubicin Induction in Young Patients With Acute Myeloid Leukemia [NCT04069208]	Phase 2	42 participants (Anticipated)	Interventional	2019-09-03	Recruiting
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia [NCT00494897]	Phase 4	374 participants (Actual)	Interventional	1996-06-30	Completed
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients [NCT03226418]	Phase 2	75 participants (Actual)	Interventional	2017-07-07	Active, not recruiting
The Clinical Application of Tumor Reversion: A Phase I Study of Sertraline (Zoloft) in Combination With Timed-sequential Cytosine Arabinoside (Ara-C) in Adults With Relapsed and Refractory Acute Myeloid Leukemia (AML) [NCT02891278]	Phase 1	6 participants (Actual)	Interventional	2016-08-11	Completed
Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia [NCT01005914]	Phase 2	11 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Increased rate of bacterial infections)
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome [NCT02521493]	Phase 3	312 participants (Anticipated)	Interventional	2015-12-23	Active, not recruiting
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) [NCT01324063]	Phase 3	160 participants (Anticipated)	Interventional	1986-11-30	Completed
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute M [NCT00651261]	Phase 3	717 participants (Actual)	Interventional	2008-04-30	Active, not recruiting
Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older [NCT01039363]	Phase 2	27 participants (Anticipated)	Interventional		Not yet recruiting
A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia [NCT02200978]	Phase 4	176 participants (Actual)	Interventional	2011-09-30	Completed
Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1) [NCT02717884]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2015-05-31	Recruiting
Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801 [NCT00931138]	Phase 3	420 participants	Interventional	1999-12-31	Completed
A Phase 1 Study Of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL) [NCT03792256]	Phase 1	15 participants (Anticipated)	Interventional	2019-04-11	Active, not recruiting
A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia [NCT00372619]	Phase 1/Phase 2	74 participants (Actual)	Interventional	2007-03-31	Completed
Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML) [NCT01025154]	Phase 2	63 participants (Actual)	Interventional	2010-01-31	Completed
A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA [NCT03416179]	Phase 3	730 participants (Actual)	Interventional	2018-04-20	Completed
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT [NCT01356290]	Phase 2	100 participants (Anticipated)	Interventional	2014-04-30	Recruiting
"A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With 7+3 Induction Chemotherapy for Patients With Acute Myeloid Leukemia" [NCT02905994]	Phase 1	0 participants (Actual)	Interventional	2016-09-30	Withdrawn(stopped due to Funding Withdrawn)
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic [NCT00553943]	Phase 2	60 participants (Actual)	Interventional	2007-07-31	Completed
The Prospective Study of FTD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. [NCT05274139]	Phase 2	20 participants (Actual)	Interventional	2017-03-02	Completed
Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study [NCT03012672]	Phase 2	50 participants (Actual)	Interventional	2016-12-30	Completed
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma [NCT02293109]	Phase 1	10 participants (Actual)	Interventional	2015-12-17	Completed
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia [NCT02575963]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2012-10-31	Completed
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma [NCT01399372]	Phase 2	91 participants (Actual)	Interventional	2011-09-30	Completed
Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [NCT00850382]	Phase 1/Phase 2	89 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients. [NCT04083911]	Phase 3	50 participants (Anticipated)	Interventional	2019-04-01	Recruiting
HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia < 60 Years [NCT02587871]	Phase 2	0 participants (Actual)	Interventional	2018-12-12	Withdrawn(stopped due to PI decided not to pursue study)
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]	Phase 3	442 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Other new drugs)
Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy [NCT03736616]	Phase 2	47 participants (Anticipated)	Interventional	2019-08-16	Recruiting
Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05228249]	Phase 1	0 participants (Actual)	Interventional	2023-04-30	Withdrawn(stopped due to PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.)
Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia [NCT00671658]	Phase 2	220 participants (Actual)	Interventional	2002-11-30	Completed
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL) [NCT00671034]	Phase 3	166 participants (Actual)	Interventional	2008-07-21	Completed
A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia [NCT00666588]	Phase 2	52 participants (Actual)	Interventional	2008-04-30	Completed
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02835729]	Phase 1	54 participants (Actual)	Interventional	2016-07-31	Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]	Phase 2/Phase 3	2,000 participants (Anticipated)	Interventional	2006-08-31	Completed
A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL [NCT00795756]	Phase 2/Phase 3	145 participants (Actual)	Interventional	2008-01-31	Completed
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT00778375]	Phase 2	122 participants (Actual)	Interventional	2008-10-31	Completed
Venetoclax in Combination With Homoharringtonine and Cytarabine in Newly Diagnosed Subjects With Acute Myeloid Leukemia: a Phase 2/3, the Single-arm, Open-label, Monocentric Study [NCT05805098]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2023-03-01	Recruiting
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes Wi [NCT05365035]	Phase 2	60 participants (Anticipated)	Interventional	2022-09-23	Recruiting
Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol [NCT00991744]	Phase 3	100 participants (Anticipated)	Interventional	2009-01-31	Suspended(stopped due to Sterility problems in DepoCyte production)
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014) [NCT02611492]	Phase 3	265 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation [NCT02784561]	Phase 4	80 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem C [NCT00199147]	Phase 4	250 participants	Interventional	2000-01-31	Recruiting
High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission [NCT00136448]	Phase 2	30 participants	Interventional	1993-02-28	Completed
A Phase I Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT03983824]	Phase 1	48 participants (Anticipated)	Interventional	2020-05-05	Recruiting
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic L [NCT03384654]	Phase 2	47 participants (Actual)	Interventional	2018-05-14	Completed
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma [NCT00779714]	Phase 3	360 participants (Anticipated)	Interventional	2008-10-31	Recruiting
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine for Patients With Mantle Cell Lymphoma Not Eligible for Intensive Regimens or Autologous Transplantation. [NCT00992134]	Phase 2	41 participants (Actual)	Interventional	2009-06-30	Completed
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias [NCT00780104]	Phase 1	16 participants (Actual)	Interventional	2007-07-31	Completed
Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine [NCT00995332]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2009-09-30	Completed
Phase I/II Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia [NCT00780143]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to Poor recruitment)
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) [NCT00199069]	Phase 4	720 participants	Interventional	1993-04-30	Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Phase I Study of Temozolomide and Intrathecal DepoCyt in Patients With Neoplastic Meningitis [NCT00515788]	Phase 1	11 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Study terminated due to slow accrual with no expansion to additional phase.)
A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma [NCT00521014]	Phase 2	14 participants (Actual)	Interventional	2007-10-31	Completed
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients [NCT00574080]	Phase 3	20 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to low accrual)
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over [NCT00005823]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-12-31	Completed
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [NCT00853008]	Phase 4	100 participants (Anticipated)	Interventional	2003-01-31	Completed
Primed Peripheral Blood Stem Cell Autologous Transplantation for Lymphoma and Hodgkin's Disease [NCT00005985]	Phase 2	213 participants (Actual)	Interventional	2000-08-31	Completed
Autologous Transplantation for Non-Hodgkin's Lymphoma and Hodgkin's Disease Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Mobilization Using Hematopoietic Cytokines Plus Chemotherapy [NCT00005998]	Phase 2	0 participants (Actual)	Interventional	2000-01-31	Withdrawn(stopped due to Withdrawn because study never enrolled patients)
Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma [NCT00006747]	Phase 2	4 participants (Actual)	Interventional	2000-11-30	Completed
A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) [NCT00006343]	Phase 3	0 participants	Interventional	2000-06-30	Completed
Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis [NCT00006367]	Phase 2	0 participants	Interventional	2000-05-31	Completed
The Clinical Observationg on HAM for Acute Myeloid Leukemia [NCT04024241]		250 participants (Anticipated)	Observational	2017-09-01	Recruiting
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) [NCT01515527]	Phase 2	160 participants (Anticipated)	Interventional	2012-02-07	Recruiting
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia [NCT01794702]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2013-02-20	Completed
Prospective , Multicentric, Randomized Phase II Study, Evaluating the Role of Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue After Conventional Chemotherapy for Primary Central Nervous System in Young Patients (< 60 y) [NCT00863460]	Phase 2	140 participants (Actual)	Interventional	2008-10-03	Active, not recruiting
LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL) [NCT00002691]	Phase 2	0 participants	Interventional	1995-08-31	Completed
Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia [NCT00005945]	Phase 3	3,054 participants (Actual)	Interventional	2000-06-30	Completed
Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years [NCT00742625]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2008-09-30	Completed
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults [NCT00797810]	Phase 4	25 participants (Anticipated)	Interventional	2006-12-31	Recruiting
AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. [NCT00180102]	Phase 4	600 participants (Anticipated)	Interventional	2003-12-31	Completed
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years [NCT00085124]	Phase 3	500 participants (Actual)	Interventional	2003-12-31	Completed
Treatment of Older Adults With Acute Lymphoblastic Leukemia [NCT00973752]	Phase 2	30 participants (Actual)	Interventional	2009-08-31	Completed
A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years [NCT04087967]	Phase 3	162 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML). [NCT01641250]	Phase 1	44 participants (Actual)	Interventional	2012-08-31	Completed
A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT00440726]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2006-08-04	Completed
Efficacy and Safety of Cladribine in Combination With G-CSF,Low-dose Cytarabine and Aclarubicin in Newly Diagnosed Unfit Patients With Acute Myeloid Leukemia [NCT04254640]	Phase 2	34 participants (Anticipated)	Interventional	2021-03-01	Not yet recruiting
Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies [NCT00439556]	Phase 2	40 participants (Actual)	Interventional	2007-02-13	Completed
A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [NCT00290433]	Phase 2	55 participants (Actual)	Interventional	2003-09-30	Completed
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma [NCT00392990]	Phase 2	25 participants (Actual)	Interventional	2007-02-06	Completed
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies [NCT02718755]	Phase 2	0 participants (Actual)	Interventional	2018-05-31	Withdrawn(stopped due to Problem with drug supply)
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [NCT00136084]	Phase 3	238 participants (Actual)	Interventional	2002-08-31	Completed
Phase Ib Study of Fludarabine, Cytarabine (Ara-C) and Pegylated Erwinase (Pegcrisantaspase) in Patients With Relapsed or Refractory Leukemia [NCT04526795]	Phase 1	62 participants (Anticipated)	Interventional	2021-04-09	Recruiting
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) P [NCT04240002]	Phase 1/Phase 2	97 participants (Anticipated)	Interventional	2020-09-04	Recruiting
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML) [NCT03330821]	Phase 1/Phase 2	53 participants (Anticipated)	Interventional	2018-04-18	Active, not recruiting
An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukemia [NCT00513305]	Phase 3	67 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Study has been stopped by sponsor decision)
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies [NCT00381680]	Phase 3	275 participants (Actual)	Interventional	2007-03-31	Completed
A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) [NCT00333840]	Phase 3	1,106 participants (Actual)	Interventional	2000-06-30	Completed
A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML) [NCT01066494]	Phase 2	20 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Thera [NCT01067274]	Phase 3	0 participants (Actual)	Interventional	2010-04-30	Withdrawn(stopped due to Study abandoned)
A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Pr [NCT00317642]	Phase 3	326 participants (Actual)	Interventional	2006-08-31	Completed
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma [NCT02532192]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Withdrawal of study support.)
A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia [NCT00469859]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2007-06-30	Completed
A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis [NCT00288626]	Phase 2	25 participants (Actual)	Interventional	2006-07-31	Completed
An Open, Multi-center, Randomized Trial Comparing Haploidentical HSCTs From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies [NCT04547049]	Phase 3	160 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage [NCT01701323]	Phase 1	7 participants (Actual)	Interventional	2012-12-10	Terminated
Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma [NCT00470275]	Phase 2	10 participants (Actual)	Interventional	2007-05-31	Completed
A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma [NCT00080886]	Phase 2	68 participants (Actual)	Interventional	2002-05-08	Completed
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) [NCT00199004]	Phase 4	60 participants (Anticipated)	Interventional	2004-04-30	Completed
Phase I/II Study of Bortezomib (VELCADE) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma [NCT00477412]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2007-04-03	Completed
Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation [NCT00209222]	Phase 3	360 participants (Anticipated)	Interventional	2004-07-31	Recruiting
Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning [NCT00238368]	Phase 2	59 participants (Actual)	Interventional	2004-02-29	Completed
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL [NCT02366663]	Phase 3	3 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to Withdrawal of sponsor support)
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma [NCT01840566]	Phase 1	17 participants (Actual)	Interventional	2013-04-30	Active, not recruiting
Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents [NCT01953770]		3,000 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults [NCT04530565]	Phase 3	348 participants (Anticipated)	Interventional	2021-01-25	Recruiting
Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults [NCT00131027]	Phase 3	240 participants (Anticipated)	Interventional	2002-09-30	Recruiting
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT02626338]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2016-02-29	Completed
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study [NCT01987297]	Phase 4	738 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics [NCT01999413]	Phase 2	30 participants (Actual)	Interventional	2013-11-30	Completed
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy [NCT03069352]	Phase 3	211 participants (Actual)	Interventional	2017-05-23	Active, not recruiting
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) in Complete Remission [NCT04914676]	Phase 2	58 participants (Anticipated)	Interventional	2022-03-08	Recruiting
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Dia [NCT02085408]	Phase 3	727 participants (Actual)	Interventional	2011-02-04	Active, not recruiting
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma [NCT01908777]	Phase 2	47 participants (Actual)	Interventional	2013-07-16	Active, not recruiting
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma [NCT00335140]	Phase 2	26 participants (Actual)	Interventional	2007-08-23	Terminated(stopped due to slow accrual)
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [NCT03878199]	Phase 1/Phase 2	47 participants (Anticipated)	Interventional	2019-02-20	Recruiting
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma [NCT02008006]	Phase 2	21 participants (Actual)	Interventional	2014-07-09	Terminated(stopped due to Insufficient recruitment and unavailability of the treatment)
A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor With Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients With Persistent, Relapsed or Refractory Acute Myeloid Leukemia [NCT04050280]	Phase 2	39 participants (Anticipated)	Interventional	2019-11-01	Recruiting
"Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the a-Tac BEAM Regimen" [NCT01476839]	Phase 1	25 participants (Actual)	Interventional	2012-11-09	Active, not recruiting
A Phase I Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia [NCT00081822]	Phase 1	23 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia [NCT02024308]	Phase 4	62 participants (Anticipated)	Interventional	2010-11-30	Recruiting
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MD [NCT02029950]	Phase 1	50 participants (Actual)	Interventional	2013-12-16	Completed
Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML [NCT00005863]	Phase 3	0 participants	Interventional	1998-08-31	Completed
An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics [NCT05260528]	Phase 2	210 participants (Anticipated)	Interventional	2023-05-03	Recruiting
Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. O [NCT00006363]	Phase 3	720 participants (Actual)	Interventional	2000-11-30	Completed
A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma [NCT00007852]	Phase 2	44 participants (Actual)	Interventional	2000-09-01	Completed
A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infecte [NCT00001048]	Phase 2	90 participants	Interventional		Completed
Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies. [NCT00389428]	Phase 1	48 participants (Actual)	Interventional	2006-09-30	Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]	Phase 2	60 participants (Actual)	Interventional	2001-02-28	Completed
Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive [NCT00556127]	Phase 2	94 participants (Actual)	Interventional	2002-06-30	Completed
A Phase II, Single Arm Study of Tislelizumab Combined With DNA Demethylation Agent +/- CAG Regimen in the Treatment of Patients With High-risk AML or AML Patients Older Than 60 Years of Age Who Are Unfit for Intensive Chemotherapy [NCT04541277]	Phase 2	55 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients. [NCT01908621]	Phase 3	90 participants (Actual)	Interventional	2013-03-20	Completed
A Randomized, Open-label, Two-period, Two-way Crossover Bioequivalence Study of Two (Cytarabine: Daunorubicin) Liposome for Injection in Elderly AML Subjects [NCT05801835]		36 participants (Anticipated)	Interventional	2023-08-25	Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hemato [NCT04891757]	Phase 1	144 participants (Anticipated)	Interventional	2021-06-14	Recruiting
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia [NCT04269213]	Phase 2	46 participants (Anticipated)	Interventional	2021-07-29	Recruiting
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia [NCT04220684]	Phase 1	21 participants (Anticipated)	Interventional	2020-06-01	Recruiting
Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study [NCT03765541]	Phase 3	142 participants (Anticipated)	Interventional	2020-01-13	Recruiting
A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II Protocol [NCT03710772]	Phase 2	50 participants (Anticipated)	Interventional	2019-05-01	Active, not recruiting
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) [NCT01190930]	Phase 3	9,350 participants (Actual)	Interventional	2010-08-09	Active, not recruiting
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia [NCT00594555]	Phase 2	20 participants (Anticipated)	Interventional	2007-11-30	Withdrawn(stopped due to Principal Investigator resigned position with the University of Cincinnati, closing study at this site will reopen study in new position)
Open Randomized Prospective Clinical Study of Rituximab Combined With Fotemustine, Pemetrexed, Dexamethasone Versus Rituximab Plus Methotrexate, Cytarabine, and Dexamethasone in the Treatment of Primary Central Nervous System Lymphoma [NCT04083066]	Phase 4	20 participants (Anticipated)	Interventional	2019-09-05	Recruiting
A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression [NCT01056523]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2010-01-31	Completed
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms [NCT03589729]	Phase 2	100 participants (Anticipated)	Interventional	2018-09-19	Recruiting
A Trial of Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (ATACC AML) [NCT03568994]	Early Phase 1	26 participants (Actual)	Interventional	2018-07-10	Active, not recruiting
A Prospective, Single Arm, Multicenter Clinical Study to Evaluate the Efficacy of Venetoclax Combined With Azacytidine or DA Regimen in Prevention the Relapse of Consecutive MRD Positive AML Patients [NCT05361057]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-01	Recruiting
S0629, Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Phase II Study of Tandem Autologous Transplant and Maintenance Treatment for Patients With Symptomatic Disease [NCT00723658]	Phase 2	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to lack of accrual)
Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. [NCT02722733]	Phase 3	90 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study [NCT00866307]	Phase 1	104 participants (Actual)	Interventional	2009-02-23	Completed
A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT01004497]	Phase 2	51 participants (Actual)	Interventional	2010-03-31	Completed
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia [NCT00613457]	Phase 3	2,039 participants (Actual)	Interventional	2000-09-30	Completed
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Re [NCT03793478]	Phase 1/Phase 2	65 participants (Anticipated)	Interventional	2018-08-15	Recruiting
An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma. [NCT00517699]	Phase 2	5 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Study was terminated early due to lack of enrollment.)
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT03182244]	Phase 3	276 participants (Actual)	Interventional	2018-01-15	Active, not recruiting
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [NCT03393611]	Phase 1	14 participants (Actual)	Interventional	2012-11-30	Completed
Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52 [NCT00505921]	Phase 2	27 participants (Actual)	Interventional	2003-03-31	Terminated(stopped due to Slow Accrual.)
A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas [NCT00669812]	Phase 2	60 participants (Anticipated)	Interventional	2008-02-29	Recruiting
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171]	Phase 2	78 participants (Anticipated)	Interventional	2023-11-20	Recruiting
Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS) [NCT00411281]	Phase 3	0 participants (Actual)	Interventional	2006-03-31	Withdrawn(stopped due to Per Group Chair: This study will not move forward.)
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies [NCT05292664]	Phase 1	92 participants (Anticipated)	Interventional	2023-03-29	Recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy [NCT02724163]	Phase 3	700 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study [NCT02396043]	Phase 2	50 participants (Anticipated)	Interventional	2015-03-31	Recruiting
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With [NCT05658640]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2023-04-01	Not yet recruiting
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26) [NCT00689845]		120 participants (Anticipated)	Interventional	2007-06-30	Recruiting
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT01186328]	Phase 1	6 participants (Actual)	Interventional	2010-08-24	Terminated(stopped due to Enzon Pharmaceuticals decided to end its development of EZN-3042.)
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia [NCT03563560]	Phase 1	10 participants (Actual)	Interventional	2018-05-15	Completed
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients [NCT04168138]		20 participants (Anticipated)	Interventional	2019-11-01	Recruiting
Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT01892371]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2013-11-12	Completed
Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia [NCT02848183]	Phase 2	350 participants	Interventional	2016-01-31	Recruiting
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen [NCT00992446]	Phase 2	27 participants (Actual)	Interventional	2010-09-02	Completed
Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia [NCT00906945]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2011-02-28	Completed
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia [NCT05660473]	Phase 2	100 participants (Anticipated)	Interventional	2022-10-31	Recruiting
ACUTE MYELOID LEUKAEMIA TRIAL 12 [NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML) [NCT03303339]	Phase 1/Phase 2	72 participants (Actual)	Interventional	2017-11-17	Completed
Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission. [NCT00540956]		40 participants (Anticipated)	Interventional	2006-11-30	Completed
A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT01390337]	Phase 1	19 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia [NCT01408160]	Phase 1	18 participants (Actual)	Interventional	2013-04-30	Terminated
Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies. [NCT01414231]	Phase 3	850 participants (Anticipated)	Interventional	2002-04-30	Recruiting
Phase II Trial of Venetoclax in Combination With Azacitidine and CAG as Induction Therapy in Patients With Refractory/Relapse Acute Myeloid Leukemia [NCT05807347]	Phase 2	42 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia [NCT01429610]	Phase 2	78 participants (Actual)	Interventional	2011-11-30	Active, not recruiting
Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL [NCT00275015]	Phase 2	169 participants (Actual)	Interventional	1998-01-31	Completed
A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia [NCT00276601]	Phase 2	0 participants	Interventional	2004-10-31	Completed
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantl [NCT01527149]	Phase 2	37 participants (Actual)	Interventional	2011-12-06	Active, not recruiting
The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation [NCT03585686]	Phase 2	12 participants (Anticipated)	Interventional	2018-06-26	Recruiting
Phase II Evaluation of Gemtuzumab Ozogamicin in Combination With Cytarabine in Untreated Patients Above the Age of 60 Years With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome [NCT00195000]	Phase 2	43 participants (Actual)	Interventional	2003-05-31	Completed
Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study [NCT00006122]	Phase 2	106 participants (Actual)	Interventional	2000-06-30	Completed
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies [NCT00423826]		0 participants	Expanded Access	2007-01-31	No longer available
Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia [NCT00096148]	Phase 2	120 participants (Actual)	Interventional	2004-10-31	Terminated(stopped due to Administratively complete.)
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) [NCT00199017]	Phase 4	75 participants (Anticipated)	Interventional	2004-04-30	Completed
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial [NCT05382390]	Phase 3	130 participants (Anticipated)	Interventional	2022-01-21	Recruiting
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01831232]		24 participants (Actual)	Interventional	2013-05-31	Completed
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia [NCT00774046]	Phase 2	32 participants (Actual)	Interventional	2002-12-31	Completed
Clinical Observation on the Efficacy and Safety of CLAE Regimen (Cladribine + Cytarabine + Etoposide) in the Treatment of Relapsed/Refractory T- Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma [NCT04679506]		50 participants (Anticipated)	Observational [Patient Registry]	2020-12-31	Not yet recruiting
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML [NCT01861002]	Phase 1	15 participants (Actual)	Interventional	2013-05-22	Completed
Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00618501]	Phase 2	50 participants (Anticipated)	Interventional	2005-10-31	Completed
A Randomized, Multi-center, Open-label Phase III Bridging Study to Compare Efficacy of Liposomal Cytarabine-Daunorubicin for Injection With Cytarabine and Daunorubicin in Treating Older Patients With High-Risk (Secondary) Acute Myeloid Leukemia [NCT06182592]	Phase 3	120 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) [NCT05712278]	Phase 1	12 participants (Anticipated)	Interventional	2023-06-16	Recruiting
A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia [NCT00186966]	Phase 3	394 participants (Actual)	Interventional	2002-03-31	Completed
Dose-Finding (Phase 1) Study of Continuous Infusion Cladribine, Cytarabine and Mitoxantrone (CI-CLAM) for Adults With Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Treated at UW/SCCA [NCT04196010]	Phase 1	13 participants (Actual)	Interventional	2020-05-08	Terminated(stopped due to Terminated due to unfavorable risk-benefit ratio of investigational regimen.)
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) [NCT00180128]	Phase 4	80 participants (Anticipated)	Interventional	2000-01-31	Recruiting
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy [NCT03701308]	Phase 2/Phase 3	670 participants (Anticipated)	Interventional	2019-03-28	Suspended(stopped due to End of Initial Phase of Multi-phase protocol)
Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) [NCT00187122]		42 participants (Actual)	Interventional	1993-03-31	Completed
Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II [NCT00187161]	Phase 2	68 participants (Actual)	Interventional	1994-11-30	Completed
Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study [NCT00093483]	Phase 1	61 participants (Actual)	Interventional	2002-04-30	Completed
A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous St [NCT00499018]	Phase 3	399 participants (Anticipated)	Interventional	2006-01-31	Active, not recruiting
Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leu [NCT00470197]	Phase 1	35 participants (Actual)	Interventional	2007-04-30	Completed
Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00151242]	Phase 2/Phase 3	920 participants (Actual)	Interventional	2004-07-31	Completed
Large Cell Lymphoma, Pilot Study III [NCT00187070]		8 participants (Actual)	Interventional	1997-12-31	Completed
Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase [NCT00219765]	Phase 1/Phase 2	30 participants	Interventional	2001-05-31	Terminated
Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia [NCT00187057]		6 participants (Actual)	Interventional	2002-09-30	Completed
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT01371630]	Phase 1/Phase 2	276 participants (Anticipated)	Interventional	2011-08-26	Recruiting
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946]	Phase 3	800 participants (Actual)	Interventional	2005-04-30	Completed
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia [NCT00526409]	Phase 4	40 participants (Anticipated)	Interventional	2005-06-30	Completed
[NCT02937662]	Phase 2	60 participants (Anticipated)	Interventional	2016-10-31	Recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
DLCL002 Protocol for Young Patients With Newly Diagnosed High Risk Aggressive B-cell Lymphoma, a Multicenter Phase II Study [NCT03837873]	Phase 2	118 participants (Anticipated)	Interventional	2019-01-21	Recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT03488225]	Phase 2	4 participants (Actual)	Interventional	2018-03-28	Terminated(stopped due to the study was closed early due to competing trials)
PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL) [NCT00002676]	Phase 2	36 participants (Actual)	Interventional	1995-07-31	Completed
A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma [NCT00002982]	Phase 2	0 participants	Interventional	1997-01-31	Completed
A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [NCT00004086]	Phase 1	0 participants	Interventional	1997-06-30	Active, not recruiting
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML) [NCT01839240]	Phase 1	50 participants (Actual)	Interventional	2012-06-06	Completed
A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT01478074]	Phase 1	0 participants (Actual)	Interventional	2011-11-30	Withdrawn(stopped due to The treatment planned was determined to be of low feasibility as no subject was found eligible and able to enroll after screening over 30 subjects)
A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [NCT00428558]	Phase 3	200 participants (Actual)	Interventional	2007-07-31	Completed
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia [NCT00430118]	Phase 3	4,559 participants (Actual)	Interventional	2000-07-31	Completed
Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) [NCT00121303]	Phase 3	600 participants (Anticipated)	Interventional	2005-01-31	Completed
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer [NCT00480090]	Phase 2	10 participants (Actual)	Interventional	2007-04-30	Completed
FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT00488709]	Phase 4	47 participants (Actual)	Interventional	2003-05-31	Completed
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) [NCT01246752]	Phase 3	143 participants (Actual)	Interventional	2011-02-10	Terminated(stopped due to decreased recrucial rate as the likelihood of achieving the envisioned patient number in a realistic time-frame was very low.)
Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia) [NCT01247493]	Phase 2	108 participants (Actual)	Interventional	2007-06-30	Completed
FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemi [NCT00487448]	Phase 4	200 participants (Anticipated)	Interventional	1998-07-31	Completed
Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients [NCT01246622]	Phase 1	32 participants (Actual)	Interventional	2011-02-07	Completed
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand [NCT05146739]	Phase 1	18 participants (Anticipated)	Interventional	2023-12-23	Recruiting
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia [NCT05024552]	Phase 1	22 participants (Anticipated)	Interventional	2021-08-23	Recruiting
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) [NCT03964090]	Phase 2	65 participants (Anticipated)	Interventional	2019-06-27	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02310321]	Phase 1/Phase 2	84 participants (Actual)	Interventional	2015-02-26	Active, not recruiting
Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed AML at High Risk for Induction Mortality [NCT02286726]	Phase 2	56 participants (Actual)	Interventional	2015-05-04	Completed
Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly [NCT00503594]	Phase 2	92 participants (Anticipated)	Interventional	2007-07-31	Recruiting
Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia [NCT00505700]	Phase 1	36 participants (Anticipated)	Interventional	2003-07-31	Completed
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive [NCT00526305]	Phase 4	100 participants (Anticipated)	Interventional	2000-01-31	Completed
A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies [NCT00047021]	Phase 2	3 participants (Actual)	Interventional	2001-11-30	Completed
Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00151255]	Phase 3	500 participants (Anticipated)	Interventional	2004-06-30	Completed
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia [NCT02930109]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2016-09-30	Recruiting
LAL-BR/2001: Study Treatment to Low Risk ALL [NCT00526175]	Phase 4	150 participants (Anticipated)	Interventional	2001-06-30	Completed
[NCT00529880]	Phase 2	19 participants (Anticipated)	Interventional	2004-12-31	Recruiting
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias [NCT04623944]	Phase 1	90 participants (Anticipated)	Interventional	2020-09-21	Recruiting
Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma [NCT02845882]	Phase 3	150 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) [NCT04956042]	Phase 1/Phase 2	28 participants (Anticipated)	Interventional	2021-08-27	Recruiting
A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02236013]	Phase 1	80 participants (Actual)	Interventional	2015-01-07	Completed
LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma [NCT04043494]	Phase 3	683 participants (Anticipated)	Interventional	2019-08-23	Recruiting
Ma-Spore ALL 2010 Study [NCT02894645]	Phase 4	500 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML [NCT03850535]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2019-03-25	Terminated(stopped due to Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.)
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion [NCT03570983]	Phase 2	100 participants (Anticipated)	Interventional	2018-09-05	Recruiting
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia [NCT02306291]	Phase 1/Phase 2	91 participants (Actual)	Interventional	2015-03-31	Completed
A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia [NCT00354276]	Phase 2	85 participants (Anticipated)	Interventional	2006-05-31	Active, not recruiting
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone and in Combination With Cytarabine (Ara-C) in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome With Wild-Type TP53 [NCT02909972]	Phase 1	55 participants (Actual)	Interventional	2016-09-30	Completed
Primary Comparison of Liposomal Anthracycline Based Treatment Versus Conventional Care Strategies Before Allogeneic Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML [NCT04061239]	Phase 2	150 participants (Anticipated)	Interventional	2019-08-19	Recruiting
Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML) [NCT01830777]	Phase 1	22 participants (Actual)	Interventional	2013-05-31	Completed
A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia [NCT03519984]	Phase 1	3 participants (Actual)	Interventional	2018-05-09	Terminated(stopped due to Study drug supply issue)
Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial [NCT00632827]	Phase 2	21 participants (Actual)	Interventional	2008-07-01	Terminated(stopped due to Manufacturing shortage of both Diftitox and Doxil)
A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymp [NCT01555541]	Phase 2	19 participants (Actual)	Interventional	2012-05-25	Completed
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia [NCT04801797]	Phase 2	172 participants (Anticipated)	Interventional	2021-05-20	Recruiting
A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(>/= 10% Blasts); or CML in Myeloid Blasts Phase [NCT00067028]	Phase 2	116 participants (Actual)	Interventional	2003-12-31	Completed
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality [NCT01804101]		48 participants (Actual)	Interventional	2013-05-07	Completed
BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION [NCT00002502]	Phase 2	0 participants	Interventional	1992-07-31	Completed
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL [NCT00002532]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
A PHASE II STUDY OF MITOXANTRONE AND HIGH-DOSE ARA-C FOLLOWED BY INTENSIVE CONSOLIDATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR MYELOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) [NCT00002598]	Phase 2	30 participants (Anticipated)	Interventional	1994-06-30	Completed
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]	Phase 3	392 participants (Anticipated)	Interventional	1995-08-31	Completed
A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With [NCT00002718]	Phase 2	31 participants (Actual)	Interventional	1995-11-30	Completed
A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies-POG/CCG Intergroup Study [NCT00002970]	Phase 2	148 participants (Actual)	Interventional	1997-06-30	Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]	Phase 4	225 participants	Interventional	1999-10-31	Completed
Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study [NCT00004056]	Phase 1	35 participants (Actual)	Interventional	1999-10-31	Completed
The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and t [NCT00004128]	Phase 3	2,000 participants (Anticipated)	Interventional	1999-09-30	Active, not recruiting
A Study to Determine the Safety and Efficacy of Using CD8-High Density Microparticles (CD8-HDM) to Deplete CD8+ Cells From Donor Lymphocyte Infusion in Order to Reduce Graft-versus-Host Disease (GvHD) Without Compromising an Anti-Leukemia Effect in Patien [NCT00004878]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to study never opened)
Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant [NCT00005802]	Phase 1/Phase 2	0 participants	Interventional	1999-06-30	Completed
A Data Collection Study to Compare the Outcome for Children With Advanced Unilateral Retinoblastoma Treated With or Without Post-Enucleation Chemotherapy ± Radiotherapy on RB 2005 11 With Historical Controls Receiving no Additional Therapy [NCT00360750]		0 participants	Interventional	2005-09-30	Active, not recruiting
A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation [NCT01773408]	Phase 1	122 participants (Actual)	Interventional	2013-02-28	Completed
A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refrac [NCT03467256]	Phase 1/Phase 2	18 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin [NCT02243436]	Phase 1/Phase 2	67 participants (Actual)	Interventional	2014-11-11	Completed
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation [NCT02632708]	Phase 1	153 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma [NCT01035463]	Phase 1/Phase 2	74 participants (Actual)	Interventional	2009-11-12	Completed
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication [NCT01477606]	Phase 2	451 participants (Actual)	Interventional	2012-05-31	Completed
A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older [NCT00066794]	Phase 2	69 participants (Actual)	Interventional	2004-07-31	Completed
A Phase I Study of Triapine in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies [NCT00077181]	Phase 1	48 participants (Actual)	Interventional	2004-01-31	Completed
A Phase I Study Of VNP40101M And Cytarabine For Patients With Hematologic Malignancies [NCT00070538]	Phase 1	0 participants	Interventional	2003-06-30	Completed
A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias [NCT00258271]	Phase 1	18 participants (Anticipated)	Interventional	2005-03-31	Completed
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [NCT03150004]	Phase 2	90 participants (Anticipated)	Interventional	2017-06-14	Recruiting
A Phase 1/2 Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MB07133 in Subjects With Unresectable Hepatocellular Carcinoma and Child-Pugh Class A Liver Function [NCT00073736]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2003-09-30	Completed
A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia [NCT00107523]	Phase 1	0 participants	Interventional	2005-01-31	Completed
Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia [NCT00274807]	Phase 2	40 participants (Actual)	Interventional	2001-06-30	Completed
A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse [NCT00112554]	Phase 3	420 participants (Anticipated)	Interventional	2005-03-31	Completed
Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia [NCT00130195]	Phase 2	100 participants (Actual)	Interventional	2002-09-30	Completed
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies [NCT04778410]	Phase 2	59 participants (Anticipated)	Interventional	2021-06-28	Active, not recruiting
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia [NCT06001788]	Phase 1	171 participants (Anticipated)	Interventional	2023-12-31	Recruiting
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia [NCT00039130]	Phase 2	105 participants (Actual)	Interventional	2002-05-31	Completed
A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytar [NCT00093600]	Phase 1	69 participants (Actual)	Interventional	2004-02-29	Completed
A Phase I Study of R115777 (Zarnestra) in Combination With Induction Chemotherapy in Patients With Newly Diagnosed, High Risk Acute Myeloid Leukemia [NCT00124644]	Phase 1	30 participants	Interventional	2006-03-31	Terminated(stopped due to "Withdrawn due to toxicity problems")
A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia [NCT05726110]	Phase 3	50 participants (Anticipated)	Interventional	2023-01-29	Recruiting
Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia [NCT00343369]		550 participants (Anticipated)	Interventional	2003-01-31	Recruiting
A Phase I And Pharmacological Trial Of 17-Allylamino -17-demethoxygeldanamycin (17-AAG) And Cytarabine In Refractory Leukemia And Myelodysplastic Syndrome [NCT00098423]	Phase 1	42 participants (Actual)	Interventional	2004-11-30	Completed
A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML) [NCT00101153]	Phase 1	24 participants (Actual)	Interventional	2007-04-30	Completed
Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant [NCT00107354]	Phase 1	0 participants	Interventional	1998-12-31	Completed
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia [NCT00480064]	Phase 3	360 participants (Actual)	Interventional	1995-07-31	Completed
Phase II Study: 2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES) [NCT00483067]	Phase 2	13 participants (Actual)	Interventional	1998-03-31	Completed
A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01154439]	Phase 1	11 participants (Actual)	Interventional	2010-10-31	Completed
Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML). [NCT05987696]	Phase 1	102 participants (Anticipated)	Interventional	2023-08-10	Not yet recruiting
Pilot Study in AIDS-Related Lymphomas [NCT00002524]	Phase 2	46 participants (Actual)	Interventional	1993-06-30	Completed
Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML [NCT02275663]	Phase 2	37 participants (Anticipated)	Interventional	2014-12-31	Recruiting
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia [NCT00143975]	Phase 2	95 participants (Actual)	Interventional	2004-06-30	Completed
An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Synd [NCT03459859]	Phase 1	12 participants (Actual)	Interventional	2018-05-21	Completed
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia [NCT01801046]	Phase 1	10 participants (Actual)	Interventional	2013-03-06	Terminated(stopped due to Insufficient Accrual)
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia [NCT00801489]	Phase 2	270 participants (Anticipated)	Interventional	2007-04-04	Recruiting
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma [NCT00004192]	Phase 2	60 participants (Anticipated)	Interventional	2000-05-01	Completed
A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL [NCT00003578]	Phase 3	500 participants (Anticipated)	Interventional	1993-01-31	Active, not recruiting
A Randomized Phase II Study of the Combination of 5-Azacytidine With Valproic Acid (VPA) Versus Low-Dose Ara-C in Patients With AML/MDS Not Eligible for Other Studies [NCT00382590]	Phase 2	11 participants (Actual)	Interventional	2005-08-31	Completed
Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas [NCT00472056]	Phase 2	93 participants (Actual)	Interventional	2005-03-31	Completed
A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT00439296]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2006-05-22	Terminated(stopped due to The study was stopped due to poor accrual and lack of funding.)
"Randomized Phase I/II Study of 5-Azacytidine in Combination With Cytosine Arabinoside in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome - SPORE" [NCT00569010]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2005-12-31	Completed
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age. [NCT00788892]	Phase 2	126 participants (Actual)	Interventional	2008-10-31	Completed
Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML and High-Risk MDS Patients at Least 60 Years of Age [NCT00839982]	Phase 1/Phase 2	35 participants (Actual)	Interventional	2008-11-30	Completed
Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224) [NCT00928200]	Phase 1	1 participants (Actual)	Interventional	2009-04-13	Terminated(stopped due to Study was terminated due to lack of accrual.)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [NCT01008462]	Phase 2	16 participants (Actual)	Interventional	2010-03-18	Completed
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia [NCT02135874]	Phase 2	18 participants (Actual)	Interventional	2014-10-27	Completed
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma [NCT00501826]	Phase 2	160 participants (Anticipated)	Interventional	2007-07-11	Recruiting
Multicenter,Open Label,Phase 2 Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia [NCT06068621]	Phase 2	200 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A Phase 1b Study With Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) [NCT04190550]	Phase 1	24 participants (Anticipated)	Interventional	2021-02-04	Active, not recruiting
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia [NCT01184898]		36 participants (Actual)	Interventional	2010-07-31	Completed
Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia [NCT01363128]	Phase 2	72 participants (Actual)	Interventional	2011-07-12	Completed
Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL) [NCT03125642]	Phase 2	150 participants (Anticipated)	Interventional	2017-04-20	Recruiting
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as F [NCT04214249]	Phase 2	124 participants (Anticipated)	Interventional	2021-02-17	Recruiting
Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. [NCT00184041]	Phase 2	47 participants (Actual)	Interventional	2004-07-31	Completed
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging [NCT02392429]	Phase 2	57 participants (Anticipated)	Interventional	2016-04-20	Active, not recruiting
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance [NCT02896582]	Phase 2	86 participants (Actual)	Interventional	2016-10-31	Active, not recruiting
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00187005]	Phase 3	53 participants (Actual)	Interventional	1998-07-31	Terminated(stopped due to Toxicity)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]	Phase 2	11 participants (Actual)	Interventional	2015-07-15	Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia [NCT00195104]	Phase 1/Phase 2	87 participants (Actual)	Interventional	2003-09-17	Completed
Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous Sys [NCT00210314]	Phase 2	79 participants (Actual)	Interventional	2003-07-31	Completed
A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT06177067]	Phase 1	24 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Prospective Pilot Trial of Arsenic Trioxide (Trisenox®) in Combination With Cytosine Arabinoside in Patients With Advanced or Transformed Myelofibrosis [NCT00572065]	Early Phase 1	21 participants (Actual)	Interventional	2008-02-29	Completed
Study of the Efficacy and Safety of Venetoclax Plus Azacytidine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia (AML) Patients With Adverse Risk Features [NCT05939180]	Phase 2/Phase 3	108 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed Acute Promyelocytic Leukemia (APL) [NCT00591526]	Phase 3	250 participants (Actual)	Interventional	2000-06-30	Completed
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study [NCT01729845]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2012-12-20	Completed
Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program [NCT00495287]	Phase 3	573 participants (Actual)	Interventional	2006-11-30	Completed
A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia [NCT01249430]	Phase 1	24 participants (Actual)	Interventional	2011-01-20	Completed
A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [NCT00513188]		0 participants (Actual)	Interventional	2007-02-28	Withdrawn
Phase II Trial of CLAG-M in Relapsed ALL [NCT01513603]	Phase 2	50 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial [NCT01516580]	Phase 3	482 participants (Actual)	Interventional	2011-12-31	Active, not recruiting
A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies [NCT02433483]	Phase 2	4 participants (Actual)	Interventional	2015-05-22	Terminated(stopped due to The study was closed due to poor accrual and because of competing protocols.)
Phase I/II Study on Cytarabine and Idarubicin Combined With Escalating Doses of Clofarabine as Induction Therapy in Patients With Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) [NCT01534702]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2012-01-31	Recruiting
[NCT01540812]		418 participants (Actual)	Observational	2012-02-29	Completed
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia [NCT01319981]	Phase 2	31 participants (Actual)	Interventional	2013-03-05	Completed
A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS [NCT00002534]	Phase 3	0 participants	Interventional	1993-05-31	Completed
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin [NCT00002618]	Phase 3	242 participants (Anticipated)	Interventional	1994-12-31	Completed
Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia [NCT00002744]	Phase 3	1,970 participants (Actual)	Interventional	1996-05-31	Completed
Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756]	Phase 2	221 participants (Actual)	Interventional	1996-06-30	Completed
Phase II Study of Intrathecal Therapy With DepoCyt for Active Lymphomatous or Leukemic Meningitis [NCT00523939]	Phase 2	4 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Low accrual.)
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]	Phase 3	179 participants (Actual)	Interventional	1997-02-28	Completed
Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL) [NCT00003061]	Phase 2	50 participants (Anticipated)	Interventional	1997-07-31	Completed
A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies [NCT00003073]	Phase 1	15 participants (Anticipated)	Interventional	1997-02-28	Active, not recruiting
BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma [NCT00006695]	Phase 2	50 participants (Actual)	Interventional	2000-04-01	Completed
A Pilot Study of Dose Intensification of Methotrexate and Cyclophosphamide in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Non-Hodgkins Lymphoma and B-Cell All- A Limited Institution Phase III Pilot Study [NCT00003217]	Phase 1	20 participants (Actual)	Interventional	1998-03-31	Completed
Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies [NCT00281879]	Phase 2	200 participants (Actual)	Interventional	2006-02-28	Terminated
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation. [NCT00002657]	Phase 2	20 participants (Actual)	Interventional	1995-05-31	Completed
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia [NCT00022126]	Phase 2	6 participants (Actual)	Interventional	2002-11-30	Completed
A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase [NCT00023920]	Phase 2	60 participants (Actual)	Interventional	2001-07-31	Terminated(stopped due to Administratively complete.)
A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease [NCT00025636]	Phase 3	220 participants (Anticipated)	Interventional	2001-07-31	Active, not recruiting
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission [NCT00027547]	Phase 1/Phase 2	0 participants	Interventional	2001-07-31	Completed
A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent [NCT02019069]	Phase 2	11 participants (Actual)	Interventional	2014-02-03	Completed
A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) [NCT00012051]	Phase 3	340 participants (Anticipated)	Interventional	2000-09-30	Completed
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma [NCT00000689]	Phase 1	18 participants	Interventional		Completed
A Phase I/II Trial of STI571 and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia [NCT00015834]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2001-05-31	Completed
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia [NCT00015873]	Phase 3	350 participants (Anticipated)	Interventional	1999-05-31	Completed
A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for [NCT00015951]	Phase 2	0 participants	Interventional	2001-04-30	Completed
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia [NCT00016302]		100 participants (Actual)	Interventional	2001-04-30	Completed
Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive [NCT00016887]	Phase 3	0 participants	Interventional	2000-12-31	Active, not recruiting
A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma [NCT00040690]	Phase 2	120 participants (Anticipated)	Interventional	2008-11-30	Completed
Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma [NCT00345865]	Phase 2	473 participants (Actual)	Interventional	2005-08-24	Completed
A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies [NCT00064090]	Phase 1	0 participants	Interventional	2003-03-31	Completed
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study [NCT00070174]	Phase 2	350 participants (Actual)	Interventional	2003-12-31	Completed
Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma [NCT00074191]	Phase 2	1 participants (Actual)	Interventional	2000-01-31	Completed
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML) [NCT00074737]	Phase 2	53 participants (Actual)	Interventional	2004-04-30	Completed
Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study [NCT00077116]	Phase 2	31 participants (Actual)	Interventional	2003-11-30	Completed
Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab [NCT00137995]	Phase 3	481 participants (Actual)	Interventional	2003-06-30	Completed
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma [NCT03019640]	Phase 2	22 participants (Actual)	Interventional	2017-10-10	Completed
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML [NCT00542971]	Phase 1/Phase 2	78 participants (Actual)	Interventional	2007-10-31	Completed
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) [NCT00275106]	Phase 3	600 participants (Anticipated)	Interventional	2004-09-30	Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias [NCT00016016]	Phase 1/Phase 2	53 participants (Anticipated)	Interventional	2001-02-28	Completed
An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia [NCT00129168]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2005-08-31	Completed
PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA [NCT00018954]	Phase 2	0 participants	Interventional	1992-10-31	Completed
A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma [NCT00020943]	Phase 2	79 participants (Actual)	Interventional	2001-06-30	Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051) [NCT00022737]	Phase 3	220 participants (Actual)	Interventional	2002-10-31	Completed
Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia [NCT00025038]	Phase 2	100 participants (Actual)	Interventional	2001-06-30	Completed
A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT00028899]	Phase 1	47 participants (Actual)	Interventional	2002-07-31	Completed
A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis [NCT00029523]	Phase 4	100 participants	Interventional	2001-04-30	Completed
A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia. [NCT00037596]	Phase 2	0 participants	Interventional	2000-08-31	Completed
Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia [NCT00276809]	Phase 2	30 participants (Anticipated)	Interventional	2001-06-30	Completed
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age [NCT00039117]	Phase 1	32 participants (Actual)	Interventional	2002-04-30	Completed
A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia [NCT00019409]	Phase 3	0 participants (Actual)	Interventional	1999-10-31	Withdrawn
A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) [NCT00049179]	Phase 2	33 participants (Actual)	Interventional	2003-04-30	Completed
Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse [NCT00049569]		126 participants (Anticipated)	Interventional	2003-01-31	Completed
A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older [NCT00023777]	Phase 2	71 participants (Actual)	Interventional	2001-08-31	Completed
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC [NCT00052299]	Phase 3	472 participants (Actual)	Interventional	2002-09-30	Completed
A Dose-ranging Phase I/II Study of STI571 in Combination With Cytarabin in Patients With First Chronic Phase Chronic Myeloid Leukemia [NCT00028847]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2001-04-30	Active, not recruiting
A Phase II Study of Rituximab (IND #7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia [NCT00058461]	Phase 2	82 participants (Anticipated)	Interventional	2003-11-30	Terminated
Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring [NCT02971397]	Phase 2	40 participants (Actual)	Interventional	2016-11-30	Active, not recruiting
A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma [NCT00069966]	Phase 2	0 participants	Interventional	2003-04-30	Active, not recruiting
Randomised Controlled Study Comparing Fast Track and Standard Care Protocol on the Functional Outcomes and Hospital Stay of Total Knee Arthroplasty [NCT03869996]		64 participants (Anticipated)	Interventional	2019-02-25	Recruiting
A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML) [NCT00070551]	Phase 1	51 participants (Actual)	Interventional	2003-09-30	Completed
Protocol for the Treatment of Adults Aged NCT00209833]	Phase 2/Phase 3	200 participants	Interventional	1999-01-31	Active, not recruiting
A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic M [NCT00219739]	Phase 3	789 participants (Actual)	Interventional	2003-09-30	Completed
Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Centra [NCT00074178]	Phase 2	22 participants (Actual)	Interventional	2000-01-31	Completed
Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia [NCT00131053]	Phase 2	120 participants (Anticipated)	Interventional	2002-09-30	Recruiting
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies [NCT00080925]	Phase 1	20 participants (Anticipated)	Interventional	2004-02-29	Completed
A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [NCT00053105]	Phase 1	0 participants	Interventional	2002-02-28	Active, not recruiting
Irinotecan And Cytarabine In Refractory or Relapsed Acute Myeloid Leukemia And In Chronic Myelogenous Leukemia In Myeloid Blast Transformation: Efficacy And In Vitro Correlates [NCT00053144]	Phase 1	0 participants	Interventional	1999-11-30	Completed
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00165178]	Phase 3	498 participants (Actual)	Interventional	2000-09-30	Completed
Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in N [NCT00055874]	Phase 3	1,551 participants (Actual)	Interventional	2002-06-30	Completed
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. [NCT00180115]	Phase 4	400 participants	Interventional	1996-02-29	Completed
A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma [NCT00058292]	Phase 1	44 participants (Actual)	Interventional	2000-04-30	Completed
Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood [NCT00047268]	Phase 3	0 participants	Interventional	1998-07-31	Active, not recruiting
A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL). [NCT00195871]	Phase 2	155 participants (Actual)	Interventional	2004-02-29	Active, not recruiting
A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia ( [NCT00199186]	Phase 2	0 participants	Interventional	2002-03-31	Recruiting
ALL Adult Consortium Trial: Adult ALL Trial [NCT00476190]	Phase 2	112 participants (Anticipated)	Interventional	2007-04-30	Active, not recruiting
Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission [NCT01794169]	Phase 2	130 participants (Anticipated)	Interventional	2013-03-31	Terminated(stopped due to Poor recruitment)
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00558519]	Phase 2	318 participants (Actual)	Interventional	2008-03-12	Active, not recruiting
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML [NCT02412475]	Phase 1	3 participants (Actual)	Interventional	2015-02-21	Terminated(stopped due to We opened a competing study with the TACL consortium)
Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial [NCT00003437]	Phase 3	1,800 participants (Anticipated)	Interventional	1997-01-31	Active, not recruiting
Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study [NCT00003593]	Phase 3	254 participants (Actual)	Interventional	1999-06-30	Completed
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [NCT00472849]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2007-05-31	Completed
Phase I/II Trial of VELCADE® (Bortezomib) in Combination With Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemias [NCT00410423]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2006-01-31	Completed
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]	Phase 2/Phase 3	745 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
A Prospective, Multicenter, Single Arm Clinical Study to Evaluate Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia [NCT04415008]	Phase 2	40 participants (Anticipated)	Interventional	2020-06-01	Recruiting
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML [NCT03021330]	Phase 3	1,100 participants (Anticipated)	Interventional	2017-02-08	Recruiting
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation [NCT00609739]	Phase 1/Phase 2	1 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Low accrual)
T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation [NCT00578461]		26 participants (Actual)	Interventional	2007-10-31	Terminated
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors [NCT00578539]		24 participants (Actual)	Interventional	2007-10-31	Terminated
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage [NCT01670084]	Phase 2	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to No Accrual)
A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma [NCT00003388]	Phase 2	38 participants (Anticipated)	Interventional	1999-07-26	Completed
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China [NCT02405676]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
An Open-label, Multi-center Phase Ib/II Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) [NCT05100303]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia [NCT03286634]	Phase 2	60 participants (Anticipated)	Interventional	2017-04-18	Recruiting
A Non-Myeloablative Conditioning Regimen for Allogeneic Transplantation With Clofarabine, Cytarabine, and Thymoglobulin for Myelodysplastic Syndrome and Acute Myeloid Leukemia [NCT00593645]	Phase 2	7 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to toxicities were worse than expected)
The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China [NCT03173612]		132 participants (Anticipated)	Interventional	2016-08-31	Recruiting
A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia [NCT02144675]	Phase 2	27 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia [NCT05303792]	Phase 2	66 participants (Anticipated)	Interventional	2023-02-27	Recruiting
Parent-Administered Low-Dose Cytarabine to Children and Adolescents With Cancer at Home - a Feasibility Study [NCT05372536]		15 participants (Anticipated)	Interventional	2022-03-11	Recruiting
Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT00866749]	Phase 2	120 participants (Actual)	Interventional	2006-09-12	Completed
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA [NCT01838395]	Phase 2	42 participants (Actual)	Interventional	2013-04-30	Completed
"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms" [NCT02756572]	Phase 2	30 participants (Actual)	Interventional	2016-09-22	Completed
Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission [NCT01656252]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Study stopped per Novartis request due to futility from another study.)
A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib With CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [NCT05627232]	Phase 1	24 participants (Anticipated)	Interventional	2023-08-28	Recruiting
A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT04845035]	Phase 2	23 participants (Anticipated)	Interventional	2024-01-31	Recruiting
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL [NCT03150693]	Phase 3	310 participants (Anticipated)	Interventional	2017-06-01	Suspended(stopped due to Unacceptable Toxicity)
Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML [NCT01870596]	Phase 2	32 participants (Actual)	Interventional	2013-05-31	Completed
An Multicenter, Randomized, Controlled, Prospective Clinical Study of Mitoxantrone Liposome Combined With PTCy as Conditioning Regimen in Allo-HSCT in Acute Leukemia [NCT05739630]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2023-01-01	Recruiting
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma [NCT03583424]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2018-09-10	Active, not recruiting
A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma [NCT02518750]	Phase 2	3 participants (Actual)	Interventional	2016-11-23	Terminated(stopped due to Due to slow accrual)
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia [NCT00002818]	Phase 1	15 participants (Actual)	Interventional	1995-02-28	Completed
A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia [NCT06084819]	Phase 2	200 participants (Anticipated)	Interventional	2023-08-01	Recruiting
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT05032183]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2022-02-17	Recruiting
Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose [NCT00266136]	Phase 3	3,500 participants (Actual)	Interventional	1999-06-30	Completed
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia [NCT01656031]	Phase 2	39 participants (Actual)	Interventional	2005-02-28	Completed
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT04752163]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2021-03-25	Completed
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome [NCT02212561]	Phase 1	19 participants (Actual)	Interventional	2014-08-31	Completed
Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas [NCT00244946]	Phase 1	15 participants (Actual)	Interventional	2004-03-31	Completed
A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia [NCT01681537]	Phase 1	36 participants (Actual)	Interventional	2012-09-30	Completed
Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML [NCT01435343]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2012-07-31	Completed
Dose Escalation Study of Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients [NCT00602225]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2007-12-31	Completed
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome [NCT02488408]	Phase 1/Phase 2	121 participants (Actual)	Interventional	2014-09-30	Active, not recruiting
A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008) [NCT02270788]	Phase 1	10 participants (Actual)	Interventional	2015-04-02	Completed
A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML [NCT00268229]	Phase 1	21 participants (Actual)	Interventional	2003-07-31	Completed
Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen [NCT00270881]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2006-01-31	Completed
Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML) [NCT00273884]	Phase 2	80 participants	Interventional	2005-08-31	Completed
Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Relat [NCT00310128]	Phase 2	0 participants (Actual)	Interventional	2006-02-28	Withdrawn(stopped due to Drug supply unavailable)
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study [NCT00416819]		10 participants (Actual)	Interventional	2003-09-30	Completed
AML Therapy With Irradiated Allogeneic Cells [NCT02105116]		6 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to No patients were eligible to receive the experimental component of the protocol therapy.)
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia [NCT05735184]	Phase 1	212 participants (Anticipated)	Interventional	2023-07-18	Recruiting
A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia [NCT03904251]	Phase 1	13 participants (Actual)	Interventional	2019-07-18	Terminated(stopped due to slow accrual)
A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT03441048]	Phase 1	26 participants (Actual)	Interventional	2018-05-22	Active, not recruiting
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Mye [NCT02668653]	Phase 3	539 participants (Actual)	Interventional	2016-09-01	Completed
A Phase I Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia [NCT00295841]	Phase 1	53 participants (Actual)	Interventional	2005-02-28	Completed
Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients [NCT01876953]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-09-13	Terminated(stopped due to Due to the budget issues, the study discontinued at Phase II.)
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C) [NCT00303290]	Phase 1	76 participants (Actual)	Interventional	2000-01-31	Completed
Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm. [NCT01497002]	Phase 3	1,222 participants (Actual)	Interventional	2005-04-30	Completed
A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor [NCT01500161]	Phase 2	1 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Insufficient accruals)
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma [NCT01511562]	Phase 2	113 participants (Actual)	Interventional	2012-09-30	Active, not recruiting
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML) [NCT01627041]	Phase 2	178 participants (Actual)	Interventional	2011-09-16	Active, not recruiting
A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML) [NCT01635296]	Phase 1	43 participants (Actual)	Interventional	2012-07-31	Completed
Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk MDS [NCT01636609]	Phase 1	18 participants (Actual)	Interventional	2012-11-20	Terminated(stopped due to In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was cancelled.)
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. [NCT01607645]	Phase 2	7 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to The study was terminated early because there were other competing protocols.)
Efficacy and Safety of Chidamide in CBF Leukemia [NCT03031262]	Phase 1/Phase 2	250 participants (Anticipated)	Interventional	2017-02-08	Recruiting
Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study. [NCT01645839]	Phase 3	74 participants (Actual)	Interventional	2011-08-30	Completed
A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups [NCT00003815]	Phase 3	0 participants	Interventional	1994-06-30	Active, not recruiting
A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial [NCT01653067]	Phase 2	88 participants (Anticipated)	Interventional	2012-09-30	Active, not recruiting
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) [NCT00528398]	Phase 2	111 participants (Actual)	Interventional	1994-09-30	Completed
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia [NCT05317403]	Phase 1	40 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） [NCT01690507]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2012-11-30	Completed
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome [NCT03572764]	Phase 1	20 participants (Actual)	Interventional	2018-12-14	Active, not recruiting
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [NCT01700946]	Phase 2	80 participants (Actual)	Interventional	2013-04-15	Completed
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy [NCT01890746]	Phase 2	148 participants (Actual)	Interventional	2013-09-05	Completed
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022) [NCT06175702]		150 participants (Anticipated)	Observational	2023-12-25	Not yet recruiting
Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients [NCT05249959]	Phase 2	56 participants (Anticipated)	Interventional	2022-04-21	Recruiting
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies [NCT00968760]	Phase 1	34 participants (Actual)	Interventional	2011-06-20	Completed
A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies [NCT02280525]	Phase 1	8 participants (Actual)	Interventional	2015-03-05	Completed
A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Beam Followed by Autologous Stem Cell Transplantation for Poor Risk/Relapsed B-Cell Lymphoma [NCT00695409]	Phase 2	122 participants (Actual)	Interventional	2008-03-18	Completed
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leu [NCT01768897]	Phase 1	67 participants (Actual)	Interventional	2013-01-31	Completed
AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA [NCT01769911]		0 participants (Actual)	Interventional	2015-02-28	Withdrawn
Safety and Efficacy of Implementing Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain in Emergency Department [NCT01770444]		681 participants (Actual)	Interventional	2012-12-31	Completed
A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia [NCT01779843]	Phase 1	22 participants (Actual)	Interventional	2013-04-30	Completed
An Open-Label, Single-Dose Study Designed to Assess the Mass Balance Recovery of an Intravenous Microdose of [14C]-Elacytarabine in Healthy Male Subjects [NCT01783964]	Phase 1	6 participants (Actual)	Interventional	2013-02-28	Completed
A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia [NCT01787474]	Phase 1	30 participants (Actual)	Interventional	2014-05-19	Completed
Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia [NCT03258931]	Phase 3	510 participants (Anticipated)	Interventional	2018-08-15	Recruiting
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838]	Phase 2	25 participants (Actual)	Interventional	2003-02-28	Completed
A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission [NCT01843179]	Phase 2	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Lack of Funding)
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML) [NCT04250051]	Phase 1	25 participants (Anticipated)	Interventional	2020-12-21	Recruiting
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06. [NCT00003407]	Phase 2	0 participants (Actual)	Interventional	2001-02-13	Withdrawn(stopped due to The P.I deceased.)
"Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. 7+3 for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)" [NCT01349972]	Phase 2	172 participants (Actual)	Interventional	2011-04-30	Completed
Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma [NCT00367497]	Phase 2	5 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to The stopping rule was applied because of low response rates.)
A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin Lymphoma [NCT03349281]	Phase 1	6 participants (Actual)	Interventional	2019-03-25	Completed
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) [NCT02921061]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2016-11-17	Completed
Safety and Efficiency of Anti-CD19/CD22 Tandem Fully Human Chimeric Antigen Receptor (CAR)-Transduced T-cell Therapy for Pediatric and Young Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: a Single Centre, Non-randomised, Open [NCT04499573]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2020-07-27	Active, not recruiting
Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders [NCT00357305]	Phase 1	25 participants (Actual)	Interventional	2006-05-31	Completed
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME [NCT01546038]	Phase 2	255 participants (Actual)	Interventional	2012-06-27	Completed
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma [NCT00000801]	Phase 2	33 participants	Interventional		Completed
Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML [NCT03586609]	Phase 2	145 participants (Anticipated)	Interventional	2018-10-25	Recruiting
Phase II Study of High-Dose Cytarabine, Cisplatin, and Dexamethasone Followed By Cyclophosphamide, Etoposide, Total Body Irradiation, and Autologous Bone Marrow Rescue in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [NCT00002481]	Phase 2	0 participants	Interventional	1990-03-31	Active, not recruiting
TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS [NCT00002499]	Phase 2/Phase 3	0 participants	Interventional	1990-01-31	Active, not recruiting
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY [NCT00002517]	Phase 3	0 participants	Interventional	1993-03-31	Completed
ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA [NCT00002547]	Phase 2	280 participants (Actual)	Interventional	1987-08-31	Completed
A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT04898894]	Phase 1	42 participants (Anticipated)	Interventional	2021-11-15	Recruiting
"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5" [NCT00002565]	Phase 3	61 participants (Actual)	Interventional	1994-05-25	Completed
Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II [NCT00002571]	Phase 2	52 participants (Actual)	Interventional	1994-06-30	Completed
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric P [NCT05751044]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study [NCT00002757]	Phase 3	1,148 participants (Actual)	Interventional	2001-06-30	Completed
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant [NCT01621477]	Phase 2	34 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Study was terminated in August 2016 due to replacement by a new study.)
Phase II Study of the Combination of High-Dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement [NCT00992602]	Phase 2	3 participants (Actual)	Interventional	2011-04-30	Completed
A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma [NCT04871607]	Phase 2	33 participants (Anticipated)	Interventional	2021-11-02	Recruiting
Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT01449344]	Phase 3	128 participants (Actual)	Interventional	2009-05-09	Active, not recruiting
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study [NCT02633137]	Phase 2	49 participants (Actual)	Interventional	2015-12-14	Completed
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax [NCT05192889]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2022-08-25	Recruiting
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases [NCT00716066]	Phase 2	80 participants (Anticipated)	Interventional	2008-06-30	Recruiting
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma [NCT01614197]	Phase 1	16 participants (Actual)	Interventional	2015-07-03	Completed
A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic [NCT01463046]	Phase 1	29 participants (Actual)	Interventional	2012-01-31	Completed
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms [NCT05656248]	Phase 2	25 participants (Anticipated)	Interventional	2023-01-17	Recruiting
A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia [NCT05558124]	Phase 1	18 participants (Anticipated)	Interventional	2022-09-22	Recruiting
Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies [NCT00014495]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2000-11-30	Completed
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma [NCT03623373]	Phase 2	13 participants (Actual)	Interventional	2018-11-29	Active, not recruiting
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute [NCT00634244]	Phase 2	92 participants (Actual)	Interventional	2008-10-31	Completed
T2007-002 A Phase II Study of Clofarabine With Etoposide and Cyclophosphamide in Relapsed/Refractory AML (IND 104,650) [NCT00939653]	Phase 2	6 participants (Actual)	Interventional	2009-07-10	Terminated(stopped due to Due to insufficient research institution participation and patient enrollment)
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China [NCT05313958]	Phase 2/Phase 3	43 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Clinical Study on the Safety and Efficacy of QN-030a in Acute Myeloid Leukemia With Minimal Residual Disease [NCT05601830]	Phase 1	18 participants (Anticipated)	Interventional	2022-10-28	Recruiting
A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma [NCT05506410]		100 participants (Anticipated)	Observational [Patient Registry]	2022-08-12	Recruiting
Clinical Study of Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated Acute Myeloid Leukemia [NCT05053425]		30 participants (Anticipated)	Interventional	2021-10-20	Recruiting
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia [NCT02416908]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2015-06-16	Completed
Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors [NCT01350232]		2 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Poor accrual)
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [NCT02688140]	Phase 3	280 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [NCT00000658]	Phase 3	250 participants	Interventional		Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN [NCT00002494]	Phase 2	134 participants (Actual)	Interventional	1992-05-31	Completed
Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) [NCT00199082]	Phase 4	650 participants (Anticipated)	Interventional	2002-07-31	Completed
HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR CHILDREN WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA [NCT00002638]	Phase 2	30 participants (Anticipated)	Interventional	1995-03-31	Completed
CYTOREDUCTIVE CHEMOTHERAPY WITH MITOXANTRONE, CYTOSINE ARABINOSIDE AND ETOPOSIDE FOLLOWED BY RECOMBINANT HUMAN G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA [NCT00002674]	Phase 2	30 participants (Anticipated)	Interventional	1994-10-31	Completed
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]	Phase 2	156 participants (Actual)	Interventional	1996-01-31	Completed
A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma [NCT00002590]	Phase 2	221 participants (Actual)	Interventional	1994-07-31	Completed
Phase II Study of Age-Adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL) [NCT01662050]	Phase 2	57 participants (Actual)	Interventional	2012-03-20	Completed
Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Sec [NCT00002926]	Phase 3	80 participants (Anticipated)	Interventional	1996-12-31	Active, not recruiting
A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients [NCT01555268]	Phase 1	24 participants (Actual)	Interventional	2011-10-31	Completed
Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 [NCT00003436]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-07-31	Completed
PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL [NCT00002800]	Phase 2	60 participants (Anticipated)	Interventional	1996-07-31	Completed
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study [NCT00002812]	Phase 3	2,078 participants (Actual)	Interventional	1996-09-30	Completed
Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years [NCT00003190]	Phase 3	640 participants (Actual)	Interventional	1998-01-31	Completed
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mer [NCT00003934]	Phase 3	420 participants (Actual)	Interventional	1999-06-30	Completed
A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine [NCT00003694]	Phase 2	60 participants (Actual)	Interventional	1999-03-31	Completed
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia [NCT00003700]	Phase 2	163 participants (Actual)	Interventional	1999-01-31	Completed
A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00003268]	Phase 1	0 participants	Interventional	1998-01-31	Completed
PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS [NCT00096122]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2004-09-30	Completed
Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study [NCT00004114]	Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study never opened)
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03808610]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2019-04-03	Recruiting
A Phase 2 Trial to Evaluate the Efficacy of Bortezomib, Cytarabine, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT02840539]	Phase 2	19 participants (Actual)	Interventional	2016-10-11	Completed
Clinical Study on QN-023a Targeting CD33 in Relapsed/Refractory Acute Myeloid Leukemia [NCT05601466]	Phase 1	18 participants (Anticipated)	Interventional	2022-10-28	Recruiting
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen [NCT02342782]	Phase 1	20 participants (Actual)	Interventional	2020-06-08	Active, not recruiting
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia [NCT00199095]	Phase 4	40 participants	Interventional	1997-02-28	Completed
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) [NCT00198978]	Phase 4	377 participants (Actual)	Interventional	2003-01-31	Completed
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia [NCT02583893]	Phase 2	39 participants (Actual)	Interventional	2015-10-07	Completed
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase [NCT00022490]	Phase 2	24 participants (Actual)	Interventional	2001-06-30	Terminated
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study [NCT00005596]	Phase 3	1,076 participants (Actual)	Interventional	2000-04-30	Completed
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma [NCT01859819]	Phase 2	45 participants (Actual)	Interventional	2013-01-31	Completed
An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation. [NCT04217278]	Phase 2/Phase 3	333 participants (Actual)	Interventional	2020-01-27	Active, not recruiting
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Ge [NCT00085709]	Phase 3	637 participants (Actual)	Interventional	2004-07-31	Completed
Clofarabine With Cytarabine for MRD Positive Leukemia [NCT01158885]	Phase 2	2 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Study terminated for lack of accrual.)
An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myeloid Leukaemia Ineligible for Intensive Treatment [NCT00632749]	Phase 2	68 participants (Actual)	Interventional	2008-05-31	Completed
Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT01289457]	Phase 1/Phase 2	282 participants (Actual)	Interventional	2011-02-02	Completed
Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma [NCT05253495]	Phase 2	80 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Phase I Dose Escalation Study of Millennium 9708 in Combination With Induction and Consolidation Chemotherapy in Adults >= 60 Years With Acute Myeloid Leukemia [NCT02582359]	Phase 1	39 participants (Actual)	Interventional	2016-01-31	Completed
Evaluation of Functional Rehabilitation Fast Track Total Hip Arthroplasty vs Standard Care: a Randomized Controlled Trial [NCT04211987]		93 participants (Actual)	Interventional	2018-03-13	Completed
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia [NCT02299518]	Phase 1	23 participants (Actual)	Interventional	2015-05-18	Completed
Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study [NCT04121819]	Phase 2	40 participants (Anticipated)	Interventional	2019-10-01	Recruiting
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]	Phase 4	1,883 participants (Actual)	Interventional	2003-04-30	Completed
Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP) [NCT02983097]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to Phase II: no scientific interests are given anymore)
Zevalin And Rituxan For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma [NCT00073957]	Phase 2	25 participants (Actual)	Interventional	2003-12-31	Completed
UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy [NCT00083551]	Phase 3	668 participants (Actual)	Interventional	1998-08-31	Completed
ChiCGB Versus BEAM With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma - A Prospective, Multi-centered, Randomized Clinical Trial [NCT05466318]	Phase 3	306 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Prospective Institutional Study for the Treatment of Children With Newly Diagnosed Langerhans Cell Histiocytosis Using a Cytarabine Contained Protocol [NCT04773366]	Phase 3	200 participants (Anticipated)	Interventional	2018-07-01	Recruiting
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00186875]	Phase 2	47 participants (Actual)	Interventional	2003-11-30	Completed
Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, or Are Refractory to, Hypomethylator Therapy [NCT01444742]	Phase 2	81 participants (Actual)	Interventional	2011-11-16	Completed
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy [NCT03969420]	Phase 2	11 participants (Actual)	Interventional	2020-01-15	Terminated(stopped due to Business decision to terminate the development of alvocidib program on 17 November 2020. Patients permitted on treatment until April 22, 2021. The last end-of-treatment follow-up completed on May 14, 2021.)
A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes [NCT01692197]	Phase 2	43 participants (Actual)	Interventional	2013-02-01	Completed
Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML [NCT02485353]		2 participants (Actual)	Interventional	2015-10-20	Terminated(stopped due to Safety concerns)
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML) [NCT02343939]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2015-07-01	Terminated
A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. [NCT04688021]	Phase 2	46 participants (Anticipated)	Interventional	2020-12-03	Recruiting
Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML) [NCT02532010]	Phase 2	13 participants (Actual)	Interventional	2015-06-15	Terminated(stopped due to The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.)
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia [NCT03031249]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2017-02-08	Recruiting
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) [NCT00882206]	Phase 2	15 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow accrual)
A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemi [NCT01721876]	Phase 3	666 participants (Actual)	Interventional	2013-01-29	Completed
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome [NCT00002578]	Phase 2	35 participants (Anticipated)	Interventional	1994-08-31	Completed
Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study [NCT01615757]	Phase 3	180 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia [NCT01253070]	Phase 2	54 participants (Actual)	Interventional	2011-04-01	Completed
Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia [NCT00038610]	Phase 2	54 participants (Actual)	Interventional	2001-03-31	Completed
Randomized Phase II Study of Clofarabine Alone Versus Clofarabine in Combination With Low-Dose Cytarabine in Previously Untreated Patients >= 60 Years With AML and High-Risk MDS [NCT00088218]	Phase 2	95 participants (Actual)	Interventional	2004-07-31	Completed
Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in Selected Elderly Patients at High Risk of Anthracycline Toxicity [NCT00334074]	Phase 2	30 participants (Actual)	Interventional	2005-08-31	Completed
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm [NCT01101880]	Phase 2	50 participants (Actual)	Interventional	2010-08-31	Completed
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT03118466]	Phase 2	41 participants (Actual)	Interventional	2017-09-25	Active, not recruiting
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia [NCT04158739]	Phase 1	16 participants (Actual)	Interventional	2020-01-22	Active, not recruiting
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patie [NCT04029688]	Phase 1/Phase 2	183 participants (Anticipated)	Interventional	2020-01-27	Recruiting
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents [NCT03206671]	Phase 3	650 participants (Anticipated)	Interventional	2017-08-03	Recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for [NCT02088541]	Phase 2	317 participants (Actual)	Interventional	2014-03-31	Completed
AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA [NCT00002552]	Phase 2	40 participants (Anticipated)	Interventional	1993-10-31	Completed
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY [NCT00002768]	Phase 2	51 participants (Actual)	Interventional	1996-06-30	Completed
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members [NCT00000703]		45 participants	Interventional		Completed
A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) [NCT00002798]	Phase 3	880 participants (Actual)	Interventional	1996-08-31	Completed
EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY [NCT00002816]	Phase 3	120 participants (Anticipated)	Interventional	1996-12-31	Completed
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI [NCT00002665]	Phase 2	50 participants (Anticipated)	Interventional	1995-07-31	Completed
INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LE [NCT00002701]	Phase 3	750 participants (Anticipated)	Interventional	1995-10-31	Active, not recruiting
A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission [NCT00003602]	Phase 3	400 participants (Anticipated)	Interventional	1998-03-31	Active, not recruiting
A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [NCT00003632]	Phase 2	30 participants (Anticipated)	Interventional	1998-09-30	Completed
CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA [NCT00002761]	Phase 1/Phase 2	0 participants (Actual)	Interventional	1996-02-29	Withdrawn(stopped due to PI left institution)
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]	Phase 2	0 participants	Interventional	1996-07-31	Completed
A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT00004862]	Phase 1	24 participants (Actual)	Interventional	1999-10-31	Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]	Phase 3	1,500 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG [NCT00003758]	Phase 2	60 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML [NCT02249091]	Phase 2	42 participants (Actual)	Interventional	2014-09-30	Completed
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis [NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
PROSPECTIVE RANDOMISED STUDY TO COMPARE LOW-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA VS HIGH-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA IN PATIENTS WITH NEWLY DIAGONISED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA [NCT00002869]	Phase 3	800 participants (Anticipated)	Interventional	1995-04-30	Active, not recruiting
A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic A [NCT00003619]	Phase 1/Phase 2	0 participants	Interventional	1998-02-28	Completed
The Unrelated Donor Marrow Transplantation Trial [NCT00003187]	Phase 2/Phase 3	19 participants (Actual)	Interventional	1995-05-31	Completed
A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma [NCT00004903]	Phase 2	0 participants	Interventional	1999-10-31	Active, not recruiting
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30% [NCT02520011]	Phase 2	104 participants (Actual)	Interventional	2016-03-14	Terminated(stopped due to Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.)
A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia [NCT01849276]	Phase 1	2 participants (Actual)	Interventional	2015-03-11	Terminated(stopped due to Slow accrual)
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT02419469]	Phase 2	1 participants (Actual)	Interventional	2015-11-13	Terminated(stopped due to Slow Accrual)
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]	Phase 2	0 participants	Interventional	1990-02-28	Completed
RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL [NCT00002549]	Phase 3	1,520 participants (Anticipated)	Interventional	1993-11-30	Active, not recruiting
PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA [NCT00002609]	Phase 2	40 participants (Actual)	Interventional	1994-08-31	Completed
PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML [NCT00002771]	Phase 3	750 participants (Anticipated)	Interventional	1995-01-31	Active, not recruiting
High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia [NCT00002945]	Phase 3	61 participants (Actual)	Interventional	1996-12-31	Completed
A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia [NCT01769209]	Phase 2	18 participants (Actual)	Interventional	2013-03-31	Completed
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed AML [NCT01829503]	Phase 2	44 participants (Actual)	Interventional	2013-02-28	Completed
A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine [NCT01960387]	Phase 2	2 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to lack of accrual)
A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation [NCT01969435]	Phase 2	50 participants (Actual)	Interventional	2014-03-19	Completed
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) [NCT02044796]	Phase 1/Phase 2	199 participants (Actual)	Interventional	2014-01-23	Completed
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer [NCT03654716]	Phase 1	21 participants (Actual)	Interventional	2018-11-01	Completed
A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leu [NCT01238211]	Phase 2	61 participants (Actual)	Interventional	2010-12-14	Completed
Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha [NCT00003405]	Phase 2	0 participants (Actual)	Interventional	1998-04-30	Withdrawn(stopped due to No enrollment)
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML [NCT03504410]	Phase 3	200 participants (Actual)	Interventional	2018-11-12	Terminated(stopped due to Futile)
Non-Hodgkin's Lymphoma T Cell Protocol [NCT00003423]	Phase 3	100 participants (Anticipated)	Interventional	1995-05-31	Active, not recruiting
Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm [NCT00002805]	Phase 2	115 participants (Actual)	Interventional	1997-08-31	Completed
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN [NCT00002865]	Phase 2	25 participants (Actual)	Interventional	1995-04-30	Completed
A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma [NCT00003957]	Phase 2	3 participants (Actual)	Interventional	1998-12-31	Completed
Pilot Study of Intensive Chemotherapy Followed by Peripheral Blood Stem Cell Harvesting for Autotransplantation of Adults With Chronic Myelogenous Leukemia and High Risk Acute Leukemia [NCT00004905]	Phase 2	0 participants	Interventional	1999-10-31	Completed
"Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin 7+3 Regimen" [NCT00004215]	Phase 2	0 participants	Interventional	1999-08-31	Completed
Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children [NCT00003729]	Phase 2	13 participants (Actual)	Interventional	1998-12-31	Terminated(stopped due to low accrual)
Phase I Study of UCN-01 and Cytarabine (ARA-C) in Patients With Acute Myelogenous Leukemia, and Myelodysplastic Syndromes [NCT00004263]	Phase 1	16 participants (Actual)	Interventional	1999-12-31	Completed
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]	Phase 2	36 participants (Actual)	Interventional	1999-03-31	Completed
Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy [NCT00005589]	Phase 3	460 participants (Anticipated)	Interventional	1999-10-31	Completed
A Phase II Trial of Cisplatinum, Cytosine Arabinoside, Dexamethasone (DHAP) With Rituxan in Patients With Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma [NCT00005601]	Phase 2	58 participants (Actual)	Interventional	2000-10-31	Completed
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 [NCT00005793]	Phase 1/Phase 2	41 participants (Actual)	Interventional	1999-07-31	Completed
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies [NCT02483000]	Phase 1	3 participants (Actual)	Interventional	2017-02-01	Terminated(stopped due to Closed early due to lack of funding)
A Pilot Study of Mitoxantrone-Based Four Drug Reinduction in Combination With Bortezomib for Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Children and Young Adults [NCT02535806]	Phase 2	2 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Funding source discontinued)
Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [NCT02464657]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2015-07-31	Completed
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients NCT00534469]	Phase 2	60 participants (Actual)	Interventional	2000-02-08	Active, not recruiting
Phase Ib Trial of Gilteritinib in Combination With Mitoxantrone, Cladribine, Cytarabine and Filgrastim (GM-CLAG) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia [NCT05330377]	Phase 1	0 participants (Actual)	Interventional	2023-03-31	Withdrawn(stopped due to Sponsor withdrew funding)
A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies [NCT02419755]	Phase 2	12 participants (Actual)	Interventional	2015-04-14	Terminated(stopped due to Accrual goals were no longer feasible based on restrictions imposed by the DSMB.)
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]	Phase 3	1,000 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02326584]	Phase 1	116 participants (Actual)	Interventional	2014-12-31	Completed
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) [NCT01564784]	Phase 3	326 participants (Actual)	Interventional	2012-08-02	Completed
A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year [NCT00480987]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to Lack of support.)
Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Pegaspargase in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia: a Phase 2 Clinical Trial [NCT03318419]	Phase 2	50 participants (Anticipated)	Interventional	2016-01-01	Recruiting
The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment [NCT03988205]	Phase 4	3 participants (Actual)	Interventional	2019-08-28	Terminated(stopped due to Low accrual)
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma [NCT01451515]	Phase 2	23 participants (Actual)	Interventional	2012-05-25	Completed
A Multi-center Randomized Open-label Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of Acute Myeloid Leukemia Patients [NCT03045627]	Phase 2	120 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia [NCT02305563]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2015-01-27	Terminated(stopped due to Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.)
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) [NCT05518383]	Phase 4	300 participants (Anticipated)	Interventional	2022-05-25	Recruiting
RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) [NCT00002719]	Phase 3	500 participants (Anticipated)	Interventional	1995-12-31	Completed
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [NCT02400281]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-09-30	Completed
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy [NCT02441803]	Phase 2	11 participants (Actual)	Interventional	2015-09-14	Active, not recruiting
A Multicenter，Open-label，Randomized Study on the Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old [NCT02432911]		300 participants (Anticipated)	Interventional	2015-04-30	Recruiting
A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission [NCT02428543]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2013-07-31	Active, not recruiting
Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia [NCT00003079]	Phase 1	30 participants (Actual)	Interventional	1997-09-30	Completed
Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens [NCT02413021]	Phase 1	40 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Le [NCT05020665]	Phase 3	15 participants (Actual)	Interventional	2021-11-30	Terminated(stopped due to Termination was due to significant challenges associated with study enrollment in a genetic subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other challenges associated with post-COVID impacts.)
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. [NCT05049473]	Phase 2	100 participants (Anticipated)	Interventional	2014-01-31	Recruiting
A Randomized Controlled Study of Dasatinib Combined With Reduced Intensive Consolidation Chemotherapy in Newly Diagosed Philadelphia Chromesome Positive Adult Lymphoblastic Leukemia [NCT05026229]		60 participants (Anticipated)	Interventional	2021-09-06	Recruiting
Phase II CCOP Trial of High Dose Methotrexate/ARA-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants [NCT00003311]	Phase 2	19 participants (Actual)	Interventional	1998-05-20	Completed
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients &l [NCT04115631]	Phase 2	360 participants (Actual)	Interventional	2019-12-13	Active, not recruiting
A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia [NCT00005962]	Phase 2	0 participants	Interventional	2000-10-04	Completed
PROSPECTIVE RANDOMISED STUDY TO COMPARE INTERFERON-ALPHA-n1 (WELLFERON) VS 'IDAC' CHEMOTHERAPY AND AUTOGRAFTING FOLLOWED BY INTERFERON ALPHA-n1 (WELLFERON) IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA [NCT00002868]	Phase 3	744 participants (Anticipated)	Interventional	1997-11-20	Completed
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With [NCT01412879]	Phase 2	53 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy [NCT02287233]	Phase 1/Phase 2	94 participants (Actual)	Interventional	2014-12-31	Completed
Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients：a Single Arm, Open-labelled, Phase 2 Study [NCT03016988]	Phase 2	50 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia [NCT00955916]	Phase 2	38 participants (Actual)	Interventional	2009-08-31	Completed
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia [NCT02560025]	Phase 2	42 participants (Actual)	Interventional	2015-12-31	Completed
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2016-01-29	Active, not recruiting
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia [NCT01853228]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2013-10-22	Terminated(stopped due to EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.)
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies [NCT01921387]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-10-09	Completed
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]	Phase 2	30 participants (Actual)	Interventional	2015-08-01	Completed
A Randomized Controlled Study on the Efficacy and Safety of MA-BUCY2 Protocol in the Conditioning of Haploidentical Stem Cell Transplantation in Patients With High-risk Acute Myeloid Leukemia [NCT05814731]		264 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
Multicenter Randomized Controlled Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Carmustine, Etoposide and Cytarabine (Modified BEAM Protocol) for T Cell Lymphoma Underwent Autologous Stem Cell Transplantation [NCT05814718]		122 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
A Phase 1 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms [NCT04797767]	Phase 1	20 participants (Anticipated)	Interventional	2022-02-04	Recruiting
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]	Phase 2	67 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03298984]	Phase 1	32 participants (Actual)	Interventional	2017-09-25	Completed
A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation [NCT02577406]	Phase 3	319 participants (Actual)	Interventional	2015-12-30	Active, not recruiting
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm [NCT03531918]	Phase 1/Phase 2	66 participants (Actual)	Interventional	2018-09-14	Completed
A Multicenter Randomized Control Clinical Trail of Evaluating Effect of Demethylation Drug Combined With Chemotherapy in Patients With Intermediate-risk AML After Hematological Complete Remission [NCT03417427]	Phase 2	100 participants (Anticipated)	Interventional	2018-02-01	Recruiting
A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia [NCT00452374]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2004-11-30	Completed
Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations [NCT03381781]	Phase 2	100 participants (Anticipated)	Interventional	2018-03-31	Not yet recruiting
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS) [NCT02121418]		12 participants (Actual)	Interventional	2014-06-30	Completed
A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) [NCT01880437]	Phase 2	38 participants (Actual)	Interventional	2013-09-30	Terminated
Clinical Study on the Efficacy and Safety of Auto-HSCT in Adult Patients With Burkitt Lymphoma, Lymphoblastic Lymphoma, and Acute Lymphoblastic Leukemia Who Received TCCA Conditioning Regimen [NCT06060782]	Phase 1	28 participants (Anticipated)	Interventional	2023-10-01	Recruiting
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation [NCT05813132]		60 participants (Actual)	Interventional	2022-12-01	Completed
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm [NCT04195945]	Phase 2	60 participants (Anticipated)	Interventional	2020-03-11	Recruiting
LS1781: Phase 2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma and Patients With Clonal Cytopenia of Undetermined Significance [NCT03418038]	Phase 2	55 participants (Anticipated)	Interventional	2018-03-23	Recruiting
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]	Phase 2/Phase 3	790 participants (Actual)	Interventional	2017-03-29	Active, not recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]	Phase 3	5,937 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML [NCT02658487]	Phase 2	42 participants (Actual)	Interventional	2016-03-31	Active, not recruiting
A Study of Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy in Patients With Acute Myeloid Leukemia Who Had Relapsed/Refractory Disease or Positive Minimal Residual Disease [NCT05362942]	Phase 2	52 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
An Expanded Access Study for Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Therapy in Japan [NCT04509622]	Phase 3	14 participants (Actual)	Interventional	2020-10-05	Completed
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML [NCT01696084]	Phase 3	309 participants (Actual)	Interventional	2012-12-13	Completed
A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia [NCT00831766]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2009-06-25	Completed
A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia [NCT00863434]	Phase 2	2 participants (Actual)	Interventional	2009-02-28	Terminated
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior [NCT01588951]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2013-12-31	Terminated(stopped due to Low accrual)
A Single-arm, Prospective, Single-center, Phase II Clinical Study of Penpulimab Combined With RMA in the Treatment of Newly Diagnosed Primary CNS Lymphoma [NCT05347641]	Phase 2	23 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia [NCT03826992]	Phase 1	21 participants (Anticipated)	Interventional	2018-12-27	Recruiting
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730 [NCT03817320]	Phase 1/Phase 2	31 participants (Anticipated)	Interventional	2019-02-12	Recruiting
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]	Phase 3	680 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]	Phase 3	6,136 participants (Actual)	Interventional	2010-06-30	Completed
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol [NCT00136435]	Phase 2	100 participants (Anticipated)	Interventional	2002-06-30	Active, not recruiting
A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation [NCT02957032]	Phase 1	30 participants (Anticipated)	Interventional	2016-04-13	Terminated(stopped due to New agents for the same indication impacted on patients' recruitment)
Venetoclax Combining Chidamide and Azacitidine (VCA) Regimen Followed by Dicitabine Combined With Liposome Mitoxantrone, Cytarabine, and G-CSF (D-MAG) Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) : A Multi [NCT05603884]	Phase 2	66 participants (Anticipated)	Interventional	2022-12-01	Recruiting
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies [NCT05536154]		68 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]	Phase 3	400 participants (Anticipated)	Interventional	1997-04-30	Completed
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) [NCT00003239]	Phase 2	90 participants (Actual)	Interventional	1998-03-31	Completed
A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older [NCT00004217]	Phase 2	55 participants (Anticipated)	Interventional	2000-02-29	Completed
[NCT00004643]	Phase 2	10 participants	Interventional	1995-02-28	Completed
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study [NCT00005585]	Phase 3	838 participants (Actual)	Interventional	2000-04-30	Completed
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study [NCT00005603]	Phase 3	276 participants (Actual)	Interventional	2000-03-31	Completed
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study [NCT00003671]	Phase 2	59 participants (Actual)	Interventional	1998-12-31	Completed
Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study [NCT00003827]	Phase 2	25 participants (Anticipated)	Interventional	1999-01-31	Active, not recruiting
Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma [NCT00392834]	Phase 2	34 participants (Actual)	Interventional	2006-09-30	Completed
Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias [NCT00407966]	Phase 2	45 participants (Actual)	Interventional	2006-10-31	Completed
Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, P [NCT00795002]	Phase 2	78 participants (Actual)	Interventional	2008-11-30	Completed
A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT01272245]	Phase 2	36 participants (Actual)	Interventional	2011-07-31	Completed
Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00844298]	Phase 2	91 participants (Actual)	Interventional	2009-01-31	Completed
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma [NCT03383406]	Phase 2	30 participants (Anticipated)	Interventional	2016-12-01	Enrolling by invitation
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML) [NCT01802333]	Phase 3	754 participants (Actual)	Interventional	2013-02-12	Completed
A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma [NCT01653418]	Phase 2	10 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Due to the high rate of morbidity and mortality)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]	Phase 3	4,772 participants (Anticipated)	Interventional	2019-10-31	Recruiting
Mature B-Cell Lymphoma And Leukemia Study III [NCT01046825]	Phase 2/Phase 3	128 participants (Actual)	Interventional	2010-09-09	Active, not recruiting
Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma [NCT01516593]	Phase 2	19 participants (Actual)	Interventional	2011-11-30	Completed
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alt [NCT02042391]	Phase 2	60 participants (Actual)	Interventional	2015-02-03	Completed
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma [NCT02728531]	Phase 1	18 participants (Actual)	Interventional	2016-04-18	Completed
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myelo [NCT03250338]	Phase 3	322 participants (Anticipated)	Interventional	2018-06-05	Recruiting
Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma [NCT01538472]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2003-09-30	Completed
Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia [NCT02985372]	Phase 3	30 participants (Anticipated)	Interventional	2016-12-31	Enrolling by invitation
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ [NCT03589326]	Phase 3	245 participants (Actual)	Interventional	2018-10-04	Active, not recruiting
MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) [NCT04385290]	Phase 1/Phase 2	214 participants (Anticipated)	Interventional	2020-09-04	Recruiting
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies [NCT00405743]	Phase 1/Phase 2	153 participants (Actual)	Interventional	2006-05-31	Completed
AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients [NCT02440568]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2015-06-05	Terminated
Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations [NCT02323607]	Phase 1	13 participants (Actual)	Interventional	2016-01-12	Completed
Epacadostat With Cladribine and Cytarabine (ECC) in Relapsed / Refractory AML Patients Fit for Intensive Chemotherapy; a Phase I Study. [NCT03491579]	Phase 1	0 participants (Actual)	Interventional	2018-12-31	Withdrawn(stopped due to IMP will not be further developed)
Epacadostat With Idarubicin and Cytarabine (EIC) for First-line Treatment of AML Patients Fit for Intensive Chemotherapy; a Phase I Study [NCT03444649]	Phase 1	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to IMP will not be further developed)
International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma [NCT00006455]	Phase 3	885 participants (Actual)	Interventional	1999-11-26	Completed
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation [NCT03412409]	Phase 2	50 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials [NCT05564390]	Phase 2	750 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid L [NCT05554406]	Phase 2	268 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial [NCT05554393]	Phase 2	153 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents [NCT03020030]	Phase 3	560 participants (Actual)	Interventional	2017-03-03	Active, not recruiting
A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment（ALIVE） [NCT04716114]	Phase 3	315 participants (Anticipated)	Interventional	2021-03-24	Recruiting
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial [NCT00005803]	Phase 1/Phase 2	76 participants (Actual)	Interventional	1999-09-30	Completed
A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome [NCT02666950]	Phase 2	3 participants (Actual)	Interventional	2017-05-05	Completed
A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) [NCT03026842]	Phase 4	180 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
Safety and Efficacy of Chemotherapy Combined With Adoptive Transfer of Human Leukocyte Antigen (HLA)-Haploidentical Donor Lymphocyte Infusion (DLI) in Older Patients With Righ-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT02046122]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2014-07-31	Completed
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age [NCT02029417]	Phase 2	2 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Major revisions needed in study)
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913 (GLASDEGIB), AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS A SINGLE AGENT IN JAPANESE PATIENTS WITH SELECT HEMATOLOGIC MALIGNANCIES AND IN [NCT02038777]	Phase 1	48 participants (Actual)	Interventional	2014-03-25	Active, not recruiting
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [NCT04128748]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2020-05-27	Recruiting
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)) [NCT04047641]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2019-10-22	Recruiting
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML [NCT03214562]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2017-09-26	Recruiting
A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma [NCT02504359]	Phase 1	11 participants (Actual)	Interventional	2015-07-20	Completed
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia [NCT03900949]	Phase 1	18 participants (Anticipated)	Interventional	2019-03-13	Recruiting
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia [NCT05645718]	Phase 2	27 participants (Anticipated)	Interventional	2023-07-14	Recruiting
Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) [NCT02649764]	Phase 1	15 participants (Actual)	Interventional	2016-05-04	Completed
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [NCT05681260]	Phase 3	200 participants (Anticipated)	Interventional	2023-02-06	Recruiting
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies [NCT05510089]		62 participants (Anticipated)	Interventional	2022-09-01	Recruiting
BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma [NCT00574509]	Phase 1	34 participants (Actual)	Interventional	1996-03-04	Completed
A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease [NCT01702961]		75 participants (Actual)	Interventional	2002-06-30	Completed
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol C Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric [NCT05745714]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia [NCT02101983]		11 participants (Actual)	Interventional	2011-05-31	Completed
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort [NCT02059239]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2014-06-04	Completed
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than [NCT04687761]	Phase 1/Phase 2	84 participants (Anticipated)	Interventional	2020-11-04	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002766 (1) [back to overview]	Complete Remission (CR)
NCT00003631 (1) [back to overview]	Objective Response
NCT00004228 (2) [back to overview]	Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00004228 (2) [back to overview]	Event-free Survival
NCT00005803 (4) [back to overview]	Non-Relapse Mortality
NCT00005803 (4) [back to overview]	Engraftment of HLA Identical PBSC Allografts
NCT00005803 (4) [back to overview]	Overall Survival (OS)
NCT00005803 (4) [back to overview]	Progression Free-survival (PFS)
NCT00014495 (1) [back to overview]	Maximum Tolerated Dose
NCT00022490 (1) [back to overview]	The Rate of Major Cytogenetic Response at 6 Months
NCT00025259 (4) [back to overview]	Event-free Survival
NCT00025259 (4) [back to overview]	Grade 3 or 4 Non-hematologic Toxicity
NCT00025259 (4) [back to overview]	Overall Survival
NCT00025259 (4) [back to overview]	Disease Response Assessed by Modified RECIST Criteria
NCT00038610 (3) [back to overview]	Disease-Free Survival Rate at 2-year and 5-year.
NCT00038610 (3) [back to overview]	Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate
NCT00038610 (3) [back to overview]	Overall Survival Rate at 2-year and 5-year.
NCT00039130 (3) [back to overview]	Complete Response Rate
NCT00039130 (3) [back to overview]	2 Year Overall Survival
NCT00039130 (3) [back to overview]	2 Year Event Free Survival
NCT00039377 (5) [back to overview]	5 Year Overall Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]	Disease Free Survival
NCT00039377 (5) [back to overview]	5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]	Overall Survival
NCT00039377 (5) [back to overview]	Number of Participants Who Achieved a BCR-ABL Response at 12 Months
NCT00041132 (3) [back to overview]	Overall Survival
NCT00041132 (3) [back to overview]	Progression-free Survival
NCT00041132 (3) [back to overview]	Response
NCT00046930 (3) [back to overview]	Progression-free Survival (PFS)
NCT00046930 (3) [back to overview]	Overall Survival (OS)
NCT00046930 (3) [back to overview]	Response
NCT00049517 (3) [back to overview]	Overall Survival (Consolidation Phase)
NCT00049517 (3) [back to overview]	Overall Survival (Induction Phase)
NCT00049517 (3) [back to overview]	Disease-free Survival (Consolidation Phase)
NCT00054327 (5) [back to overview]	Incidence of Recurrent Disease
NCT00054327 (5) [back to overview]	Number of Patients With Overall Survival at 2 Years.
NCT00054327 (5) [back to overview]	Rates of Durable Engraftment
NCT00054327 (5) [back to overview]	Toxicity as Measured by CTC v2.0
NCT00054327 (5) [back to overview]	Graft-versus-host Disease (GVHD)
NCT00057811 (4) [back to overview]	Grade ≥ 3 Stomatitis
NCT00057811 (4) [back to overview]	Response Rate
NCT00057811 (4) [back to overview]	Toxic Death
NCT00057811 (4) [back to overview]	Minimal Residual Disease
NCT00061945 (6) [back to overview]	Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]	Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]	Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]	Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]	Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]	Overall Survival
NCT00067028 (2) [back to overview]	Overall Response Rate (ORR)
NCT00067028 (2) [back to overview]	Participants With a Response
NCT00071799 (16) [back to overview]	Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT00071799 (16) [back to overview]	Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT00071799 (16) [back to overview]	Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
NCT00071799 (16) [back to overview]	Summary of Subgroup Analyses for Kaplan-Meier Estimates for Time to Death From Any Cause
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Death From Any Cause
NCT00071799 (16) [back to overview]	Duration of Any Hematologic Improvement
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimate for Median Time to Transformation to Acute Myeloid Leukemia (AML) or Death From Any Cause, Whichever Occurred First
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)
NCT00071799 (16) [back to overview]	Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML) Based on the Last Bone Marrow Assessment
NCT00071799 (16) [back to overview]	Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals
NCT00071799 (16) [back to overview]	Number of Participants Who Died
NCT00071799 (16) [back to overview]	Time to Disease Progression, Relapse After Complete or Partial Remission, or Death From Any Cause
NCT00071799 (16) [back to overview]	Number of Participants Considered Hematologic Responders by Investigator Determinations Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS)
NCT00071799 (16) [back to overview]	Number of Participants in Different Categories of Adverse Experiences During Core Study Period
NCT00071799 (16) [back to overview]	Number of Participants Showing Hematologic Improvement Using International Working Group (IWG 2000) Criteria for Myelodysplastic Syndrome (MDS) Assessed by Independent Review Committee
NCT00071799 (16) [back to overview]	Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
NCT00073957 (3) [back to overview]	Best Response
NCT00073957 (3) [back to overview]	Event Free Survival
NCT00073957 (3) [back to overview]	Response Rate = Complete and Partial Response at 12 Weeks.
NCT00074165 (1) [back to overview]	Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Negative.
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Positive.
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00075725 (7) [back to overview]	Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00078949 (4) [back to overview]	Response Rate of Patients After 2 Courses of Chemotherapy
NCT00078949 (4) [back to overview]	Toxic Effect
NCT00078949 (4) [back to overview]	Event-free Survival of Patients on Maintenance Randomization (Period 2)
NCT00078949 (4) [back to overview]	Transplantation Rate of Patients After 2 Courses of Chemotherapy
NCT00083551 (1) [back to overview]	Overall Survival
NCT00084838 (19) [back to overview]	Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]	Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]	Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]	Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]	Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]	Grade 3-4 Hemorrhage Events
NCT00084838 (19) [back to overview]	Grade 3-4 Infection/Febrile Neutropenia Events
NCT00084838 (19) [back to overview]	Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]	Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]	Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]	Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]	Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]	2-yr Overall Survival
NCT00084838 (19) [back to overview]	Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]	Grade 3/4 Events
NCT00084838 (19) [back to overview]	Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]	Grade 3-4 Pulmonary Events
NCT00084838 (19) [back to overview]	Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]	Grade 3-4 Auditory/Hearing Events
NCT00085709 (3) [back to overview]	2-year Disease-free Survival (DFS)
NCT00085709 (3) [back to overview]	Toxicity
NCT00085709 (3) [back to overview]	Complete Remission
NCT00088218 (1) [back to overview]	Number of Participants With Response
NCT00096122 (1) [back to overview]	Number of Participants With Complete Response
NCT00096135 (1) [back to overview]	Event-free Survival
NCT00098774 (4) [back to overview]	4 Year Overall Survival Rate
NCT00098774 (4) [back to overview]	4 Year Progression Free Rate
NCT00098774 (4) [back to overview]	Complete Response Rate After Remission Induction
NCT00098774 (4) [back to overview]	Change From Baseline in Mini-Mental Status Evaluation at 4 Months
NCT00098839 (4) [back to overview]	Remission Re-induction (CR2) Rate
NCT00098839 (4) [back to overview]	Event-free Survival Rate
NCT00098839 (4) [back to overview]	Pharmacokinetics
NCT00098839 (4) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01%
NCT00103285 (10) [back to overview]	Early Marrow Status (EMS) by MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]	Optimal Time Point for Advance Health Related Quality of Life Intervention
NCT00103285 (10) [back to overview]	Health-related Quality of Life Relative to Physical, Social and Emotional Impairment
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]	Overall Survival Probability (OS) According to Induction Day 29 MRD Status
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-Low Patients
NCT00103285 (10) [back to overview]	Event-free Survival (EFS) for SR-High Patients.
NCT00103285 (10) [back to overview]	Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)
NCT00103285 (10) [back to overview]	Event-Free Survival Probability According to MRD Status End Induction (Day 29)
NCT00109837 (2) [back to overview]	Continuous Complete Remission at 1 Year
NCT00109837 (2) [back to overview]	Toxicity
NCT00126191 (2) [back to overview]	Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt
NCT00126191 (2) [back to overview]	Disease Free Survival
NCT00133991 (5) [back to overview]	Event-free Survival
NCT00133991 (5) [back to overview]	Overall Response Rate
NCT00133991 (5) [back to overview]	Overall Survival
NCT00133991 (5) [back to overview]	Relapse Pattern
NCT00133991 (5) [back to overview]	Percentage of Participants Experiencing Grade 3-5 Toxicity
NCT00136084 (7) [back to overview]	Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
NCT00136084 (7) [back to overview]	Minimal Residual Disease (MRD).
NCT00136084 (7) [back to overview]	Relationship of Inhibition of DNA Synthesis and Clinical Response
NCT00136084 (7) [back to overview]	To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy
NCT00136084 (7) [back to overview]	Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.
NCT00136084 (7) [back to overview]	To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy
NCT00136084 (7) [back to overview]	Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)
NCT00137111 (7) [back to overview]	Continuous Complete Remission Since Week 56 Therapy.
NCT00137111 (7) [back to overview]	Minimal Residual Disease (MRD)
NCT00137111 (7) [back to overview]	Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)
NCT00137111 (7) [back to overview]	Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]	Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]	Overall Event-free Survival (EFS)
NCT00137111 (7) [back to overview]	Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).
NCT00166439 (3) [back to overview]	Overall Response Rate After Two Cycles of ROAD
NCT00166439 (3) [back to overview]	Overall Survival
NCT00166439 (3) [back to overview]	Progression-free Survival
NCT00176462 (1) [back to overview]	Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00186875 (4) [back to overview]	Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186875 (4) [back to overview]	Response Rate
NCT00186875 (4) [back to overview]	Overall Survival (OS)
NCT00186875 (4) [back to overview]	Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00260832 (2) [back to overview]	Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Incomplete Platelet Recovery (CRp)
NCT00260832 (2) [back to overview]	Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML.
NCT00288626 (20) [back to overview]	MS Relapse-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Number of New T2-Weighted Lesions From Baseline
NCT00288626 (20) [back to overview]	Overall Survival
NCT00288626 (20) [back to overview]	Percent Change From Screening in Brain Volume
NCT00288626 (20) [back to overview]	Event-Free Survival Probability During the 3 Years After Transplant
NCT00288626 (20) [back to overview]	Survival From Treatment-Related Mortality
NCT00288626 (20) [back to overview]	Survival From MS-Related Mortality
NCT00288626 (20) [back to overview]	Event-Free Survival Probability During the 5 Years After Transplant
NCT00288626 (20) [back to overview]	Percent of Participants Who Experienced All-Cause Morbidity
NCT00288626 (20) [back to overview]	Percent of Participants Who Experienced All-Cause Morbidity Within 12 Months of Post-HCT
NCT00288626 (20) [back to overview]	Time to Neutrophil Engraftment
NCT00288626 (20) [back to overview]	Time to Platelet Engraftment
NCT00288626 (20) [back to overview]	Change From Baseline in Extended Disability Status Scale (EDSS)
NCT00288626 (20) [back to overview]	Change From Baseline in Number of Gadolinium-Enhanced Lesions
NCT00288626 (20) [back to overview]	Change From Baseline in T1-Weighted Lesion Volume
NCT00288626 (20) [back to overview]	Change From Baseline in T2-Weighted Lesion Volume
NCT00288626 (20) [back to overview]	Disease-Modifying Therapy Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Event-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	MRI Activity-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	MS Progression-Free Survival Probability After Transplant
NCT00290433 (1) [back to overview]	3 Year Progression-Free Survival Rate
NCT00290498 (2) [back to overview]	Response Rate R-HCVAD vs. R-CHOP
NCT00290498 (2) [back to overview]	Progression Free Survival (Rate)
NCT00299182 (2) [back to overview]	Platelet (PLT) Nadir
NCT00299182 (2) [back to overview]	Days Platelets Count of < 100K/μL
NCT00302003 (4) [back to overview]	Event Free Survival (EFS)
NCT00302003 (4) [back to overview]	Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).
NCT00302003 (4) [back to overview]	Intensive Therapy Free Survival (ITFS).
NCT00302003 (4) [back to overview]	Overall Survival
NCT00317642 (12) [back to overview]	Disease-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Disease-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)
NCT00317642 (12) [back to overview]	Duration of Remission (DOR) Per IRRP Assessment-Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Duration of Remission (DOR) Per IRRP Assessment-Overall and by Randomized Strata (CSR 9-July-12)
NCT00317642 (12) [back to overview]	Event-free Survival by IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)
NCT00317642 (12) [back to overview]	Four-Month Event-free Survival Per IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Four-Month Event-free Survival Per IRRP Assessment - Overall and by Randomized Strata (CSR 9-July-12)
NCT00317642 (12) [back to overview]	Event-free Survival by IRRP Assessment - Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Overall Survival - Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Overall Survival - Overall and by Randomized Strata (CSR 9-July-12)
NCT00317642 (12) [back to overview]	Best Response Per Independent Response Review Panel (IRRP) Assessment - Overall and by Calculated Strata (CSR 7-April-11)
NCT00317642 (12) [back to overview]	Participants With Adverse Events (CSR 7-April-11)
NCT00333840 (10) [back to overview]	Percentage of Participants With Major Molecular Response (Second-line Treatment)
NCT00333840 (10) [back to overview]	Percentage of Participants With Major Molecular Response (First-line Treatment)
NCT00333840 (10) [back to overview]	Percentage of Participants With Event Free Survival Events (All Randomized Participants)
NCT00333840 (10) [back to overview]	Percentage of Participants With Best Cytogenetic Response (First-line Treatment)
NCT00333840 (10) [back to overview]	Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)
NCT00333840 (10) [back to overview]	Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)
NCT00333840 (10) [back to overview]	Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)
NCT00333840 (10) [back to overview]	Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)
NCT00333840 (10) [back to overview]	Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)
NCT00333840 (10) [back to overview]	Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)
NCT00334074 (2) [back to overview]	Response Rate (Complete Response [CR] Plus Partial Response [PR]) of Clofarabine Plus Cytarabine in Patients With Relapsed/Refractory AML, Untreated MDS, CML in Blast Phase, or in Selected Untreated Patients With High Risk of Anthracycline Toxicity
NCT00334074 (2) [back to overview]	Number of Participants Who Had an Adverse Event While on Treatment With Clofarabine Plus Cytarabine
NCT00335140 (1) [back to overview]	Complete Response Rate - Locally Reviewed
NCT00336583 (2) [back to overview]	Worst Toxicity Grade by Patient
NCT00336583 (2) [back to overview]	Overall Response Rate
NCT00337168 (4) [back to overview]	Toxicity
NCT00337168 (4) [back to overview]	Expression of Nucleoside Transporters
NCT00337168 (4) [back to overview]	Number of Patients With Very Poor Risk Cytogenetics
NCT00337168 (4) [back to overview]	Number of Patients With Complete Remission
NCT00345865 (5) [back to overview]	Number of Participants With Hematopoietic Recovery After Transplantation
NCT00345865 (5) [back to overview]	Number of Participants With 2 Years Progression Free Survival
NCT00345865 (5) [back to overview]	Number of Participants With 2 Years Overall Survival
NCT00345865 (5) [back to overview]	Number of Participants With 1 Year Progression Free Survival
NCT00345865 (5) [back to overview]	Number of Participants With 1 Year Overall Survival
NCT00354107 (1) [back to overview]	Response
NCT00368355 (3) [back to overview]	Severe GVHD Rate
NCT00368355 (3) [back to overview]	Engraftment Rate After Transplant
NCT00368355 (3) [back to overview]	Early Post BMT Toxicities
NCT00369317 (10) [back to overview]	Overall Survival (OS) at 3 Years
NCT00369317 (10) [back to overview]	Percentage of Patients Experiencing Grade 3 or 4 Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00369317 (10) [back to overview]	Prevalence of Leukemia Phenotype of DS Patients < 4 Years of Age at Diagnosis by Flow Cytometry
NCT00369317 (10) [back to overview]	Prevalence of of GATA1 Mutations of DS Patients < 4 Years of Age at Diagnosis
NCT00369317 (10) [back to overview]	Proportions of Patients in Morphologic Remission With Positive MRD by Flow Cytometry
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00369317 (10) [back to overview]	Event-free Survival (EFS) at 3 Years
NCT00369317 (10) [back to overview]	Induction Remission Rate
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00372593 (7) [back to overview]	Toxicities, Including Infectious Complications
NCT00372593 (7) [back to overview]	Remission Induction Rate After 2 Courses of Induction Therapy
NCT00372593 (7) [back to overview]	Overall Survival at 3 Years
NCT00372593 (7) [back to overview]	Mortality
NCT00372593 (7) [back to overview]	Time to Marrow Recovery
NCT00372593 (7) [back to overview]	Event-free Survival at 3 Years
NCT00372593 (7) [back to overview]	Disease-free Survival (DFS)
NCT00372619 (2) [back to overview]	Overall Response (CR for ALL Patients), (CR + CRp for AML Patients)
NCT00372619 (2) [back to overview]	Safety and Tolerability as Measured by CTCAE v3.0
NCT00381680 (6) [back to overview]	Adjusted Event Free Survival
NCT00381680 (6) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00381680 (6) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00381680 (6) [back to overview]	Frequency and Severity of Adverse Effects
NCT00381680 (6) [back to overview]	Event Free Survival. EFS
NCT00381680 (6) [back to overview]	Event Free Survival (EFS)
NCT00382590 (1) [back to overview]	Number of Participants With Response
NCT00392834 (1) [back to overview]	Overall Survival (OS) at 1 Year
NCT00392990 (4) [back to overview]	Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]	Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)
NCT00392990 (4) [back to overview]	Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]	Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00400946 (10) [back to overview]	Asparaginase-Related Toxicity Rate
NCT00400946 (10) [back to overview]	Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]	Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]	5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00400946 (10) [back to overview]	5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]	Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]	Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]	Post-Induction Nadir Serum Asparaginase Activity Level
NCT00407966 (1) [back to overview]	Complete Response
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00410423 (2) [back to overview]	Complete Response Rate to 1.3mg/m^2 of Bortezomib With Mitoxantrone and Etoposide in Phase II
NCT00410423 (2) [back to overview]	Number of Participants With Dose Limiting Toxicity in Phase I
NCT00416598 (2) [back to overview]	Number of Participants Who Completed Maintenance Decitabine.
NCT00416598 (2) [back to overview]	Disease-free Survival (DFS) Rate at 1 Year
NCT00422591 (2) [back to overview]	Overall Survival (OS)
NCT00422591 (2) [back to overview]	Event-Free Survival (EFS)
NCT00429416 (5) [back to overview]	Rate of Engraftment of Non-Myeloablative Transplants
NCT00429416 (5) [back to overview]	Rate of Serious Infectious Complications
NCT00429416 (5) [back to overview]	Number of Patients Who Achieve a CD4 Count > 200/Micro-liters
NCT00429416 (5) [back to overview]	Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality
NCT00429416 (5) [back to overview]	Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)
NCT00439296 (3) [back to overview]	Number of Patients That Achieved Complete Response to ABT-751
NCT00439296 (3) [back to overview]	Number of Patients With Occurrence of Toxic Death
NCT00439296 (3) [back to overview]	Number of Patients That Experienced Dose Limiting Toxicity From ABT-751
NCT00439556 (2) [back to overview]	Number of Participants With Dose Limiting Toxicity (DLT)
NCT00439556 (2) [back to overview]	Disease-free Survival
NCT00450801 (4) [back to overview]	Number of Patients Experiencing Adverse Events.
NCT00450801 (4) [back to overview]	Response Rate
NCT00450801 (4) [back to overview]	Overall Survival Rate
NCT00450801 (4) [back to overview]	Progression-free Survival Rate
NCT00452374 (2) [back to overview]	Number of Participants With a Complete Response or Partial Response
NCT00452374 (2) [back to overview]	Maximum Tolerated Dose (MTD) Oxaliplatin
NCT00469859 (2) [back to overview]	>80% Inhibition of FLT3 Phosphorylation in a Majority of Post-treatment Trough Time Points
NCT00469859 (2) [back to overview]	Dose-limiting Toxicity
NCT00470275 (1) [back to overview]	Response
NCT00472056 (1) [back to overview]	Disease-free Survival (DFS)
NCT00472849 (2) [back to overview]	Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days or Dose Level 3: 4 Days)
NCT00472849 (2) [back to overview]	Overall Response: Number of Participants With Complete Remission, Nodular Partial Remission, and Partial Remission
NCT00477412 (4) [back to overview]	Time to Failure (Phase II)
NCT00477412 (4) [back to overview]	Overall Survival
NCT00477412 (4) [back to overview]	Number of Participants With Overall Response Rate
NCT00477412 (4) [back to overview]	Maximum Tolerated Dose of Bortezomib (Phase I)
NCT00480987 (1) [back to overview]	Number of Participants With Objective Response
NCT00505921 (1) [back to overview]	Participant Progression Free Survival at 2 Years
NCT00512252 (10) [back to overview]	Relapse-free Survival
NCT00512252 (10) [back to overview]	Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML
NCT00512252 (10) [back to overview]	Overall Survival
NCT00512252 (10) [back to overview]	Treatment Failure
NCT00512252 (10) [back to overview]	Safety and Tolerability of AMD3100 + MEC.
NCT00512252 (10) [back to overview]	Phase II Only: Complete Response Rate of AMD3100 + MEC
NCT00512252 (10) [back to overview]	Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of Total Leukocytes (Phase I)
NCT00512252 (10) [back to overview]	Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of AML Blasts (Phase I)
NCT00512252 (10) [back to overview]	Time to Platelet Recovery
NCT00512252 (10) [back to overview]	Time to Neutrophil Recovery
NCT00513305 (6) [back to overview]	Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate
NCT00513305 (6) [back to overview]	Number of Participants Who Experienced Early Death
NCT00513305 (6) [back to overview]	Number of Participants Who Died or Were Censored by 24 Months
NCT00513305 (6) [back to overview]	Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate
NCT00513305 (6) [back to overview]	Number of Participants Who Experienced Induction (Thirty-Day) Mortality
NCT00513305 (6) [back to overview]	Percentage of Participants in Complete Remission (CR)
NCT00520130 (17) [back to overview]	Immune Reconstitution of Normal Killer (NK) Cells
NCT00520130 (17) [back to overview]	Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations
NCT00520130 (17) [back to overview]	Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations
NCT00520130 (17) [back to overview]	Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire
NCT00520130 (17) [back to overview]	Changes in CD8 T Cell Receptor Vbeta Repertoire
NCT00520130 (17) [back to overview]	Toxicities
NCT00520130 (17) [back to overview]	Percentage of Participants With Late Treatment Related Mortality
NCT00520130 (17) [back to overview]	Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)
NCT00520130 (17) [back to overview]	Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)
NCT00520130 (17) [back to overview]	Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells
NCT00520130 (17) [back to overview]	Overall Survival
NCT00520130 (17) [back to overview]	Early Treatment Related Mortality
NCT00520130 (17) [back to overview]	Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT00520130 (17) [back to overview]	Days to Engraftment of Lymphocytes
NCT00520130 (17) [back to overview]	Days to Engraftment of Platelets
NCT00520130 (17) [back to overview]	Days to Engraftment of Neutrophils
NCT00520130 (17) [back to overview]	Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells
NCT00521014 (1) [back to overview]	Progression-free Survival Rate
NCT00534469 (2) [back to overview]	Disease-Free Survival at 2-Year Post-Transplant by Cytogenetic Risk
NCT00534469 (2) [back to overview]	Disease-Free Survival at 2-Year Post-Transplant
NCT00541866 (5) [back to overview]	Remission Rates (CR+CRp)
NCT00541866 (5) [back to overview]	All Cause Mortality
NCT00541866 (5) [back to overview]	Leukemia-free Survival (LFS)
NCT00541866 (5) [back to overview]	Incidence of Dose-Limiting Toxicity (DLT) to Determine Maximum Tolerated Dose in Schedule A and Schedule B of Dose Escalation Phase (Group 1 and Group 2)
NCT00541866 (5) [back to overview]	Overall Survival
NCT00542971 (2) [back to overview]	Number of Participants With Complete Response
NCT00542971 (2) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00549848 (6) [back to overview]	Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
NCT00549848 (6) [back to overview]	Probability of Overall Survival
NCT00549848 (6) [back to overview]	Probability of Event-free Survival
NCT00549848 (6) [back to overview]	Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
NCT00549848 (6) [back to overview]	Probability of CNS Relapse
NCT00549848 (6) [back to overview]	Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00558519 (5) [back to overview]	Overall Survival
NCT00558519 (5) [back to overview]	Complete Response Rate
NCT00558519 (5) [back to overview]	Disease-free Survival
NCT00558519 (5) [back to overview]	Event-free Survival
NCT00558519 (5) [back to overview]	Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
NCT00569010 (1) [back to overview]	Number of Participants With Complete Remission
NCT00571493 (3) [back to overview]	Preliminary Estimate of Overall Response Rate (ORR)
NCT00571493 (3) [back to overview]	Maximum Tolerated Dose (MTD) of Bortezomib
NCT00571493 (3) [back to overview]	Progression-free Survival (PFS), and Overall Survival (OS)
NCT00577629 (5) [back to overview]	1 Year Progression-free Survival Rate
NCT00577629 (5) [back to overview]	Disease-free Survival
NCT00577629 (5) [back to overview]	Overall Response
NCT00577629 (5) [back to overview]	Overall Survival
NCT00577629 (5) [back to overview]	Secondary Malignancies
NCT00578461 (1) [back to overview]	Median Percentage of Treg Cells at 1 Year Post Transplant
NCT00578539 (1) [back to overview]	Median Percentage of Treg Cells at 1 Year Post Transplant
NCT00591630 (1) [back to overview]	Number of Participants With a 2-Year Progression-Free Survival (PFS)
NCT00593645 (8) [back to overview]	Engraftment as Measured by Percent Donor Chimerism
NCT00593645 (8) [back to overview]	Engraftment as Measured by Percent Donor Chimerism
NCT00593645 (8) [back to overview]	Disease-free Survival
NCT00593645 (8) [back to overview]	Median Time to Progression
NCT00593645 (8) [back to overview]	Overall Survival
NCT00593645 (8) [back to overview]	Rate of Acute Graft-versus-host Disease (GVHD)
NCT00593645 (8) [back to overview]	Rate of Chronic Graft-versus-host Disease (GVHD)
NCT00593645 (8) [back to overview]	Engraftment as Measured by Percent Donor Chimerism
NCT00594815 (2) [back to overview]	Total Number of Participants Who Experienced Acute Treatment Related Adverse Events
NCT00594815 (2) [back to overview]	Progression Free Survival
NCT00602225 (9) [back to overview]	Disease-free Survival
NCT00602225 (9) [back to overview]	Overall Survival
NCT00602225 (9) [back to overview]	Response Rates by Cytogenetic Risk Category
NCT00602225 (9) [back to overview]	Response Rates by Cytogenetic Risk Category and Clofarabine Dose
NCT00602225 (9) [back to overview]	Response Rates by Duration First Complete Remission (CR1)
NCT00602225 (9) [back to overview]	Response Rates by Salvage Number
NCT00602225 (9) [back to overview]	Maximum Tolerated Dose of Clofarabine
NCT00602225 (9) [back to overview]	Efficacy
NCT00602225 (9) [back to overview]	Dose-limiting Toxicity as Assessed by NCI CTCAE v3.0
NCT00609739 (4) [back to overview]	Disease-free Survival
NCT00609739 (4) [back to overview]	Patients With Graft-Versus-Host-Disease
NCT00609739 (4) [back to overview]	Patients Who Relapsed
NCT00609739 (4) [back to overview]	Patients With Regimen-Related Toxicity
NCT00620321 (6) [back to overview]	Percentage of Participants With Response to LY2181308 Sodium in Combination With Idarubicin and Cytarabine (Remission Rates)
NCT00620321 (6) [back to overview]	Change From Baseline in Survivin Index at Day 2
NCT00620321 (6) [back to overview]	Area Under the Curve of LY2181308 Over the Dosing Interval
NCT00620321 (6) [back to overview]	Pharmacodynamics: Number of Participants With Survivin Protein Expression
NCT00620321 (6) [back to overview]	Number of Participants Who Died Due to Progressive Disease or Unknown Cause During the 21 Days Post Study Treatment Follow-Up
NCT00620321 (6) [back to overview]	Number of Participants With Adverse Events (Safety Profile)
NCT00632749 (21) [back to overview]	AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State
NCT00632749 (21) [back to overview]	AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
NCT00632749 (21) [back to overview]	AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
NCT00632749 (21) [back to overview]	AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
NCT00632749 (21) [back to overview]	Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
NCT00632749 (21) [back to overview]	Response (Complete Remission [CR], Complete Remission With Incomplete Blood Count Recovery [CRi])
NCT00632749 (21) [back to overview]	Cmax (Maximum Measured Concentration of BI 811283 in Plasma)
NCT00632749 (21) [back to overview]	Incidence and Intensity of AEs Graded According to CTCAE (Version 3.0)
NCT00632749 (21) [back to overview]	Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)
NCT00632749 (21) [back to overview]	Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)
NCT00632749 (21) [back to overview]	The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.
NCT00632749 (21) [back to overview]	Remission Duration
NCT00632749 (21) [back to overview]	Relapse Free Survival
NCT00632749 (21) [back to overview]	Incidence of Dose Limiting Toxicity (DLT)
NCT00632749 (21) [back to overview]	Overall Survival (OS)
NCT00632749 (21) [back to overview]	Event Free Survival (EFS)
NCT00632749 (21) [back to overview]	Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
NCT00632749 (21) [back to overview]	Cmax (Maximum Measured Concentration of Cytarabine in Plasma)
NCT00632749 (21) [back to overview]	Partial Remission
NCT00632749 (21) [back to overview]	AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
NCT00632749 (21) [back to overview]	AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State
NCT00632827 (4) [back to overview]	Overall Survival Rate
NCT00632827 (4) [back to overview]	Median Time to Response
NCT00632827 (4) [back to overview]	Complete Response Rate
NCT00632827 (4) [back to overview]	Progression Free Survival
NCT00634244 (2) [back to overview]	The Rate of Treatment Failure
NCT00634244 (2) [back to overview]	The Rate of Complete Remission (CR+CRi)
NCT00651261 (5) [back to overview]	Complete Response Rate
NCT00651261 (5) [back to overview]	Overall Survival (OS)
NCT00651261 (5) [back to overview]	Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant
NCT00651261 (5) [back to overview]	Event- Free Survival
NCT00651261 (5) [back to overview]	Disease-free Survival (DFS)
NCT00656617 (2) [back to overview]	Progression Free Survival (PFS) at 7 Months
NCT00656617 (2) [back to overview]	Participant Response
NCT00666588 (5) [back to overview]	Proteasome Inhibition Activity
NCT00666588 (5) [back to overview]	NF-kB Activity by Enzyme-linked Immunosorbent Assay (ELISA)
NCT00666588 (5) [back to overview]	Feasibility of Stem Cell Quantitation: Percentage of Leukemia Initiation Cells (LIC) Depletion
NCT00666588 (5) [back to overview]	Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp]) During Course 1
NCT00666588 (5) [back to overview]	Dose Limiting Toxicity
NCT00669877 (2) [back to overview]	Overall Response Rate: Percentage of Participants With Complete Remission (CR) or Partial Remission (PR)
NCT00669877 (2) [back to overview]	Complete Remission Rate: Percentage of Participants With Complete Remission (CR)
NCT00671034 (9) [back to overview]	Plasma and CSF Concentrations of Asparagine in ug/ml
NCT00671034 (9) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction
NCT00671034 (9) [back to overview]	Immunogenicity
NCT00671034 (9) [back to overview]	Percentage of Participants With Complete Remission at the End of Induction
NCT00671034 (9) [back to overview]	Percentage of Participants With Event-free Survival (EFS)
NCT00671034 (9) [back to overview]	Asparaginase Level
NCT00671034 (9) [back to overview]	Pharmacodynamics (PD)
NCT00671034 (9) [back to overview]	Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)
NCT00671034 (9) [back to overview]	Toxicities During Post Induction Intensification Therapy (All Grades)
NCT00671658 (1) [back to overview]	Number of Participants With a Response
NCT00691015 (8) [back to overview]	Incidence of Infections, Including Bacterial, Fungal, and Viral Infections (i.e., CMV and EBV Reactivation, Including Post-transplant Lymphoproliferative Disorders)
NCT00691015 (8) [back to overview]	Severity of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.
NCT00691015 (8) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Incidence of Chronic GVHD.
NCT00691015 (8) [back to overview]	Karnofsky Performance Status Performance Status
NCT00691015 (8) [back to overview]	Overall Survival.
NCT00691015 (8) [back to overview]	Time to Engraftment (i.e., Absolute Neutrophil Recovery [ANC > 500/mm³] )
NCT00695409 (8) [back to overview]	2-Year Cumulative Incidence of Progression
NCT00695409 (8) [back to overview]	2-Year Overall Survival
NCT00695409 (8) [back to overview]	Time to Neutrophil Recovery
NCT00695409 (8) [back to overview]	2-Year Progression-Free Survival
NCT00695409 (8) [back to overview]	Number of Patients With Active Disease at ASCT Achieving CR/PR by Day 100 After ASCT
NCT00695409 (8) [back to overview]	Number of Patients With RIT/ZBEAM Developing Therapy Induced MDS and AML
NCT00695409 (8) [back to overview]	Time to Platelet Recovery
NCT00695409 (8) [back to overview]	100-Day Treatment-Related Mortality
NCT00703820 (2) [back to overview]	Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.
NCT00703820 (2) [back to overview]	Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00732498 (4) [back to overview]	Progression-free Survival at 1 Year
NCT00732498 (4) [back to overview]	Overall Response Rate
NCT00732498 (4) [back to overview]	Median Time to Progression
NCT00732498 (4) [back to overview]	Complete Response Rate
NCT00742625 (4) [back to overview]	Remission Induction Response
NCT00742625 (4) [back to overview]	Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine
NCT00742625 (4) [back to overview]	Overall Survival
NCT00742625 (4) [back to overview]	Disease-free Survival
NCT00774046 (7) [back to overview]	Overall Survival
NCT00774046 (7) [back to overview]	Overall Survival in Patients Undergoing Autologous Stem Cell Transplant
NCT00774046 (7) [back to overview]	Relapse-free Survival
NCT00774046 (7) [back to overview]	Numbers of Stem Cells Collected
NCT00774046 (7) [back to overview]	Feasibility of Stem Cell Collection
NCT00774046 (7) [back to overview]	Disease-free Survival in Patients Undergoing Autologous Stem Cell Transplant
NCT00774046 (7) [back to overview]	Response to Induction Chemotherapy (CR or PR)
NCT00778375 (6) [back to overview]	Overall Response Rate (CR, CRp/CRi and PR)
NCT00778375 (6) [back to overview]	Complete Remission (CR) Rate for First 60 Participants
NCT00778375 (6) [back to overview]	Disease-free (DFS) or Relapse-free Survival (RFS) Time
NCT00778375 (6) [back to overview]	Event Free Survival (EFS)
NCT00778375 (6) [back to overview]	Median Overall Survival (OS)
NCT00778375 (6) [back to overview]	Number of Participants With Complete Remission [Complete Response (CR), Complete Response With Platelet Recover (CRp) or Complete Response With Incomplete Marrow Recovery (CRi)]
NCT00780143 (1) [back to overview]	Dose Limiting Toxicity
NCT00788892 (6) [back to overview]	Overall Survival Rate at 1 Year
NCT00788892 (6) [back to overview]	Remission Duration/Time to Remission
NCT00788892 (6) [back to overview]	Rate of Stem Cell Transplant
NCT00788892 (6) [back to overview]	Number of Participants With Complete Remission
NCT00788892 (6) [back to overview]	Event Free Survival
NCT00788892 (6) [back to overview]	Aplasia Rate
NCT00792948 (3) [back to overview]	Continuous Complete Remission (CCR) Rate
NCT00792948 (3) [back to overview]	Overall Survival (OS)
NCT00792948 (3) [back to overview]	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00795002 (3) [back to overview]	Disease-free Survival
NCT00795002 (3) [back to overview]	Number of Participants Experiencing Death From Any Cause Within 60 Days of Starting FLAM
NCT00795002 (3) [back to overview]	Complete Response
NCT00804856 (22) [back to overview]	Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals
NCT00804856 (22) [back to overview]	Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib
NCT00804856 (22) [back to overview]	Best Overall Response
NCT00804856 (22) [back to overview]	Phase II: Time to Remission
NCT00804856 (22) [back to overview]	Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
NCT00804856 (22) [back to overview]	Phase II: Remission Duration
NCT00804856 (22) [back to overview]	Phase II: Relapse - Free Survival
NCT00804856 (22) [back to overview]	Phase II: Overall Survival
NCT00804856 (22) [back to overview]	Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)
NCT00804856 (22) [back to overview]	Phase II: Event Free Survival
NCT00804856 (22) [back to overview]	Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))
NCT00804856 (22) [back to overview]	QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1
NCT00804856 (22) [back to overview]	Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
NCT00804856 (22) [back to overview]	Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
NCT00804856 (22) [back to overview]	Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
NCT00804856 (22) [back to overview]	Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
NCT00804856 (22) [back to overview]	Apparent Volume of Distribution of Volasertib at Steady State (VSS)
NCT00804856 (22) [back to overview]	Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours
NCT00804856 (22) [back to overview]	Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)
NCT00804856 (22) [back to overview]	Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment
NCT00804856 (22) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)
NCT00804856 (22) [back to overview]	Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
NCT00831766 (5) [back to overview]	Phase II: Complete Response Rate of Participants Treated at Maximum Tolerated Dose (MTD)
NCT00831766 (5) [back to overview]	Median Overall Survival (OS)
NCT00831766 (5) [back to overview]	Rate of Lenalidomide Related Toxicity During Maintenance Therapy
NCT00831766 (5) [back to overview]	Phase I: Recommended Phase II Dose
NCT00831766 (5) [back to overview]	Median Progression-Free Survival (PFS)
NCT00839982 (4) [back to overview]	Disease Free Survival
NCT00839982 (4) [back to overview]	Maximum Tolerated Dose
NCT00839982 (4) [back to overview]	Number of Patients With Dose Limiting Toxicity
NCT00839982 (4) [back to overview]	Overall Survival
NCT00840177 (4) [back to overview]	Overall Survival (OS)
NCT00840177 (4) [back to overview]	Relapse-free Survival (RFS)
NCT00840177 (4) [back to overview]	Complete Remission (CR) Rate (Including CR With Incomplete Recovery)
NCT00840177 (4) [back to overview]	Frequency and Severity of Toxicity as Assessed by NCI CTCAE Version 3.0
NCT00844298 (1) [back to overview]	Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy
NCT00863434 (3) [back to overview]	Disease-free Survival
NCT00863434 (3) [back to overview]	Minimal Residual Disease as Assessed by Bone Marrow Flow Cytometry
NCT00863434 (3) [back to overview]	Overall Survival
NCT00866307 (2) [back to overview]	AALL08P1 Feasibility Outcome
NCT00866307 (2) [back to overview]	AALL08P1 Safety Outcome
NCT00866749 (4) [back to overview]	Participants Achieving Negative Minimal Residual Disease (MRD)
NCT00866749 (4) [back to overview]	3-Year Event-Free Survival (EFS)
NCT00866749 (4) [back to overview]	Overall Survival
NCT00866749 (4) [back to overview]	Participants With a Complete Response (CR)
NCT00866918 (4) [back to overview]	Overall Survival (OS)
NCT00866918 (4) [back to overview]	Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00866918 (4) [back to overview]	Hematologic Remission Rate
NCT00866918 (4) [back to overview]	Event-free Survival (EFS)
NCT00873093 (7) [back to overview]	Severe Adverse Events (SAE) Rate.
NCT00873093 (7) [back to overview]	Toxic Death Rate
NCT00873093 (7) [back to overview]	Event Free Survival
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2
NCT00873093 (7) [back to overview]	Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00873093 (7) [back to overview]	Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy
NCT00882206 (4) [back to overview]	Response to Treatment
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00882206 (4) [back to overview]	Level of Methylation
NCT00906945 (13) [back to overview]	Phase I and Phase II: Safety and Tolerability of Regimen as Measured by Grade and Frequency of Adverse Events Exceeding 10% in Total Frequency
NCT00906945 (13) [back to overview]	Phase II: Complete Response Rate (CR+CRi)
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Neutrophil Recovery
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Neutrophil Recovery
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Platelet Recovery
NCT00906945 (13) [back to overview]	Relapse Free-survival Rate
NCT00906945 (13) [back to overview]	Characterize the Effects of Plerixafor Plus G-CSF on Fold Change in CXCR4 Clone 12G5 Relative Mean Fluorescent Intensity
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Platelet Recovery
NCT00906945 (13) [back to overview]	Characterize the Effects of Plerixafor Plus G-CSF on Fold Change in CXCR4 Clone 1D9 Relative Mean Fluorescent Intensity
NCT00906945 (13) [back to overview]	Characterize the Mobilization of Leukemic Cells With Plerixafor Plus G-CSF as Measured by Fold Change in AML Blast Count
NCT00906945 (13) [back to overview]	Characterize the Mobilization of Leukemic Cells With Plerixafor Plus G-CSF as Measured by Fold Change in White Blood Cells
NCT00906945 (13) [back to overview]	Overall Survival
NCT00906945 (13) [back to overview]	Phase I: Maximum Tolerated Dose of Plerixafor Plus G-CSF When Combined With MEC
NCT00907517 (3) [back to overview]	Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
NCT00907517 (3) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an AE
NCT00907517 (3) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT00928200 (1) [back to overview]	Occurrence of a Dose-Limiting Toxicity
NCT00939653 (2) [back to overview]	Achievement of Complete Remission (CR) at Reinduction
NCT00939653 (2) [back to overview]	Death
NCT00945815 (2) [back to overview]	Complete Remission
NCT00945815 (2) [back to overview]	Number of Patients With Grade 3 Through 5 Treatment-Related Adverse Events
NCT00955916 (3) [back to overview]	Median Progression Free Survival (PFS)
NCT00955916 (3) [back to overview]	Overall Response Rate (ORR)
NCT00955916 (3) [back to overview]	Median Overall Survival (OS)
NCT00964743 (1) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00968253 (3) [back to overview]	Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)
NCT00968253 (3) [back to overview]	Overall Response Rate (OR) Where OR = CR + CRp + CRi
NCT00968253 (3) [back to overview]	Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)
NCT00973752 (1) [back to overview]	Overall Survival at One Year
NCT00992446 (4) [back to overview]	Median Time to Disease Progression
NCT00992446 (4) [back to overview]	Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant
NCT00992446 (4) [back to overview]	Event-free Survival
NCT00992446 (4) [back to overview]	Overall Survival
NCT00992602 (2) [back to overview]	Survival Free of Neurological Progression, Measured in Weeks
NCT00992602 (2) [back to overview]	Overall Survival
NCT01008462 (7) [back to overview]	Number of Patients Who Had Infections
NCT01008462 (7) [back to overview]	Number of Patients Who Engrafted
NCT01008462 (7) [back to overview]	Event-Free Survival (EFS)
NCT01008462 (7) [back to overview]	Overall Survival
NCT01008462 (7) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease
NCT01008462 (7) [back to overview]	Non-relapse Mortality (NRM)
NCT01008462 (7) [back to overview]	Number of Patients With Relapsed/Progressive Disease
NCT01019317 (1) [back to overview]	Participants With a Complete Response
NCT01025154 (2) [back to overview]	Median Event-Free Survival (EFS)
NCT01025154 (2) [back to overview]	Overall Response: Number of Participants With Complete Remission or Complete Remission Without Platelet Recovery
NCT01035463 (3) [back to overview]	Overall Survival
NCT01035463 (3) [back to overview]	Maximum Tolerated Dose of Lenalidomide (Phase I)
NCT01035463 (3) [back to overview]	Event-free Survival
NCT01056523 (5) [back to overview]	Overall Response Rate
NCT01056523 (5) [back to overview]	Blast Response
NCT01056523 (5) [back to overview]	Complete Response Rate
NCT01056523 (5) [back to overview]	Partial Response
NCT01056523 (5) [back to overview]	Recommended Phase II Dose (RP2D) of Ribavirin When Given in Combination With Low-dose Ara-C
NCT01101880 (5) [back to overview]	Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts
NCT01101880 (5) [back to overview]	Overall Survival
NCT01101880 (5) [back to overview]	Time to Progression
NCT01101880 (5) [back to overview]	Event Free Survival
NCT01101880 (5) [back to overview]	Duration of Remission
NCT01141712 (12) [back to overview]	Relapse/Progression
NCT01141712 (12) [back to overview]	Treatment-Related Mortality (TRM)
NCT01141712 (12) [back to overview]	Overall Survival (OS)
NCT01141712 (12) [back to overview]	Hematologic Function
NCT01141712 (12) [back to overview]	HIV Single-Copy Polymerase Chain Reaction (PCR)
NCT01141712 (12) [back to overview]	Immunologic Reconstitution
NCT01141712 (12) [back to overview]	Complete Remission (CR) and/or Partial Response (PR)
NCT01141712 (12) [back to overview]	Cumulative Incidence of Neutrophil Recovery
NCT01141712 (12) [back to overview]	Cumulative Incidence of Platelet Recovery
NCT01141712 (12) [back to overview]	Number of Participants Experiencing Infections
NCT01141712 (12) [back to overview]	Number of Participants Experiencing Toxicity
NCT01141712 (12) [back to overview]	Progression-Free Survival (PFS)
NCT01158885 (1) [back to overview]	Number of Patients With Dose-Limiting Toxicity (DLT)
NCT01184898 (4) [back to overview]	Complete Response in the Absence of Platelet Recovery
NCT01184898 (4) [back to overview]	Complete Response
NCT01184898 (4) [back to overview]	Partial Response
NCT01184898 (4) [back to overview]	Association Between the Magnitude of mTOR Target Inhibition Post-treatment in Leukemic Blasts and Clinical Response in Patients With High Risk AML Treated With Sirolimus MEC
NCT01190930 (41) [back to overview]	DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
NCT01190930 (41) [back to overview]	Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
NCT01190930 (41) [back to overview]	Event Free Survival (EFS) for B-LLy Patients
NCT01190930 (41) [back to overview]	Overall Survival (OS) for B-LLy Patients
NCT01190930 (41) [back to overview]	Sample Collection of Central Path Review Slides in B-LLy Patients
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]	DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
NCT01190930 (41) [back to overview]	DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
NCT01190930 (41) [back to overview]	Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
NCT01190930 (41) [back to overview]	Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
NCT01191801 (7) [back to overview]	Overall Survival
NCT01191801 (7) [back to overview]	All Cause Mortality
NCT01191801 (7) [back to overview]	Overall Remission (OR) Rate Based on the IWG Response Criteria
NCT01191801 (7) [back to overview]	Leukemia-Free Survival (LFS)
NCT01191801 (7) [back to overview]	Event Free Survival (EFS)
NCT01191801 (7) [back to overview]	Complete Remission (CR) Rate Based on Modified International Working Group (IWG) Criteria.
NCT01191801 (7) [back to overview]	All Cause Mortality
NCT01238211 (7) [back to overview]	Overall Survival
NCT01238211 (7) [back to overview]	Disease-free Survival
NCT01238211 (7) [back to overview]	Cumulative Incidence of Relapse
NCT01238211 (7) [back to overview]	Complete Response Rate
NCT01238211 (7) [back to overview]	30 Day Survival Rate
NCT01238211 (7) [back to overview]	Cumulative Incidence of Death
NCT01238211 (7) [back to overview]	Event-free Survival
NCT01253070 (3) [back to overview]	Overall Survival (OS) Rate
NCT01253070 (3) [back to overview]	Event-free Survival
NCT01253070 (3) [back to overview]	OS
NCT01256398 (6) [back to overview]	Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]	Disease Free Survival (DFS)
NCT01256398 (6) [back to overview]	Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]	Overall Survival (OS)
NCT01256398 (6) [back to overview]	Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]	Response
NCT01272245 (5) [back to overview]	Percentage of Participants With Complete Remission (CR)
NCT01272245 (5) [back to overview]	Overall Survival
NCT01272245 (5) [back to overview]	Induction Mortality
NCT01272245 (5) [back to overview]	Evaluation of CR Duration
NCT01272245 (5) [back to overview]	Disease-free Survival
NCT01289457 (4) [back to overview]	Event-Free Survival (EFS) at 2 Years
NCT01289457 (4) [back to overview]	Response Rates of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI)
NCT01289457 (4) [back to overview]	Overall Survival
NCT01289457 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine, Idarubicin, and Cytarabine
NCT01294449 (1) [back to overview]	All-Cause Mortality
NCT01319981 (3) [back to overview]	Overall Survival
NCT01319981 (3) [back to overview]	Complete Response Duration
NCT01319981 (3) [back to overview]	Number of Patients With Complete Remission at One Year
NCT01349972 (6) [back to overview]	Complete Response Rate
NCT01349972 (6) [back to overview]	Overall Survival
NCT01349972 (6) [back to overview]	Number of Patients With Minimal Residual Disease
NCT01349972 (6) [back to overview]	Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade
NCT01349972 (6) [back to overview]	Progression-free Survival
NCT01349972 (6) [back to overview]	Disease-free Survival
NCT01363128 (3) [back to overview]	Number of Participants With Complete Remission (CR)
NCT01363128 (3) [back to overview]	4-Year Overall Survival
NCT01363128 (3) [back to overview]	4-year Event Free Survival
NCT01371981 (18) [back to overview]	Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II
NCT01371981 (18) [back to overview]	Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Cancer Module
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Sorafenib Steady State Concentration
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	Change in Shortening Fraction
NCT01371981 (18) [back to overview]	Change in Ejection Fraction
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	Bortezomib Clearance
NCT01371981 (18) [back to overview]	Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module
NCT01399372 (5) [back to overview]	Percentage of Participants With Neurocognitive Failure
NCT01399372 (5) [back to overview]	Overall Survival
NCT01399372 (5) [back to overview]	Percentage of Participants Experiencing Partial Response or Complete Response
NCT01399372 (5) [back to overview]	Progression-free Survival
NCT01399372 (5) [back to overview]	Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
NCT01412879 (4) [back to overview]	5-year Overall Survival (OS)
NCT01412879 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01412879 (4) [back to overview]	Progression-Free Survival (PFS) at 2 Years
NCT01412879 (4) [back to overview]	Response Rate (Complete and Partial Response)
NCT01444742 (2) [back to overview]	Overall Survival (OS)
NCT01444742 (2) [back to overview]	Number of Participants With Complete Response (CR)
NCT01451515 (4) [back to overview]	Probability of Overall Survival (OS)
NCT01451515 (4) [back to overview]	Minimal Residual Disease (MRD)
NCT01451515 (4) [back to overview]	Minimal Disseminated Disease (MDD)
NCT01451515 (4) [back to overview]	Probability of Event-free Survival (EFS)
NCT01527149 (9) [back to overview]	Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM
NCT01527149 (9) [back to overview]	Time-to-tumor Progression (TTP) at 3 Years
NCT01527149 (9) [back to overview]	Median Progression-free Survival (PFS)
NCT01527149 (9) [back to overview]	Number of Participants With at Least One Serious Adverse Event
NCT01527149 (9) [back to overview]	Percentage of Participants With Autologous Stem Cell Transplantation
NCT01527149 (9) [back to overview]	Proportion of Patients Experiencing a Complete Response
NCT01527149 (9) [back to overview]	Median of Serum Complement CD20 Levels
NCT01527149 (9) [back to overview]	Change From Baseline in Percentage of Cells Positive for Ki67
NCT01527149 (9) [back to overview]	Median Overall Survival (OS)
NCT01538472 (2) [back to overview]	Overall Survival Median
NCT01538472 (2) [back to overview]	3-Year Overall Survival
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Infinity (AUCinf) of LDAC in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	AUCinf of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	AUCtau of Cytarabine and Ara-U in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCtau of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Cmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Cmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (AEs) at Phase 1B (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 1B (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Time to Cmax (Tmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Tmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B
NCT01546038 (70) [back to overview]	Tmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Tmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Baseline
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 1B
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Lead-In
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	Pre-dose Plasma Concentration (Ctrough) of Glasdegib in Phase 2 Fit on Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01555541 (9) [back to overview]	Number of Patients Achieving Mobilization-adjusted Complete Response (maCR)
NCT01555541 (9) [back to overview]	Number of Participants With Successful Platelet Engraftments
NCT01555541 (9) [back to overview]	Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization
NCT01555541 (9) [back to overview]	Overall Survival Rate (OS)
NCT01555541 (9) [back to overview]	Number of Patients Who Advance From Partial Response (PR) to Complete (CR)
NCT01555541 (9) [back to overview]	Number of Patients Who Received OVA and Then Met Criteria to Proceed to ASCT and Achieved a CR/Partial Response (PR) Post-ASCT
NCT01555541 (9) [back to overview]	Median Time to Progression
NCT01555541 (9) [back to overview]	Number of Participants With Successful Neutrophil Engraftments
NCT01555541 (9) [back to overview]	Progression Free Survival Rate
NCT01564784 (12) [back to overview]	Overall Survival (OS)
NCT01564784 (12) [back to overview]	Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) Score
NCT01564784 (12) [back to overview]	Percentage of Participants Achieving MRD Negativity (Based on Central Laboratory Analysis) in Participants Achieving a CR/CRi (Per EAC Assessment)
NCT01564784 (12) [back to overview]	Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)
NCT01564784 (12) [back to overview]	Change From Baseline in EQ-5D VAS
NCT01564784 (12) [back to overview]	Progression-Free Survival (PFS)
NCT01564784 (12) [back to overview]	Percentage of Participants With Veno-Occlusive Liver Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS) Following Post Study HSCT
NCT01564784 (12) [back to overview]	Maximum Observed Inotuzumab Ozogamicin Serum Concentration (Cmax) and Pre-Dose Inotuzumab Ozogamicin Serum Concentration (Ctrough) Following Single and Multiple Dosing
NCT01564784 (12) [back to overview]	Percentage of Participants Who Had a Hematopoietic Stem-Cell Transplant (HSCT)
NCT01564784 (12) [back to overview]	Change From Baseline in EuroQol 5 Dimension Health Questionnaire (EQ-5D) Index Score
NCT01564784 (12) [back to overview]	Cytogenetic Status (Based on Local Laboratory Analysis) of Participants With CR/CRi (Per EAC Assessment)
NCT01564784 (12) [back to overview]	Duration of Remission (DoR) for Participants Who Achieved CR/CRi (Per Investigator Assessment)
NCT01588951 (1) [back to overview]	Relapse Free Survival
NCT01607645 (13) [back to overview]	Number of Participants Who Achieved Morphologic CR
NCT01607645 (13) [back to overview]	Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction
NCT01607645 (13) [back to overview]	CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000
NCT01607645 (13) [back to overview]	Duration of Moderate Neutropenia Defined as an ANC Less Than 1000
NCT01607645 (13) [back to overview]	Severe Prolonged Aplasia
NCT01607645 (13) [back to overview]	Duration of Severe Neutropenia Defined as an ANC Less Than 500
NCT01607645 (13) [back to overview]	TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine
NCT01607645 (13) [back to overview]	Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0
NCT01607645 (13) [back to overview]	CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL
NCT01607645 (13) [back to overview]	Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM
NCT01607645 (13) [back to overview]	CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01614197 (1) [back to overview]	Minimum Residual Disease (MRD) Levels Present at End of Cycle 1 Therapy in Patients
NCT01621477 (7) [back to overview]	Incidence and Severity of Acute Graft Versus Host Disease (GVHD)
NCT01621477 (7) [back to overview]	One-year Survival (OS)
NCT01621477 (7) [back to overview]	Incidence and Severity of Chronic Graft Versus Host Disease (GVHD)
NCT01621477 (7) [back to overview]	Number of Participants With Transplant Related Mortality (TRM)
NCT01621477 (7) [back to overview]	Event-Free Survival (EFS)
NCT01621477 (7) [back to overview]	Disease-Free Survival (DFS)
NCT01621477 (7) [back to overview]	Incidence of Malignant Relapse
NCT01653418 (9) [back to overview]	Time to Platelet Engraftment After V-BEAM.
NCT01653418 (9) [back to overview]	Overall Response Rate (ORR)
NCT01653418 (9) [back to overview]	Number of Participants With Progression-free Survival (PFS)
NCT01653418 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT01653418 (9) [back to overview]	Very Good Partial Response Rate (VGPR+nCR+sCR+CR)
NCT01653418 (9) [back to overview]	Time to Neutrophil Engraftment After V-BEAM.
NCT01653418 (9) [back to overview]	Complete Response Rate (Complete Response + Stringent Complete Response)
NCT01653418 (9) [back to overview]	Treatment Related Mortality (TRM) of V-BEAM
NCT01653418 (9) [back to overview]	Toxicity of V-BEAM
NCT01656031 (1) [back to overview]	Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML
NCT01656252 (2) [back to overview]	Phase I - Dose Level With Best Kinetics of Platelet Count Recovery
NCT01656252 (2) [back to overview]	Phase I- Optimal Tolerated Dose of Eltrombopag
NCT01661881 (3) [back to overview]	Complete Remission (CR) Rate After 6 Cycles
NCT01661881 (3) [back to overview]	Autologous Stem Cell Transplant (ASCT) Rate
NCT01661881 (3) [back to overview]	1 Year Progression-Free Survival
NCT01692197 (4) [back to overview]	Overall Response
NCT01692197 (4) [back to overview]	Duration of Response
NCT01692197 (4) [back to overview]	Overall Survival
NCT01692197 (4) [back to overview]	Disease-free Survival
NCT01696084 (6) [back to overview]	Proportion of Subjects With a Response
NCT01696084 (6) [back to overview]	Rate of Achieving Morphologic Leukemia-free State
NCT01696084 (6) [back to overview]	Remission Duration
NCT01696084 (6) [back to overview]	Event-free Survival
NCT01696084 (6) [back to overview]	Overall Survival
NCT01696084 (6) [back to overview]	Proportion of Subjects Receiving a Stem Cell Transplant
NCT01700946 (4) [back to overview]	Median CD20 Expression Levels
NCT01700946 (4) [back to overview]	3-year Event-free Survival Rates in Patients With Relapsed ALL
NCT01700946 (4) [back to overview]	Mean of CD20 Expression Levels
NCT01700946 (4) [back to overview]	3-year Overall Survival Rate of Patients With Relapsed ALL
NCT01702961 (3) [back to overview]	Median Days to Neutrophil Engraftment
NCT01702961 (3) [back to overview]	Disease-free Survival
NCT01702961 (3) [back to overview]	Number of Participants With Overall Best Response Achieved After Transplantation
NCT01721876 (4) [back to overview]	Event-free Survival (EFS)
NCT01721876 (4) [back to overview]	Objective Response (OR)
NCT01721876 (4) [back to overview]	Overall Survival (OS)
NCT01721876 (4) [back to overview]	Relapse-free Survival (RFS)
NCT01729845 (4) [back to overview]	Duration of Relapse-free Survival (for Patients Achieving CR or CRp)
NCT01729845 (4) [back to overview]	Most Efficacious and Tolerated Dosage of Decitabine (Period 1)
NCT01729845 (4) [back to overview]	Remission Rate Including CR and CRp
NCT01729845 (4) [back to overview]	Overall Survival
NCT01769209 (7) [back to overview]	Complete Response (CR)
NCT01769209 (7) [back to overview]	Complete Response Without Platelet Recovery (CRp)
NCT01769209 (7) [back to overview]	Related Adverse Events (Grade 3, 4, 5)
NCT01769209 (7) [back to overview]	Response Rate (RR)
NCT01769209 (7) [back to overview]	Progression-free Survival (PFS)
NCT01769209 (7) [back to overview]	Overall Survival (OS)
NCT01769209 (7) [back to overview]	Failure-free Survival (FFS)
NCT01794702 (4) [back to overview]	Number of Participants With a Response
NCT01794702 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine
NCT01794702 (4) [back to overview]	Overall Survival
NCT01794702 (4) [back to overview]	To Determine the Disease-free Survival (DFS).
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS)
NCT01802333 (10) [back to overview]	Event-free Survival (EFS)
NCT01802333 (10) [back to overview]	Overall Survival (OS)
NCT01802333 (10) [back to overview]	Prevalence of the Mutation NPM1 in Patients on This Study.
NCT01802333 (10) [back to overview]	Rate of Allogeneic HCT
NCT01802333 (10) [back to overview]	Cytogenetic Risk Distribution of Patients on This Study
NCT01802333 (10) [back to overview]	Frequency and Severity of Toxicities
NCT01802333 (10) [back to overview]	EFS of Arm I Compared to Arm II
NCT01802333 (10) [back to overview]	Complete Response (CR) Rate
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS) Among High Risk Patients
NCT01804101 (2) [back to overview]	Overall Remission Rate (CR+CRp)
NCT01804101 (2) [back to overview]	Treatment-related Mortality Rate. (TRM)
NCT01806571 (5) [back to overview]	Overall Survival(OS) Rate
NCT01806571 (5) [back to overview]	Proportion of Complete Responses (CR or CRi) During Induction Therapy
NCT01806571 (5) [back to overview]	Disease Free Survival(DFS) Rate
NCT01806571 (5) [back to overview]	Duration of Complete Response
NCT01806571 (5) [back to overview]	Incidence of Adverse Events as Assessed by NCI CTCAE Version 4.0
NCT01829503 (12) [back to overview]	Numbers of Patients (Out of 44) Experiencing Adverse Events With CTCAE Grade ≥ 3 or Adverse Events Grade ≥ 4
NCT01829503 (12) [back to overview]	Number of Participants by Best Clinical Response Experienced
NCT01829503 (12) [back to overview]	Functional Assessment of Cancer Therapy: Health-related Quality of Life (HRQOL) Measure
NCT01829503 (12) [back to overview]	Demographic Characteristics and Clinical Measures as Potential Predictors of Overall Survival (OS)
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response
NCT01829503 (12) [back to overview]	Overall Survival (OS)
NCT01829503 (12) [back to overview]	Relapse-Free Survival in Participants With Complete Response, Complete Response With Incomplete Count Recovery or Partial Response, and Received Maintenance Therapy
NCT01829503 (12) [back to overview]	Relapse-Free Survival in Participants With Complete Response or Complete Response With Incomplete Count Recovery.
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response, Complete Response With Incomplete Count Recovery, or Partial Response
NCT01829503 (12) [back to overview]	Overall Survival (OS) in Participants Who Experienced Complete Response or Complete Response With Incomplete Count Recovery
NCT01829503 (12) [back to overview]	Proportion of Participants With Survival to Four and Eight Weeks and One Year
NCT01829503 (12) [back to overview]	Proportion of Participants With Clinical Response (CR)
NCT01831232 (6) [back to overview]	Rate of Complete Remission (CR), Remission With Incomplete Blood Count Recovery (CRi) and Partial Remission (PR)
NCT01831232 (6) [back to overview]	Number of Biomarker-positive Participants With Clinical Responses
NCT01831232 (6) [back to overview]	Number of Participants With TRM.
NCT01831232 (6) [back to overview]	Overall Survival
NCT01831232 (6) [back to overview]	Progression Free Survival (PFS)
NCT01831232 (6) [back to overview]	Number of Participants With Good Complete Remission (CR)
NCT01849276 (1) [back to overview]	Evaluate Toxicity by Assessing the Adverse Events of Metformin and Cytarabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Event-Free Survival
NCT01853228 (13) [back to overview]	Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
NCT01853228 (13) [back to overview]	Phase 1 and 2: Overall Survival (OS)
NCT01853228 (13) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine
NCT01853228 (13) [back to overview]	Phase 2: Overall Response Rate
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28
NCT01853228 (13) [back to overview]	Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine
NCT01853228 (13) [back to overview]	Phase 1 and 2: Total Clearance of Decitabine
NCT01853228 (13) [back to overview]	Phase 2: Duration of Response
NCT01853228 (13) [back to overview]	Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment
NCT01861002 (1) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
NCT01870596 (1) [back to overview]	Response Rate(CR/CRi) Rate
NCT01876953 (1) [back to overview]	Maximum Tolerated Dose of Dasatinib (Phase I)
NCT01880437 (4) [back to overview]	Percentage of Participants With CR, CRi, MLFS or PR at Anytime During Study Treatment
NCT01880437 (4) [back to overview]	Percentage of Participants With an Event of Death During the Study
NCT01880437 (4) [back to overview]	Median Overall Survival (OS) Time
NCT01880437 (4) [back to overview]	Duration of Overall Response (DOR)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(24-∞)
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(0-t)
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(24-∞)
NCT01890746 (44) [back to overview]	Incidence of Hemorrhagic Events
NCT01890746 (44) [back to overview]	Incidence of Hemorrhagic Events
NCT01890746 (44) [back to overview]	Number of Participants Who Required Medical Resource Utilization
NCT01890746 (44) [back to overview]	Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters
NCT01890746 (44) [back to overview]	Percentage of Participants With Disease Response Rate and Type of Response
NCT01890746 (44) [back to overview]	Summary of Absolute Neutrophil Counts (ANC)
NCT01890746 (44) [back to overview]	Summary of Hemoglobin
NCT01890746 (44) [back to overview]	Summary of Hemoglobin
NCT01890746 (44) [back to overview]	Summary of Platelet Counts Over Time
NCT01890746 (44) [back to overview]	Summary of Platelet Counts Over Time
NCT01890746 (44) [back to overview]	Worst-case Post Baseline Change in Blood Pressure Values From Baseline
NCT01890746 (44) [back to overview]	Worst-case Post Baseline Change in Temperature Values From Baseline
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(24-t)
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(0-∞)
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(24-t)
NCT01890746 (44) [back to overview]	Maximum Duration (Days) of Platelet Transfusion Independence
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(0-∞)
NCT01890746 (44) [back to overview]	Overall Survival (OS)
NCT01890746 (44) [back to overview]	Summary of Absolute Neutrophil Counts (ANC)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)
NCT01890746 (44) [back to overview]	Number of Participants Who Achieved Platelet Count Recovery by Day 21
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(0-t)
NCT01890746 (44) [back to overview]	Number of Participants With Liver Events.
NCT01890746 (44) [back to overview]	Number of Platelet Transfusions Per Week Within Cycles
NCT01890746 (44) [back to overview]	Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days
NCT01890746 (44) [back to overview]	Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)
NCT01890746 (44) [back to overview]	Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)
NCT01890746 (44) [back to overview]	Time to Neutrophil Engraftment
NCT01890746 (44) [back to overview]	Time to Platelet Count Recovery >=20 Gi/L
NCT01890746 (44) [back to overview]	Time to Platelet Recovery >=100 Gi/L
NCT01890746 (44) [back to overview]	Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).
NCT01890746 (44) [back to overview]	Worst-case Change From Baseline in Pulse Rate Values
NCT01921387 (4) [back to overview]	Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)
NCT01921387 (4) [back to overview]	The Lowest Antibody (Yttrium 90-BC8-DOTA) Dose (mg/kg) That is Consistent With a Favorable Biodistribution Rate >= 80% in Lymphoma Patients
NCT01921387 (4) [back to overview]	Estimated Dose to Tumor Sites Based on the Tumor to Normal Organ Ratios Derived From Dosimetry Estimates Coupled With the Absorbed Dose to Normal Organs Based on the Administered Activity of Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
NCT01921387 (4) [back to overview]	Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA
NCT01960387 (1) [back to overview]	Complete Clinical Response
NCT01969435 (11) [back to overview]	Safety and Toxicity as Measured by Treatment Related Non-hematologic Adverse Events
NCT01969435 (11) [back to overview]	Efficacy as Measured by Response Rates
NCT01969435 (11) [back to overview]	Treatment-related Mortality (TRM)
NCT01969435 (11) [back to overview]	Time to Engraftment (Platelet)
NCT01969435 (11) [back to overview]	Time to Engraftment (Neutrophil)
NCT01969435 (11) [back to overview]	Progression-free Survival Rate (PFS)
NCT01969435 (11) [back to overview]	Relapse Free Survival
NCT01969435 (11) [back to overview]	Disease-free Survival
NCT01969435 (11) [back to overview]	Disease-free Survival
NCT01969435 (11) [back to overview]	Overall Survival (OS) Rate
NCT01969435 (11) [back to overview]	Progression-free Survival (PFS) Rate
NCT01979536 (3) [back to overview]	Occurrence of Grade 3+ Non-hematologic Adverse Events
NCT01979536 (3) [back to overview]	Event Free Survival (EFS)
NCT01979536 (3) [back to overview]	Prognostic Significance of Minimal Residual Disease
NCT02019069 (9) [back to overview]	Participants Experiencing of Serious Adverse Events
NCT02019069 (9) [back to overview]	Serious Adverse Events
NCT02019069 (9) [back to overview]	Response Rate (RR)
NCT02019069 (9) [back to overview]	Duration of Remission (DOR) Following Induction With CPX-351
NCT02019069 (9) [back to overview]	Early Induction Mortality (Day 30 After 1st Induction)
NCT02019069 (9) [back to overview]	Complete Response (CR)
NCT02019069 (9) [back to overview]	Mortality at Day 60 After 1st Induction
NCT02019069 (9) [back to overview]	Overall Survival (OS)
NCT02019069 (9) [back to overview]	Complete Response With Incomplete Count Recovery (CRi)
NCT02029417 (1) [back to overview]	Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
NCT02038777 (68) [back to overview]	Multiple Dose- Steady State Accumulation Ratio (Rss) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort
NCT02038777 (68) [back to overview]	Overall Survival: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants Achieving Disease Modifying Response (DMR): Expansion Cohort
NCT02038777 (68) [back to overview]	Single Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Maximum Observed Plasma Concentration (Cmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Terminal Plasma Half-life (T1/2) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Accumulation Ratio (Rac) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Volume of Distribution (Vz/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose Cmax, Minimum Observed Plasma Concentration (Cmin), Average Observed Plasma Concentration (Cavg), Trough Plasma Concentration (Ctrough) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau and AUCinf of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, and Ctrough of Ara-uridine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Ara-uridine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Percentage of Participants With Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants With CR/CRi and DMR: Combination Cohort 3
NCT02038777 (68) [back to overview]	Single Dose- Area Under the Plasma Concentration Curve: From Time Zero to End of Dosing Interval (AUCtau), From Time Zero to Last Quantifiable Concentration (AUClast) and From Time Zero to Infinity (AUCinf) of PF-04449913 for Monotherapy Cohort
NCT02038777 (68) [back to overview]	Time to Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Time to Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02044796 (4) [back to overview]	Overall Survival (Phase II)
NCT02044796 (4) [back to overview]	Remission Rate (Complete Remission and Complete Remission With Incomplete Platelet Count Recovery) of This Regimen in Patients With Relapsed/Refractory Disease (Phase II)
NCT02044796 (4) [back to overview]	Number of Participants With Dose Limiting Toxicities of Mitoxantrone (Phase I, Dose Level 4)
NCT02044796 (4) [back to overview]	Minimal Residual Disease Negative Complete Remission Rate in Patients With Newly Diagnosed Disease (Phase II)
NCT02046122 (8) [back to overview]	Number of Days to Hematopoietic Recovery
NCT02046122 (8) [back to overview]	Rate of Efficacy
NCT02046122 (8) [back to overview]	Percentage of Subjects With Unacceptable Toxicity
NCT02046122 (8) [back to overview]	Percentage of Subjects With Acute GVHD
NCT02046122 (8) [back to overview]	Overall Survival
NCT02046122 (8) [back to overview]	Number of Participants With Immune Recovery
NCT02046122 (8) [back to overview]	Disease Free Survival
NCT02046122 (8) [back to overview]	Number of Subjects With Unacceptable Toxicity
NCT02059239 (8) [back to overview]	Overall Survival at Day 365 Post-Transplant
NCT02059239 (8) [back to overview]	Disease Response Following Salvage Chemotherapy
NCT02059239 (8) [back to overview]	Number of Patients Achieving Platelet Engraftment
NCT02059239 (8) [back to overview]	Number of Patients Achieving Neutrophil Engraftment
NCT02059239 (8) [back to overview]	Progression-Free Survival After Stem Cell Transplant
NCT02059239 (8) [back to overview]	Transplant-Related Mortality
NCT02059239 (8) [back to overview]	Disease Response 30 Days Post-Transplant
NCT02059239 (8) [back to overview]	Disease Response at 1 Year Post-Transplant
NCT02085408 (4) [back to overview]	Disease-free Survival for Maintenance
NCT02085408 (4) [back to overview]	Overall Survival by Donor Status
NCT02085408 (4) [back to overview]	Overall Survival
NCT02085408 (4) [back to overview]	Proportion of Patients With Complete Remission
NCT02088541 (14) [back to overview]	Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)
NCT02088541 (14) [back to overview]	Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)
NCT02088541 (14) [back to overview]	Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]
NCT02088541 (14) [back to overview]	Duration of Response (DOR)
NCT02088541 (14) [back to overview]	Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)
NCT02088541 (14) [back to overview]	Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)
NCT02088541 (14) [back to overview]	Overall Survival
NCT02088541 (14) [back to overview]	Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)
NCT02088541 (14) [back to overview]	Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]
NCT02088541 (14) [back to overview]	Percentage of Participants With Disease Control Rate (DCR)
NCT02088541 (14) [back to overview]	Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)
NCT02088541 (14) [back to overview]	Percentage of Participants With Overall Response Rate (ORR)
NCT02088541 (14) [back to overview]	Duration of Disease Control Rate
NCT02088541 (14) [back to overview]	Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0)
NCT02101853 (4) [back to overview]	Overall Survival (OS) of LR Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of HR and IR Relapse Patients
NCT02101983 (2) [back to overview]	Number of Participants Who Successfully Completed the of Quality of Life Form
NCT02101983 (2) [back to overview]	Number of Participants With Grades 3 to 5 Non-hematologic Toxicity.
NCT02112916 (6) [back to overview]	Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]	Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]	EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]	Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02121418 (2) [back to overview]	Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS
NCT02121418 (2) [back to overview]	Response Rate
NCT02144675 (1) [back to overview]	Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
NCT02249091 (8) [back to overview]	Percentage of Patients Transplanted After Induction Therapy (Stem Cell Transplantation)
NCT02249091 (8) [back to overview]	Early Death Rate
NCT02249091 (8) [back to overview]	Overall Survival
NCT02249091 (8) [back to overview]	Number of Participants With Partial Remission (PR) = Rate of PR
NCT02249091 (8) [back to overview]	Event-Free Survival
NCT02249091 (8) [back to overview]	Number of Participants With CR/CRi = Overall Reponse Rate
NCT02249091 (8) [back to overview]	Relapse-Free Survival
NCT02249091 (8) [back to overview]	Progression-Free Survival
NCT02286726 (2) [back to overview]	Number of Participants Who Experienced Dose-limiting Toxicity (DLT)
NCT02286726 (2) [back to overview]	Number of Participants With a Response
NCT02287233 (27) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02287233 (27) [back to overview]	Time to First Response of CR + CRi
NCT02287233 (27) [back to overview]	Time to Best Response of CR Plus CRh
NCT02287233 (27) [back to overview]	Time to Best Response of CR + CRi
NCT02287233 (27) [back to overview]	Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax
NCT02287233 (27) [back to overview]	Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to Last Measurable Concentration (AUCt) of Cytarabine
NCT02287233 (27) [back to overview]	Phase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine
NCT02287233 (27) [back to overview]	Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax
NCT02287233 (27) [back to overview]	Time to First Response of CR Plus CRh
NCT02287233 (27) [back to overview]	Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Cytarabine
NCT02287233 (27) [back to overview]	Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax
NCT02287233 (27) [back to overview]	Post Baseline Transfusion Independence Rate
NCT02287233 (27) [back to overview]	Duration of CR Plus CRi
NCT02287233 (27) [back to overview]	Duration of CRi
NCT02287233 (27) [back to overview]	Overall Response Rate
NCT02287233 (27) [back to overview]	Post Baseline Transfusion Independence Rate Among Participants Transfusion-dependent at Baseline
NCT02287233 (27) [back to overview]	Overall Survival (OS)
NCT02287233 (27) [back to overview]	Phase 1: Number of Participants With Dose-limiting Toxicities
NCT02287233 (27) [back to overview]	Duration of CR Plus CRh
NCT02287233 (27) [back to overview]	Duration of Complete Response
NCT02287233 (27) [back to overview]	CR Plus CRi Rate by Initiation of Cycle 2
NCT02287233 (27) [back to overview]	CR Plus CRh Rate by Initiation of Cycle 2
NCT02287233 (27) [back to overview]	CR Plus CRh Rate
NCT02287233 (27) [back to overview]	Complete Remission With Partial Hematologic Recovery (CRh) Rate
NCT02287233 (27) [back to overview]	Complete Remission Rate
NCT02287233 (27) [back to overview]	Complete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate
NCT02287233 (27) [back to overview]	Duration of Post Baseline Transfusion Independence
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QT Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QRS Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QRS Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QRS Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QRS Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QRS Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: PR Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: PR Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: PR Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: PR Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: Heart Rate - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: Heart Rate - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: Heart Rate - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: Heart Rate - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: Heart Rate - Phases 1 and 2
NCT02305563 (49) [back to overview]	Time of Maximum Observed Ulocuplumab Serum Concentration (Tmax) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: PR Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Overall Survival (OS) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Overall Rate of Remission in Participants Treated With Ulocuplumab at Two Different Dose Levels 800 mg and 1000 mg in Combination With LDAC - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) - Phase 1
NCT02305563 (49) [back to overview]	Number of Participants With SAEs - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) in Treatment Cycle 1 - Phase 1
NCT02305563 (49) [back to overview]	Number of Participants With Anti-drug Antibodies (ADA) Positive for Ulocuplumab - Phases 1 and 2
NCT02305563 (49) [back to overview]	Number of Participants With AEs Leading to Discontinuation - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With AEs Leading to Discontinuation - Phase 1
NCT02305563 (49) [back to overview]	Number of Participants With AEs - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With Adverse Events (AEs) - Phase 1
NCT02305563 (49) [back to overview]	Number of Participants With >= Grade 3 AEs - Phase 1
NCT02305563 (49) [back to overview]	Number of Deaths- Phase 2
NCT02305563 (49) [back to overview]	Number of Deaths - Phase 1
NCT02305563 (49) [back to overview]	Duration of Response in Participants With CR/CRi Treated With LDAC Only - Phase 2
NCT02305563 (49) [back to overview]	Best Overall Response (BOR) - Phase 2
NCT02305563 (49) [back to overview]	Best Overall Response (BOR) - Phase 1
NCT02305563 (49) [back to overview]	Area Under the Ulocuplumab Concentration-time Curve in One Dosing Interval [AUC(TAU)] - Phases 1 and 2
NCT02305563 (49) [back to overview]	Area Under the Ulocuplumab Concentration-time Curve From Time Zero to the Last Quantifiable Concentration [AUC(0-T)] - Phases 1 and 2
NCT02305563 (49) [back to overview]	Duration of Response in Participants With CR/CRi Treated With Ulocuplumab at Two Different Dose Levels 800 mg and 1000 mg in Combination With LDAC - Phase 2
NCT02305563 (49) [back to overview]	Maximum Observed Serum Concentration (Cmax) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Trough Observed Serum Concentration (Ctrough) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Trough Observed Serum Concentration (Ctrough) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Trough Observed Serum Concentration (Ctrough) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Trough Observed Serum Concentration (Ctrough) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Trough Observed Serum Concentration (Ctrough) - Phases 1 and 2
NCT02305563 (49) [back to overview]	Rate of Complete Remission (CR/CRi) and Overall Rate of Remission in Participants Treated With LDAC Only - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With Laboratory Abnormalities - Phase 2
NCT02305563 (49) [back to overview]	Number of Participants With Laboratory Abnormalities - Phase 1
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QT Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QT Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QT Interval - Phases 1 and 2
NCT02305563 (49) [back to overview]	Change From Baseline of Electrocardiogram (ECG) Endpoints: QT Interval - Phases 1 and 2
NCT02339740 (2) [back to overview]	Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients
NCT02339740 (2) [back to overview]	EFS in High Risk APL Patients
NCT02343939 (9) [back to overview]	Overall Survival (OS)
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT02343939 (9) [back to overview]	Percentage of Participants With Composite Complete Remission at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Morphologic Complete Remission (CR) at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Overall Response at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants Who Experienced Laboratory Abnormalities
NCT02343939 (9) [back to overview]	Duration of Exposure of Entospletinib
NCT02343939 (9) [back to overview]	Event Free Survival (EFS)
NCT02366663 (4) [back to overview]	Time to Neutrophil Engraftment
NCT02366663 (4) [back to overview]	Time to Platelet Engraftment
NCT02366663 (4) [back to overview]	Number of Patients With Complete or Partial Response at Day 30
NCT02366663 (4) [back to overview]	Number of Patients With Grade 3-5 Toxicities Graded by the NCI CTCAE Version 4.0
NCT02416908 (9) [back to overview]	Safety and Tolerability of Treatment as Measured by Incidence of Grade 3-4 Adverse Events Occurring in >5% of Participants
NCT02416908 (9) [back to overview]	Time to Platelet Engraftment
NCT02416908 (9) [back to overview]	Time to Neutrophil Engraftment
NCT02416908 (9) [back to overview]	Relapse-free Survival
NCT02416908 (9) [back to overview]	Overall Survival
NCT02416908 (9) [back to overview]	Number of Participants Who Were Able to Undergo Hematopoietic Stem Cell Transplantation
NCT02416908 (9) [back to overview]	Event-free Survival
NCT02416908 (9) [back to overview]	Duration of Remission
NCT02416908 (9) [back to overview]	Complete Remission Rate (CR + CRi)
NCT02419469 (1) [back to overview]	Event Free Survival (EFS)
NCT02419755 (1) [back to overview]	Number of Relevant Toxicities Related to Therapy
NCT02420717 (4) [back to overview]	Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02420717 (4) [back to overview]	Progression-free Survival
NCT02420717 (4) [back to overview]	Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02420717 (4) [back to overview]	Overall Survival
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
NCT02421939 (12) [back to overview]	Percentage of Participants With Composite Complete Remission (CRc Rate)
NCT02421939 (12) [back to overview]	Change From Baseline in Brief Fatigue Inventory (BFI)
NCT02421939 (12) [back to overview]	Number of Participants With Adverse Events
NCT02421939 (12) [back to overview]	Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
NCT02421939 (12) [back to overview]	Duration of Remission
NCT02421939 (12) [back to overview]	Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
NCT02421939 (12) [back to overview]	Duration of Overall Survival (OS)
NCT02421939 (12) [back to overview]	Duration of Leukemia-Free Survival (LFS)
NCT02421939 (12) [back to overview]	Duration of Event-Free Survival (EFS)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) Rate
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
NCT02433483 (8) [back to overview]	1-year Cumulative Incidence of Acute Graft Versus Host Disease (GVHD)
NCT02433483 (8) [back to overview]	Time to Platelet Recovery
NCT02433483 (8) [back to overview]	Proportion of Participants Who Experience Therapeutic Success
NCT02433483 (8) [back to overview]	Number of Participants by Stratum Who Complete 2 Cycles of Therapy
NCT02433483 (8) [back to overview]	Median Time to Neutrophil Recovery
NCT02433483 (8) [back to overview]	3-year Overall Survival (OS)
NCT02433483 (8) [back to overview]	Percent Donor Chimerism
NCT02433483 (8) [back to overview]	3-year Event Free Survival (EFS)
NCT02440568 (6) [back to overview]	Toxicity: Describe by the Adverse Events as Assessed by the CTCAE Grading
NCT02440568 (6) [back to overview]	Time to Hematologic Recovery
NCT02440568 (6) [back to overview]	Event Free Survival
NCT02440568 (6) [back to overview]	Optimally Tolerated Dose
NCT02440568 (6) [back to overview]	Progression Free Survival
NCT02440568 (6) [back to overview]	Overall Participant Survival
NCT02464657 (4) [back to overview]	Relapse Free Survival
NCT02464657 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Nivolumab
NCT02464657 (4) [back to overview]	Event-Free Survival (EFS)
NCT02464657 (4) [back to overview]	Overall Survival
NCT02481310 (2) [back to overview]	To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.
NCT02481310 (2) [back to overview]	12-month PFS (Progression Free Survival) of Treatment With Ixazomib in Combination With DA-EPOCH-R (Phase II)
NCT02483000 (3) [back to overview]	Dosimetry of Yttrium Y 90 DOTA-biotin
NCT02483000 (3) [back to overview]	Incidence of Toxicity, Defined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02483000 (3) [back to overview]	Overall Survival
NCT02485353 (2) [back to overview]	Rate of Complete Remission
NCT02485353 (2) [back to overview]	Procedure or Procedure Related Adverse Events
NCT02520011 (2) [back to overview]	Complete Response (CR) Rate in Patients With Relapsed or Refractory AML
NCT02520011 (2) [back to overview]	Response to Treatment
NCT02532010 (7) [back to overview]	Remission Duration
NCT02532010 (7) [back to overview]	Relapse-free Survival
NCT02532010 (7) [back to overview]	Overall Survival
NCT02532010 (7) [back to overview]	Complete Remission Rate
NCT02532010 (7) [back to overview]	Event-free Survival
NCT02532010 (7) [back to overview]	Time to Complete Response
NCT02532010 (7) [back to overview]	Overall Remission Rate
NCT02535806 (4) [back to overview]	Number of Subject With Adverse Events
NCT02535806 (4) [back to overview]	Post-induction Level of Minimal Residual Disease Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]	Remission Rate Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]	2-year Overall Survival Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02545283 (25) [back to overview]	Overall Survival in Clinically Actionable Mutation-Defined Subpopulation (FLT3, IDH1 and IDH2) in TP53 WT Population
NCT02545283 (25) [back to overview]	Percentage of Participants With Complete Response (CR) in Clinically Actionable Mutation-Defined Subpopulation (FLT3, IDH1 and IDH2) in TP53 WT Population
NCT02545283 (25) [back to overview]	Total Duration of Study Treatment
NCT02545283 (25) [back to overview]	Number of Participants With Clinical Laboratory Abnormalities in Hematology Tests at the Greatest Severity, According to NCI-CTCAE v4.03
NCT02545283 (25) [back to overview]	Number of Participants With Clinical Laboratory Abnormalities in Biochemistry Tests at the Greatest Severity, According to NCI-CTCAE v4.03
NCT02545283 (25) [back to overview]	Cumulative Dose of Idasanutlin and Cytarabine
NCT02545283 (25) [back to overview]	Cumulative Dose of Idasanutlin and Cytarabine
NCT02545283 (25) [back to overview]	Change From Baseline in Systolic Blood Pressure Over Time
NCT02545283 (25) [back to overview]	Change From Baseline in Respiratory Rate Over Time
NCT02545283 (25) [back to overview]	Change From Baseline in Pulse Rate Over Time
NCT02545283 (25) [back to overview]	Change From Baseline in Heart Rate, as Measured by Electrocardiogram
NCT02545283 (25) [back to overview]	Change From Baseline in Electrocardiogram Parameters: PQ, PR, RR, QRS, QT and QTcF Intervals
NCT02545283 (25) [back to overview]	Change From Baseline in Diastolic Blood Pressure Over Time
NCT02545283 (25) [back to overview]	Change From Baseline in Body Temperature Over Time
NCT02545283 (25) [back to overview]	Percentage of Participants With Overall Remission (CR, CRp, and CRi) at the End of Induction According to HMRA in TP53 WT Population
NCT02545283 (25) [back to overview]	Percentage of Participants Undergoing HSCT Following Complete Response (CR), in TP53 WT Population
NCT02545283 (25) [back to overview]	Percentage of Participants in Complete Response (CR) at the End of Induction According to Hematologic Malignancy Response Assessment (HMRA) in TP53 WT Population
NCT02545283 (25) [back to overview]	Overall Survival in TP53 WT Population
NCT02545283 (25) [back to overview]	Number of Treatment Cycles Started
NCT02545283 (25) [back to overview]	Number of Participants With Adverse Events Leading to Discontinuation
NCT02545283 (25) [back to overview]	Number of Participants With Adverse Events Leading to Death up to Day 60
NCT02545283 (25) [back to overview]	Number of Participants With Adverse Events Leading to Death up to Day 30
NCT02545283 (25) [back to overview]	Number of Participants Who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03)
NCT02545283 (25) [back to overview]	Event-Free Survival (EFS) According to HMRA in TP53 WT Population
NCT02545283 (25) [back to overview]	Duration of Remission Following CR (DOR) in TP53 WT Population
NCT02553460 (1) [back to overview]	Percentage of Treatment-related Mortality (TRM)
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT02560025 (6) [back to overview]	1 Year Overall Survival Rate
NCT02560025 (6) [back to overview]	Median Duration of Remission
NCT02560025 (6) [back to overview]	Number of Participants With Serious Adverse Events
NCT02560025 (6) [back to overview]	Median Relapse Free Survival
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities
NCT02577406 (20) [back to overview]	The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities
NCT02577406 (20) [back to overview]	Time to Response
NCT02577406 (20) [back to overview]	Time to Treatment Failure
NCT02577406 (20) [back to overview]	Change From Baseline in EQ-5D-5L Health Utility Index
NCT02577406 (20) [back to overview]	Complete Remission Rate
NCT02577406 (20) [back to overview]	Duration of Response
NCT02577406 (20) [back to overview]	Event-Free Survival
NCT02577406 (20) [back to overview]	Hematologic Improvement Rate
NCT02577406 (20) [back to overview]	Treatment Mortality at 30 Days
NCT02577406 (20) [back to overview]	Overall Remission Rate
NCT02577406 (20) [back to overview]	Treatment Mortality at 60 Days
NCT02577406 (20) [back to overview]	One-Year Survival Rate
NCT02577406 (20) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)
NCT02577406 (20) [back to overview]	The Number of Participants Experiencing Adverse Events (AEs)
NCT02577406 (20) [back to overview]	Overall Response Rate
NCT02577406 (20) [back to overview]	Overall Survival (OS)
NCT02577406 (20) [back to overview]	The Number of Participants That Underwent Hematopoietic Stem Cell Transplantation (HSCT)
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology
NCT02577406 (20) [back to overview]	The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Evaluation of Phosphorylated BCL--2 Associated Death Promoter Protein (pBAD)
NCT02587598 (22) [back to overview]	Determination of the Safety and Tolerability of INCB053914 as Measured by the Number of Participants With Adverse Events
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: CL/F of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Tmax of Combination Group B INCB053914 80 mg + Azatcitidine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Ctau of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02587598 (22) [back to overview]	Pharmacokinetics: AUCtau of INCB053914 Monotherapy
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cl/F of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmin of Combination Treatment Group A INCB053914 50 mg + Cytarabine
NCT02587598 (22) [back to overview]	Pharmacokinetics: Cmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
NCT02626338 (1) [back to overview]	Clinical Response to Crenolanib With Standard Salvage Chemotherapy
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Area Under the Curve
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Clearance
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Time of Maximum Concentration
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Volume of Distribution
NCT02642965 (11) [back to overview]	Number of Participants With a Dose-limiting Toxicity
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial or Incomplete Platelet Recovery) After First Cycle of Therapy
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial Platelet Recovery) After up to 2 Cycles
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Clearance
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Volume of Distribution
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Area Under the Curve
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Time of Maximum Concentration
NCT02658487 (6) [back to overview]	Overall Survival
NCT02658487 (6) [back to overview]	Leukemia-free Survival (LFS or DFS)
NCT02658487 (6) [back to overview]	Event-free Survival
NCT02658487 (6) [back to overview]	Complete Remission Rate (CR)
NCT02658487 (6) [back to overview]	Rate of CR/CRi
NCT02658487 (6) [back to overview]	Frequency of Grade 3-5 Adverse Event Related to Cytarabine and Vosaroxin (7+V)
NCT02666950 (5) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Events Considered At Least Possibly Related to Treatment
NCT02666950 (5) [back to overview]	Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline
NCT02666950 (5) [back to overview]	Complete Response Rate (CR or CRi) Per the National Comprehensive Cancer Network (NCCN) Guidelines or According to Specific Criteria From Expert Panels
NCT02666950 (5) [back to overview]	Overall Survival
NCT02666950 (5) [back to overview]	Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression
NCT02668653 (5) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02728050 (8) [back to overview]	Overall Survival (OS)
NCT02728050 (8) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone
NCT02728050 (8) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Sorafenib
NCT02728050 (8) [back to overview]	Phase I and II: Rate of Minimal Residual Disease Negative (MRDneg) Complete Response (CR)
NCT02728050 (8) [back to overview]	Relapse-free Survival (RFS)
NCT02728050 (8) [back to overview]	Event-free Survival (EFS)
NCT02728050 (8) [back to overview]	Number of Participants With Adverse Events
NCT02728050 (8) [back to overview]	Overall Response Rate (ORR)
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 28
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - GENDER
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Patient-reported Outcomes for Trial Participants
NCT02756572 (19) [back to overview]	Treatment Related Mortality Among Patients Who Received Early Transplant vs Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 84
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - TREATMENT RELATED MORTALITY
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - AGE
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Resource Utilization Data for Trial Participants
NCT02756572 (19) [back to overview]	Acute Graft Versus Host Disease Among Patients Who Received Early Transplant
NCT02797470 (1) [back to overview]	Percentage of Participants Who Achieve a Timely Engraftment
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02834390 (10) [back to overview]	Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02873338 (10) [back to overview]	Number of Subjects Who Achieved Morphologic Complete Remission
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 30
NCT02873338 (10) [back to overview]	Time to Recovery of Neutrophils
NCT02873338 (10) [back to overview]	Time to Platelet Recovery
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 90
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 60.
NCT02873338 (10) [back to overview]	Time to Leukemia-free Survival
NCT02873338 (10) [back to overview]	Duration of Event-free Survival
NCT02873338 (10) [back to overview]	Number of Subjects Who Achieved Composite Complete Remission
NCT02873338 (10) [back to overview]	Duration of Morphologic Complete Remission
NCT02921061 (6) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs) (Phase I)
NCT02921061 (6) [back to overview]	Number of Participants With Overall Survival
NCT02921061 (6) [back to overview]	Number of Participants With Relapse-free Survival
NCT02921061 (6) [back to overview]	Number of Participants With Minimal Residual Disease Negative (MRDneg) Complete Remission (Phase II)
NCT02921061 (6) [back to overview]	Number of Participants With Event-free Survival
NCT02921061 (6) [back to overview]	Number of Participants Who Achieved Remission (Complete Remission [CR]/CR With Incomplete Peripheral Blood Count Recovery [CRi])
NCT02927938 (1) [back to overview]	2 Year Relapse Free Survival (RFS)
NCT02954653 (9) [back to overview]	Duration of Objective Response Rate (ORR) [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]
NCT02954653 (9) [back to overview]	Objective Response Rate (ORR) - Percentage of Participants With Objective Response [Part 1]
NCT02954653 (9) [back to overview]	Progression Free Survival [Part 1]
NCT02954653 (9) [back to overview]	Incidence of Anti-Drug Antibodies (ADA) Against PF-06747143 [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Hematology Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Chemistry Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [Part 1]
NCT03019640 (2) [back to overview]	Number of Participants Who Survived
NCT03019640 (2) [back to overview]	Treatment-related Mortality Within 30 Days (TRM30)
NCT03069352 (19) [back to overview]	Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a
NCT03069352 (19) [back to overview]	Change From Baseline in Global Health Status / Quality of Life
NCT03069352 (19) [back to overview]	Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
NCT03069352 (19) [back to overview]	Percentage of Participants With Post Baseline Red Blood Cell (RBC) Transfusion Independence
NCT03069352 (19) [back to overview]	Percentage of Participants With Post Baseline Platelet Transfusion Independence
NCT03069352 (19) [back to overview]	Overall Survival (OS) by Mutation Subgroups
NCT03069352 (19) [back to overview]	Percentage of Participants With Platelet Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) and Minimal Residual Disease (MRD) Response
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh)
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Initiation of Cycle 2
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) and Minimal Residual Disease (MRD) Response
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh) by Initiation of Cycle 2
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission
NCT03069352 (19) [back to overview]	Overall Survival After an Additional 6-Months Follow-up
NCT03069352 (19) [back to overview]	Overall Survival (OS)
NCT03069352 (19) [back to overview]	Event-free Survival (EFS)
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Partial Hematologic Recovery (CR + CRh) by Mutation Subgroup
NCT03069352 (19) [back to overview]	Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) by Mutation Subgroup
NCT03071276 (3) [back to overview]	The Overall Response (OR) Rate (Complete Response + Incomplete Count Recovery + Partial Response)
NCT03071276 (3) [back to overview]	Complete Response
NCT03071276 (3) [back to overview]	Complete Response or Complete Response With Incomplete Count Recovery
NCT03118466 (6) [back to overview]	Overall Survival
NCT03118466 (6) [back to overview]	Treatment-related Mortality
NCT03118466 (6) [back to overview]	Number of Patients That Achieved Platelet Recovery
NCT03118466 (6) [back to overview]	Complete Response Rate
NCT03118466 (6) [back to overview]	Number of Patients That Achieved ANC Recovery
NCT03118466 (6) [back to overview]	Transfusion Support: Number of Red Blood Cell and Platelet Transfusions
NCT03135028 (3) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT)
NCT03135028 (3) [back to overview]	Percentage of Participants With AEs and Laboratory Abnormalities Not Defined as DLT
NCT03135028 (3) [back to overview]	Plasma Concentration of ENTO
NCT03298984 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Alvocidib
NCT03298984 (5) [back to overview]	Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria
NCT03298984 (5) [back to overview]	Recommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3
NCT03298984 (5) [back to overview]	Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib
NCT03298984 (5) [back to overview]	Minimal Residual Disease (MRD) Using Standardized Techniques
NCT03303339 (13) [back to overview]	Phase 2: Overall Survival (OS)
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants Who Achieved a Complete Response (CR)
NCT03303339 (13) [back to overview]	Phase 2: Event-free Survival (EFS)
NCT03303339 (13) [back to overview]	Phase 2: Duration of Response (DOR)
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants Who Achieved a Morphologic Leukemia-free (MLF) State
NCT03303339 (13) [back to overview]	Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status
NCT03303339 (13) [back to overview]	Number of Participants Who Experienced Dose Limiting Toxicities (DLT)
NCT03303339 (13) [back to overview]	Phase 2: Number of Participants With Partial Response (PR)
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Time to Reach the Maximum Observed Plasma Concentration (Tmax) for Onvansertib
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Plasma Terminal Elimination Half-life (t1/2) for Onvansertib
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Maximum Observed Plasma Concentration (Cmax) for Onvansertib
NCT03303339 (13) [back to overview]	Pharmacokinetic Parameter: Area Under the Curve Over the First 24 Hours AUC(0-24) for Onvansertib
NCT03303339 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03384654 (13) [back to overview]	Event-free Survival (EFS)
NCT03384654 (13) [back to overview]	Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL
NCT03384654 (13) [back to overview]	Minimal Residual Disease (MRD) Negative Rate
NCT03384654 (13) [back to overview]	Minimum Observed Serum Concentration (Cmin) of Daratumumab
NCT03384654 (13) [back to overview]	Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]	Number of Participants With Anti-daratumumab Antibodies
NCT03384654 (13) [back to overview]	Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]	Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
NCT03384654 (13) [back to overview]	Relapse-free Survival (RFS)
NCT03384654 (13) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03384654 (13) [back to overview]	Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
NCT03384654 (13) [back to overview]	Overall Survival (OS)
NCT03384654 (13) [back to overview]	Overall Response Rate (ORR)
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Non-intensive Study: Time to Response
NCT03416179 (30) [back to overview]	Intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Non-intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03488225 (5) [back to overview]	Event-Free Survival
NCT03488225 (5) [back to overview]	Participants to Achieve Complete Remission (CR):
NCT03488225 (5) [back to overview]	Overall Survival
NCT03488225 (5) [back to overview]	Number of Participants With Minimal Residual Disease (MRD) Negativity
NCT03488225 (5) [back to overview]	Number of Participants With Adverse Events
NCT03504410 (1) [back to overview]	Complete Remission (CR)
NCT03518112 (5) [back to overview]	Participants With a Response
NCT03518112 (5) [back to overview]	Overall Survival
NCT03518112 (5) [back to overview]	Number of Participants Negative for Minimal Residual Disease (MRD)
NCT03518112 (5) [back to overview]	Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death
NCT03518112 (5) [back to overview]	Duration of Response
NCT03531918 (10) [back to overview]	Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: Alapasia (MRDneg)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: CR/CRi
NCT03531918 (10) [back to overview]	Event-free Survival (EFS) Rate (Phase 2)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: CRi (MRDneg)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: MLFS (MRDneg)
NCT03531918 (10) [back to overview]	Overall Survival
NCT03531918 (10) [back to overview]	Relapse-free Survival of GO3 Cohort
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) Rates and Remission Rates: CR
NCT03531918 (10) [back to overview]	30-day All-cause Mortality
NCT03575325 (3) [back to overview]	Complete Remission Rate (CR) + CR With Incomplete Recovery (CRi)
NCT03575325 (3) [back to overview]	Overall Survival (OS)
NCT03575325 (3) [back to overview]	Progression Free Survival (PFS)
NCT03589326 (1) [back to overview]	Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase
NCT03623373 (4) [back to overview]	Pre-transplant Complete Response Rate
NCT03623373 (4) [back to overview]	Overall Response Rate (ORR = Complete Response (CR) + Partial Response (PR)) of Subjects
NCT03623373 (4) [back to overview]	Safety and Tolerability of Regimen in Subjects With MCL as Measured by Treatment Related Non-hematologic Toxicity of Grade 3 or Higher
NCT03623373 (4) [back to overview]	Stem Cell Mobilization Success Rate With Cytarabine and Rituximab
NCT03634228 (4) [back to overview]	Event Free Survival (EFS)
NCT03634228 (4) [back to overview]	Maximum Tolerated Dose (MTD) (Phase I)
NCT03634228 (4) [back to overview]	Overall Survival
NCT03634228 (4) [back to overview]	Participants With a Response
NCT03813147 (8) [back to overview]	Elimination Half-life of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Maximum Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Area Under the Plasma Concentration Versus Time Curve of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Total Plasma Clearance of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03813147 (8) [back to overview]	Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Number of Participants With Antitumor Activity of MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Number of Participants With Adverse Events Attributable to MLN4924 (Pevonedistat)
NCT03813147 (8) [back to overview]	Maximum Time to Concentration of MLN4924 (Pevonedistat) Added to the 3-drug Backbone of Azacitidine (Aza), Fludarabine, and Cytarabine Re-induction for Pediatric Patients With Recurrent/Refractory AML and MDS
NCT03850535 (3) [back to overview]	Dose Escalation Phase: Number of Participants With Dose-Limiting Toxicities (DLTs) During the First Cycle of Induction Treatment
NCT03850535 (3) [back to overview]	Number of Participants With at Least One Adverse Event
NCT03850535 (3) [back to overview]	Number of Participants With Grade ≥3 Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
NCT03860844 (13) [back to overview]	AML: Ceoi of Isatuximab
NCT03860844 (13) [back to overview]	AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]	Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]	Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]	Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]	AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03988205 (2) [back to overview]	Number of Participants Adherent to Recommendations
NCT03988205 (2) [back to overview]	Number of Participants Adherent to Readmission Recommendations
NCT04158739 (4) [back to overview]	Antitumor Activity of Flotetuzumab
NCT04158739 (4) [back to overview]	Maximum Tolerated Dose or Recommended Phase 2 Dose of Flotetuzumab
NCT04158739 (4) [back to overview]	Maximum Concentration (C Max)
NCT04158739 (4) [back to overview]	Dose Limiting Toxicities Due to Flotetuzumab
NCT04326439 (8) [back to overview]	Proportion of Patients Who Develop Infection and/or Febrile Neutropenia During Each Treatment Course
NCT04326439 (8) [back to overview]	Disease-free Survival (DFS) for Patients Who Are MRD Negative
NCT04326439 (8) [back to overview]	Duration of Hospital Admission in Patients That Developed Infection and Febrile Neutropenia at the End of Each Treatment Cycle
NCT04326439 (8) [back to overview]	Duration of Hospital Admission in Patients That Developed Infection and Febrile Neutropenia at the End of Each Treatment Cycle
NCT04326439 (8) [back to overview]	Cardiotoxicity in Patients With de Novo AML That Receive the Four-cycle Aflac-AML Regimen With the Inclusion of Dexrazoxane
NCT04326439 (8) [back to overview]	Overall Survival (OS)
NCT04326439 (8) [back to overview]	Minimal Residual Disease (MRD) Negative Status
NCT04326439 (8) [back to overview]	Event-free Survival (EFS) in Low Risk Patients and High Risk Patients

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

Intervention	participants (Number)
	Complete Remission	Complete Response (CR)	Failure	Failure-Progression	Relapse
All-2	50	14	5	8	1
L-20	50	11	14	10	0

Intervention	participants (Number)
	Failure	Minor Response (MR)	Partial Response (PR)	Progression Free (P-Free)	Complete Response (CR)	Progression of Disease (POD)
Group A - Favorable Prognostic Group	3	2	1	41	0	0
Group B - Intermediate Prognostic Group	6	1	2	31	2	1
Group C - Unfavorable Prognostic Group	3	0	4	7	1	0

Intervention	percentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM	96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens	84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens	88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy	81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens	85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens	85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment	92

Intervention	Participants (Count of Participants)
	6 Months	1 Year	1.5 Years	2 Years	3 Years
Chemoresistant Group	14	10	9	8	8
Chemosensitive Group	39	31	27	26	23
Unknown Chemosensitivity Group	1	0	0	0	0

Intervention	Probability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	0.89
Arm II (RER With CR [ABVE-PC, IFRT])	0.87
Arm III (RER With CR [ABVE-PC])	0.84
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	0.87
Arm V (RER With PD)	0.70
Arm VI (SER [DECA, ABVE-PC, IFRT])	0.79
Arm VII (SER [ABVE-PC, IFRT])	0.74

Intervention	Probability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	0.93
Arm II (RER With CR [ABVE-PC, IFRT])	0.98
Arm III (RER With CR [ABVE-PC])	0.98
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	0.98
Arm VI (SER [DECA, ABVE-PC, IFRT])	0.96
Arm VII (SER [ABVE-PC, IFRT])	0.93

Intervention	participants (Number)
	Complete Remission	Partial Remission	Molecular Complete Remission	Induction Death
Hyper-CVAD + Imatinib	42	1	17	1

Intervention	percentage of patients (Number)
Patients With HLA-matched Sibling Donor	53
Patients Without HLA-matched Sibling Donors	51

Intervention	participants (Number)
	Complete Molecular Response	Major Molecular Response
Entire Cohort	9	4

Intervention	Participants (Number)
	Complete Remission	Morphologic Complete Remission	Partial Remission	Relapse	Unevaluable
Placebo	96	12	0	90	23
Zosuquidar	98	12	2	67	33

Intervention	participants (Number)
Regimen A	4
Regimen B-1	2
Regimen B-2	0
Regimen B-3	1
Regimen C	2
Regimen D	0

Intervention	days (Mean)
Regimen A	17.9
Regimen B-1	15.75
Regimen B-2	13
Regimen B-3	18.25
Regimen C	13.9
Regimen D	10.5

Intervention	participants (Number)
	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4
Regimen A	0	2	6	2	0
Regimen B-1	1	1	2	0	0
Regimen B-2	1	0	1	0	1
Regimen B-3	1	0	0	3	0
Regimen C	1	1	5	3	0
Regimen D	0	0	0	0	2

Intervention	participants (Number)
	Incidence of grade ≥ 3 stomatitis	No incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	4	41
Group C (Chemotherapy, Monoclonal Antibody Therapy)	6	34

Intervention	participants (Number)
	Toxic death	No toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)	0	45
Group C (Chemotherapy, Monoclonal Antibody Therapy)	2	38

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	58.6
Phase II - Alemtuzumab and Combination Chemotherapy	19.8

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	33.6
Phase II - Alemtuzumab and Combination Chemotherapy	23.1

Intervention	Percentage of Participants (Number)
Clofarabine + Ara-C	36
Clofarabine + Idarubicin	44
Clofarabine + Idarubicin + Ara-C	24

Intervention	participants (Number)
	Baseline Independent; On-Treatment Independent	Baseline Independent; On-Treatment Dependent
Azacitidine	126	15
Conventional Care	102	50

Intervention	participants (Number)
	Baseline Dependent; On-Treatment Independent	Baseline Dependent; On-Treatment Dependent
Azacitidine	50	61
Conventional Care	13	101

Intervention	months (Number)
	Age <65 years	Age >= 65 years	Age >= 75 years	Gender: Male	Gender: Female	FAB: Refractory anemia with excess blasts (RAEB)	FAB: RAEB in transformation	WHO: RAEB 1	WHO: RAEB 2	WHO: Other (AML, CMMoL-1 and 2, indeterminate)	IPSS: Intermediate 2	IPSS: High
Azacitidine	11.31	24.46	8.92	24.46	25.11	34.66	17.25	11.54	21.11	20.46	34.66	19.21
Conventional Care	7.87	13.87	6.20	15.02	14.85	15.21	15.25	6.72	15.02	15.25	16.89	14.52

cytarabine

Description

Cross-References

Synonyms (233)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (4)

Pathways (26)

Protein Targets (60)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (304)

Molecular Functions (117)

Ceullar Components (55)

Bioassays (1002)

Research

Studies (15,030)

Study Types

Clinical Trials (1164)

Trial Overview

Trial Outcomes

Complete Remission (CR)

Objective Response

Percentage of Patients With Overall Survival as Assessed by Time to Death

Event-free Survival

Non-Relapse Mortality

Engraftment of HLA Identical PBSC Allografts

Overall Survival (OS)

Progression Free-survival (PFS)

Maximum Tolerated Dose

The Rate of Major Cytogenetic Response at 6 Months

Event-free Survival

Grade 3 or 4 Non-hematologic Toxicity

Overall Survival

Disease Response Assessed by Modified RECIST Criteria

Disease-Free Survival Rate at 2-year and 5-year.

Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate

Overall Survival Rate at 2-year and 5-year.

Complete Response Rate

2 Year Overall Survival

2 Year Event Free Survival

5 Year Overall Survival for Autologous & Allogeneic Transplant Groups

Disease Free Survival

5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups

Overall Survival

Number of Participants Who Achieved a BCR-ABL Response at 12 Months

Overall Survival

Progression-free Survival

Response

Progression-free Survival (PFS)

Overall Survival (OS)

Response

Overall Survival (Consolidation Phase)

Overall Survival (Induction Phase)

Disease-free Survival (Consolidation Phase)

Incidence of Recurrent Disease

Number of Patients With Overall Survival at 2 Years.

Rates of Durable Engraftment

Toxicity as Measured by CTC v2.0

Graft-versus-host Disease (GVHD)

Grade ≥ 3 Stomatitis

Response Rate

Toxic Death

Minimal Residual Disease

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Disease-free Survival, for Only Complete Response Patients

Number of Participants Achieving Complete Remission

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

Overall Survival

Overall Response Rate (ORR)

Participants With a Response

Summary of Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline

Summary of Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline

Intervention	participants (Number)
	Overall (Complete + Partial Remission)	Complete Remission	Partial Remission	Stable Disease
Azacitidine	51	30	21	75
Conventional Care	21	14	7	65

Intervention	participants (Number)
	Patients with >=1 treatment emergent AE (TEAE)	Patients with >=1 treatment related TEAE	Patients with >=1 serious TEAE	Patients with >=1 serious treatment related TEAE	Patients w TEAE leading to discontinued treatment	Patients w TEAE leading to dose reduction	Patients w TEAE leading to dose interruption
Azacitidine	175	169	114	43	22	20	82
Best Supportive Care Only	97	1	71	0	4	0	0
Low-dose Cytarabine	44	34	27	13	6	2	12
Standard Chemotherapy	19	19	14	13	2	0	0

Intervention	participants (Number)
	Any Improvement n=177, 178	Erythroid Response - Major n=157, 160	Erythroid Response - Minor n=157, 160	Platelet Response - Major n=141, 129	Platelet Response - Minor n=138, 127	Neutrophil Response - Major n=131, 111	Neutrophil Response - Minor n=131, 111
Azacitidine	87	62	2	46	6	25	5
Conventional Care	51	17	1	18	4	20	9

Intervention	Participants (Count of Participants)
	CR	PR	SD	PD
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab	8	1	1	15

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	86.2
Prednisone, Capizzi Methotrexate <10 Years	93.8
Prednisone, Capizzi Methotrexate >= 10 Years	63.1
Predisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	74.6

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	93.1
Prednisone, Capizzi Methotrexate <10 Years	86.5
Prednisone, Capezzi Methotrexate >= 10 Years	83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)	74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	98.1
Prednisone, Capizzi Methotrexate <10 Years	93.3
Prednisone, Capizzi Methotrexate >= 10 Years	90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old	94.5
Prednisone and High Dose Methotrexate >=10 Years	90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)	78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25.0

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	80
Prednisone, Capizzi Methotrexate <10 Years	34.7
Prednisone, Capizzi Methotrexate >= 10 Years	39
Prednisone and High Dose Methotrexate < 10 Yrs Old	55
Prednisone and High Dose Methotrexate >=10 Years	47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	49.4

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	91.2
Prednisone, Capizzi Methotrexate <10 Years	82.1
Prednisone, Capezzi Methotrexate >= 10 Years	73.5
Predisone and High Dose Methotrexate < 10 Yrs Old	80.8
Prenisone and High Dose Methotrexate >=10 Years	75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)	61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	44.4

Intervention	Participants with a given type of AE (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT (serum glut. oxaloacetic transaminase)	Acidosis (metabolic or respiratory)	Adult respiratory distress syndrome (ARDS)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Alkalosis (metabolic or respiratory)	Allergic reaction/hypersens. (inc drug fever)	Amylase	Anorexia	Apnea	Ataxia (incoordination)	Bicarbonate, serum-low	Bilirubin (hyperbilirubinemia)	Blood/Bone Marrow-Other (Specify)	Bronchospasm, wheezing	Calcium, serum-low (hypocalcemia)	Cardiac Arrhythmia-Other (Specify)	Cardiac General-Other (Specify)	Cardiac troponin I (cTnI)	Cardiac troponin T (cTnT)	Cardiac-ischemia/infarction	Colitis	Colitis, infectious (e.g., Clostridium difficile)	Confusion	Constipation	Cough	Creatinine	DIC (disseminated intravascular coagulation)	Death not assoc with CTCAE term-Multi-organ failu	Dehydration	Diarrhea	Distention/bloating, abdominal	Dizziness	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Edema, larynx	Edema: limb	Edema: viscera	Enteritis (inflammation of the small bowel)	Esophagitis	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever (in the absence of neutropenia)	Fistula, GI - Rectum	Fistula, GU - Vagina	Flu-like syndrome	GGT (gamma-glutamyl transpeptidase)	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hematoma	Hemoglobin	Hemolysis	Hemorrhage, CNS	Hemorrhage, GI - Abdomen NOS	Hemorrhage, GI - Jejunum	Hemorrhage, GI - Lower GI NOS	Hemorrhage, GI - Oral cavity	Hemorrhage, GI - Rectum	Hemorrhage, GU - Bladder	Hemorrhage, GU - Kidney	Hemorrhage, GU - Urinary NOS	Hemorrhage, GU - Uterus	Hemorrhage, GU - Vagina	Hemorrhage, pulmonary/upper respiratory - Lung	Hemorrhage, pulmonary/upper respiratory - Nose	Hemorrhage/Bleeding-Other (Specify)	Hepatobiliary/Pancreas-Other (Specify)	Hiccoughs (hiccups, singultus)	Hypertension	Hypotension	Hypoxia	Infec with Grade 3 or 4 neut - Abdomen NOS	Infec with Grade 3 or 4 neut - Anal/perianal	Infec with Grade 3 or 4 neut - Appendix	Infec with Grade 3 or 4 neut - Bladder (urin	Infec with Grade 3 or 4 neut - Blood	Infec with Grade 3 or 4 neut - Bone (osteomy	Infec with Grade 3 or 4 neut - Brain + Spina	Infec with Grade 3 or 4 neut - Bronchus	Infec with Grade 3 or 4 neut - Catheter-rela	Infec with Grade 3 or 4 neut - Cecum	Infec with Grade 3 or 4 neut - Colon	Infec with Grade 3 or 4 neut - Dental-tooth	Infec with Grade 3 or 4 neut - Heart (endoca	Infec with Grade 3 or 4 neut - Lip/perioral	Infec with Grade 3 or 4 neut - Liver	Infec with Grade 3 or 4 neut - Lung (pneumon	Infec with Grade 3 or 4 neut - Meninges (men	Infect with Grade 3 or 4 neut - Mucosa	Infec with Grade 3 or 4 neut - Nerve-periphe	Infec with Grade 3 or 4 neut - Oral cavity-g	Infec with Grade 3 or 4 neut - Pelvis NOS	Infec with Grade 3 or 4 neut- Pharynx	Infec with Grade 3 or 4 neut - Rectum	Infec with Grade 3 or 4 neut - Sinus	Infec with Grade 3 or 4 neut - Skin (celluli	Infec with Grade 3 or 4 neut - Small bowel N	Infec with Grade 3 or 4 neut - Upper airway	Infection with Grade 3 or 4 neut - Urinary tract	Infec with Grade 3 or 4 neut - Vulva	Infec with Grade 3 or 4 neut - Wound	Infec with normal ANC or Grade 1/2 neut - Blood	Infec with norm ANC or Gr 1/2 neut, Catheter-rel	Infec with norm ANC or Grade 1/2 neut - Colon	Infec with norm ANC or Gr 1/2 neutr- Dental-tooth	Infec with norm ANC or Gr 1/2 neut - Heart	Infec with norm ANC or Gr 1/2 neutrophils - Liver	Infec with norm ANC or Gr 1/2 neut-Lung (pneumoni)	Infec with norm ANC or Gr 1/2 neut - Muscle	Inf with norm ANC or Gr 1/2 neut-Oral cavity-gums	Infec with norm ANC or Gr 1/2 neut - Scrotum	Infec with norm ANC or Gr 1/2 neut-Skin	Infec with norm ANC or Gr 1/2 neut-Urinary tract	Infection with unknown ANC - Blood	Infection with unknown ANC - Catheter-related	Infection with unknown ANC - Dental-tooth	Infection with unknown ANC - Joint	Infection with unknown ANC - Liver	Infection with unknown ANC - Lung (pneumonia)	Infection with unknown ANC - Mucosa	Infection with unknown ANC - Sinus	Infection with unknown ANC - Skin (cellulitis)	Infection with unknown ANC - Urinary tract NOS	Infection with unknown ANC - Wound	Infection-Other (Specify)	Left ventricular diastolic dysfunction	Left ventricular systolic dysfunction	Leukocytes (total WBC)	Leukoencephalopathy (radiolographic findings)	Liver dysfunction/failure (clinical)	Lymphopenia	Magnesium, serum-low (hypomagnesemia)	Metabolic/Laboratory-Other (Specify)	Mood alteration - anxiety	Mood alteration - depression	Mucositis/stomatitis (clinical exam) - Esophagus	Mucositis/stomatitis (clinical exam) - Large bowel	Mucositis/stomatitis (clinical exam) - Larynx	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (clinical exam) - Pharynx	Mucositis/stomatitis (func/sympt) - Esophagus	Mucositis/stomatitis (func/sympt)- Oral cavity	Mucositis/stomatitis (func/sympt) - Pharynx	Muscle weakness (func/sym, Whole body/generalized	Nasal cavity/paranasal sinus reactions	Nausea	Necrosis, GI - Rectum	Neurology-Other (Specify)	Neuropathy: motor	Neuropathy: sensory	Neutrophils/granulocytes (ANC/AGC)	Nystagmus	Obstruction/stenosis of airway - Trachea	Ocular/Visual-Other (Specify)	Opportunistic infec assoc with Gr 2 lymphopenia	PTT (Partial thromboplastin time)	Pain - Abdomen NOS	Pain - Anus	Pain - Back	Pain - Bone	Pain - Chest/thorax NOS	Pain - Extremity-limb	Pain - Eye	Pain - Head/headache	Pain - Joint	Pain - Muscle	Pain - Oral-gums	Pain - Rectum	Pain - Throat/pharynx/larynx	Pain-Other (Specify)	Pancreatic endocrine: glucose intolerance	Perforation, GI - Colon	Pericardial effusion (non-malignant)	Pericarditis	Petechiae/purpura	Phosphate, serum-low (hypophosphatemia)	Platelets	Pleural effusion (non-malignant)	Pneumonitis/pulmonary infiltrates	Portal vein flow	Potassium, serum-high (hyperkalemia)	Potassium, serum-low (hypokalemia)	Proctitis	Pulmonary/Upper Respiratory-Other (Specify)	Rash/desquamation	Renal failure	Rigors/chills	Seroma	Serum sickness	Sodium, serum-high (hypernatremia)	Sodium, serum-low (hyponatremia)	Somnolence/depressed level of consciousness	Atrial fibrillation	Sinus tachycardia	Supraventricular arrhythmia NOS	Syncope (fainting)	Syndromes-Other (Specify)	Thrombosis/embolism (vascular access-related)	Thrombosis/thrombus/embolism	Thrombotic microangiopathy	Tumor lysis syndrome	Typhlitis (cecal inflammation)	Uric acid, serum-high (hyperuricemia)	Vasovagal episode	Ventricular arrhythmia - Ventricular fibrillation	Vision-blurred vision	Vomiting
Ara-C Consolidation	22	17	2	2	3	2	0	0	1	2	1	2	0	4	2	0	3	1	0	0	3	4	1	4	0	0	1	0	0	0	1	4	1	3	0	10	0	1	0	0	0	22	183	16	0	0	1	4	15	0	1	144	1	0	0	0	1	2	0	0	0	0	0	1	0	4	12	0	0	2	4	6	0	4	0	4	47	1	0	1	13	1	2	3	0	0	1	22	1	1	0	2	0	1	0	2	9	1	0	6	1	0	6	4	1	0	1	0	9	0	0	1	0	0	7	1	0	2	1	2	1	0	3	0	0	4	1	2	151	1	0	50	1	4	1	0	0	0	0	2	0	0	1	1	2	0	7	1	1	2	1	193	0	1	0	0	1	3	1	1	4	2	1	1	8	0	1	0	0	0	0	0	0	0	0	3	6	226	3	5	0	0	19	0	1	1	0	1	0	0	0	4	0	0	0	0	4	2	1	4	0	0	1	1	1	0	0	5
Ara-C+Daunomycin	11	11	0	0	10	2	1	0	0	13	0	0	0	11	1	0	7	0	2	1	0	1	6	10	1	0	0	2	0	0	0	19	0	0	1	6	1	0	0	0	3	25	196	8	0	0	0	0	12	0	1	87	0	1	1	0	0	0	1	0	0	0	2	1	0	1	5	0	1	3	1	2	0	2	1	1	25	0	1	1	6	0	2	2	1	0	1	27	0	2	0	3	0	1	1	3	3	1	0	6	0	0	0	1	0	0	0	0	0	0	1	0	0	1	3	1	1	0	0	2	0	1	3	1	1	4	0	1	96	0	1	23	1	5	0	1	1	1	1	11	2	2	9	2	1	0	13	0	1	0	0	110	1	0	1	2	0	5	0	0	0	1	1	0	1	0	0	1	0	1	0	0	1	0	0	2	9	130	1	1	0	2	15	1	0	9	6	0	0	0	0	15	0	1	0	0	3	0	1	4	1	2	4	0	0	0	1	5
Ara-C+Daunomycin+Mylotarg	29	32	2	7	15	3	1	6	0	14	0	0	1	14	0	1	13	0	0	0	0	2	2	8	3	1	0	3	2	1	0	5	0	2	1	10	1	0	1	1	1	24	178	6	1	1	0	1	22	1	1	101	0	5	0	1	0	1	1	2	1	1	0	1	5	3	8	3	0	2	5	8	1	0	0	2	30	0	0	0	5	0	5	1	1	1	0	22	0	1	1	2	1	0	0	2	4	0	1	6	0	1	0	0	0	1	0	1	6	1	0	0	2	0	0	3	0	0	0	0	0	1	4	1	0	4	0	1	106	0	4	21	1	3	1	0	0	0	0	6	2	0	4	1	0	1	7	0	1	0	1	111	0	0	0	0	0	8	0	1	0	2	0	0	8	1	0	0	0	0	1	1	0	1	1	6	10	145	1	3	2	4	21	0	1	6	8	0	1	0	2	8	1	0	1	1	1	0	0	4	0	2	3	1	0	1	0	2
Post-consolidation G.O.	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4	22	1	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	4	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	41	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	43	0	0	0	1	0	0	1	1	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	1	40	0	0	0	0	3	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1